86th EAS Congress
Lisbon, Portugal
May 05-08, 2018
INDEX

INTRODUCTION
4  WELCOME LETTER
6  ABOUT EAS

GENERAL INFORMATION
12  COMMITTEES & FACULTY LIST
14  GOOD TO KNOW
16  CONGRESS FLOORPLAN
20  ABOUT LISBON

SCIENTIFIC INFORMATION
22  CME ACCREDITATION
27  INFORMATION FOR PRESENTERS

SCIENTIFIC PROGRAMME
36  PROGRAMME AT A GLANCE
43  EAS KEYNOTE LECTURES
48  THE ANITSCHKOW PRIZE
50  YOUNG INVESTIGATOR AWARDS
53  HALL NAME EULOGY
   OF DISTINGUISHED SCIENTISTS

PROGRAMME
58  Saturday - May 05, 2018
62  Sunday - May 06, 2018
72  Monday - May 07, 2018
82  Tuesday - May 08, 2018

87  SCIENCE AT A GLANCE PRESENTATIONS
135  POSTER SESSIONS

LIST OF COMPANIES
207  LIST OF COMPANIES
220  EXHIBITORS LIST & MAP
221  ACKNOWLEDGEMENTS

INDEX OF AUTHORS
225  INDEX

NOTE
235  NOTES
Dear Friends & Colleagues,
On behalf of the European Atherosclerosis Society (EAS) and the Sociedade Portuguesa de Aterosclerose (Portuguese Society of Atherosclerosis, PSA) we are delighted to welcome you to Portugal, to the beautiful and historic city of Lisbon and the 86th EAS Congress.

The EAS 2018 Lisbon Congress programme, both scientific and social, provides the international scientific community opportunities for high-level interdisciplinary exchange, as leaders in clinical and basic science come together from around the world to explore the latest top research into the mechanisms, diagnosis and treatment of atherosclerosis and related vascular disease. Be inspired by the award-winning Anitschkow Lecture, by outstanding Keynote lectures, by state-of-the-art Plenary sessions, and focussed Workshops and Advanced Clinical Seminars.

We firmly believe that the personal meeting - presenting and discussing one’s work with others, and sparking ideas from others’ work - is the key to progress in science. Make your contribution to the discussion by taking part in the Science at a Glance sessions, and viewing the Posters.

WELCOME LETTER
Young Investigator Fellowships are an important EAS initiative offering early-career scientists the chance to take part in the Congress, to learn through presenting their own research, attending the scientific programme, and getting to know others in the field. Congratulations to all attending EAS 2018 on a Fellowship – we encourage you to make the most of this opportunity to progress your career.

On behalf of the organising committees we wish you a successful Congress. May you gain new friends, new ideas, and return home inspired to take your studies of atherosclerosis and related vascular disease to new levels.

Welcome and enjoy!

Alberto Mello e Silva  
Congress Chair

Christoph S. Binder  
Chair, Scientific Programme Committee

Lale Tokgözoğlu  
EAS President

Jan Borén  
Co-Chair, Scientific Programme Committee

Alberto Mello e Silva  
Congress Chair

Lale Tokgözoğlu  
EAS President

Jan Borén  
Co-Chair, Scientific Programme Committee

Alberto Mello e Silva  
Congress Chair

Lale Tokgözoğlu  
EAS President

Jan Borén  
Co-Chair, Scientific Programme Committee

Alberto Mello e Silva  
Congress Chair

Lale Tokgözoğlu  
EAS President

Jan Borén  
Co-Chair, Scientific Programme Committee

Alberto Mello e Silva  
Congress Chair

Lale Tokgözoğlu  
EAS President

Jan Borén  
Co-Chair, Scientific Programme Committee

Alberto Mello e Silva  
Congress Chair

Lale Tokgözoğlu  
EAS President

Jan Borén  
Co-Chair, Scientific Programme Committee

Alberto Mello e Silva  
Congress Chair

Lale Tokgözoğlu  
EAS President

Jan Borén  
Co-Chair, Scientific Programme Committee

Alberto Mello e Silva  
Congress Chair

Lale Tokgözoğlu  
EAS President

Jan Borén  
Co-Chair, Scientific Programme Committee

Alberto Mello e Silva  
Congress Chair

Lale Tokgözoğlu  
EAS President
The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”. For more than 50 years the Society’s expertise has been used to teach clinicians how to manage lipid disorders and how to prevent atherosclerosis.

By offering to our members access to educational materials, and opportunities to take part in Congress and courses, and by providing a forum in which new developments can be discussed, EAS contributes to the development of knowledge in the field, and ultimately to the improved treatment of persons with cardiovascular disease and lipid disorders.

In recent years the Society has made a particular effort to recruit young scientists and clinicians also from other related disciplines. The European Atherosclerosis Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis.
EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. Through a regular series of Featured Commentaries EAS puts into perspective topical issues of relevance to our members.

The Society organises an annual Congress for approximately 2500 delegates.

EAS runs a programme of Advanced Courses for both basic scientists and clinicians.

EAS Academy is the Society’s online e-Learning resource, containing a range of educational material and self-teaching programmes.

EAS is co-organiser of the European Lipoprotein Club (ELC) annual scientific meeting.

EAS coordinates the FH Studies Collaboration, working to establish an international registry of observational studies on FH.
WHY SHOULD I BECOME AN EAS MEMBER?

CONTINUE YOUR PROFESSIONAL DEVELOPMENT WITH EAS EDUCATIONAL ACTIVITIES - ADVANCED COURSES & EAS ACADEMY
EAS membership offers opportunities to deepen your theoretical skills and/or practical knowledge, which you can then apply in your own research or clinical practice.
The Society organises educational activities such as Advanced Courses (many CME accredited by EBAC), and offers a wealth of online learning material, such as webcasts, videos and quizzes, on the Society’s educational platform, EAS Academy. As an EAS member, you have access to the very latest uploaded material, EAS Academy’s Premium content.

STAY WELL INFORMED WITH EAS PUBLICATIONS
EAS membership makes it easier for those working in the field to stay abreast of the latest developments in the field. In addition to access to the Society’s own publications of Consensus position papers and Guidelines, EAS membership includes complimentary access to *Atherosclerosis* Journal (worth ca. 300 €), and members receive by email newsletters and featured commentaries on topical issues.

INTERACT WITH LEADING EXPERTS IN THE FIELD AT EAS CONGRESS
The participants at EAS annual Congress are world leaders in atherosclerosis research and clinical practice, and the size and format of the Congress lends itself to networking and interaction.
EAS members are encouraged to submit their findings as an abstract to Congress, where they can participate at significantly reduced registration fee (savings of at least 100 € compared to non-member fees).
APPLY FOR GRANTS AND PRIZES AS AN EAS MEMBER
EAS individual members may apply for the Society’s travel grants to attend Congress, and, where eligible, may apply for the Society’s Prizes.

GREAT VALUE MEMBERSHIP BENEFITS AT AFFORDABLE ANNUAL SUBSCRIPTION RATES
EAS’ aim is to provide access to learning that will help our members to manage lipid disorders and to prevent and treat atherosclerosis. We keep our annual membership subscription rates low – 40 € (persons over 35) or 20 € (persons 35 or younger) – so that as many as possible can afford to become members.

HOW TO BECOME AN EAS MEMBER?
If you’re not an EAS member and would like to become one, you should complete the application form on the Society website and pay the annual subscription fee. Once your application is approved, and the subscription payment processed, you become eligible for membership benefits for one calendar year from that date at www.eas-society.org.
CONGRESS CHAIR
Alberto Mello e Silva, Portugal

EAS EXECUTIVE COMMITTEE
President
Lale Tokgözoglu, Turkey
Vice-President
Jan Borén, Sweden
Past President
Alberico L. Catapano, Italy
Secretary
Arnold von Eckardstein, Switzerland
Treasurer
Paolo Parini, Sweden

Scientific Programme Committee
Christoph J. Binder, Austria - Chair
Jan Borén, Sweden - Co-Chair
Martin Bennett, United Kingdom
Eric Bruckert, France
Alberico L. Catapano, Italy
Geesje Dallinga-Thie, The Netherlands
Ulrich Laufs, Germany
Alberto Mello e Silva, Portugal
Giuseppe Danilo Norata, Italy
Sanni Söderlund, Finland
Marja-Riitta Taskinen, Finland
Lale Tokgözoglu, Turkey
Michal Vrablik, Czech Republic

LOCAL ORGANISING COMMITTEE
Alberto Mello e Silva, Lisbon - Chair
Luís Andrade, Porto
Francisco Araújo, Lisbon
José Lomelino Araújo, Lisbon
Luciana Couto, Porto
Pedro Marques da Silva, Lisbon
José Pereira de Moura, Coimbra
João Sequeira Duarte, Lisbon
Manuel Teixeira Veríssimo, Coimbra

CONGRESS COMMITTEE
Marja-Riitta Taskinen, Finland - Chair
Giuseppe Danilo Norata, Italy - Co-chair
Jan Borén, Sweden
Sanni Söderlund, Finland

APPROCIATION AND THANKS
WE WOULD LIKE TO THANK THE REVIEWERS OF THE SUBMITTED ABSTRACTS FOR THEIR VALUABLE HELP AND ASSISTANCE
FACULTY LIST

Luis Miguel Da Silva Andrade, Portugal
Francisco Araújo, Portugal
Marcello Arca, Italy
Maurizio Averna, Italy
Lina Badimon, Spain
Jeroen J. Bax, The Netherlands
Macej Banach, Poland
Martin Bennett, United Kingdom
Erik A.L. Biessen, The Netherlands
Christoph J. Binder, Austria
Jan Borén, Sweden
Christos Bourantas, United Kingdom
Eric Bruckert, France
Giuseppe Caligiuri, France
Alberico L. Catapano, Italy
John Chapman, France
Christopher Cannon, USA
Luciana Couto, Portugal
J. Wouter Jukema, The Netherlands
Takeshi Kimura, Japan
Petri Kovanen, Finland
Ulf Landmesser, Germany
Ulrich Laufs, Germany
Nicholas J. Leeper, USA
Eran Leitersdorf, Israel
Peter Libby, USA, France
José Lomelino Araujo, Portugal
Aldons J. Lusis, USA
Francois Mach, Switzerland
Aldo Pietro Maggioni, Italy
Ziad Mallat, United Kingdom
Adil Mardinoglu, Sweden
Pedro Marques Da Silva, Portugal
Miguel Angel Martinez-Gonzalez, Spain
Luis Masana, Spain
Steffen Massberg, Germany
Yuji Matsuzawa, Japan
Manuel Mayr, United Kingdom
Alberto Mello E Silva, Portugal
Erkin Mirrakhimov, Kyrgyzstan
Samia Mora, USA
Philippe Moulin, France
Willem J.M. Mulder, The Netherlands, USA
Giuseppe Danilo Norata, Italy
Katarina Öörn, Finland
Gary K. Owens, USA
Chris Packard, United Kingdom
Paulo Parini, Sweden
Gerard Pasterkamp, The Netherlands
José Pereira De Moura, Portugal
Pablo Perez-Martinez, Spain
Massimo Piepoli, Italy
Fausto J. Pinto, Portugal
Xavier Pinto, Spain
Matteo Pirro, Italy
Andrea Poli, Italy
Michael Potente, Germany
Kausik Ray, United Kingdom
Zeilko Reiner, Croatia
Patrick Rensen, The Netherlands
Gabriele Riccardi, Italy
Jennifer Robinson, USA
Stefano Romeo, Sweden
Emilio Ros, Spain
Lars Rydén, Sweden
Naveed A. Sattar, United Kingdom
Johannes Schmid, Austria
Heribert Schunkert, Germany
Eleonora Scorletti, United Kingdom
Joao Sequeira Duarte, Portugal
Peter Sever, United Kingdom
Sanni Söderlund, Finland
Bart Staels, France
Gabriel P. Steg, France
Erik Stroes, The Netherlands
Filip K. Swirski, USA
Ira Tabas, USA
Alan Tall, USA
Marja-Riitta Taskinen, Finland
Manuel Teixeira Veríssimo, Portugal
Lale Tokgözüoğlu, Turkey
Peter Tontonoz, USA
Peter Toth, USA
Alexandros Tselepis, Greece
Sotiros Tsimikas, USA
Anne Tybaerg-Hansen, Denmark
Viola Vaccarino, USA
Jan M. Van Deursen, USA
Arnold Von Eckardstein, Switzerland
Michal Vrablik, Czech Republic
Nick J. Wareham, United Kingdom
Olov Wiklund, Sweden
Joseph L. Witztum, USA
Seppo Yla-Herttuala, Finland
Salim Yusuf, Canada
Laurent Yvan-Charvet, France
Jose L. Zamorano, Spain
GOOD TO KNOW

VENUE
Centro de Congressos de Lisboa
Praça das Indústrias, nº 1300-307
Lisboa, Portugal

OFFICIAL LANGUAGE
The official language of the Congress is English and all presentations will be made in English.

CLOTHING
Clothing is informal for all occasions.

CLIMATE
The average temperature in Lisbon in May reaches up to around 19°C, and dips no lower than 13°C in the evenings.

REGISTRATION DESK OPENING HOURS
The Organising Secretariat is at the guests’ disposal in the Foyer C (main entrance) according to the following schedule:
- Saturday May 05  hrs 08.00-20.00
- Sunday May 06  hrs 07.30-18.30
- Monday May 07  hrs 07.30-18.30
- Tuesday May 08  hrs 08.30-13.00

EXHIBITION OPENING HOURS
An exhibition of pharmaceuticals, technical and research products takes place in the Pavilion 4 on the First Floor according to the following schedule:
- Saturday May 05  hrs 18.00-21.00
- Sunday May 06  hrs 08.00-17.00
- Monday May 07  hrs 08.00-17.30
- Tuesday May 08  hrs 08.00-12.30

CONGRESS NAME BADGE
Participants are kindly requested to wear their badge during all sessions and events. Congress badges are personalized with the following colours:
- Delegates white
- Faculty red
- Exhibitors green
- EAS Staff blue
- Press yellow
- Guests pink

GETTING AROUND LISBON FOR FREE
Please, collect your travel card at the Registration desk.

HOW TO GET CPD/CME CREDITS
Participants interested in obtaining CPD/CME credits are kindly requested to scan their badge at the entrance and exit each day. Bar Code Scanners are located at the entrance of the Congress area.

REFRESHMENTS
Coffee and refreshments will be served to Congress participants in the Exhibition Area from Sunday May 06 to Tuesday May 08 as indicated in the programme.
A cash bar will be available at the first floor near the Pavilion 4 main access.

BE CONNECTED
Wi-fi is available for Congress participants throughout the public areas of the Congress venue.
Click the EAS2018 net to access the free Congress wi-fi.
EAS 2018 APP
Install the EAS2018 interactive mobile App on your smartphone and portable devices to access all the Congress information you could need during the Congress:
• See the overview of sessions, speakers and exhibitors
• Create your own programme for the event, including bookmarking the sessions you wish to attend
• Receive real-time updates
Download the EAS App now to enhance your congress experience! (available on the App Store or Google Play)

CONGRESS ABSTRACTS
The Congress abstracts will be published online in the August issue of the Atherosclerosis Journal.

MOBILE PHONE & PHOTOGRAPHY
Participants are kindly requested to keep their mobile phones switched off in session halls and refrain from taking pictures during sessions.

NON-SMOKING POLICY
The EAS congress is a non-smoking event. Smoking in the Congress area is not allowed.

CLOAKROOM
A cloakroom is available for participants according to the scientific schedule of the Congress. The cloakroom and oversize deposit are located in the Foyer C at the Ground Floor near the Registration desk. Participants are kindly requested not to leave their personal belongings after the closing time.

LIABILITY AND INSURANCE
The Congress Secretariat and Organisers cannot accept liability for personal accidents or loss or damage to private property of participants, either during or as result of the Congress. Participants are advised to take out their own personal travel and health insurance for their trip.

SAFETY AND SECURITY
Please do not leave bags or suitcases unattended at any time, whether inside or outside the session halls.

WEBCASTING
Selected sessions will be recorded and will be available on the Society’s educational platform EAS Academy following the Congress.

PRIVACY DISCLOSURE AND PUBLISHING OF IMAGES
Pursuant to article 13 of Legislative Decree no. 196/2003, the personal data of the participants, their videos and photos made during the event, will be used by AIM Italy s.r.l. for purposes related to the communication and the valorization of the event. Such personal data will be communicated only to those people who are in charge of the activities necessary to the aforementioned purposes. Photos and videos will be also published on the website and social networks of AIM Group International (and on the website and social networks of the event, if any). The treatment will be carried out with appropriate tools ensuring security and confidentiality and may be also carried out by computerized tools that are able to memorize, manage and transmit the personal data. The data controller is AIM Italy s.r.l., with legal seat in Milan, Via Giuseppe Ripamonti 129, VAT no. 00943621003, e-mail: info.aimcongress@aimgroup.eu. With regard to the personal data granted, included photos and videos, each participant can exercise the rights set forth in article 7 of Legislative Decree n. 196/2003 by contacting the data Controller.
USEFUL CONTACTS

CONGRESS ORGANISER

AIM Group International - Milan Office
Via Ripamonti 129 - 20141 Milan, Italy
Phone +39 02 56601.1
e-mail: eas2018@aimgroup.eu

ACCOMMODATION

AIM Group International - Lisbon Office
Avenida Conde Valbom, 6 - 5th floor
1050-068 Lisboa – Portugal
Phone +351 21 324 5054
e-mail: eas2018.hotel@aimgroup.eu
The EAS 2018 Mobile App allows you an instant access to all sessions, presentations, posters, abstracts, exhibitors & maps

Browse sessions by day, topic, type or track

Browse the list of speakers, their biographies and which sessions they will be presenting in

Create your personalised agenda for easy conference attendance

Visit the exhibitors section

Receive the latest news
Portugal’s capital, Lisbon, lies on the north bank of the Tagus Estuary, on the European Atlantic coast. A historical city, Lisbon is one of the oldest cities in the world, and the second oldest city in Europe. There the sun shines 290 days a year, and the temperature rarely drops below 15°C. The city has approximately 600,000 inhabitants, approaching 1.9 million if one includes the various satellite towns of Greater Lisbon.

For pure pleasure, Lisbon has much to recommend it – its gastronomy, its Fado, its monuments and heritage, and, not least, its people. Take a walk through Lisbon, and experience for yourself the distinctive charm of its winding streets and the rich history of the old Lisbon neighbourhoods.

- **The Jerónimos Monastery** was proclaimed a UNESCO World Heritage Site in 1983. This notable 16th century work of architecture became part of Portuguese identity and culture.
- **Museu Nacional de Arte Antiga** houses the most relevant public collection, from the 12th to the 19th century. Painting, sculpture, silver, gold and jewellery, decorative arts - Portuguese, European, African and Oriental.
- **Museu Nacional do Coches** the museum houses a unique collection in the world consisting of vehicles from the 17th, 18th and 19th centuries including coaches, berlins, sedan chairs and carriages.
- **Arco da Rua Augusta** Climb up one of Lisbon’s iconic buildings for a unique view of the city. Open to the public since 9 August 2013, the Arch leaves Lisbon at your feet, literally.
EDUCATIONAL OBJECTIVES
After participating in this educational event, learners should be able to:
• address individual needs in compliance with their Continuous Professional Development (CPD) plan
• exchange ideas and knowledge in the field of atherosclerosis and related cardiovascular conditions across continents, institutions, and individuals
• discuss the innovative new therapeutic agents targeting LDL cholesterol
• identify possible programmatic collaborations to more effectively address regional, national and local responses to atherosclerosis around the world and overcome barriers that limit access to prevention, care and services
• discuss the latest scientific advantages in the field of atherosclerosis and related cardiovascular conditions
• summarise the latest research outcomes in the field of atherosclerosis and related cardiovascular conditions

TARGET AUDIENCE
Specialists in the field of clinical chemistry, diabetes, endocrinology, primary care and more.

ACCREDITATION STATEMENT AND CREDIT DESIGNATION
EUROPEAN BOARD FOR ACCREDITATION IN CARDIOLOGY (EBAC)
An application has been made to European Board for accreditation in Cardiology (EBAC) for CME Accreditation of this event.

In compliance with EBAC guidelines, all speakers/chairpersons participating in the EBAC sessions have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

EACCME®-UEMS
An application has been made to the EACCME® for CME accreditation of this event

AMERICAN MEDICAL ASSOCIATION (AMA)
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme
ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Programme of The Royal College of Physicians and Surgeons of Canada. For more information, visit: www.royalcollege.ca

EBAC ACCREDITED EDUCATIONAL PROGRAMME
EBAC Accredited Educational Programmes will be taking place during the Congress as follows:

PATIENT JOURNEY AFTER ACUTE CORONARY SYNDROMES: CAN WE IMPROVE OUTCOMES?
Saturday, May 05, 2018, 16.20-17.50
In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
This programme is supported by an educational grant from MSD.

FROM NUTRITION TO PERSONALIZED NUTRITION IN DYSLIPIDAEMIAS
Sunday, May 06, 2018, 13.30-15.00
In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
This programme is supported by an educational grant from BASF, Raisio, Unilever.

EXPLORING NEW METABOLIC PATHWAYS TO CONTROL DYSLIPIDAEMIAS
Sunday, May 06, 2018, 13.30-14.30
In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
This programme is supported by an educational grant from Esperion.
OPTIMIZING DYSLIPIDEMIA MANAGEMENT: THE VALUE OF COMBINATION THERAPY

**Sunday, May 06, 2018, 14.30-15.30**

In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This programme is supported by an educational grant from **Sanofi**

---

THERAPEUTIC APPROACHES TO THE VERY HIGH RISK PATIENT: WHAT IS NEW?

**Monday, May 07, 2018, 13.30-15.00**

In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This programme is supported by an educational grant from **Sanofi and Regeneron**

---

NEW TARGETS FOR CONTROLLING DYSLIPIDAEMIAS AND ATHEROSCLEROSIS

**Monday, May 07, 2018, 13.30-14.30**

In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This programme is supported by an educational grant from **Akcea**

---

LOWERING ATHEROGENETIC LIPOPROTEINS: THE CV BENEFIT

**Monday, May 07, 2018, 13.30-15.00**

In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This programme is supported by an educational grant from **Mylan**
OMEGA 3 FATTY ACIDS: THEIR ROLE IN CV PREVENTION

Monday, May 07, 2018, 14.30-15.30

In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This programme is partially supported by an educational grant from Amarin

CREDIT BREAKDOWN

Please, visit the website for final information on credit points.
DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST

In compliance with EBAC/EACCME guidelines, all speakers participating in this program have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

TO RECEIVE YOUR CERTIFICATES

The CME/CPD certificates (EBAC and EACCME-UEMS) will be available after completing the online evaluation and credit claiming procedure. The process take about 5 minutes. We thank you for your feedback as it is important part of CME/CPD accreditation and helps improve future educational activities.

The certificate of attendance can be downloaded through our attendance tool platform together with UEMS/EBAC Certificates. Please check we have the correct email address at the Registration desk.
INFORMATION FOR PRESENTERS

SPEAKERS READY ROOM
A Speakers Ready Room will be available throughout the entire Congress for speakers. The room is located on the first floor of the Congress venue.
All Speakers are expected to produce a Power Point presentation.
Presentations should be saved on a USB memory stick and delivered to the Speakers Ready Room either the day before the session or at least two hours before the beginning of the session. PCs at the Speakers Ready Room will be available to make changes to the presentation.
The use of the Speakers’ own laptop for presentation is not allowed.

Peak hours of operation in the Speakers Ready Room are during lunch time and breaks. We highly recommend Speakers and Authors to preferably visit the Speakers Ready Room early in the morning or during the sessions.

ORAL PRESENTATIONS
(for Speakers and Authors)
These few instructions are provided to let Speakers and Authors prepare a presentation that will allow the audience to get the maximum benefit from their speech, and will enable the organisers to ensure that the Sessions will be conducted smoothly.

Presentations have to be prepared in Microsoft PowerPoint (2013) and should be PC formatted (not Mac formatted). The recommended format for PPT presentations is 16:9.
Please bring a backup copy of your presentation with you. You should copy your PowerPoint and all movies to a folder on a USB thumb drive. PowerPoint does NOT embed movies. They must be placed in the same folder as your PowerPoint.
Use high-contrast lettering and readable standard font (minimum font size 24); use high-contrast colors: light text on dark background or vice versa.
If Speakers and Authors create their presentations using a different system from MS Windows (such as Mac or Linux), they are kindly requested to provide presentations in a Windows compatible format and to go to the Speakers Ready Room to fix possible compatibility issues with technicians.

Time keeping is crucial: practice your presentation in advance and ensure that you stay in time
• the presentation should be kept strictly within the timeframe given to you,
• the Moderators will keep strict time control during the presentations,
• a countdown clock will be provided, keep an eye on it.
SCIENCE AT A GLANCE

EAS is proud to have Science at a glance E-Poster session that will be located in Foyer E and Foyer F of the Congress Centre, providing the unique opportunity for convivial scientific discussions and exchange. For programme details please refer to the Science at a Glance section.

SESSION 1 - SUNDAY, MAY 06  h. 13.45-14.45

<table>
<thead>
<tr>
<th>TOPICS</th>
<th>SESSION CHAIR</th>
<th>SAG NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIPOPROTEIN(A) METABOLISM</td>
<td>Sotirios Tsimikas, USA</td>
<td>SAG1.1 - SAG1.6</td>
</tr>
<tr>
<td>INFLAMMATION AND IMMUNITY: HUMAN PERSPECTIVES</td>
<td>Ira Tabas, USA</td>
<td>SAG12.1 - SAG12.6</td>
</tr>
<tr>
<td>SMOOTH MUSCLE CELLS BIOLOGY - SESSION 1</td>
<td>Martin Bennett, UK</td>
<td>SAG16.1 - SAG16.4</td>
</tr>
<tr>
<td>TREATMENT OF CVD</td>
<td>Eric Stroes, The Netherlands</td>
<td>SAG22.1 - SAG22.6</td>
</tr>
<tr>
<td>NOVEL PERSPECTIVES OF VASCULAR DISEASE</td>
<td>Francisco Araújo, Portugal</td>
<td>SAG23.1 - SAG23.5</td>
</tr>
<tr>
<td>DIABETES AND INSULIN SENSITIVITY</td>
<td>Bart Staels, France</td>
<td>SAG24.1 - SAG24.6</td>
</tr>
<tr>
<td>VASCULAR IMAGING AND INTERVENTIONS</td>
<td>Sanni Söderlund, Finland</td>
<td>SAG30.1 - SAG30.6</td>
</tr>
<tr>
<td>FH - AROUND THE WORLD</td>
<td>Alexandros Tselepis, Greece</td>
<td>SAG36.1 - SAG36.6</td>
</tr>
<tr>
<td>BILE ACIDS AND CELLULAR LIPID METABOLISM</td>
<td>Alex K. Groen, The Netherlands</td>
<td>SAG4.1 - SAG4.6</td>
</tr>
<tr>
<td>Atherosclerotic Risk</td>
<td>Zeljko Reiner, Croatia</td>
<td>SAG40.1 - SAG40.6</td>
</tr>
<tr>
<td>INTERESTING BIOMARKERS</td>
<td>Katarina Öörn, Finland</td>
<td>SAG43.1 - SAG43.6</td>
</tr>
<tr>
<td>NEW DATA ON PCSK9</td>
<td>José Pereira De Moura, Portugal</td>
<td>SAG45.1 - SAG45.6</td>
</tr>
</tbody>
</table>
## SESSION 2 - SUNDAY, MAY 06  h. 14.45-15.45

<table>
<thead>
<tr>
<th>TOPICS</th>
<th>SESSION CHAIR</th>
<th>SAG NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>VASCULAR BIOLOGY - SESSION 1</td>
<td>Johannes Schmid, Austria</td>
<td>SAG18.1 - SAG18.6</td>
</tr>
<tr>
<td>HOW TO PROTECT THE VESSEL WALL?</td>
<td>Giuseppina Caligiuri, France</td>
<td>SAG21.1 - SAG21.6</td>
</tr>
<tr>
<td>TRIGLYCERIDES AND FATTY ACIDS</td>
<td>João Sequeira Duarte, Portugal</td>
<td>SAG25.1 - SAG25.6</td>
</tr>
<tr>
<td>DIABETES AND VASCULAR RISK</td>
<td>Luís Andrade, Portugal</td>
<td>SAG27.1 - SAG27.6</td>
</tr>
<tr>
<td>NAFLD</td>
<td>Stefano Romeo, Sweden</td>
<td>SAG28.1 - SAG28.6</td>
</tr>
<tr>
<td>GENES AND ENVIRONMENT</td>
<td>Ruth Frikke-Schmidt, Denmark</td>
<td>SAG31.1 - SAG31.6</td>
</tr>
<tr>
<td>NUTRITION - WHAT TO EAT?</td>
<td>Emilio Ros, Spain</td>
<td>SAG32.1 - SAG32.4</td>
</tr>
<tr>
<td>HOW TO PREDICT CVD RISK?</td>
<td>José Lomelino Araújo, Portugal</td>
<td>SAG39.1 - SAG39.6</td>
</tr>
<tr>
<td>CLINICAL ASPECTS OF LIPIDS, GENETICS, AND INTERVENTIONS I</td>
<td>Wouter Jukema, The Netherlands</td>
<td>SAG5.1 - SAG5.6</td>
</tr>
<tr>
<td>CHOLESTEROL EFFLUX AND REVERSE CHOLESTEROL TRANSPORT</td>
<td>Peter Tontonoz, USA</td>
<td>SAG6.1 - SAG6.6</td>
</tr>
<tr>
<td>LDL METABOLISM, OXIDATION AND LIPID ACCUMULATION</td>
<td>Pedro Marques da Silva, Portugal</td>
<td>SAG8.1 - SAG8.6</td>
</tr>
</tbody>
</table>
## INFORMATION FOR PRESENTERS

### SCIENCE AT A GLANCE

**SESSION 3 - MONDAY, MAY 07 h. 13.45-14.45**

<table>
<thead>
<tr>
<th>TOPICS</th>
<th>SESSION CHAIR</th>
<th>SAG NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENDOTHELIAL CELL BIOLOGY</td>
<td>Seppo Ylä-Herttuala, Finland</td>
<td>SAG11.1 - SAG11.6</td>
</tr>
<tr>
<td>IMMUNE REGULATION IN ATHEROSCLEROSIS</td>
<td>Ziad Mallat, UK</td>
<td>SAG15.1 - SAG15.6</td>
</tr>
<tr>
<td>VASCULAR BIOLOGY - SESSION 2</td>
<td>Erik Biessen, The Netherlands</td>
<td>SAG19.1 - SAG19.6</td>
</tr>
<tr>
<td>RISK PREDICTIONS IN DIABETES</td>
<td>Michal Vrablik, Czech Republic</td>
<td>SAG26.1 - SAG26.6</td>
</tr>
<tr>
<td>LIPOPROTEIN RECEPTORS AND LIPID LAYERS</td>
<td>Geesje M. Dallinga-Thie, The Netherlands</td>
<td>SAG3.1 - SAG3.6</td>
</tr>
<tr>
<td>DIET AND BLOOD VESSELS</td>
<td>Samia Mora, USA</td>
<td>SAG33.1 - SAG33.6</td>
</tr>
<tr>
<td>OBESITY</td>
<td>Luciana Couto, Portugal</td>
<td>SAG34.1 - SAG34.6</td>
</tr>
<tr>
<td>DEADLY TRIANGLE: FH-PAD-CAD</td>
<td>Guy De Backer, Belgium</td>
<td>SAG37.1 - SAG37.6</td>
</tr>
<tr>
<td>MECHANISMS OF VASCULAR DISEASES</td>
<td>Manuel Mayr, UK</td>
<td>SAG42.1 - SAG42.6</td>
</tr>
<tr>
<td>FH IN CLINICAL PRACTISE</td>
<td>Kausik Ray, UK</td>
<td>SAG44.1 - SAG44.6</td>
</tr>
<tr>
<td>THE POWER OF GENES</td>
<td>Ewa Ehrenborg, Sweden</td>
<td>SAG46.1 - SAG46.6</td>
</tr>
<tr>
<td>CLINICAL ASPECTS OF LIPIDS, GENETICS, AND INTERVENTIONS II</td>
<td>Petri Kovanen, Finland</td>
<td>SAG71 - SAG7.5</td>
</tr>
</tbody>
</table>
# SESSION 4 - MONDAY, MAY 07  h. 14.45-15.45

<table>
<thead>
<tr>
<th>TOPICS</th>
<th>SESSION CHAIR</th>
<th>SAG NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOVELTIES IN THE PATHOGENESIS OF ATHEROSCLEROSIS</td>
<td>Patrick Rensen, The Netherlands</td>
<td>SAG10.1 - SAG10.6</td>
</tr>
<tr>
<td>IMAGING</td>
<td>Fausto Pinto, Portugal</td>
<td>SAG13.1 - SAG13.6</td>
</tr>
<tr>
<td>INFLAMMATION AND MONOCYTE/MACROPHAGE FUNCTION</td>
<td>Filip K. Swirski, USA</td>
<td>SAG14.1 - SAG14.5</td>
</tr>
<tr>
<td>SMOOTH MUSCLE CELLS BIOLOGY - SESSION 2</td>
<td>Gary Owens, USA</td>
<td>SAG17.1 - SAG17.4</td>
</tr>
<tr>
<td>HDL METABOLISM</td>
<td>Matti Jauhiainen, Finland</td>
<td>SAG21 - SAG2.6</td>
</tr>
<tr>
<td>VASCULAR BIOLOGY - SESSION 3</td>
<td>Laurent Yvan-Charvet, France</td>
<td>SAG20.1 - SAG20.6</td>
</tr>
<tr>
<td>CVD RISK MODELS</td>
<td>Olov Wiklund, Sweden</td>
<td>SAG29.1 - SAG29.6</td>
</tr>
<tr>
<td>GENETICS OF FH AND DYSLIPIDEMIA</td>
<td>Anne Tybjaerg-Hansen, Denmark</td>
<td>SAG35.1 - SAG35.7</td>
</tr>
<tr>
<td>EFFECTS OF STATIN TREATMENT IN SPECIAL POPULATIONS</td>
<td>Philippe Moulin, France</td>
<td>SAG38.1 - SAG38.5</td>
</tr>
<tr>
<td>DYSLIPIDEMIA</td>
<td>Manuel Teixeira Veríssimo, Portugal</td>
<td>SAG41.1 - SAG41.6</td>
</tr>
<tr>
<td>CLINICAL ASPECTS OF LIPIDS, GENETICS, AND INTERVENTIONS III</td>
<td>Ulrich Laufs, Germany</td>
<td>SAG9.1 - SAG9.6</td>
</tr>
</tbody>
</table>
POSTER

All posters will be on display for the duration of the Congress from Saturday afternoon May 05 to lunchtime on Tuesday May 08. Each poster has been given a number and should be fixed to the board marked with the same number. Each Author is asked to stand by their poster during the allocated poster viewing session. The 1.5 hour slots have been allocated according to poster number. Please see the Poster Overview below for the date and time of your poster presentation. The Organisers are not responsible for loss of any posters that have not been removed by the end of the sessions on May 08. For programme details please refer to the Poster session section.

POSTER OVERVIEW

SUNDAY, MAY 06  h. 17.00-18.30

<table>
<thead>
<tr>
<th>TOPIC: ATHEROSCLEROSIS</th>
<th>POSTER BOARD IN AUDITORIUM VIII</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 INFLAMMATION AND IMMUNITY IN ATHEROSCLEROSIS</td>
<td>P1.001 - P1.041BIS</td>
</tr>
<tr>
<td>1.2 MACROPHAGES IN LIPID METABOLISM AND ATHEROSCLEROSIS</td>
<td>P1.2.042 - P1.2.049</td>
</tr>
<tr>
<td>1.3 ENDOTHELIAL DYSFUNCTION: CLINICAL ASSESSMENT</td>
<td>P1.3.050 - P1.3.060BIS</td>
</tr>
<tr>
<td>1.4 ENDOTHELIUM AND SMOOTH MUSCLE CELLS</td>
<td>P1.4.061 - P1.4.086BIS</td>
</tr>
<tr>
<td>1.5 EXTRACELLULAR MATRIX AND ATHEROSCLEROSIS</td>
<td>P1.5.087 - P1.5.092</td>
</tr>
<tr>
<td>1.6 VASCULAR BIOLOGY OF THE ARTERIAL WALL</td>
<td>P1.6.093 - P1.6.110</td>
</tr>
<tr>
<td>1.7 HORMONES AND ATHEROSCLEROSIS</td>
<td>P1.7.111 - P1.7.117</td>
</tr>
<tr>
<td>1.8 IMAGING ATHEROSCLEROSIS</td>
<td>P1.8.118 - P1.8.125</td>
</tr>
<tr>
<td>1.9 ATHEROSCLEROSIS REGRESSION</td>
<td>P1.9.126 - P1.9.131</td>
</tr>
<tr>
<td>1.10 ANEURYSMS AND ARTERIOPATHIES</td>
<td>P1.10.132 - P1.10.139</td>
</tr>
<tr>
<td>1.11 COAGULATION AND THROMBOSIS</td>
<td>P1.11.140 - P1.11.149</td>
</tr>
</tbody>
</table>
### SUNDAY, MAY 06  h. 17.00-18.30

**TOPIC: LIPIDIS, LIPOPROTEINS, AND ADIPOSE TISSUE**

<table>
<thead>
<tr>
<th>LIPID AND LIPOPROTEIN METABOLISM</th>
<th>POSTER BOARD IN PAVILION 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>TG-RICH LIPOPROTEIN METABOLISM</td>
<td>P2.2.180 - P2.2.187</td>
</tr>
<tr>
<td>LIPOPROTEINS: LP(A)</td>
<td>P2.3.188 - P2.3.206</td>
</tr>
<tr>
<td>LIPOPROTEIN RECEPTORS</td>
<td>P2.4.207 - P2.4.214</td>
</tr>
<tr>
<td>HDL METABOLISM</td>
<td>P2.5.215 - P2.5.222</td>
</tr>
<tr>
<td>CHOLESTEROL EFFLUX AND REVERSE</td>
<td>P2.6.223 - P2.6.233</td>
</tr>
<tr>
<td>ADIPOSE TISSUE BIOLOGY</td>
<td>P2.7.234 - P2.7.239</td>
</tr>
</tbody>
</table>

### MONDAY, MAY 07  h. 17.00-18.30

**TOPIC: GENETICS**

<table>
<thead>
<tr>
<th>FAMILIAL DYSLIPIDEMIAS</th>
<th>POSTER BOARD IN PAVILION 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>GENE-ENVIRONMENT</td>
<td>P3.2.270 - P3.2.276</td>
</tr>
<tr>
<td>INTERACTIONS</td>
<td></td>
</tr>
<tr>
<td>GENOMICS, GWAS, AND</td>
<td>P3.3.277 - P3.3.288</td>
</tr>
<tr>
<td>POPULATION GENETICS</td>
<td></td>
</tr>
<tr>
<td>EPGENETICS AND MICRORNAS</td>
<td>P3.4.289 - P3.4.295</td>
</tr>
</tbody>
</table>

### MONDAY, MAY 07  h. 17.00-18.30

**TOPIC: CLINICAL MANIFESTATIONS**

<table>
<thead>
<tr>
<th>NON-ALCOHOLIC FATTY LIVER DISEASE</th>
<th>POSTER BOARD IN PAVILION 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHRONIC KIDNEY DISEASE</td>
<td>P4.2.302 - P4.2.310</td>
</tr>
<tr>
<td>DIABETES AND INSULIN RESISTANCE</td>
<td>P4.3.311 - P4.3.334</td>
</tr>
<tr>
<td>DIABETIC ANGIOPATHIES</td>
<td>P4.4.335 - P4.4.351</td>
</tr>
<tr>
<td>NUTRITION AND OBESITY</td>
<td>P4.5.352 - P4.5.363BIS</td>
</tr>
</tbody>
</table>
## INFORMATION FOR PRESENTERS

### POSTER OVERVIEW

**MONDAY, MAY 07  h. 17.00-18.30**

<table>
<thead>
<tr>
<th>TOPIC: EPIDEMIOLOGY, RISK MANAGEMENT, AND TREATMENT</th>
<th>POSTER BOARD IN PAVILION 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1 EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE AND RISK FACTORS</td>
<td>P5.1.364 - P5.1.410</td>
</tr>
<tr>
<td>5.2 GENDER AND CARDIOVASCULAR RISK</td>
<td>P5.2.411 - P5.2.416</td>
</tr>
<tr>
<td>5.3 EPIDEMIOLOGY OF DYSLIPIDEMIAS</td>
<td>P5.3.417 - P5.3.431</td>
</tr>
<tr>
<td>5.4 LIPID-LOWERING THERAPIES</td>
<td>P5.4.432 - P5.4.456</td>
</tr>
<tr>
<td>5.5 PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE</td>
<td>P5.5.458 - P5.5.499BIS</td>
</tr>
<tr>
<td>5.6 NOVEL RISK MARKERS</td>
<td>P5.6.500 - P5.6.531</td>
</tr>
</tbody>
</table>
**SATURDAY, MAY 05**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-08.30</td>
<td>Anitschkow Hall AUDITORIUM I</td>
<td>First Floor</td>
</tr>
<tr>
<td>08.30-08.45</td>
<td>Egaz Moniz Hall AUDITORIUM II</td>
<td>First Floor</td>
</tr>
<tr>
<td>08.45-09.00</td>
<td>Garcia de Orta Hall AUDITORIUM VI</td>
<td>Ground Floor</td>
</tr>
<tr>
<td>09.45-10.00</td>
<td>Carolina Beatriz Angelo Hall AUDITORIUM VII</td>
<td>Ground Floor</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td></td>
<td>SYSTEM MEDICINE FOCUSING ON METABOLIC SYNDROME “RESOLVE GROUP”</td>
</tr>
<tr>
<td>08.30-08.45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.45-09.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45-10.00</td>
<td></td>
<td>EAS JOINT SYMPOSIUM WITH MENARINI INTERNATIONAL FOUNDATION THE MULTIFACETED ASPECTS OF CV PREVENTION: FROM NUTRITION TO THERAPY</td>
</tr>
<tr>
<td>09.00-09.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.15-09.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30-09.45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-10.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15-10.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-10.45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.45-11.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00-11.20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.20-11.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30-11.45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.45-12.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.15-12.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.45-13.00</td>
<td></td>
<td>LUNCH BREAK</td>
</tr>
<tr>
<td>11.30-11.45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.45-12.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.15-12.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.45-13.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**KEY**

- **PLENARY SESSION**
- **WORKSHOP**
- **ORAL COMMUNICATIONS SESSION/OTHER**
- **EBAC ACCREDITED SESSION**
- **SCIENCE AT A GLANCE SESSION**
- **INDUSTRY SPONSORED SESSION**
- **SOCIAL EVENT**
- **BREAK LUNCH POSTER**
- **POSTER VIEWING SESSION**
<table>
<thead>
<tr>
<th>Time</th>
<th>Anitschkow Hall AUDITORIUM I</th>
<th>Egaz Moniz Hall AUDITORIUM II</th>
<th>Garcia de Orta Hall AUDITORIUM VI</th>
<th>Carolina Beatriz Angelo Hall AUDITORIUM VII</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First Floor</td>
<td>First Floor</td>
<td>Ground Floor</td>
<td>Ground Floor</td>
</tr>
<tr>
<td>13.00-13.15</td>
<td></td>
<td></td>
<td>EAS JOINT SYMPOSIUM WITH MENARINI INTERNATIONAL FOUNDATION</td>
<td>THE MULTIFACETED ASPECTS OF CV PREVENTION: FROM NUTRITION TO THERAPY</td>
</tr>
<tr>
<td>13.15-13.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30-13.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.45-14.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.15-14.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-14.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.45-15.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00-15.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.15-15.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00-16.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.20-16.30</td>
<td></td>
<td></td>
<td>SYSTEM MEDICINE FOCUSING ON METABOLIC SYNDROME “RESOLVE GROUP”</td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00-17.50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.50-18.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00-18.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.15-19.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.15-19.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.30-21.00</td>
<td></td>
<td></td>
<td></td>
<td>WELCOME RECEPTION</td>
</tr>
<tr>
<td>Time</td>
<td>Anitschkow Hall AUDITORIUM I</td>
<td>Egaz Moniz Hall AUDITORIUM II</td>
<td>Garcia de Orta Hall AUDITORIUM VI</td>
<td>Carolina Beatriz Angelo Hall AUDITORIUM VII</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td>First Floor</td>
<td>First Floor</td>
<td>Ground Floor</td>
<td>Ground Floor</td>
</tr>
<tr>
<td>08.30-08.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.45-09.00</td>
<td>PLENARY SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00-09.15</td>
<td>RISK FACTORS AND PREDICTORS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.15-09.30</td>
<td>FOR CARDIOVASCULAR DISEASE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30-09.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45-10.00</td>
<td>INDUSTRY SPONSORED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-10.15</td>
<td>BREAKFAST SYMPOSIUM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15-10.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-10.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.45-11.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00-11.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.15-11.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30-11.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.45-12.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.15</td>
<td>ADVANCED CLINICAL SEMINAR</td>
<td>WORKSHOP GENETICS,</td>
<td>WORKSHOP LIPOPROTEIN RECEPTORS</td>
<td>WORKSHOP IMMUNE CELL CROSSTALK</td>
</tr>
<tr>
<td>12.15-12.30</td>
<td>DEBATE: EVIDENCE BASED CVD</td>
<td>METABOLOMICS AND CARIOVASCULAR</td>
<td>AND REGULATION</td>
<td>IN ATHEROSCLEROSIS</td>
</tr>
<tr>
<td>12.30-12.45</td>
<td>PREVENTION IN DIABETES TODAY</td>
<td>RISK FACTORS, IAS/EAS JOINT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.45-13.00</td>
<td></td>
<td>SESSION</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SUNDAY, MAY 06**
<table>
<thead>
<tr>
<th>Time</th>
<th>Anitschkow Hall (AUDITORIUM I)</th>
<th>Egaz Moniz Hall (AUDITORIUM II)</th>
<th>Garcia de Orta Hall (AUDITORIUM VI)</th>
<th>Carolina Beatriz Angelo Hall (AUDITORIUM VII)</th>
<th>SCIENCE AT A GLANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00-13.15</td>
<td>First Floor</td>
<td>First Floor</td>
<td>Ground Floor</td>
<td>Ground Floor</td>
<td></td>
</tr>
<tr>
<td>13.15-13.30</td>
<td>Keynote Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.45-14.00</td>
<td>EBAC Accredited Session</td>
<td>From Nutrition to Personalized Nutrition in Dyslipidaemias</td>
<td>Exploring New Metabolic Pathways to Control Dyslipidaemias</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.15</td>
<td>Industry Sponsored Special Lecture</td>
<td></td>
<td>EBAC Accredited Session</td>
<td>SCIENCE AT A GLANCE</td>
<td>Session 1</td>
</tr>
<tr>
<td>14.15-14.30</td>
<td>SCIENCE AT A GLANCE</td>
<td>Session 1</td>
<td>SCIENCE AT A GLANCE</td>
<td>Session 2</td>
<td></td>
</tr>
<tr>
<td>14.30-14.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.45-15.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00-15.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.15-15.30</td>
<td>Coffee Break, Exhibition &amp; Poster Viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-15.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.45-16.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00-16.15</td>
<td>Workshop</td>
<td></td>
<td>Late Breaking Insight into Lipoprotein Function</td>
<td>Advanced Clinical Seminar</td>
<td></td>
</tr>
<tr>
<td>16.15-16.30</td>
<td>Novel Targets for Dyslipidemia and Cardiovascular Disease</td>
<td></td>
<td>Life After Acute Coronary Syndromes; Can We Prevent Further Events?</td>
<td>Role of Endothelial and SMC Cells in Atherogenesis</td>
<td></td>
</tr>
<tr>
<td>16.30-16.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.45-17.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00-18.30</td>
<td>Wine and Science - Poster Viewing Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SCIENTIFIC PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>First Floor</th>
<th>Second Floor</th>
<th>Ground Floor</th>
<th>Ground Floor/First Floor</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-08.30</td>
<td>INDUSTRY SPONSORED BREAKFAST SYMPOSIUM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30-08.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.45-09.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00-09.15</td>
<td>PLENARY SESSION PATHOGENESIS OF Atherosclerosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.15-09.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30-09.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45-10.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-10.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15-10.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-10.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.45-11.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00-11.15</td>
<td>COFFEE BREAK, EXHIBITION &amp; POSTER VIEWING</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.15-11.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30-11.45</td>
<td>ESC-EAS JOINT SESSION CAN WE REALLY PREVENT Atherosclerosis?</td>
<td>WORKSHOP ADVANCED RESEARCH SEMINAR: SYSTEM MEDICINE IN CARDIOMETABOLIC DISEASES</td>
<td>ORAL COMMUNICATION SESSION IMMUNITY AND Atherosclerosis</td>
<td>WORKSHOP NOVEL TECHNOLOGIES FOR CARDIOVASCULAR RESEARCH</td>
</tr>
<tr>
<td>11.45-12.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.15-12.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-12.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.45-13.00</td>
<td>BREAK, EXHIBITION &amp; POSTER VIEWING</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Anitschkow Hall</td>
<td>Egaz Moniz Hall</td>
<td>Garcia de Orta Hall</td>
<td>Carolina Beatriz Angelo Hall</td>
</tr>
<tr>
<td>----------</td>
<td>----------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>13.00-13.15</td>
<td>KEYNOTE LECTURE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.15-13.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30-13.45</td>
<td>EBAC ACCREDITED SESSION</td>
<td>THERAPEUTIC APPROACHES TO THE VERY HIGH RISK PATIENT: WHAT IS NEW?</td>
<td>INDUSTRY SPONSORED SPECIAL LECTURE</td>
<td></td>
</tr>
<tr>
<td>13.45-14.00</td>
<td>EBAC ACCREDITED SESSION</td>
<td>NEW TARGETS FOR CONTROLLING DYSLIPIDAEMIAS AND ATHEROSCLEROSIS</td>
<td>EBAC ACCREDITED SESSION</td>
<td>LOWERING ATHEROGENIC LIPOPROTEINS: THE CV BENEFIT</td>
</tr>
<tr>
<td>14.00-14.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.15-14.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-14.45</td>
<td>EBAC ACCREDITED SESSION</td>
<td>OMEGA 3 FATTY ACIDS: THEIR ROLE IN CV PREVENTION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.45-15.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00-15.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.15-15.30</td>
<td>COFFEE BREAK, EXHIBITION &amp; POSTER VIEWING</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-15.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.45-16.00</td>
<td>LATE BREAKING CLINICAL STUDIES</td>
<td>ADVANCED CLINICAL SEMINAR FROM IMAGING STUDIES: WHAT IS MEANT BY SIGNIFICANT ATHEROSCLEROSIS?</td>
<td>WORKSHOP CHOLESTEROL AND CELLULAR LIPOPROTEIN METABOLISM</td>
<td>WORKSHOP MACROPHAGES AND FOAM-CELLS IN THE VESSEL WALL</td>
</tr>
<tr>
<td>16.00-16.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.15-16.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-16.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.45-17.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00-17.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.15-17.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30-17.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.45-18.30</td>
<td>WINE and SCIENCE - POSTER VIEWING SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TUESDAY, MAY 08

<table>
<thead>
<tr>
<th>Time</th>
<th>Anitschkow Hall</th>
<th>Egaz Moniz Hall</th>
<th>Garcia de Orta Hall</th>
<th>Carolina Beatriz Angelo Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>AUDITORIUM I</strong></td>
<td><strong>AUDITORIUM II</strong></td>
<td><strong>AUDITORIUM VI</strong></td>
<td><strong>AUDITORIUM VII</strong></td>
</tr>
<tr>
<td></td>
<td><strong>First Floor</strong></td>
<td><strong>First Floor</strong></td>
<td><strong>Ground Floor</strong></td>
<td><strong>Ground Floor</strong></td>
</tr>
<tr>
<td>08.00-08.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30-08.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.45-09.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00-09.15</td>
<td>PLENARY SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.15-09.30</td>
<td>STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30-09.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45-10.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-10.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15-10.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-10.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.45-11.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00-11.15</td>
<td>COFFEE BREAK, EXHIBITION &amp; POSTER VIEWING</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.15-11.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30-11.45</td>
<td>ADVANCED CLINICAL SEMINAR</td>
<td>WORKSHOP HEALTHY FOOD AND LIFESTYLE TO PREVENT AND TREAT ATHEROMETABOLIC DISEASES</td>
<td>ORAL COMMUNICATION SESSION OBESITY AND ADIPOSE TISSUE BIOLOGY</td>
<td>WORKSHOP MOLECULAR-CELLULAR MECHANISMS THAT MEDIATE VASCULAR DISEASE</td>
</tr>
<tr>
<td>11.45-12.00</td>
<td>GUIDELINES IN REALITY QUESTIONS RAISED BY THE GUIDELINES (FOUR CASES)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.15-12.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-12.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EAS KEYNOTE LECTURE
EAS KEYNOTE LECTURE

PETER LIBBY
Cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH)
Mallinckrodt Professor of Medicine at Harvard Medical School (HMS)
Honorary doctorate University of Lille, France

Dr. Libby’s clinical and research interests include vascular biology, atherosclerosis and preventive cardiology. His research laboratory studies the messengers created by the body that may produce arterial plaque, as well as normal and abnormal function of smooth muscle and endothelial cells. Dr. Libby discovered that vascular wall cells can produce as well as respond to pro-inflammatory cytokines. This discovery suggested autocrine and paracrine cytokine inflammatory signaling in arterial disease, and laid the groundwork for a new field in atherosclerosis research in laboratories worldwide.

Dr. Libby has fostered the rapid translation to the clinic of the concepts of inflammation in arterial pathophysiology that emerged from his own laboratory work over the last twenty years. He has inspired, enabled, and participated in a number of the clinical studies that have placed inflammation at the forefront of current thinking about the diagnosis, risk stratification, and therapeutic approaches to atherosclerotic cardiovascular disease.

Dr. Libby has received numerous awards for his research accomplishments, including the Gold Medal of the European Society of Cardiology (2011), the Basic Research Prize of the American Heart Association (2011), the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society (2013), the Special Award of the Heart Failure Association of the European Society of Cardiology (2014), the Ernst Jung Gold Medal for Medicine (2016), and the Earl
Benditt Award from the North American Vascular Biology Organization (2017). He has received a number of lifetime achievement awards from various organizations. Dr. Libby is a Consulting Editor to Circulation Research (since 2015), and an editorial board member of Arteriosclerosis Thrombosis, and Vascular Biology.

Dr. Libby has published extensively in numerous high impact journals including Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine, and Nature. He is an Editor of Braunwald’s Heart Disease, having served as the Editor-in Chief of the 8th Edition, and has also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to many editions of Harrison’s Principles of Internal Medicine. Dr. Libby has held numerous visiting professorships and delivered more than 100 major named or keynote lectures throughout the world.
Marja-Riitta Taskinen is Emerita Professor of Medicine and her team is a member of the Research Program Unit, Diabetes & Obesity Research program at the University of Helsinki. Her research team at Biomedicum Helsinki focuses on lipoprotein kinetics in health and metabolic disorders including diabetes and dyslipidaemias, as well as the genetics of familial dyslipidaemias. The central themes of her research group have focused on the pathophysiology of lipid and lipoprotein metabolism in health and disease, in particular in Type 1 & 2 diabetes, genetics and treatment of dyslipidemias and prevention of CVD.

Professor Taskinen’s outstanding achievements have been recognized by several international associations. These include the Claude Bernard Award (European Association for Study of Diabetes [EASD] 2002), Edwin Bierman Award (American Diabetes Association 2004), Novartis Award (2006), the Pohjola and Suomi Mutual Medical Award by the Finnish Medical Foundation (2012), and the Jean Vague/Per Björntorp Award by the International Chair on Cardiometabolic Risk (May, 2017). In November this year, Professor Taskinen was awarded the prestigious Robert Levy Memorial lecture at the 2017 American Heart Association Scientific Sessions, Anaheim, California, USA.
Professor Taskinen has been extensively involved in the activities of the European Atherosclerosis Society (President of EAS 2006-2008), International Atherosclerosis Society, EASD and International Diabetes Federation. Professor Taskinen is a member of the European Society of Cardiology/EAS Guidelines Committee on Management of Dyslipidaemias and is also a member of EAS Consensus Panel. She has published extensively in high-impact journals (H-index 85).

Her research group is currently a partner in a EU-project RESOLVE (FP7-HEALTH-2012-INNOVATION-1), which started in 2013. Professor Taskinen is also a member of NIH (1R01HL113315-01) funded consortium “Genomic and Metabolomic Profiling of Finnish Familial Dyslipidemia Families” that started in 2012.
THE ANITSCHKOW PRIZE

THE ANITSCHKOW PRIZE RECIPIENT 2018 IS PROFESSOR ANNE TYBJÆRГ-HANSEN

Anne Tybjærg-Hansen
Copenhagen, Denmark

Anne Tybjærg-Hansen MD DMSc, is Chief Physician at the Department of Clinical Biochemistry, Section for Molecular Genetics, at Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Professor of Clinical Biochemistry with Focus on Translational Molecular Cardiology at the University of Copenhagen, Copenhagen, Denmark.

She graduated as a medical doctor from the University of Copenhagen in 1981 and the scientific education included 1 year at the University of Copenhagen and the Lipid Clinic at Rigshospitalet, 3 years at Hagedorn Research Laboratory, Gentofte, Denmark; and 3 years at British Heart Foundation’s Molecular Biology Research Group, London, UK.

Professor Tybjærg-Hansen is a member of the steering committees of the Copenhagen City Heart Study and the Copenhagen General Population Study and the past chairman of the European Lipoprotein Club.

Anitschkow Prize Winner

Professor Tybjærg-Hansen is a world-wide recognized leader in the field of atherosclerosis-related human genetics research and in the evaluation of risks to population health. Her creative and groundbreaking work has influenced, and continues to have significant impact on, Atherosclerosis Societies in Europe in their efforts to understand the mechanisms of atherosclerosis. She initiated the genetic part of the Copenhagen City Heart Study and finalized the collection and thorough analysis of data obtained in this exemplary study. She has envisioned and demonstrated that this biobank is of major importance for the identification of the genetic contribution to lipid metabolism, atherosclerosis, and cardiovascular disease. In fact, Professor Tybjærg-Hansen is a pioneer in using genetics to understand the importance of individual genes for the development of diseases in general. Her approach has been highly original, novel, and continues to be performed at an outstanding level.
The research
Professor Tybjaerg-Hansen has made major contributions to the understanding of the genetics of lipoproteins and their association with atherosclerotic cardiovascular disease. In her early work at the British Heart Foundation’s Molecular Biology Research Group, she was involved in the evolution of screening for mutations in patients with a clinical diagnosis of FH, as well as elucidation of the genetic basis of familial defective apolipoprotein B-100. Subsequent research by Professor Tybjaerg-Hansen was aided by the use of the Mendelian randomization approach to interrogate the causal nature of genetic variants with ischaemic heart disease risk. Major advances were made in determining causal associations between genetic variants influencing plasma levels of lipoprotein(a) and triglycerides (as a marker of remnant cholesterol) and risk of ischaemic heart disease, whereas other variants influencing C-reactive protein and high-density lipoprotein cholesterol levels, were shown not to be causal. Her research linking variants of APOC3, involved in the regulation of triglyceride-rich lipoproteins, with risk for ischaemic heart disease has been pivotal to the development of novel therapeutic approaches to the management of elevated triglycerides. Added to this, her research group has investigated links between genetic expression of cholesterol transporters and risk for ischaemic heart disease and gallstone disease, delineated elevated body mass index as a causal risk factors to gallstone disease, and showed an association between visible age-related signs (such as male baldness) and risk of ischaemic heart disease in the general population. Recent collaborative approaches have also investigated associations between lipoprotein variants and Alzheimer’s dementia, and identified new susceptibility loci for type 2 diabetes and shared aetiological pathways with coronary heart disease.
THE RECIPIENT OF THE AWARD FOR OUTSTANDING PUBLICATION IN CLINICAL RESEARCH IS CHRISTIAN MEDOM MADSEN

Christian Medom Madsen, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark – is awarded for the publications “Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies” and “U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies” published in European Heart Journal.

Christian Medom Madsen received his MD from the University of Copenhagen in 2013 following which he completed clinical rotations within different medical specialties. In 2016 he initiated his PhD at the Department of Clinical Biochemistry, Herlev and Gentofte Hospital and the University of Copenhagen under the supervision of Prof. Børge G. Nordestgaard and MD, PhD Anette Varbo. His research revolves around large-scale epidemiological studies and their use within the field of lipidology, with specific focus on novel thinking about HDL in human health and disease. He has written 8 scientific articles as first author and co-authored another 8 articles. He is currently supervising 2 younger scientists.
YOUNG INVESTIGATOR AWARDS

THE RECIPIENT OF THE AWARD FOR OUTSTANDING PUBLICATION IN BASIC RESEARCH IS JOSÉ JAVIER FUSTER

Dr. José Javier Fuster, Boston University School of Medicine, Boston, USA is awarded for the publication “Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice” published in Science.

Dr. José Javier Fuster is a basic researcher specialized in the investigation of age-related mechanisms of atherosclerotic cardiovascular disease and linked metabolic dysfunction. After completing his PhD at the University of Valencia and the Institute of Biomedicine of Valencia in Spain, Dr. Fuster undertook postdoctoral training at Boston University School of Medicine, where he investigated new mechanisms of systemic inflammation and metabolic dysfunction linked to visceral adiposity. In 2015, he was promoted to Instructor of Medicine, and started a new line of research aimed at evaluating the potential contribution to atherosclerosis of somatic mutations in the hematopoietic system. In 2017, he was promoted to Assistant Professor of Medicine, and he provided the first experimental evidence supporting the notion that some somatic mutations that lead to clonal hematopoiesis are causally connected to atherosclerosis development (Fuster et al, Science 2017). Dr. Fuster is currently a tenure-track Assistant Professor at the University of Virginia in Charlottesville, USA.
HALL NAME EULOGY OF DISTINGUISHED SCIENTISTS
In 1913, experimental pathologist Dr. Nikolai N. Anitschkow showed that simply feeding to rabbits purified cholesterol dissolved in sunflower oil induced vascular lesions closely resembling those of human atherosclerosis, both grossly and microscopically. Controls fed with only the sunflower oil showed no lesions. It is fair to say that this paper marked the beginning of the modern era of atherosclerosis research.

However, the landmark studies by Dr. Anitschkow were largely rejected at the time. An important reason for this was that the findings were inconsistent with the prevailing view of atherosclerosis. It was generally accepted to be an inevitable accompaniment of aging (the “senescence hypothesis”). If the full significance of his findings had been appreciated at the time, we might have saved more than 30 years in the long struggle to settle the cholesterol controversy.

In honour of Dr. Nikolai N. Anitschkow, the “Anitschkow Prize in Atherosclerosis Research” awarded annually by the EAS recognizes outstanding research in the field of atherosclerosis and linked metabolic disturbances.
Antonio Caetano de Abreu Freire Egas Moniz was born in Avanca, Portugal, on November 29, 1874.

Egas Moniz combined a successful career both as a clinician and a teacher, with a strong intervention in the political field. He joined the Faculty of Medicine at Coimbra University and received further education at Bordeaux and Paris and became Professor at Coimbra in 1902. In 1911 he transferred to the new Chair in Neurology at Lisbon where he remained until his death. He also worked for a period as a physician at the Hospital Santa Maria, Lisbon. Moniz entered politics in 1903 and served as a Deputy in the Portuguese Parliament until 1917 when he was nominated Portuguese Ambassador to Spain. Later in 1917 he was appointed Minister of Foreign Affairs and he was President of the Portuguese Delegation at the Paris Peace Conference in 1918.

But we should also remember Egas Moniz for the development of cerebral angiography and one of the founders of modern psychosurgery with the development of prefrontal leucotomy. Between 1926 and 1931 he injected radio-opaque dyes into arteries allowing the first images of the brain cerebral vessels in vivo. This was initially used for the recognition and localization of brain tumours but also for the for the descriptions of situations of the arterial cerebral flow interruption. He reported several clinical cases of these arterial occlusions and connected the clinical presentation with the velocity of the narrowing and occlusion of the vessel, a landmark of atherothrombotic disease.

Antonio Caetano de Abreu Freire Egas Moniz is mostly remembered as The Nobel Prize in Physiology or Medicine 1949 “for his discovery of the therapeutic value of leucotomy in certain psychoses”.

EGAS MONIZ (1874-1955) 
(AUDITORIUM II)
Garcia de Orta was born circa 1501, in Castelo de Vide, Portugal. His parents, were expelled from Spain in 1492 by the Catholic Kings. He took his Bachelor of Arts degree and received a degree in Medicine and Natural Philosophy in Salamanca and Alcaná de Henares. He then returned to Portugal to practice medicine with such a success that he became D. João III king’s doctor.

He taught at Lisbon University, but although all his success and reputation, his Jewish background did not go unnoticed by the Inquisition. As a safety measure, he was then appointed as the personal physician of Martim Afonso de Sousa, Viceroy of India. In Goa he became familiar with a wide variety of plants, and other natural products used to treat patients (like aloe, camphor, opium and many others) and he introduced them into western medicine. In 1563, “Colloquies of Simple and Drugs and Medicinal Things of India” was published. This is a remarkable work focusing on applications in Medicine of several plant species of India, thanks to Ortas's capacity of observation and registration of nature.

Garcia de Orta was a precursor in the globalization of medicine, gathering different knowledges in the purpose of treating patients in the best way we can.
Carolina Beatriz Ângelo was born in 1878 in Guarda, on the north of Portugal. In 1897, she began her degree at the Medical-Surgical School of Lisbon, graduating in 1902.

She became the first Portuguese female surgeon. But Beatriz Ângelo also has a place in history due to her social and political activism, standing up for women emancipation, the separation of the Church from the State and the proclamation of a republic state. In fact, the first red and green flags (still the national flag colours), a symbol of the successful revolution in 1910, were secretly made by Beatriz Ângelo and colleagues.

Already a widow in the 1911 elections, she asked the national election commission for a special permission to vote, a privilege reserved to men. She justified that she was by then, the head of the family. There was a gap in the Electoral Law of the Republican Regime because it was not stated that the right to vote was forbidden to women. She was the first woman to vote in Southern Europe.

Carolina represents the need and commitment on civic responsibility that doctors, scientists and ordinary citizens must pursue, in order to make societies more just and respectful of individual rights.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>DIET AND CVD THE EPIDEMIOLOGICAL VIEW</td>
<td>Salim Yusuf (USA)</td>
</tr>
<tr>
<td>09.00</td>
<td>WHY DOES THE DIET RICH IN UNSATURATED FAT PROTECT AGAINST CARdioVASCULAR DISEASE? DIFFERENCES BETWEEN NUTS AND EXTRA VIRGIN OLIVE OIL</td>
<td>Emilio Ros (Spain)</td>
</tr>
<tr>
<td>09.30</td>
<td>EFFECTS OF THE DIFFERENT DIETARY FATTY ACIDS ON HEALTH: FOCUS ON PUFA N-6. NEW EVIDENCES AND CONTROVERSIES</td>
<td>Andrea Poli (Italy)</td>
</tr>
<tr>
<td>10.00</td>
<td>MOLECULAR AND BIOCHEMICAL MECHANISMS INVOLVED IN THE PROTECTIVE EFFECT OF MEDITERRANEAN DIET AGAINST ATHEROSCLEROSIS</td>
<td>Alvaro Hernández (Spain)</td>
</tr>
<tr>
<td>10.30</td>
<td>DISCUSSION</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td>DIET AND HEALTH: WHAT IS THE ROLE OF MICROBIOTA?</td>
<td>Pablo Perez-Martinez (Spain)</td>
</tr>
<tr>
<td>12.30</td>
<td>LIFESTYLE AND GENETICS AN INTERACTION CONTRIBUTING TO CV RISK</td>
<td>Brian A. Ference (United Kingdom)</td>
</tr>
<tr>
<td>13.00</td>
<td>DISCUSSION</td>
<td></td>
</tr>
<tr>
<td>13.30</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
14.30 PREVENTION OF CVD GUIDELINES FROM DIETARY AND LIFESTYLE INTERVENTION TO THERAPY
Massimo Piepoli (Italy)

15.00 LIPID-MODIFYING EFFECTS OF NUTRACEUTICALS: AN EVIDENCE-BASED APPROACH
Matteo Pirro (Italy)

15.30 FINAL DISCUSSION

14.30-16.00
Garcia de Orta Hall
AUDITORIUM VI
INDUSTRY SPONSORED EDUCATIONAL SYMPOSIUM

Supported session not included in the CME/CPD programme.
For programme details please refer to the Industry Sponsored Sessions booklet.
16.20-17.50
Anitschkow Hall
AUDITORIUM I

EBAC ACCREDITED SESSION

The educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hours of External CME Credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters to this 90 minute programme, including content and presenters. We acknowledge financial support in the form of an educational grant, received from MSD in support of the programme.

PATIENT JOURNEY AFTER ACUTE CORONARY SYNDROMES: CAN WE IMPROVE OUTCOMES?

Chairs: Jan Borén (Sweden)
       Peter Toth (USA)

16.20  HOSPITAL MANAGEMENT AFTER ACUTE CORONARY SYNDROMES: IS THE RISK OVER?
       José Luis Zamorano (Spain)

16.45  OPTIMISING THERAPY THROUGH CARDIAC REHABILITATION
       Anselm Gitt (Germany)

17.10  SCIENCE VERSUS REALITY IN LONG TERM MANAGEMENT: TIME FOR A PARADIGM SHIFT?
       Lale Tokgözoğlu (Turkey)

17.35  DISCUSSION
18.00-19.30
Anitschkow Hall
AUDITORIUM I
OPENING CEREMONY, INCLUDING ANITSCHKOW LECTURE

WELCOME FROM EAS PRESIDENT
Lale Tokgözoğlu (Turkey)

WELCOME FROM NATIONAL DEPARTMENT & HEALTH REPRESENTATIVE

WELCOME FROM EAS 2018 CONGRESS CHAIR
Alberto Mello e Silva (Portugal)

WELCOME FROM IAS PRESIDENT
Yuji Matsuzawa (Japan)

YOUNG INVESTIGATOR AWARD

INTRODUCTION TO ANITSCHKOW PRIZE WINNER: Anne Tybjaerg-Hansen
Lale Tokgözoğlu (Turkey)

THE ANITSCHKOW LECTURE:
GENETICS OF CARDIOVASCULAR DISEASE: FROM UGLY DUCKLING TO BEAUTIFUL SWAN
Anne Tybjaerg-Hansen (Denmark)

MUSICAL ENTERTAINMENT
by Lisbon Fado Trio

CLOSING REMARKS AND INVITATION TO WELCOME RECEPTION
Alberto Mello e Silva (Portugal)
08.00-08.45
Garcia de Orta Hall
AUDITORIUM VI
INDUSTRY SPONSORED
BREAKFAST SYMPOSIUM
Supported session not included in the CME/CPD programme.
For programme details please refer to the Industry Sponsored Sessions booklet.

09.00-11.00
Anitschkow Hall
AUDITORIUM I
PLENARY SESSION
RISK FACTORS AND PREDICTORS FOR CARDIOVASCULAR DISEASE
Chairs: Alberto Mello e Silva (Portugal)
Lale Tokgözoğlu (Turkey)

09.00  IMAGING AND CVD RISK ESTIMATION
(POPULATION STUDIES)
Valentin Fuster (USA)

09.30  LESSONS FROM EPIDEMIOLOGY AND
ENVIRONMENTAL CVD RISK FACTORS
Salim Yusuf (Canada)

10.00  STRESS, BEHAVIOR AND
CARDIOVASCULAR DISEASE
Viola Vaccarino (USA)

10.30  IS THERE NEED TO REVISE GOALS FROM LIPID LOWERING?
Ulf Landmesser (Germany)
SCIENTIFIC PROGRAMME

SUNDAY, MAY 06

11.30-12.45
Anitschkow Hall
AUDITORIUM I
ADVANCED CLINICAL SEMINAR
DEBATE: EVIDENCE BASED CVD PREVENTION IN DIABETES TODAY
Chairs: Kausik Ray (United Kingdom)
       Marja-Riitta Taskinen (Finland)

11.30 SHOULD THE MAIN TARGET BE HYPERGLYCAEMIA OR SHOULD WE FOCUS ON OTHER RISK-FACTORS?
       Naveed A. Sattar (United Kingdom),
       Lars Rydén (Sweden)

11.30-12.45
Egas Moniz Hall
AUDITORIUM II
WORKSHOP
GENETICS, METABOLOMICS AND CARIOVASCULAR RISK FACTORS.
IAS/EAS JOINT SESSION
Chairs: Yuji Matsuzawa (Japan)
       Lale Tokgözoğlu (Turkey)

11.30 HIGH-RESOLUTION LIPOPROTEIN PHENOTYPES AND CARDIOVASCULAR OUTCOMES
       Samia Mora (USA)

11.50 MINING THE BLOOD FOR NEW CARDIOMETABOLIC MARKERS
       Robert Gerszten (USA)

12.10 GENES CAN PROTECT YOU FROM CVD- BEYOND CLASSICAL RISK FACTORS
       Heribert Schunkert (Germany)

12.30 GENES CAN HURT YOU TO DEVELOP CVD BEYOND CLASSICAL RISK FACTORS
       Stefano Romeo (Sweden)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>DISTANT CONTROL OF PLAQUE FORMATION</td>
</tr>
<tr>
<td>11.50</td>
<td>FUNCTIONAL IMMUNE CELL INTERACTIONS AND PLAQUE DEVELOPMENT</td>
</tr>
<tr>
<td>12.10</td>
<td>CHOLESTEROL EFFLUX PATHWAYS SUPPRESS INFLAMMASOME</td>
</tr>
<tr>
<td></td>
<td>GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST LIRAGLUTIDE IMPACTS IMMUNE CELL</td>
</tr>
<tr>
<td></td>
<td>PHENOTYPES IN APOLIPOPROTEIN E DEFICIENT MICE DURING PROGRESSION AND</td>
</tr>
<tr>
<td></td>
<td>REGRESSION OF PRE-ESTABLISHED ATHEROSCLEROSIS</td>
</tr>
<tr>
<td></td>
<td>R. Bruen, S Curley, S Kajani, M O’reilly, A Hogan, D O’shea, F Mcgillicuddy,</td>
</tr>
<tr>
<td></td>
<td>O Belton (Ireland)</td>
</tr>
<tr>
<td>12.30</td>
<td>SAA ACTIVATES THE NLRP3 INFLAMMASOME</td>
</tr>
<tr>
<td></td>
<td>F. De Beer, M. De Beer, P. Shridas, N. Webb (USA)</td>
</tr>
</tbody>
</table>
SUNDAY, MAY 06

11.30-12.45
Garcia de Orta Hall
AUDITORIUM VI
WORKSHOP
LIPOPROTEIN RECEPTORS AND REGULATION
Chairs: Geesje M. Dallinga-Thie (The Netherlands)
Giuseppe Danilo Norata (Italy)

11.30 LIPOPROTEIN METABOLISM IN THE BRAIN
Joachim Herz (USA)

11.50 PCSK9/LDLR AXIS IN PANCREATIC FUNCTION
Giuseppe Danilo Norata (Italy)

12.10 PCSK9 DEFICIENCY RESULTS IN ALTERED GLUCOSE CONTROL AND INCREASED ECTOPIC FAT ACCUMULATION IN EXPERIMENTAL MODELS AND IN HUMANS

12.20 THE ROLE OF HEPARAN SULFATE PROTEOGLYCANS IN PCSK9-INDUCED LDL RECEPTOR DEGRADATION
C. Gustafsen, J. Vilstrup, P. Madsen, S. Glerup (Denmark)

12.30 PERSISTENT MONOCYTE ACTIVATION IN PATIENTS WITH ELEVATED LDL CHOLESTEROL LEVELS DURING STATIN TREATMENT
SCIENTIFIC PROGRAMME
SUNDAY, MAY 06

13.00-13.30
Anitschkow Hall
AUDITORIUM I
KEYNOTE LECTURE
Chairs: Christoph J. Binder (Austria)
Petri Kovanen (Finland)

13.00 ANTI-INFLAMMATORY THERAPY AND
RESOLUTION OF INFLAMMATION,
THEORY AND PRACTICE
Peter Libby (USA, France)

13.30-15.00
Anitschkow Hall
AUDITORIUM I
INDUSTRY SPONSORED
EDUCATIONAL SYMPOSIUM
Supported session not included
in the CME/CPD programme.
For programme details please refer to the
Industry Sponsored Sessions booklet.

13.30-15.00
Egas Moniz Hall
AUDITORIUM II
EBAC ACCREDITED SESSION
The educational programme is accredited
by the European Board for Accreditation In
Cardiology (EBAC) for 1 hours of External CME
Credits. Each participant should claim only
those hours of credit that have actually been
spent in the educational activity.
EBAC works according to the quality standards of
the European Accreditation Council for Continuing
Medical Education (EACCME), which is an institution
of the European Union of Medical Specialists (UEMS).
EAS have independently organised all matters to
this 90 minute programme, including content and
presenters. We acknowledge financial support in the
form of an educational grant, received from BASF,
RAISIO and UNILEVER in support of the programme.

FROM NUTRITION TO PERSONALIZED
NUTRITION IN DYSLIPIDAEMIAS
Chairs: Philippe Moulin (France)
Michal Vrablík (Czech Republic)

13.30 FOOD4ME: THE EXPERIENCE
Michael Gibney (Ireland)

13.55 DIETARY FAT VS CARBOHYDRATES
Gabriele Riccardi (Italy)

14.20 REDUCING CHOLESTEROL BY DIETARY MEANS
Eric Bruckert (France)

14.45 DISCUSSION
67

SCIENTIFIC PROGRAMME

SUNDAY, MAY 06

13.30-14.15
Garcia de Orta Hall
AUDITORIUM VI
INDUSTRY SPONSORED
SPECIAL LECTURE

Supported session not included in the CME/CPD programme.
For programme details please refer to the Industry Sponsored Sessions booklet.

13.30-14.30
Carolina Beatriz Ângelo Hall
AUDITORIUM VII
EBAC ACCREDITED SESSION

The educational programme is accredited by the European Board for Accreditation In Cardiology (EBAC) for 1 hours of External CME Credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters to this 60 minute programme, including content and presenters. We acknowledge financial support in the form of an educational grant, received from ESPERION in support of the programme.

EXPLORING NEW METABOLIC PATHWAYS TO CONTROL DYSLIPIDAEMIAS

Chairs: Christoph Binder (Austria)
Kausik Ray (United Kingdom)

13.30 VALIDATING PHARMACOLOGICAL TARGETS BY GENETICS:
THE CASE OF ATP CITRATE LYASE
Brian A. Ference (United Kingdom)

13.50 BEMPEDOIC ACID: THE CLINICAL EXPERIENCE
Maciej Banach (Poland)

14.10 DISCUSSION
SCIENTIFIC PROGRAMME
SUNDAY, MAY 06

14.30-15.30
Carolina Beatriz Ângelo Hall
AUDITORIUM VII

EBAC ACCREDITED SESSION
The educational programme is accredited by the European Board for Accreditation In Cardiology (EBAC) for 1 hours of External CME Credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters to this 60 minute programme, including content and presenters. We acknowledge financial support in the form of an educational grant, received from SANOFI in support of the programme.

OPTIMIZING DYSLIPIDEMIA MANAGEMENT: THE VALUE OF COMBINATION THERAPY
Chairs: Alberto Mello e Silva (Portugal)
Olov Wiklund (Sweden)

14.30 THE CV BENEFIT OF COMBINATION THERAPY
Christopher Cannon (USA)

14.50 INCREMENTAL VALUE OF ESTABLISHED THERAPIES FOR DYSLIPIDAEMIC PATIENTS
Luis Masana (Spain)

15.10 DISCUSSION

15.45-17.00
Anitschkow Hall
AUDITORIUM I

WORKSHOP
NOVEL TARGETS FOR DYSLIPIDEMIA AND CARDIOVASCULAR DISEASE
Chairs: Ulrich Laufs (Germany)
Sotirios Tsimikas (USA)

15.45 NANOMEDICINE AS NOVEL Atherosclerosis Therapy
Willem J.M. Mulder (The Netherlands - USA)

16.05 ARE WE READY TO TEST THE LP(A) HYPOTHESIS?
Sotirios Tsimikas (USA)

16.25 IDENTIFICATION OF THE KEY MOLECULAR EVENTS TRIGGERED BY LIPOPROTEIN (A) IN PERIPHERAL MONOCYTES
M. Bahjat, I. Nicorescu, R. Hoogeveen, S. Bekkering, J. Kroon, E. Stroes (The Netherlands)

16.35 DEVELOPMENT OF ANTISENSE DRUG TARGETING PCSK9
M. Harada-Shiba, F. Wada, K. Tachibana, T. Yamamoto, T. Kobayashi (Japan)
16.00 DIFFERENTIATION AND ANTAGONISTIC REGULATION OF TRANSENDOHELIAL TRANSPORT OF HDL AND LDL BY SPHINGOSINE-1-PHOSPHATE RECEPTORS 1 AND 3
V. Velagapudi, F. Poti, R. Feuerborn, M. Yalcinkaya, L. Rohrer, J. Nofer, A. von Eckardstein (Switzerland, Italy, Germany)

16.15 THE APOLIPOPROTEIN M/SIP AXIS CONTROLS TRIGLYCERIDE METABOLISM AND BROWN FAT ACTIVITY

16.30 A DEEP INTRONIC VARIANT IN LDLR CAUSING FAMILIAL HYPERCHOLESTEROLEMIA: TIME TO WIDEN THE SCOPE?

15.45-17.00
Egas Moniz Hall
AUDITORIUM II
LATE BREAKING INSIGHT INTO LIPOPROTEIN FUNCTION
Chairs: Philippe Moulin (France) Erik Stroes (The Netherlands)

15.45 EICOSAPENTAENOIC ACID INHIBITED OXIDIZED HDL-INDUCED LOSS OF ENDOTHELIAL NITRIC OXIDE RELEASE AS COMPARED TO FENOFIBRATE OR NIACIN IN VITRO
R. Preston Mason, Samuel C.R. Sherratt, Tadeusz Malinski (USA)
SUNDAY, MAY 06

15.45-17.00
Garcia de Orta Hall
AUDITORIUM VI
ADVANCED CLINICAL SEMINAR
LIFE AFTER ACUTE CORONARY SYNDROMES; CAN WE PREVENT FURTHER EVENTS?
Chairs: Fausto J. Pinto (Portugal)
Alexandros Tselepis (Greece)

15.45 IS IT POSSIBLE TO PREVENT RECURRENT EVENTS?
Ulf Landmesser (Germany)

16.10 LDL AFTER ACS: HOW LOW TO GO?
HOW TO GO THERE?
Jose L. Zamorano (Spain)

16.35 REALITY CHECK: GUIDELINES VERSUS REAL LIFE AFTER ACS
Fausto J. Pinto (Portugal)

16.45 LPA VARIANTS, RISK OF CORONARY DISEASE, AND ESTIMATED CLINICAL BENEFIT OF LIPOPROTEIN(A) LOWERING THERAPIES: A MENDELIAN RANDOMIZATION ANALYSIS
**SUNDAY, MAY 06**

**15.45-17.00**

**Carolina Beatriz Ângelo Hall**

**AUDITORIUM VII**

**WORKSHOP**

**ROLE OF ENDOTHELIAL AND SMC CELLS IN ATHEROGENESIS**

**Chairs:** Erik A.L. Biessen (The Netherlands)  
Michael Potente (Germany)

**15.45**  
**TRANSCRIPTIONAL CONTROL OF ENDOTHELIAL ENERGY**

Michael Potente (Germany)

**16.05**  
**VASCULAR SMOOTH MUSCLE CELLS IN ATHEROSCLEROSIS**

Gary K. Owens (USA)

**16.25**  
**CHR9P21 RISK VARIANTS AFFECT VSMC RESPONSES TO IL-1/TLR STIMULATION**

G. Basatemur, M. Ackers-Johnson, J. Schoonejans, A. Kazachenka, B. Lam, M. Ma, M. Brimpari, M. Patel, N. Saleh, D. Murphy, T. Zhao, G. Yeo, A. Ferguson-Smith, L. Vallier, S. Sinha, Z. Mallat (United Kingdom, France)

**16.35**  
**IKB KINASE 2 IN ATHEROSCLEROSIS**

M. Mussbacher, M. Salzmann, H.K. Volek, M. Kuttke, J. Basilio, B. Hösel, A. Assinger, D. Ketelhuth, J.A. Schmid (Austria)

**16.45**  
**WISP-1/CCN4 PROTECTS AGAINST ATHEROSCLEROSIS IN ATEROPRONE MICE**

H. Williams, J. Johnson, S. George (United Kingdom)
### SCIENTIFIC PROGRAMME

**MONDAY, MAY 07**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-08.45</td>
<td>Garcia de Orta H</td>
<td><strong>INDUSTRY SPONSORED BREAKFAST SYMPOSIUM</strong>&lt;br&gt;Supported session not included in the CME/CPD programme. For programme details please refer to the Industry Sponsored Sessions booklet.</td>
</tr>
<tr>
<td>09.00-11.00</td>
<td>Anitschkow H</td>
<td><strong>PLENARY SESSION</strong>&lt;br&gt;<strong>PATHOGENESIS OF ATHEROSCLEROSIS</strong>&lt;br&gt;Chairs: Jan Borén (Sweden) Arnold von Eckardstein (Switzerland)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>09.00 NEOATHEROSCLEROSIS FROM A PATHOLOGIST’S POINT OF VIEW</strong>&lt;br&gt;Finn Virmani Renu (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>09.30 DEFECTIVE INFLAMMATION RESOLUTION IN ATHEROSCLEROSIS: MECHANISMS AND THERAPEUTIC OPPORTUNITIES</strong>&lt;br&gt;Ira Tabas (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>10.00 SHIFTING CONCEPTS IN THE DESCRIPTION OF THE “VULNERABLE PLAQUE”</strong>&lt;br&gt;Gerard Pasterkamp (The Netherlands)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>10.30 RNA EDITING CONTROLS ATHEROSCLEROSIS</strong>&lt;br&gt;Stefanie Dimmeler (Germany)</td>
</tr>
</tbody>
</table>
MONDAY, MAY 07

11.30-12.45
Egas Moniz Hall
AUDITORIUM II

WORKSHOP
ADVANCED RESEARCH SEMINAR: SYSTEM MEDICINE IN CARDIOMETABOLIC DISEASES

Chairs: Ruth Frikke-Schmidt (Denmark) Manuel Mayr (United Kingdom)

11.30
WILL AGRESSIVELY LOWERING OF LDL PREVENT ATHEROSCLEROSIS?
Alberico L. Catapano (Italy)

11.50
EARLY THERAPY VERSUS LATE INTERVENTION: WHAT WORKS?
Diedrick Grobbee (The Netherlands)

12.10
WILL INHIBITING OF THROMBUS FORMATION PREVENT ACUTE CORONARY SYNDROMES?
Stephan Gielen (Germany)

12.30
REALITY CHECK: CAN WE GET TO GOALS IN GUIDELINES?
Ulrich Laufs (Germany)

11.30-12.45
Anitschkow Hall
AUDITORIUM I

ESC-EAS JOINT SESSION
CAN WE REALLY PREVENT ATHEROSCLEROSIS?

Chairs: Jeroen J. Bax (The Netherlands) Lale Tokgözoğlu (Turkey)

11.30
WILL AGRESSIVELY LOWERING OF LDL PREVENT ATHEROSCLEROSIS?
Alberico L. Catapano (Italy)

11.50
EARLY THERAPY VERSUS LATE INTERVENTION: WHAT WORKS?
Diedrick Grobbee (The Netherlands)

12.10
WILL INHIBITING OF THROMBUS FORMATION PREVENT ACUTE CORONARY SYNDROMES?
Stephan Gielen (Germany)

12.30
REALITY CHECK: CAN WE GET TO GOALS IN GUIDELINES?
Ulrich Laufs (Germany)
11.30-12.45
Garcia de Orta Hall
AUDITORIUM VI
ORAL COMMUNICATION SESSION
IMMUNITY AND ATHEROSCLEROSIS

Chair: Christoph J. Binder (Austria)
Giuseppina Caligiuri (France)

11.30 TRAINED IMMUNITY BY OXIDIZED LOW-DENSITY LIPOPROTEIN IS DEFINED BY REPROGRAMMING OF GLYCOLYTIC METABOLISM IN HUMAN MONOCYTES

11.40 FCγ RECEPTOR IIB CONTROLS HUMORAL RESPONSES TO ATHEROSCLEROSIS
A. Sage, J. Bagchi-Chakraborty, D. Tsiantoulas, J. Harrison, M.R. Clatworthy, L. Masters, K.G.C. Smith, C.J. Binder, Z. Mallat (United Kingdom)

11.50 VACCINATION WITH PREVENAR® BOOSTS THE PRODUCTION OF ANTI-PHOSPHORYLCHOLINE ANTIBODIES AND PROTECTS APOE KNOCKOUT MICE FROM ATHEROSCLEROSIS

12.00 INDOLEAMINE 2,3-DIOXYGENASE AGGRAVATES CARDIAC FUNCTION AND LEFT VENTRICULAR REMODELING AFTER ACUTE MYOCARDIAL INFARCTION

12.10 MACROPHAGE TARGETING OF MT1-MMP ATTENUATES CARDIAC DYSFUNCTION AFTER MYOCARDIAL INFARCTION BY PROMOTING ARTERIOGENESIS

12.20 THE S100A8/A9 ALARMIN STIMULATES MYELOID CELL RESPONSE AND PROMOTES CARDIAC REPAIR AFTER MYOCARDIAL INFARCTION
11.30-12.45
Carolina Beatriz Ângelo Hall
AUDITORIUM VII
WORKSHOP
NOVEL TECHNOLOGIES FOR CARDIOVASCULAR RESEARCH
Chairs: Lina Badimon (Spain)
        Seppo Y. Ylä-Herttuala (Finland)

11.30   CARDIOVASCULAR GENE THERAPY
        Seppo Y. Ylä-Herttuala (Finland)

11.50   POTENTIAL AND CAVEATS OF LIPIDOMICS FOR CARDIOVASCULAR DISEASE
        Edward A. Dennis (USA)

12.10   AQUEOUS TERMINALIA ARJUNA EXTRACT INDUCED DIFFERENTIAL PROTEIN EXPRESSION IN HYPERCHOLESTEROLEMIC RABBITS: A PROTEOMIC BASED STUDY
        R. Rather, V. Dhawan (Ethiopia)

12.20   MASSCYTOMETRY IDENTIFIES CD8 T-CELL DIVERSITY IN HUMAN ATHEROSCLEROTIC LESIONS
        B. Slütter, M. Depuydt, J. van Duijn, I. Bot, A. Wezel, H. Koppejan, R. Toes, J. Kuiper (The Netherlands)

12.30   HIGH LDL CHOLESTEROL LEVELS AND RISK OF PERIPHERAL VASCULAR DISEASES - A MENDELIAN RANDOMIZATION STUDY INCLUDING 106, 548 INDIVIDUALS FROM THE GENERAL POPULATION
        F. Emanuelsson, B.G. Nordestgaard, A. Tybjærg-Hansen, M. Benn (Denmark)

13.00-13.30
Anitschkow Hall
AUDITORIUM I
KEYNOTE LECTURE
Chairs: John Chapman (France)
        Henry Ginsberg (USA)

13.00   DISTURBANCES IN HEPATIC AND LIPOPROTEIN METABOLISM IS THE HALLMARK OF ATHEROGENIC DYSLIPEMIA
        Marja-Riitta Taskinen (Finland)
SCIENTIFIC PROGRAMME
MONDAY, MAY 07

13.30-15.00
Anitschkow Hall
AUDITORIUM I

EBAC ACCREDITED SESSION

The educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of External CME Credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters to this 90 minute programme, including content and presenters. We acknowledge financial support in the form of an educational grant, received from SANOFI and REGENERON in support of the programme.

THERAPEUTIC APPROACHES TO THE VERY HIGH RISK PATIENT: WHAT IS NEW?

Chairs: Jennifer Robinson (USA)  
Lale Tokgözoğlu (Turkey)

13.30 LIPIDS, INFLAMMATION AND CV RISK  
Erik Stroes (The Netherlands)

13.35 PCSK9 INHIBITION IN HIGH RISK PATIENTS  
Gabriel P. Steg (France)

14.20 THE IDEAL PATIENT FOR PCSK9  
J. Wouter Jukema (The Netherlands)

14.45 DISCUSSION

13.30-14.15
Egas Moniz Hall
AUDITORIUM II

INDUSTRY SPONSORED SPECIAL LECTURE

Supported session not included in the CME/CPD programme.  
For programme details please refer to the Industry Sponsored Sessions booklet
13.30-14.30
Garcia de Orta Hall
AUDITORIUM VI

EBAC ACCREDITED SESSION

The educational programme is accredited by the European Board for Accreditation In Cardiology (EBAC) for 1 hours of External CME Credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters to this 60 minute programme, including content and presenters. We acknowledge financial support in the form of an educational grant, received from AKCEA in support of the programme.

NEW TARGETS FOR CONTROLLING DYSLIPIDAEMIAS AND ATHEROSCLEROSIS

Chairs: Ruth Frikke-Schmidt (Denmark)
Paulo Parini (Sweden)

13.30 SILENCING GENES, NEW TARGETS
Sotirios Tsimikas (USA)

13.50 APOLIPOPROTEIN CIII SILENCING: THE BENEFIT IN FCS
Marcello Arca (Italy)

14.10 DISCUSSION

13.30-15.00
Carolina Beatriz Ângelo Hall
AUDITORIUM VII

EBAC ACCREDITED SESSION

The educational programme is accredited by the European Board for Accreditation In Cardiology (EBAC) for 1 hours of External CME Credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters to this 90 minute programme, including content and presenters. We acknowledge financial support in the form of an educational grant, received from MYLAN in support of the programme.

LOWERING ATHEROGENETIC LIPOPROTEINS: THE CV BENEFIT

Chairs: Marja-Riitta Taskinen (Finland)
Arnold von Eckardstein (Switzerland)

13.30 APO B CONTAINING LIPOPROTEINS A BETTER TARGET FOR CV RISK REDUCTION?
Speaker to be confirmed

13.55 HOW TO CONTROL ATHEROGENIC DYSLIPIDAEMIA
Henry Ginsberg (USA)

14.20 COMBINATION THERAPY: WHEN AND HOW
Michel Farnier (France)

14.45 DISCUSSION
MONDAY, MAY 07

14.30-15.30
Garcia de Orta Hall
AUDITORIUM VI

EBAC ACCREDITED SESSION

The educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hours of External CME Credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters to this 60 minute programme, including content and presenters. We acknowledge a partial financial support in the form of an educational grant, received from AMARIN in support of the programme.

OMEGA 3 FATTY ACIDS: THEIR ROLE IN CV PREVENTION

Chairs: Giuseppe Danilo Norata (Italy)
Alexandros Tselepis (Greece)

14.30 OMEGA 3 FATTY ACIDS & HEPATIC LIPID METABOLISM
Eleonora Scorletti (United Kingdom)

14.55 CLINICAL TRIALS IN EVALUATING OMEGA 3 FATTY ACIDS IN CV DISEASE
Aldo Pietro Maggioni (Italy)

15.10 DISCUSSION

15.45-17.00
Anitschkow Hall
AUDITORIUM I

LATE BREAKING - CLINICAL STUDIES

Chairs: Eran Leitersdorf (Israel)
Francois Mach (Switzerland)

15.45 NEW DATA ON THE CANTOS TRIAL
Speaker to be confirmed

16.05 LIPID MANAGEMENT OF PATIENTS WITH CORONARY HEART DISEASE IN 27 COUNTRIES IN EUROPE: RESULTS OF EUROASPIRE V SURVEY OF THE EUROPEAN SOCIETY OF CARDIOLOGY

16.23 EFFECT OF AN RNAI THERAPEUTIC TARGETING PCSK9 ON ATHEROGENIC LIPOPROTEINS: PRE-SPECIFIED SECONDARY ENDPOINTS IN ORION 1
16.41 LIPOPROTEIN(A), PCSK9 INHIBITION AND CARDIOVASCULAR RISK: INSIGHTS FROM THE FOURIER TRIAL
M. O’Donoghue, R. Giugliano, A. Keech, E. Kanevsky, K. Im, A. Lira Pineda, R. Somaratne, P. Sever, T. Pederson, M. Sabatine (USA, Australia, UK, Norway)

15.45-17.00
Garcia de Orta Hall
AUDITORIUM VI
WORKSHOP
CHOLESTEROL AND CELLULAR LIPID METABOLISM
Chairs: Abert K. Groen (The Netherlands) Bart Staels (France)

15.45 THE ROLE OF BILE ACIDS IN CHOLESTEROL HOMEOSTASIS
Albert K. Groen (The Netherlands)

16.05 LIPID SIGNALING PATHWAYS IN PHYSIOLOGY AND DISEASE
Peter Tontonoz (USA)

16.25 GENETIC REGULATION OF HDL CHOLESTEROL LEVELS DURING SEPSIS
L. Brunham, M. Trinder, J. Boyd (Canada)

16.35 FXR ACTIVATION NORMALIZES DYSLIPIDEMIA AND ALLEVIATES OBESITY IN WESTERN-TYPE DIET-FED APOE*3-LEIDEN.CETP TRANSGENIC MICE

15.45-17.00
Egas Moniz Hall
AUDITORIUM II
ADVANCED CLINICAL SEMINAR
FROM IMAGING STUDIES: WHAT IS MEANT BY SIGNIFICANT ATHEROSCLEROSIS?
Chairs: Zeljko Reiner (Croatia)

15.45 HIGH RISK MARKERS ON CARDIAC CT
Jeroen J. Bax (The Netherlands)

16.20 MULTIMODUALITY IMAGING IS THE WAY TO GO
Lale Tokgozoğlu (Turkey)
15.45-17.00
Carolina Beatriz Ângelo Hall
AUDITORIUM VII
WORKSHOP
MACROPHAGES AND FOAM-CELLS IN THE VESSEL WALL
Chairs: Mark Febbraio (Australia)
Katariina Öörni (Finland)

15.45
SENECENT INTIMAL FOAM CELLS ARE DELETERIOUS AT ALL STAGES OF ATHEROSCLEROSIS
Jan M. van Deursen (USA)

16.05
ROLE OF TLR4 IN LIPID INDUCED MACROPHAGE INFLAMMATION
Mark Febbraio (Australia)

16.25
ROLES OF PAD4 AND NETOSIS IN EXPERIMENTAL ATHEROSCLEROSIS AND ARTERIAL INJURY: IMPLICATIONS FOR SUPERFICIAL EROSION

16.45
NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE CROSSROAD BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM
16.35 MELANOCORTIN 1 RECEPTOR DEFICIENCY PROMOTES ATHEROSCLEROSIS IN APOLIPOPROTEIN E-/- MICE
P. Rinne, J. Kadiri, M. Velasco-Delgado, S. Nuutinen, M. Rami, E. Savontaus, S. Steffens (Finland)

17.00-17.45 Carolina Beatriz Ângelo Hall
AUDITORIUM VII
EAS MEMBERS’ ASSEMBLY
SCIENTIFIC PROGRAMME
TUESDAY, MAY 08

09.00-11.00
Anitschkow Hall
AUDITORIUM I
PLENARY SESSION
STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS
Chairs: Alberico L. Catapano (Italy)
Chris Packard (United Kingdom)

09.00 ATEROTHROMBOSIS: FROM PATHOGENESIS TO TREATMENT
Steffen Massberg (Germany)

09.30 LESSONS FROM GENETICS: RISK-SCORE AND NOVEL CANDIDATES
Brian A. Ference (United Kingdom)

10.00 NOVEL THERAPEUTIC APPROACHES USING ANTISENSE INHIBITION (TBD)
Joseph L. Witztum (USA)

10.30 STRATEGIES TO TREAT VULNERABLE PLAQUES
David Erlinge (Sweden)

11.30-12.45
Anitschkow Hall
AUDITORIUM I
ADVANCED CLINICAL SEMINAR
GUIDELINES IN REALITY - QUESTIONS RAISED BY THE GUIDELINES (FOUR CASES)
Chairs: Maciej Banach (Poland)
Olov Wiklund (Sweden)

11.30 FAMILIAL HYPERCHOLESTEROLEMIA
Kausik Ray (United Kingdom)

11.50 FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)
Maurizio Averna (Italy)

12.10 PRIMARY PREVENTION OF CVD
Guy De Backer (Belgium)

12.30 VERY HIGH RISK PATIENT - SECONDARY TREATMENT
Eric Stroes (The Netherlands)
11.30-12.45
**Egas Moniz Hall**
**AUDITORIUM II**
**WORKSHOP**
HEALTHY FOOD AND LIFESTYLE TO PREVENT AND TREAT - ATHEROMETABOLIC DISEASES

**Chairs:** Erkin Mirrakhimov (Kyrgyzstan) Emilio Ros (Spain)

11.30  **LESSONS FROM THE “PREVENTION WITH MEDITERRANEAN DIET” (PREDIMED) STUDY**
E. Ros (Spain)

11.50  **HOW TO COMBAT CVD AT A POPULATION LEVEL?**
Nick J. Wareham (United Kingdom)

12.10  **MULTI-ANCESTRY GENOME-WIDE ASSOCIATION ANALYSIS INCORPORATING SNP-SLEEP DURATION INTERACTIONS IN 63,885 INDIVIDUALS IDENTIFIES POTENTIAL NOVEL LOCI FOR SERUM LIPID LEVELS**

12.20  **BODY WEIGHT VARIABILITY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES**
D. Waters, R. Fayyad, H. Colhoun, D. Demicco, S. Bangalore (USA)

12.30  **EPA AND DHA IN ADIPOSE TISSUE AND THE RISK OF ISCHEMIC STROKE - A DANISH CASE-COHORT STUDY**
S.K. Venø, C. Bork, M.U. Jakobsen, S. Lundbye-Christensen, F.W. Bach, K. Overvad, E.B. Schmidt (Denmark)
SCIENTIFIC PROGRAMME
TUESDAY, MAY 08

11.30-12.45
Garcia De Orta Hall
AUDITORIUM VI

ORAL COMMUNICATION SESSION
OBESITY AND ADIPOSE TISSUE BIOLOGY

Chair: Ewa Ehrenborg (Sweden)

11.30 EPIGENETIC REGULATION OF WHITE ADIPOSE TISSUE PHYSIOLOGY: HISTONE DEACETYLASE 3 AS A KEY MOLECULAR SWITCH OF WHITE ADIPOSE TISSUE METABOLISM AND BROWNING
M. Crestani, R. Longo, A. Ferrari, E. Fiorino, N. Mitro, G. Cermenati, R. Silva, D. Caruso, E. De Fabiani, S.W. Hiebert (Italy)

11.40 IDENTIFICATION OF GPR120 AS A NOVEL TARGET TO ACTIVATE BROWN ADIPOSE TISSUE
M. Schilperoort, A. D. van Dam, G. Hoeke, S. Kooijman, M. Christian, P. C. N. Rensen (The Netherlands)

11.50 INCREASED HEPATIC BILE ACID PRODUCTION SHAPES THE GUT MICROBIOME AFTER COLD INDUCED BROWN ADIPOSE TISSUE ACTIVATION

12.00 LYSOSOMAL ACID LIPASE REGULATES FATTY ACID CHANNELING IN BROWN ADIPOSE TISSUE TO MAINTAIN THERMOGENESIS
M. Duta-Mare, V. Sachdev, C. Leopold, D. Kolb, N. Vujic, M. Korbelius, D. Hofer, W. Xia, K. Huber, C. Magnes, B. Radovic, J. Bogner-Strauss, D. Kratky (Austria)

12.10 BUTYRATE VIA THE GUT-BRAIN NEURAL CIRCUIT REDUCES APPETITE AND ACTIVATES BROWN ADIPOSE TISSUE

12.20 THE LONG PENTRA Xin 3 (PTX3) PLAYS A KEY ROLE IN THE IMMUNOMODULATION OF DIET INDUCED-OBESITY IN MICE
### 11.30-12.45
**Carolina Beatriz Ângelo Hall**
**AUDITORIUM VII**

**WORKSHOP**
**MOLECULAR-CELLULAR MECHANISMS THAT MEDIATE VASCULAR DISEASE**

**Chairs:** Patrick Rensen (The Netherlands)
Alan Tall (USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>THE ROLE OF EFFEROXYTOSIS IN ATHEROSCLEROSIS</td>
<td>Nicholas J. Leeper (USA)</td>
</tr>
<tr>
<td>11.50</td>
<td>CLONAL HEMATOPOIESIS IN ATHEROSCLEROSIS</td>
<td>Alan Tall (USA)</td>
</tr>
<tr>
<td>12.10</td>
<td>MACROPHAGE-SPECIFIC RIP1 DELETION REDUCES NECROTIC CORE FORMATION IN ATHEROSCLEROTIC PLAQUES OF APOE KNOCKOUT MICE</td>
<td>I. Coornaert, G Marcassoli, G.R.Y. De Meyer, W Martinet (Belgium)</td>
</tr>
</tbody>
</table>
Science at a glance
SUNDAY, MAY 06
13.45-14.45
Lipoprotein(a) metabolism
Chair: S. Tsimikas (USA)

SAG1.1 LIPOPROTEIN(A) PRIMED HEMATOPOIETIC STEM CELLS CONTRIBUTE TO AGGRAVATED
ATHEROSCLEROSIS
L. Stiekema, J.G. Schnitzler, T.T.P. Seijkens, S. Tsimikas, E. Lutgens, E.S.G Stroes (The Netherlands, USA, Germany)

SAG1.2 HIGH BASELINE LIPOPROTEIN(A) LEVEL AS A RISK FACTOR FOR CORONARY ARTERY
CALCIFICATION PROGRESSION: SUB-ANALYSIS OF A PROSPECTIVE MULTICENTER TRIAL
T. Miyoshi, K. Kotani, M. Doi, K. Nakamura, K. Kohno, Y. Koyama, H. Ito (Japan)

SAG1.3 ALIROCUMAB DECREASES PLASMA LP(A) LEVELS WITHOUT ENHANCING LP(A) LIVER
UPTAKE IN VIVO
S. Beeske, B. Poirier, E.F. Villard, J.C. Le Bail, G. Dargazanli, T.T.T. Tran, S. Ho-van Guimbal, A. Bayard
F. Tirode, D. Boulay, O. Bergis, G. Lambert, M.P. Pruniaux, P. Janiak, E. Guillot (France)

SAG1.4 IGM AUTOANTIBODIES AGAINST LIPOPROTEIN(A) AS AN “ANTI-ATHEROGENIC” FACTOR IN
PATIENTS WITH SEVERE HYPERLIPIDEMIA
H. Klesareva, O. Afanasieva, E. Utkina, M. Ezhov, A. Popova, M. Afanasieva, S. Pokrovsky (Russia)

SAG1.5 LIPOPROTEIN(A) IS ASSOCIATED WITH INCREASED CALCIFICATION AND DISEASE
PROGRESSION IN AORTIC STENOSIS PATIENTS
K.H. Zhengl, T. Pawade, J. Kroon, J. Hjortnaes, R. Verbeek, B.J. Arsenault, M.A. Rogers, E. Aikawa,
E.S.G. Stroes, S. Tsimikas, S.M. Boekholdt, M.R. Dweck (The Netherlands, United Kingdom, Canada, USA)

SAG1.6 LIPOPROTEIN(A) INCREASES CARDIOVASCULAR DISEASE RISK EVEN AT LOW LDL-CHOLESTEROL
LEVELS; THE EPIC-NORFOLK PROSPECTIVE POPULATION STUDY AND THE COPENHAGEN CITY
HEART STUDY
R.M. Hoogeveen, R. Verbeek, A. Langsted, S.L. Verweij, G.K. Hovingh, N.J. Wareham, K.T. Khaw,
S.M. Boekholdt, B.G. Nordestgaard, E.S.G. Stroes (The Netherlands, Denmark, United Kingdom)
SUNDAY, MAY 06
13.45-14.45
Inflammation and Immunity: human perspectives
Chair: I. Tabas (USA)

SAG12.1 INNATE IMMUNE ACTIVATION IS ASSOCIATED WITH PROGRESSION OF CEREBRAL SMALL VESSEL DISEASE
M.P. Noz, A. Ter Telgte, K. Wiegertjes, L.A.B Joosten, M.G. Netea, F.E. de Leeuw, N.P. Riksen
(The Netherlands, Germany)

SAG12.2 SUBSETS OF CD8+ T LYMPHOCYTE – EARLY REACTANTS IN POST-ANGIoplasty INJURY OF ARTERIES IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
A. Wachsmann, P. Maga, T. Mikolajczyk, L. Partyka, M. Maga, M. Krzanowski (Poland)

SAG12.3 MYELOID CELLS GLUTAMINOLYSIS CONTROLS MONOCYTE NUMBERS AND MACROPHAGE EFFEROCYTOSIS DURING ATHEROSCLEROSIS

SAG12.4 CORONARY ARTERY INFLAMMATORY BIOMARKER EXPRESSION DOES NOT CORRELATE WITH SYSTEMIC ELEVATION OF BIOMARKERS OR OF HSCRP
N. West, J. Corrigan, A. Brown, R. Owen, S. Hoole, S. Blatcher, D. Proudfoot (United Kingdom)

SAG12.5 ANTI-APOLIPOPROTEIN A-1 AUTOANTIBODIES ARE ASSOCIATED WITH IMMUNODEFICIENCY AND SYSTEMIC INFLAMMATION IN HIV PATIENTS
N. Satta, S. Pagano, F. Montecucco, B. Gencer, F. Mach, L. Kaiser, A. Calmy, N. Vuilleumier (Switzerland, Italy)

SAG12.6 PERIODONTAL PATHOGENS ENHANCE WNT/β-CATENIN SIGNALLING AND THEREBY MAY EXACERBATE ATHEROGENESIS
K. Wadey, O. Cameron, J.L. Brittan, N. Hellin, J.L. Johnson, H.F. Jenkinson, A.H. Nobbs, S.J. George (United Kingdom)
SUNDAY, MAY 06
13.45-14.45
Smooth muscle cells biology - Session 1
Chair: M. Bennett (United Kingdom)

SAG16.1 ABCA1 AND HDL3 ARE REQUIRED TO MODULATE SMOOTH MUSCLE CELL PHENOTYPIC SWITCH INDUCED BY CIGARETTE SMOKE
S. Castiglioni, G. Ainis Buscherini, A. Corsini, S. Bellosta (Italy)

SAG16.2 INTERMEDIN REDUCES NEOINTIMA FORMATION BY REGULATING VASCULAR SMOOTH MUSCLE CELL PHENOTYPIC VIA CAMP/PKA PATHWAY

SAG16.3 SECRETED AND ENZYMATICALLY ACTIVE LYSYL OXIDASE (LOX) DRIVES LOX-MEDIATED INHIBITION OF NEOINTIMAL GROWTH
S. Varona, M. Orriols, M. Gálan, A. Guadall, L. Cañes, S. Aguiló, J. Mártilnez-González, C. Rodríguez (Spain)

SAG16.4 THE MIRNA 30B-5P TARGETING MRNA MBNL1 LEADS TO PRO-MYOGENIC VSMC PHENOTYPE MODULATION IN MYOCARDIAL INFARCTION PATIENTS
C.C. Woo, T. Wongsurawat, X.Y. Lin, V. Sorokin (Singapore, USA)
SUNDAY, MAY 06
13:45-14:45

Treatment of CVD
Chair: E. Stroes (The Netherlands)

SAG22.1  EFFECTS OF LONG-TERM EXERCISE TRAINING ON INFLAMMASOME-RELATED MEDIATORS IN PATIENTS WITH T2DM AND CAD
H. Zaidi, R. Byrkjeland, S. Akra, S. Solheim, H. Arnesen, I. Seljeflot, T. Opstad (Norway)

SAG22.2  AZAPEPTIDE MPE-001, A CD36 LIGAND, REDUCES ATHEROSCLEROSIS LESIONS PROGRESSION AND INFLAMMATORY BIOMARKERS EXPRESSION IN APOLIPOPROTEIN E-DEFICIENT MICE
G. Frégeau, R. Sarduy, L. Ménard, S. Machane, A. Marhoug, H. Ong, S. Marleau (Canada)

SAG22.3  ALIROCUMAB EFFICACY AND SAFETY BY BODY MASS INDEX: POOLED ANALYSIS FROM 10 PHASE 3 ODYSSEY TRIALS
F. Tinahones, U. Laufs, B. Cariou, J. Yang, M.J. Louie, D. Thompson, L.A. Leiter (Spain, Germany, France, USA, Canada)

SAG22.4  STATIN-INDUCED MYOPATHY: ROLE OF THE GLUCOCORTICOID-INDUCED LEUCINE ZIPPER
J.V. Valbuena Perez, J. Hoppstädtoder, S. Bruscoli, C. Riccardi, A.K. Kiemer (Germany, Italy)

SAG22.5  THE PCSK9/LDLR AXIS IMPACTS INSULIN SECRETION AND GLUCOSE RESPONSE

SAG22.6  LEAF EXTRACT OF MORUS ALBA REDUCES THE EXPRESSION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) IN HEPG2 CELL LINE
N. Ferri, M.G. Lupo, S. Marchianò, A. Corsini (Italy)
SUNDAY, MAY 06
13.45-14.45
Novel perspectives of vascular disease
Chair: F. Araújo (Portugal)

SAG23.1 METABOLIC ENDOTOXEMIA AS RELATED TO METABOLIC SYNDROME IN AN ELDERLY MALE POPULATION AT HIGH CARDIOVASCULAR RISK
A. Awoyemi, M. Trøseid, S. Solheim, H. Arnesen, I. Seljeflot (Norway)

SAG23.2 GUT MICROBIOTA-DEPENDENT TMAO, AORTIC ATHEROSCLEROSIS AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH STROKE

SAG23.3 THE EFFECT OF DYSLIPEMIA ON EPICARDIAL DERIVED STEM CELL FUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE
L. Badimon, C. Lambert (Spain)

SAG23.4 UNSATURATED, LOW-ABUNDANT SPECIES OF HDL (LYSO)PHOSPHOLIPIDS ARE MOST AFFECTED BY ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
E. Zakiev, F. Ma, F. Rached, M.L.V. Sukhorukov, C.V. Serrano, R.D. Santos, M.J. Chapman, A. Orekhov, A. Kontush (France, Russia, Brazil)

SAG23.5 TOPIRAMATE AMELIORATES GLOMERULAR LIPIDOSIS IN WESTERN DIET FED APOE KNOCK-OUT MICE
C. Parolini, S. Manzini, M. Busnelli, E. Brambilla, E. Scanziani, G. Chiesa (Italy)
SUNDAY, MAY 06
13.45-14.45

Diabetes and insulin sensitivity
Chair: B. Staels (France)

SAG24.1 CAUSAL ASSOCIATIONS IN TYPE 2 DIABETES DEVELOPMENT
S. Marott, B.G. Nordestgaard, A. Tybjærg-Hansen, M. Benn (Denmark)

SAG24.2 LIPID PROFILE IN DIABETIC PATIENTS ON “REAL WORLD” IN MEXICAN CARDIOVASCULAR PATIENTS
L.M. Lugo Gavidia, M.O. De Los Rios Ibarra, M.A. Alcocer Gamba, A. Vargas Hernandez, A. Romero Zazueta, J.L. Barrón Rivera, J. Barragan Luna, J.L. Leiva Pons (Mexico)

SAG24.3 EFFECTS OF SITAGLIPTIN ON LIPID PROFILE IN TYPE 2 DIABETIC PATIENTS AFTER SEVEN YEARS OF THERAPY
G. Derosa, A. D’Angelo, M. Caprio, G. Catena, P. Maffioli (Italy)

SAG24.4 BLOOD LIPIDS, DIABETIC COMPLICATIONS AND THE PHYSICIAN ATTITUDES ON DYSLIPIDEMIA TREATMENT; DATA FROM THE TURKISH NATIONWIDE SURVEY OF GLYCEMIC AND OTHER METABOLIC PARAMETERS OF PATIENTS WITH DIABETES

SAG24.5 ORAL VANCOMYCIN TREATMENT DOES NOT ALTER POSTPRANDIAL INFLAMMATION IN LEAN AND OBESE, METABOLIC SYNDROME SUBJECTS

SAG24.6 ENDOPLASMIC RETICULUM STRESS AND MITOCHONDRIAL DYSFUNCTION IN OBESE PATIENTS AND THEIR ASSOCIATION WITH METABOLIC SYNDROME
SUNDAY, MAY 06
13.45-14.45
Vascular imaging and interventions
Chair: S. Söderlund (Finland)

SAG30.1 DISCREPANCIES BETWEEN CORONARY ARTERY CALCIUM SCORE AND RESULTS OF CARDIOVASCULAR RISK ENGINES IN TYPE 2 DIABETIC PATIENTS
L. Balaire, C. Marsot, M. Moret, L. Groisne, S. Villar-Fimbel, A. Villard, A. Lecus, P. Moulin, S. Charriere (France)

SAG30.2 B- MODE ULTRASOUND- GUIDED SHOCK WAVE THERAPY OF CAROTID ARTERY INTERMEDIATE STAGE ATHEROSCLEROSIS ACCOMPANIED BY ATORVASTATIN-LOADED MICROBUBBLES ADMINISTRATION
H. Mehrad, A. Foletti (Iran, Italy)

SAG30.3 CLINICAL IMPLICATION OF MULTI-SLICE COMPUTED TOMOGRAPHY CORONARYANGIOGRAPHY FOR SYMPTOMATIC PATIENTS IN CLINICAL PRACTICE
S.U. Kwon (South Korea)

SAG30.4 FEASIBILITY OF NOVEL WAVESHAPE-BASED METHODS FOR THE EXAMINATION OF PERIPHERAL ARTERY DISEASE
M. Bachler, M. Haumer, B. Hametner, C.C. Mayer, K. Glantschnig, S. Wassertheurer (Austria)

SAG30.5 DIMETHYLARGININES CORRELATE TO COMMON CAROTID ARTERY WALL LAYER DIMENSIONS AND CARDIOVASCULAR RISK FACTORS IN PREGNANT WOMEN WITH AND WITHOUT PREECLAMPSIA

SAG30.6 CULPRIT LESION VERSUS MULTI-VEssel INTERVENTION IN PATIENTS WITH CARDIOGENIC SHOCK COMPLICATING MYOCARDIAL INFARCTION: INCIDENCE AND OUTCOMES FROM THE LONDON HEART ATTACK GROUP
K. Rathod, S. Koganti, A. Mathur, A. Wragg, D. Jones (United Kingdom)
SUNDAY, MAY 06
13.45-14.45
FH - around the world
Chair: A. Tselepis (Greece)

SAG36.1 CLINICAL IMPLICATION OF FH GENE TEST: DETECTION RATES IN LDLR AND PCSK9 GENES IN JAPAN
A. Nohara, M. Kawashiri, H. Tada, M. Mika, C. Nakanishi, A. Inazu, M. Yamagishi, H. Mabuchi (Japan)

SAG36.2 EXOME SEQUENCING: A PATHFINDING MOLECULAR ANALYSIS FOR DISCOVERY OF NOVEL AND
KNOWN FAMILIAL-HYPERCHOLESTEROLAEMIA-RELATED MUTATIONS IN MALAYSIAN POPULATION
Y.A. Chua, L.K. Teh, A. Al-Khateeb, M. Muhammad, S.N.F. Ismail, H. Mohd Nawawi (Malaysia)

SAG36.3 A CASE-FINDING STRATEGY FOR FAMILIAL HYPERCHOLESTEROLAEMIA IN IRISH HOSPITALS
A. Rakovac Tisdall, V. Crowley (Ireland)

SAG36.4 TARGETED SEQUENCING AS A TOOL FOR GENETIC MUTATIONS SCREENING FOR FAMILIAL
HYPERCHOLESTEROLAEMIA PATIENTS IN MALAYSIAN POPULATION
S.A. Nazli, S.N.F. Ismail, A.Z. Razman, Y.A. Chua, A.M. Al-Khateeb, M. Muhammad, L.K. Teh,
H. Mohd Nawawi (Malaysia)

SAG36.5 CUMULATIVE LDL-C BURDEN AS A CVD RISK PREDICTOR ON FAMILIAL HYPERCHOLESTEROLEMIA
A. Ressia, N. Dell’Oca, X. Reyes, G. Fernandez, M. Stoll (Uruguay)

SAG36.6 THE WEST MIDLANDS FAMILIAL HYPERCHOLESTEROLAEMIA SCREENING PROJECT: DESIGN AND
IMPLEMENTATION
M. Williams, R. Cramb (United Kingdom)
**SUNDAY, MAY 06**

13.45-14.45

**Bile acids and cellular lipid metabolism**

Chair: A.K. Groen (The Netherlands)

**SAG4.1** BILE ACID SEQUESTRANT COLESEVELAM ENHANCES BENEFICIAL EFFECTS OF BROWN FAT ACTIVATION ON CHOLESTEROL METABOLISM IN APOE*3-LEIDEN.CETP MICE


**SAG4.2** SERUM AMYLOID A SPONTANEOUSLY SOLUBILIZES DIVERSE PHOSPHOLIPIDS AND FORMS LIPOPROTEINS

S. Jayaraman, D. Gantz, C. Haupt, M. Faendrich, O. Gursky (Usa, Germany)

**SAG4.3** CHOLERETIC AND HYPOLIPIDEMIC EFFECTS OF HIGH LEVELS OF SOLUBLE ENDOGLIN IN MICE

E. Dolezelova, A. Prasnicka, J. Cermanova, M. Hroch, R. Hysplier, A. Ticha, M. Pericacho, S. Micuda, P. Nachtigal (Czech Republic, Spain)

**SAG4.4** SIALIDASE IN ATHEROSCLEROSIS

V. Myasoedova, M. Stepanova, T. Kirichenko, A. Orekhov (Russia)

**SAG4.5** LYSOSOMAL ACID LIPASE ACTIVITY IS REDUCED IN NAFLD: MECHANISMS AND RESCUE BY PPAR-ALPHA AGONISTS

M. Gomaraschi, A.L. Fracanzani, C. Pavanello, A. Branchi, L. Calabresi, S. Fargion (Italy)

**SAG4.6** GENETIC DEPLETION OF THE SOAT2 GENE DIMINISHES DIET-INDUCED HEPATIC STEATOSIS AND IMPROVES GLUCOSE TOLERANCE IN MICE

SUNDAY, MAY 06
13.45-14.45
Atherosclerotic risk
Chair: Z. Reiner (Croatia)

SAG40.1 ASSOCIATION OF URINARY 11-DEHYDRO-THROMBOXANE B2 AND F2-ISOPROSTANES WITH MORTALITY IN ASPIRIN-TREATED STABLE CORONARY ARTERY DISEASE PATIENTS
L. Lopez, K. Dier, A. Vasudevan, T. Bottiglieri, P. McCullough (USA)

SAG40.2 CLINICAL AND LABORATORY FEATURES IN PATIENTS WITH ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE WITH POOR PLATELET RESPONSE TO ACETYLSALICYLIC ACID AFTER CORONARY BYPASS GRAFTING
A. Kosinova, I. Grinshtein, Y. Grinshtein, A. Kovalev, V. Soukhovolsky (Russia)

SAG40.3 CORRELATIONS OF PHENOTYPIC COMPOSITION OF MONOCYTES AND MONOCYTE-PLATELET COMPLEXES AND IN-HOSPITAL COMPLICATIONS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
N. Pinegina, M. Loguinova, M. Vagida, A. Shpektor, E. Vasilieva, L. Margolis (Russia, USA)

SAG40.4 CHARACTERISTICS AND TEN-YEAR PROGNOSIS OF PATIENTS TREATED WITH ASPIRIN PRIOR TO A FIRST-EVER ACUTE ISCHEMIC STROKE. DATA FROM THE ‘ATHENS STROKE OUTCOME PROJECT’
H. Milionis, F. Barkas, G. Ntaios, E. Korombki, V. Papavasileiou, K. Vemmos (United Kingdom, Greece)

SAG40.5 CYP2C19 AND CYP3A4 ACTIVITY AND ADP-INDUCED PLATELET REACTIVITY IN PATIENTS WITH STEMI TREATED BY PRASUGREL OR TICAGRELOR
J. Machal, O. Hlinomaz, K. KostolanskA, O. Pes, A. Machalova, J. Jurica (Czech Republic)

SAG40.6 FENRETINIDE EXACERBATES ATHEROSCLEROSIS IN SPITE OF BENEFICIAL METABOLIC EFFECTS
S. Manzini, M. Busnelli, C. Parolini, B. Ferrari, E. Scanziani, G. Chiesa (Italy)
SUNDAY, MAY 06
13.45-14.45
Interesting biomarkers
Chair: K. Öörni (Finland)

SAG43.1 LOW HDL CHOLESTEROL TO MONITOR LONG-TERM AVERAGE ELEVATED TRIGLYCERIDE-RICH REMNANTS: FOUR COPENHAGEN COHORTS INCLUDING 120,828 INDIVIDUALS
B. Nordestgaard, A. Langsted, A.M. Reimer-Jensen, A. Varbo (Denmark)

SAG43.2 IDENTIFICATION OF MOLECULAR FINGERPRINT IN URINE LINKED TO CARDIOVASCULAR RISK AND AGE

SAG43.3 PLASMA TRANSTHYRETIN AND RISK OF ISCHEMIC VASCULAR DISEASE IN THE GENERAL POPULATION: A PROSPECTIVE COHORT STUDY
M. Christoffersen, L.S. Hornstrup, R. Frikke-Schmidt, A. Tybjaerg-Hansen (Denmark)

SAG43.4 PLASMA OXYPHYTOSTEROL CONCENTRATIONS ARE NOT ASSOCIATED WITH CVD STATUS IN FRAMINGHAM OFFSPRING STUDY PARTICIPANTS
S. Baumgartner, R.T. Ras, E.A. Trautwein, M.C.J.M. Konings, R.P. Mensink, J. Plat (The Netherlands)

SAG43.5 EXPLORING LIPOPROTEIN PATTERNS IN GENERAL POPULATION WITH ADVANCED ‘H-NMR TESTING BY USING AN UNSUPERVISED CLUSTERING APPROACH
M. Gil Serret, E. Correig, D. Ibarretxe, D. Rodriguez, M. Pardo, C. Rodriguez, N .Plana, L. Masana, N. Amigo (Spain)

SAG43.6 AUTOANTIBODIES TO APOLIPOPROTEIN A-I AS INDEPENDENT PREDICTORS OF CARDIOVASCULAR MORTALITY IN RENAL TRANSPLANT RECIPIENTS
SUNDAY, MAY 06
13.45-14.45

New data on PCSK9
Chair: J. Pereira de Moura (Portugal)

SAG45.1 ONE-YEAR EXPERIENCE WITH MONOCLONAL ANTIBODIES AGAINST PCSK9 IN BELGIAN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
C. De Fays, A. Persu, C. Beauloye, J.L. Balligand, C. Wallemacq, E. Rietzschel, J.L. Vanoverschelde, O.S. Descamps (Belgium)

SAG45.2 MODELING THE POPULATION HEALTH BENEFITS OF LDL-C REDUCTION WITH ALIROCUMAB AMONG CARDIOVASCULAR DISEASE/HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LDL-C
R. Sanchez, K. Nasir, A. Klimchak, A. Kuznik, F. Joulain, A. Briggs (USA, France, United Kingdom)

SAG45.3 PRO-PROTEIN SUBTILISIN KEXIN-9 (PCSK9) INHIBITION IN PRACTICE: LIPID CLINIC EXPERIENCE IN 2 CONTRASTING UK CENTRES
A. Wierzbicki, M. Kohli, K. Patel, Z. McMahon, R. Ramachandran, M. Crook, T. Reynolds (United Kingdom)

SAG45.4 TREATMENT WITH ALIROCUMAB IN ONE PATIENT WITH SITOSTEROLEMIA

SAG45.5 BINDING OF PCSK9 TO CIRCULATING LDL: EFFECT OF PCSK9 MONOCLONAL ANTIBODIES ON THE LDL-BOUND PCSK9?
D. De Stefano, A. Baragetti, N. Macri, H. Tavori, S. Fazio, A.L. Catapano (USA, Italy)

SAG45.6 LOW LDL CHOLESTEROL BY PCSK9 VARIATION REDUCES CARDIOVASCULAR AND ALL-CAUSE MORTALITY - MENDELIAN RANDOMIZATION OF 109,566 INDIVIDUALS FROM COPENHAGEN
M. Benn, A. Tybjærg-Hansen, B.G. Nordestgaard (Denmark)
Vascular biology - Session 1
Chair: J. Schmid (Austria)

SAG18.1 THE EFFECT OF ADIPOSE TISSUE AND STROMAL VASCULAR FRACTION DERIVED CYTOKINES ON MONOCYTE ADHESIVENESS TO THE ENDOTHELIUM
S. Cejkova, H. Kubatova, I. Kralova Lesna, J. Fronek, F. Thieme, R. Poledne (Czech Republic)

SAG18.2 4 PROTOPORPHYRIN IX- LOADED PESDA MICROBUBBLES- MEDIATED PHOTODYNAMIC THERAPY REDUCE FOAM CELLS IN THE EARLY STAGE ATHEROSCLEROSIS
H. Mehrad, M. Farhoudi, F. Masoumi, M.R. Mohseni (Iran)

SAG18.3 P38-JNK PATHWAY MEDIATES M2 MACROPHAGES POLARIZATION IN APOE KO MICE FOLLOWING TREATMENT WITH BMP-7
D. Singla (USA)

SAG18.4 A TREATMENT WITH ANTI-PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 MONOCLONAL ANTIBODIES AFFECTS LIPID AND INFLAMMATORY PROFILES AND CIRCULATING PROGENITOR CELLS NUMBER
C.O. Aragona, V. Cairo, F. Mamone, F. Savarino, S. Tomeo, M. Scuruchi, S. Loddo, E. Imbalzano, A. Saitta, G. Mandraffino (Italy)

SAG18.5 THE AMELIORATION ON THE VASCULAR INFLAMMATORY RESPONSE BY EVOGLIPTIN, A NOVEL DIPEPTIDYL PEPTIDASE 4 INHIBITOR VIA REGULATION OF SIRT1/NF-KAPPAB INTERACTION
M.K. Cho, P.A. Nguyen, J.S. Won, E.J. Bae (South Korea)

SAG18.6 VITAMIN D DEFICIENCY INDUCES PRO-INFLAMMATORY PHENOTYPE OF EPICARDIAL ADIPOSE TISSUE ACCELERATING NEOINTIMAL HYPERPLASIA FOLLOWING CORONARY INTERVENTION
D. Agrawal, V. Swier, P. Gunasekar, J. Fleegel, M. Radwan (USA)
SUNDAY, MAY 06
14.45-15.45

How to protect the vessel wall?
Chair: G. Caligiuri (France)

SAG21.1  SPORT ACTIVITY PROTECTS FROM EXERCISE INDUCED MICROALBUMINURIA IN HYPERTENSIVE PATIENTS
M. Ehrenwald, I. Shapira, S. Shenhar-Tzarfaty, S. Berliner, O. Rogowski (Israel)

SAG21.2  READINESS FOR BEHAVIOURAL CHANGE AS A TOOL TO ESTIMATE CONTROLLING CARDIOVASCULAR RISK FACTORS
N. Eshah (Jordan)

SAG21.3  SUBCLINICAL IMPAIRMENT OF MYOCARDIAL AND ENDOTHELIAL FUNCTIONALITY IN VERY EARLY PSORIATIC AND RHEUMATOID ARTHRITIS PATIENTS: ASSOCIATION WITH VITAMIN D, INFLAMMATION AND ACTIVITY
F. Savarino, A. Lo Gullo, J.R. Carrio, C.O. Aragona, A. Suárez, F. Atzeni, A. Saitta, G. Mandraffino (Italy, Spain, Israel)

SAG21.4  DIFFERENCES IN THE EXPRESSION OF POTASSIUM CHANNELS IN THE RENAL ARTERY OF DIABETIC AND NORMAL RATS
R. Novakovic, J. Rajkovic, V. Dijokic, S. Cirovic, J. Markovic-Lipkovski, V. Kanjuh, H. Heinle, L.J. Gojkovic-Bukarica (Serbia, Germany)

SAG21.5  AORTIC VALVE SCLEROSIS IS ASSOCIATED WITH SYSTEMIC OXIDATIVE STRESS IN PATIENTS UNDERGOING SURGICAL MYOCARDIAL REVASCULARIZATION
V. Myasoedova, B. Porro, V. Valerio, S. Montanari, P. Songia, D. Moschetta, P. Grippari, L. Fusini, M. Pepi V. Cavalca, P. Poggio (Italy)

SAG21.6  TARGETING ENDOPLASMIC RETICULUM STRESS AS A THERAPY TO MANAGE ABDOMINAL AORTIC ANEURYSM DISEASE
M. Navas Madroñal, L. Vila, J. Fité, J. Martinez-Gonzalez, C. Rodriguez, M. Camacho, M. Galán (Spain)
SUNDAY, MAY 06
14.45-15.45

Triglycerides and fatty acids
Chair: J. Sequeira Duarte (Portugal)

SAG25.1 DEVELOPMENT OF A MULTIGENE PANEL SCREENING TEST FOR HYPERTRIGLYCERIDAEMIA USING NEXT GENERATION SEQUENCING

SAG25.2 IDENTIFICATION OF CASES WITH LIPOPROTEIN LIPASE DEFICIENCY IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDAEMIA

SAG25.3 MOLECULAR BASIS OF THE FAMILIAL CHYLOMICRONEMIA SYNDROME IN PATIENTS FROM THE NATIONAL DYSLIPIDEMIA REGISTRY OF THE SPANISH ATHEROSCLEROSIS SOCIETY

SAG25.4 DETECTION OF FAMILIAL CHYLOMICRONEMIA SYNDROME IN A COHORT OF PATIENTS WITH SEVERE HYPERTRIGLYCERIDAEMIA THROUGH A NEXT GENERATION SEQUENCING APPROACH
L. D’Erasmo, A. Di Costanzo, F. Cassandra, I. Minicocci, L. Polito, M. Arca (Italy)

SAG25.5 CIRCULATING CETP IS NOT RELATED TO THE HEPATIC TRIGLYCERIDE CONTENT: LESSONS FROM A LIRAGLUTIDE INTERVENTION TRIAL AND A POPULATION-BASED COHORT

SAG25.6 ASSOCIATION OF STATIN THERAPY WITH PLASMA FATTY ACIDS PROFILE AND LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 CONCENTRATION
**SUNDAY, MAY 06**

14.45-15.45

**Diabetes and vascular risk**

Chair: L. Andrade (Portugal)

**SAG27.1** GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND PROTECTION AGAINST STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS

H. Milionis, F. Barkas, M. Elisaf (Greece)

**SAG27.2** EFFECT OF TWO LOW-CALORIE DIETS WITH HIGH-PROTEIN OR STANDARD-PROTEIN ON PLASMA ADIPOKINE CONCENTRATIONS IN DIABETIC SUBJECTS WITH OVERWEIGHT OR OBESITY

R. Mateo-Gallejo, S. Pérez-Calahorra, V. Marco-Benedí, A.M. Bea, I. Lamiquiz-Moneo, L. Baila-Rueda, F. Civeira, A. Cenarro (Spain)

**SAG27.3** IN TYPE 1 DIABETES MELLITUS IMPAIRED VASCULAR FUNCTION RELATES TO THE EXPRESSION OF MYD88 IN LYMPHOMONONUCLEAR CELLS BUT NOT TO DIETARY ADVANCED GLYCATION END-PRODUCTS

M.T.K. Toyoshima, D.P. Santos-Bezerra, A. Machado-Lima, M.F.S. Goes, B. Caramelli, M.L.C. Correa-Giannella, M. Passarelli (Brazil)

**SAG27.4** PLASMA BUT NOT URINE 8-ISO-PGF2ALFA IS A PREDICTOR OF INSULIN RESISTANCE IN THE MIDDLE-AGED SUBJECTS - AN OCCUPATIONAL, COHORT-BASED STUDY

M. Janczura, A. Gielicz, K. Kotula-Horowitz, T. Iwaniec, A. Stanisz, R. Rosa, J. Dropinski, T. Domagala (Poland)

**SAG27.5** GLUCOGENE: DIABETES RISK PREDICTION AT 2 YEARS FOR CORONARY PATIENTS ON DIETARY ADVICE (FROM THE CORDIOPREV STUDY)


**SAG27.6** METFORMIN IN PATIENTS WITH DIABETES AND CHRONIC HEART FAILURE AFFECTS GUT INCRETIN RELEASE

SUNDAY, MAY 06
14.45-15.45
NAFLD
Chair: S. Romeo (Sweden)

SAG28.1 ANGPTL3 KNOCK-DOWN ALTERS HEPATOCYTE LIPID PROFILE AND METABOLISM
H. Ruhanen, P.A. Nidhina Haridas, Y. Zhou, M. Jauhiainen, R. Käkelä, V.M. Olkkonen (United Kingdom, Finland)

SAG28.2 LOSS OF FUNCTION OF EITHER LAP1 OR TORSINA, NUCLEAR MEMBRANE ASSOCIATED PROTEINS, CAUSES INHIBITION OF VLDL SECRETION AND SEVERE STEATOHEPATITIS IN CHOW FED MICE

SAG28.3 CHANGES IN LIVER ENERGY METABOLISM DURING THE PROGRESSION OF NAFLD
O. Sobotka, P. Stankova, O. Kucera, R. Endlicher, K. Nozickova, Z. Cervinkova (Czech Republic)

SAG28.4 DIFFERENTIATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) FROM SIMPLE STEATOSIS: ASSESSMENT AND VALIDATION OF NOVEL METABOLIC MARKERS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) SEVERITY
A. Goyale, A. Jain, C. Smith, M. Guerrero Misas, D. Roccarina, E. Buzzetti, E. Tschochatzis, D. Nair (United Kingdom)

SAG28.5 ENHANCED URINARY EXCRETION OF THROMBOXANE B2 IN NON-ALCOHOLIC FATTY LIVER DISEASE. IMPLICATION FOR ANTIPLATELET TREATMENT
F. Baratta, D. Pastori, M. Delben, R. Carnevale, M. Novo, G. Labbadia, F. Angelico, F. Violi (Italy)

SAG28.6 FATTY ACID BINDING PROTEIN 4 (FABP4) CONTRIBUTES TO MYOCARDIAL STEATOSIS AND INSULIN RESISTANCE IN CARDIAC CELLS
SUNDAY, MAY 06
14.45-15.45

Genes and environment
Chair: R. Frikke-Schmidt (Denmark)

SAG31.1 MEDITERRANEAN DIET, GLUCOSE HOMEOSTASIS AND INFLAMMASOME GENETIC VARIANTS: THE CORDIOPREV STUDY

SAG31.2 GENETICS, LIFESTYLE AND LDL CHOLESTEROL IN YOUNG AND APPARENTLY HEALTHY WOMEN

SAG31.3 GENE-DIET INTERACTIONS AND POSTPRANDIAL LIPEMIA RESPONSE IN CORONARY HEART DISEASE PATIENTS: FROM THE CORDIOPREV CLINICAL TRIAL

SAG31.4 INFLUENCE OF 101 GENETIC VARIANTS ON THE PREVALENCE OF TYPE 2 DIABETESMELLITUS AND THE REGULATION OF CARBOHYDRATE METABOLISM BY DIETARY INTERVENTION: CORDIOPREV STUDY

SAG31.5 GENETIC AND ENVIRONMENTAL FACTORS PREDICTORS OF THE MODIFICATION OF WEIGHT IN SUBJECTS WITH OVERWEIGHT AND OBESITY

SAG31.6 EFFECT OF PALMITATE AND TST GENE ON INFLAMMATION AND INSULIN RESISTANCE IN ADIPOCYTES
U. Sustar, D. Lainscek, S. Horvat (Slovenia)
SCIENCE AT A GLANCE

SUNDAY, MAY 06
14.45-15.45

Nutrition - what to eat?
Chair: E. Ros (Spain)

SAG32.1 EARLY LIFE PROGRAMMING WITH SUCROSE INTERFERES WITH LIPID PROFILES OF SHR RATS IN TWO SUBSEQUENT GENERATIONS
E. Skolnikova, L. Sedova, D. Krenova, V. Kren, O. Seda (Czech Republic)

SAG32.2 CARDIOPROTECTIVE EFFECT OF PROCYANIDIN B2
A. Novakovic, M. Marinko, G. Jankovic, D. Nenezic, I. Stojanovic, P. Milojevic, V. Kanjuh, Q. Yang, G.W. He (Serbia, Hong Kong, China)

SAG32.3 SIGNIFICANT METABOLIC CHANGES IN THE LIVERS OF APOE3LEIDEN.CETP MICE IN RESPONSE TO A HIGH FAT DIET
D. Nasias, V. Nidris, D. Kardassis (Greece)

SAG32.4 HIGH FAT LOAD INDUCES CHANGES IN HEPATIC FAT CONTENT DETECTABLE BY MAGNETIC RESONANCE SPECTROSCOPY
T. Blahova, J. Kvar, M. Drobny, P. Sedivy, M. Dezortova, K. Zemankova, M. Hajek (Czech Republic)
SUNDAY, MAY 06
14.45-15.45

How to predict CVD risk?
Chair: J. Lomelino Araujo (Portugal)

SAG39.1 USE OF PPI AND RISK OF ISCHEMIC EVENTS IN THE GENERAL POPULATION
F. Galimberti, M. Casula, F. Mozzanica, E. Tragni, G. Corrao, L. Scorrni, A.L. Catapano (Italy)

SAG39.2 CHANGE IN CARDIOVASCULAR DISEASE RISK AFTER INCIDENT MYOCARDIAL INFARCTION: THE TROMSØ STUDY 1994-2016

SAG39.3 ASSOCIATION OF CHOLESTEROL HOMEOSTASIS PARAMETERS WITH CARDIOVASCULAR RISK FACTORS IN HEALTHY POPULATION

SAG39.4 SECULAR TRENDS IN SERUM LIPIDS IN NORWAY, 2000-2016
E. Arnesen, K. Retterstøl (Norway)

SAG39.5 STATIN THERAPY FOR PRIMARY PREVENTION AND ITS EFFECT ON NEW-ONSET DIABETES, MACE AND ALL-CAUSE MORTALITY - A REAL-WORLD POPULATION COHORT STUDY
G. Lavie, O. Reges, M. Hoshen, A. Benis, M. Leibowitz, R. Balicer (Israel)

SAG39.6 ANTIBODIES AGAINST HDL COMPONENTS IMPROVE THE DIAGNOSTIC ACCURACY BETWEEN ISCHEMIC STROKE OR CORONARY ARTERY DISEASE AND HEALTHY CONTROLS WHEN ADDED TO TRADITIONAL CARDIOVASCULAR RISK FACTORS
SUNDAY, MAY 06
14.45-15.45
Clinical aspects of lipids, genetics, and interventions I
Chair: J.W. Jukema (The Netherlands)

SAG5.1 GENETICALLY-DETERMINED CETP CONCENTRATION DECREASES LARGE HDL AND INCREASES SMALL VLDL WITHOUT AFFECTING LDL

SAG5.2 GENOME-WIDE ASSOCIATION STUDY ON TRIGLYCERIDE RESPONSE IDENTIFIES GENETIC VARIATION IN THE LIPOPROTEIN LIPASE (LPL) GENE
D. Ibi (The Netherlands)

SAG5.3 DAPA GLIFLOZIN DECREASES SD LDL-C AND INCREASES HDL2-C IN PATIENTS WITH TYPE 2 DIABETES
Y. Ito (Japan)

SAG5.4 LIPID GOALS IN PATIENTS WITH METABOLIC SYNDROME – IS LOW-DENSITY LIPOPROTEIN-CHOLESTEROL ENOUGH?
S. Paredes, L. Fonseca, M. Alves, J. Vilaverde, J. Oliveira, I. Palma (Portugal)

SAG5.5 PLASMA NON-ESTERIFIED FATTY ACIDS (NEFA) CONCENTRATIONS MAY DECREASE WITH A GLUCOSE BASED PARENTERAL NUTRITION REGIME
J. Fortunato, P. Skorepa, V. Blaha, J.M. Horacek (Czech Republic)

SAG5.6 A POLYPHENOL-RICH DIET MODIFIES POSTPRANDIAL LIPOPROTEIN COMPOSITION
G. Della Pepa, C. Vetrani, L. Bozzetto, M. Vitale, G. Costabile, P. Cipriano, A. Mangione, L. Patti, A.A. Rivellese, G. Annuzzi (Italy)
SUNDAY, MAY 06
14.45-15.45

Cholesterol efflux and reverse cholesterol transport
Chair: P. Tontonoz (USA)

SAG6.1 THE ANTI-INFLAMMATORY EFFECT OF R3 IN ATHEROSCLEROSIS IS ASSOCIATED WITH INHIBITION OF NLRP3 INFLAMMASOME
Y. Xu, S.H. Y Si, J.Q L, X W, Y ZH Li, X Z, CH L, XH J (China)

SAG6.2 METABOLIC HIGH DENSITY LIPOPROTEIN PARTICLES IN HUMAN OBESITY – A NOVEL TOOL FOR THE MEASUREMENT OF METABOLIC INFLAMMATION?
W. Guo, Y. Lenighan, E. Dillon, S. Curley, M. O’Reilly, A. Matt, J. Gibney, A. Hogan, S. Pennington, H. Roche, D. O’Shea, F. McGillicuddy (Ireland)

SAG6.3 SODIUM SALICYLATE MODULATES REVERSE CHOLESTEROL TRANSPORT AND HDL PROTEOME WITHIN OBESITY
S. Kajani, M. O’Reilly, W. Guo, E. Dillon, F. McGillicuddy (Ireland)

SAG6.4 IMPROVEMENT OF GLYCEMIC CONTROL RESTORES ABCA-1 IN MACROPHAGES INCUBATED WITH ALBUMIN ISOLATED FROM DIABETIC SUBJECTS

SAG6.5 CHOLESTEROL EFFLUX CAPACITY OF HEALTHY OCTOGENARIANS DOES NOT ASSOCIATE WITH CORONARY CALCIUM, PLAQUE VULNERABILITY AND TELOMERE LENGTH

SAG6.6 INDEPENDENT EFFECTS OF KIDNEY FUNCTION AND CHOLESTEROL EFFLUX ON CARDIOVASCULAR MORTALITY
SUNDAY, MAY 06
14.45-15.45
LDL metabolism, oxidation and lipid accumulation
Chair: P. Marques da Silva (Portugal)

SAG8.1 OXIDISED LDL AND ANTI-OXIDISED LDL ANTIBODIES ARE REDUCED BY LIPOPROTEIN APERESIS IN A RANDOMISED CONTROLLED TRIAL ON PATIENTS WITH REFRACTORY ANGINA AND ELEVATED LIPOPROTEIN(A)
T.Z. Khan, D. Haskard, M. Caga-Anan, D.J. Pennell, M. Barbir, R.Khamis (United Kingdom)

SAG8.2 THE LIPID-DROPLET ASSOCIATED PROTEIN PERILIPIN 2 (PLIN2) PLAYS A CENTRAL ROLE IN LIPID ACCUMULATION AND CHOLESTEROL EFFLUX VIA EFFECTS ON LXR SIGNALING IN HUMAN MACROPHAGES
P. Saliba-Gustafsson, M. Pedrelli, O. Werngren, P. Parini, E. Ehrenborg (Sweden)

SAG8.3 SUSCEPTIBILITY OF LDL PARTICLES TO AGGREGATE DEPENDS ON PARTICLE LIPIDOME, IS MODIFIABLE, AND ASSOCIATES WITH FUTURE CARDIOVASCULAR DEATHS

SAG8.4 ROLE OF SPHINGOLIPIDS IN THE INFLAMMATORY AND APOPTOTIC EFFECTS OF LDL(-) ON MONOCYTES
N. Puig Grifol, L. Jin, M. Estruch, B. Pascale, J.L. Sanchez Quesada, S. Benitez Gonzalez (Spain)

SAG8.5 THE DIRECT BINDING OF ADIPONECTIN TO OXIDIZED LDL, BOTH ALONE AND IN COOPERATION WITH T-CADHERIN, INHIBITS OXIDIZED LDL ACTION
A. Kakino, Y. Fujita, S. Horiuchi, Ch. Chen, T. Sawamura (Japan, USA, Taiwan)

SAG8.6 WHY ARE HUMANS LDL-ANIMALS AND MICE ARE NOT? HEPATIC APOB MRNA EDITING AND PLASMA PLTP ACTIVITY ARE THE CAUSE, NOT CETP
M.E. Minniti, M. Pedrelli, L.L. Vedin, A.S. Delbes, K. Öörni, E.M. Wilson, S. Luquet, M. Eriksson, P. Parini (Sweden, France, Finland, USA)
MONDAY, MAY 07
13.45-14.45

Endothelial Cells Biology
Chair: S.Y. Ylä-Herttuala (Finland)

SAG11.1 INCREASED 12/15-LIPOXYGENASE MEDIATES DISTURBED FLOW-INDUCED OXIDATION OF LOW-DENSITY LIPOPROTEIN IN ENDOTHELIAL CELLS
X. Wang, C. Li, J. Chen, Y. Shen, Z. Liu, R. Zhang, W. Shen (China)

SAG11.2 INDUCTION OF NLRP3 INFLAMMASOME ACTIVATION BY HEME IN HUMAN ENDOTHELIAL CELLS
A. Toth, J. Erdei, E. Balogh, B. Nyakundi, E. Bányai, B. Ryffel, GY. Paragh, M. Cordero, V. Jeney (Hungary, France, South Africa, Spain)

SAG11.3 IMPACT OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN-CONTAINING PROTEINS (NOD) 1 AND 2 ON EXPERIMENTAL ATHEROSCLEROSIS AND LIPID METABOLISM

SAG11.4 HDL INDUCES THE EXPRESSION OF ANGIOPOIETIN LIKE 4 (ANGPTL4) GENE IN ENDOTHELIAL CELLS VIA A PI3K/AKT/FOXO1 SIGNALING PATHWAY
D. Theofilatos, P. Fotakis, E. Valanti, D. Sanoudou, V. Zannis, D. Kardassis (Greece, USA)

SAG11.5 TARGETING LIPOPROTEIN(A)-INDUCED ENDOTHELIAL CELL METABOLIC CHANGES IN ORDER TO REDUCE INFLAMMATION, LEUKOCYTE EXTRAVASATION AND THEREBY ATHEROSCLEROSIS
J.G. Schnitzler, R.M. Hoogeveen, I. Nicorescu, M Versloot, E.S.G. Stroes, J. Kroon (The Netherlands)

SAG11.6 LRG1 IS A NOVEL REGULATOR OF ENDOTHELIAL ACTIVATION AND IS SHEAR DEPENDENT: A POTENTIAL THERAPEUTIC TARGET?
# SCIENCE AT A GLANCE

## MONDAY, MAY 07

13.45-14.45

**Immune regulation in atherosclerosis**
Chair: Z. Mallat (United Kingdom)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAG15.1</td>
<td>MACROPHAGE EXPRESSION OF INTERLEUKIN-37 ATTENUATES ATHEROSCLEROSIS</td>
</tr>
<tr>
<td></td>
<td>W. Boisvert, S. McCurdy, Y. Baumer (USA)</td>
</tr>
<tr>
<td>SAG15.2</td>
<td>G-PROTEIN COUPLED RECEPTOR 55 DEFICIENCY PROMOTES ATHEROSCLEROSIS AND INFLAMMATION IN MICE</td>
</tr>
<tr>
<td></td>
<td>D. Hering, R. Guillamat-Prats, M. Rami, S. Kobold, Y. Döring, S. Steffens (Germany)</td>
</tr>
<tr>
<td>SAG15.3</td>
<td>OXIDIZED LDL INDUCED DENDRITIC CELL MATURATION AND T CELL ACTIVATION A NOVEL IMMUNOLOGICAL ROLE OF PCSK9</td>
</tr>
<tr>
<td></td>
<td>A. Liu, J. Frostegard (Sweden)</td>
</tr>
<tr>
<td>SAG15.4</td>
<td>CD22 DEFICIENCY REDUCES PLASMA TRIGLYCERIDE LEVELS WITHOUT AFFECTING ATEROSCLEROTIC LESION SIZE IN FEMALE LDLR-/- MICE</td>
</tr>
<tr>
<td></td>
<td>F.S. Porsch, M. Kiss, D. Tsiantoulas, M. Ozsvár-Kozma, L. Goederle, L. Nitschke, C.J. Binder (Austria, Germany)</td>
</tr>
<tr>
<td>SAG15.5</td>
<td>REDUCED ATHEROSCLEROSIS IN MICE WITH CONDITIONAL DELETION OF SPLEEN TYROSINE KINASE</td>
</tr>
<tr>
<td></td>
<td>D. Tsukui, Y. Kimura, T. Yanagida, H. Kono (Japan)</td>
</tr>
<tr>
<td>SAG15.6</td>
<td>PHARMACOLOGICAL INHIBITION OF MONOACYLGLYCEROL LIPASE ENHANCES IGM PLASMA LEVELS AND LIMITS ATEROGENESIS IN A CB2-DEPENDENT MANNER</td>
</tr>
<tr>
<td></td>
<td>R. Guillamat-Prats, M. Rami, L. Ring, P. Rinne, S. Lenglet, E. Lauer, A. Thomas, B. Cravatt, C. Weber, A. Faussner, S. Steffens (Germany, Switzerland, USA)</td>
</tr>
</tbody>
</table>
Vascular biology - Session 2
Chair: E.A.L. Biessen (The Netherlands)

SAG19.1 Transcriptome analysis of human macrophages reveals genes regulating cellular cholesterol efflux

SAG19.2 The role of galectin-3 and LP(a) in atherosclerosis: a combined analysis of serum levels and plaque characteristics
D. Palma, M.D. Di Taranto, M. Savoia, R. De Falco, F.P. D’Armiento, L. Del Guercio, U.M. Bracale, G. Fortunato (Italy)

SAG19.3 Atherosclerosis progression and regression induced by LDLR antisense and LDLR sense oligonucleotides in mice
F. Willecke, K. Pfeiffer, N. Anto-Michel, M.C. Gissler, A. Mullick, N. Hoppe, A. Zirlik (Germany)

SAG19.4 Ex vivo detection of vascular reactive oxygen species formation in atherosclerotic ApoE-/- mice by high resolution near-infrared fluorescence imaging
S. Manea, M.L. Antonescu, D. Stan, A.G. Lazar, M. Calin, A. Manea (Romania)

SAG19.5 Lipid core nanoparticle associated with docetaxel reduces inflammation and cell proliferation in an atherosclerosis rabbit model
M.C. Guido, B.C. Meneghini, E.R. Tavares, T.M. Tavoni, R. Kalil-Filho, R.C. Maranhão (Brazil)

SAG19.6 Influence of PCSK9 inhibition on the stabilization of atherosclerotic plaque determined by biochemical methods and magnetic resonance imaging
M. Basiak, L. Buldak, M. Konopka, M. Dziubinska-Basiak, G. Machnik, B. Okopien (Poland)
MONDAY, MAY 07
13.45-14.45
Risk predictions in diabetes
Chair: M. Vrablík (Czech Republic)

SAG26.1 ELEVATED CIRCULATING MICROVESICLES (CMVS) IN TYPE 2 DIABETES PATIENTS WITH ALBUMINURIA
V. Bratseth, G. Chiva-Blanch, R. Byrkjeland, S. Solheim, H. Arnesen, I. Seljeflot (Norway, Spain)

SAG26.2 CONTROLLING RISK FACTORS AT TARGET LEVELS AFFECTS CORONARY CT ANGIOGRAPHIC FINDINGS AND CARDIOVASCULAR EVENTS IN ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES
K.Y. Lee, B.H. Hwang, K. Chang (South Korea)

SAG26.3 THE MULTIPLE IMPLICATIONS OF DIPPER PROFILES IN HYPERTENSIVE DIABETICS PATIENTS: THE BETTER CARDIOVASCULAR PROGNOSTIC OF THOSE WITH LOWEST MEAN HEART RATE
V. Manea, C. Pop, L. Pop, M.I. Popescu (Romania)

SAG26.4 PREVENTION OF GESTATIONAL DIABETES BEFORE AND DURING PREGNANCY, SURVEY IN NORTH DELHI, INDIA: ROLE OF DAILY DIET LEAFY GREEN VEGETABLES, FRUIT, AND MILK
V. Sharma (India)

SAG26.5 SERUM UROMODULIN PREDICTS A DECLINE IN KIDNEY FUNCTION INDEPENDENTLY FROM THE PRESENCE OF TYPE 2 DIABETES
A. Leiherrer, A. Muendlein, C.H. Saely, E.M. Brandtner, K. Geiger, A. Mader, B. Larcher, P. Fraunberger, H. Drexel (Austria, Liechtenstein, USA, Austria, Switzerland)

SAG26.6 ANTIATHEROSCLEROTIC EFFECTS OF SGLT2 INHIBITORS IN TYPE 2 DIABETIC PATIENTS WITH OBESITY AND HYPERTENSION
T. Yamagishi (Japan)
MONDAY, MAY 07
13.45-14.45
Lipoprotein receptors and lipid layers
Chair: G.M. Dallinga-Thie (The Netherlands)

SAG3.1 IMPACT OF LDL RECEPTOR ON LYMPHOCYTES T CELL DIFFERENTIATION AND FUNCTION

SAG3.2 LDL RECEPTOR (LDLR) EXPRESSION AND LDL UPTAKE IN HUMAN PANCREATIC BETA CELLS
ARE REGULATED BY STATINS AND PCSK9 - CONSEQUENCE FOR GLUCOSE-STIMULATED INSULIN
SECRETION (GSIS)
S. Ramin-Mangata, A. Thedrez, B. Cariou, R. Scharfmann, E. Nobecourt, G. Lambert (Reunion
Island, France)

SAG3.3 PLASMA IDOL, SOLUBLE LDLR AND PCSK9 LEVELS AS POTENTIAL BIOMARKERS OF FAMILIAL
HYPERCHOLESTEROLEMIA IN CHILDREN

SAG3.4 AGENT-BASED MODELING PREDICTS HDL-INDEPENDENT PATHWAY OF REMOVAL OF EXCESS
SURFACE LIPIDS FROM VERY LOW DENSITY LIPOPROTEIN
Y. Paalvast, J.A. Kuivenhoven, B.M. Bakker, A.K. Groen (The Netherlands)

SAG3.5 MIRNOME STUDY AND FUNCTIONAL CHARACTERIZATION OF LDLR: AN INTEGRATED APPROACH
TO IDENTIFY PATHOGENICITY MECHANISMS IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS
WITHOUT CAUSATIVE MUTATIONS
M.D. Di Taranto, C. Giacobbe, A. Scotto di Frega, A. Cordella, G. Giurato, P. Rubba, A. Weisz,
G. Fortunato (Italy)

SAG3.6 INTERACTION OF LIPOPROTEIN PARTICLES WITH LIPID BILAYER-MEMBRANES
P. Hinterndorfer, G.J. Schütz, H. Stangl (Austria, Czech Republic, United Kingdom)
MONDAY, MAY 07
13.45-14.45
Diet and blood vessels
Chair: S. Mora (USA)

SAG33.1 PEROXISOME PROLIFERATIVE ACTIVATING FACTOR-ALPHA MEDIATED EFFECTS OF CHIOS MASTIC GUM (CMG) ON AN EXPERIMENTAL MODEL OF DIET-INDUCED ATHEROSCLEROSIS
A. Tzani, P. Konstantopoulos, I.P. Doulamis, A. Daskalopoulou, A. Liakea, M.L. Korou, D.C. Iliopoulos, N. Kavantzas, K.S. Stamatelopoulos, D.N. Perrea (Greece)

SAG33.2 ALPHA-LINOLENIC ACID AND RISK OF PERIPHERAL ARTERIAL DISEASE
C. Bork, A.N. Lasota, S. Lundbye-Christensen, A. Tjoenneland, M.U. Jakobsen, E.B. Schmidt, K. Overvad (Denmark)

SAG33.3 EFFECTS OF LEAN AND FATTY FISH AND KRILL OIL ON GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND LIPOPROTEIN SUBCLASSES: A RANDOMIZED CONTROLLED TRIAL
A. Rundblad, K.B. Holven, I. Bruheim, M.C. Myhrstad, S.M. Ulven (Norway)

SAG33.4 SUPPLEMENTATION OF OMEGA-3 PUFAS COULD IMPROVE LONG TERM PROGNOSIS AFTER PCI IN PATIENTS WITHOUT HYPERLIPIDEMIA AND DIABETES

SAG33.5 LONG-TERM ADHERENCE TO TWO HEALTHY DIETS IN CORONARY PATIENTS AFTER FIVE YEARS OF DIETARY INTERVENTION: CORDIOPREV STUDY

SAG33.6 DIET PATTERN EFFECT ON ENDOTHELIAL DAMAGE AND REGENERATIVE CAPACITY PROCESSES
MONDAY, MAY 07
13.45-14.45
Obesity
Chair: L. Couto (Portugal)

SAG34.1 OBESITY IS AN INDEPENDENT RISK FACTOR FOR PNEUMONIA IN PATIENTS ADMITTED WITH ACUTE ISCHEMIC STROKE

SAG34.2 TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY MEMBERS 10 AND 12 ARE ASSOCIATED WITH THE METABOLIC HEALTH STATUS OF MORBID OBESE PATIENTS
I. Doulamis, P. Konstantopoulos, A. Tzani, A. Antoran, A. Daskalopoulou, A. Minia, A. Charalampopoulos, D.N. Perrea, L. Alexopoulos, E. Menenakos (Greece)

SAG34.3 BARIATRIC SURGERY REVERSES DNA METHYLATION MODIFYING ONE CARBON METABOLISM

SAG34.4 MORBID OBESITY AND HYPERTENSION: THE ROLE OF PERI-RENAL FAT

SAG34.5 GENE EXPRESSION PROFILING OF GLUTEAL ADIPOSE TISSUE AFTER PROLONGED BEDREST

SAG34.6 ASSOCIATIONS BETWEEN MEASURES OF SLEEP WITH SERUM AND HEPATIC LIPID PROFILE: THE NETHERLANDS EPIDEMIOLOGY OF OBESITY STUDY
MONDAY, MAY 07
13.45-14.45
**Deadly triangle: FH-PAD-CAD**
Chair: G. De Backer (Belgium)

**SAG37.1** HIGH LIPOPROTEIN (A) LEVELS DO NOT EXACERBATE AORTIC VALVE VELOCITY IN A GROUP OF FH SUBJECTS

**SAG37.2** ONE YEAR FOLLOW-UP IN 45 PATIENTS WITH HETEROZYGOUS FAMILIA HYPERCHOLESTEROLEMIA (HEHF) AFTER TREATMENT WITH ALIROCUMAB: A REPORT FROM A TERTIARY CARE CENTER IN SEVILLE, SPAIN
A. Camacho Carrasco, J.C. Alarcón-García, A. González-Estrada, F. Espinosa-Torre, L. Márquez-López, V. Alfaro-Lara, L. Beltrán-Romero, O. Muñiz Griñalvo (Spain)

**SAG37.3** PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN PATIENTS WITH PREMATURE MYOCARDIAL INFARCTION
Y. Cui, S. Li, F. Zhang, J. Song, C. Lee, M. Wu, H. Chen (China)

**SAG37.4** PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH PHENOTYPICAL FAMILIAL HYPERCHOLESTEROLEMA IN ACUTE CORONARY SYNDROME
S. Mirzaee, P. Thein, J. Cameron, A. Nasis (Australia)

**SAG37.5** CARDIOVASCULAR PROFILE AND TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN GREECE: PRELIMINARY DATA FROM THE HELLENIC REGISTRY HELLAS-FH
C. Rizos, V. Athyros, A. Garoufi, M. Elisaf, G. Kolovou, V. Kotsis, E. Bilianou, L. Rallidis, E. Skalides, I. Skoumas, K. Tziomalos, G. Chrousos, E. Liberopoulos (Greece)

**SAG37.6** CORONARY ARTERY CALCIUM IS INDEPENDENTLY ASSOCIATED TO PULSE WAVE VELOCITY AND LDL CHOLESTEROL BURDEN IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
Mechanisms of vascular diseases
Chair: M. Mayr (United Kingdom)

SAG42.1 IMPACT OF COMBINED USE OF BETA-BLOCKERS AND RENIN-ANGIOTENSION-ALDOSTERONE SYSTEM BLOCKERS ON SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION IN PERCUTANOUS CORONARY INTERVENSION ERA
E.M. Lee, S.S. Hong, K.H. Yun, C.U. Choi, J.W. Kim, E.J. Kim, S.W. Rha, C.G. Park (South Korea)

SAG42.2 DOES LOW BLOOD PRESSURE INCREASE CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE? THE CREDO-KYOTO COHORT-1
H. Kai, T. Kimura, Y. Furukawa (Japan)

SAG42.3 IKB KINASE 2 IMPAIRS PLATELET ACTIVATION
M. Salzmann, M. Mussbacher, W.C. Schrottmair, J.B. Pointner, B. Hoesel, U. Resch, S. Bleichert, M. Moser, A. Assinger, J.A. Schmid (Sweden)

SAG42.4 DECREASE IN VON-WILLEBRAND FACTOR PROTEIN IN THE ENDOTHELIUM OF HUMAN CORONARY ATHEROSCLEROTIC PLAQUES: POSSIBLE MECHANISMS AND ROLE IN THROMBOSIS
U. Tarvala, R. El Matary, T. Nightingale, R. Poston (United Kingdom)

SAG42.5 MECHANISMS OF DIGOXIN-RELATED PLATELET ACTIVATION IN ATRIAL FIBRILLATION PATIENTS: IN VIVO AND IN VITRO STUDY
D. Pastori, C. Nocella, R. Carnevale, V. Cammisotto, F. Violi, P. Pignatelli (Italy)

SAG42.6 SUDDEN CARDIAC ARREST IN FAMILIES WITH PREMATURE ATHEROSCLEROSIS MIGHT BE DUE TO A BRUGADA LIKE SYNDROME
MONDAY, MAY 07
13.45-14.45
FH in clinical practice
Chair: K. Ray (United Kingdom)

SAG44.1 TREAT-TO-TARGET FAMILIAL HYPERCHOLESTEROLEMIA (TTT-FH): A PROSPECTIVE STUDY IN ADULT PATIENTS WITH FH. RESULTS AFTER LONG TERM INTENSIVE LIPID LOWERING TREATMENT IN A SPECIALIZED LIPID CLINIC

SAG44.2 FAMILIAL HYPERCHOLESTEROLAEMIA (FH) GENETIC TESTING IN THE UNITED KINGDOM (UK)

SAG44.3 ADAPTATION OF ACMG/AMP GUIDELINES FOR VARIANT INTERPRETATION IN FAMILIAL HYPERCHOLESTEROLEMIA - A CLINGEN FH EXPERT PANEL PILOT STUDY

SAG44.4 CLINICAL AND GENETIC FEATURES OF FAMILIAL HYPERCHOLESTEROLEMIA IN PEDIATRIC PATIENTS: THE LIPIGEN STUDY
M. Casula, A. Plastina, F. Galimberti, M. Arca, M. Averna, S. Bertolini, S. Calandra, P. Tarugi, A.L. Catapano (Italy)

SAG44.5 IMPROVING FAMILIAL DYSLIPIDAEMIA DIAGNOSIS
R. Graça, N. Rossi, A.C. Alves, A. Medeiros, M. Zimon, T. Raush, V. Benes, R. Peperkok, M. Bourbon (Portugal, Germany)

SAG44.6 ERRORS IN THE IMPUTATION OF LDL-CHOLESTEROL WHEN MAKING A PHENOTYPIC DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLAEMIA IN DRUG TREATED PATIENTS
K. Ellis, J. Pang, G. Watts (Australia)
MONDAY, MAY 07
13.45-14.45

The power of genes
Chair: E. Ehrenborg (Sweden)

SAG46.1 WHOLE GENOME SEQUENCING ASSOCIATION STUDIES OF LIPIDS LEVELS
N. Rossi, M. Falchi, M. Bourbon, A. Visconti (Portugal, United Kingdom)

SAG46.2 INFLUENCES OF APOE GENOTYPES AND CLINICAL CHARACTERISTICS ON LIPID LEVELS AND DYSLIPIDEMIA PREVALENCE IN 467 CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH TYPE 1 DIABETES
U. Groselj, M. Macedoni, T. Hovnik, E. Plesnik, P. Kotnik, N. Bratina, T. Battelino (Slovenia, Italy)

SAG46.3 POLYMORPHISM OF ANXA2 GENE MAY ACCELERATE VULNERABILITY AND CALCINOSIS IN PATIENTS WITH CORONARYATHEROSCLEROSIS
A. Averkova, V. Brazhnik, O. Koroleva, E. Zubova, G. Speshilov, D. Sizgunov, A. Rogozhina, D. Zateyshchikov (Russia)

SAG46.4 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA IN A MONOCHORIONIC DIAVINOTIC TWIN
N.S. Mohd Nor, A. Mahmood Al-Khateeb, Y.A. Chua, S.N.F. Ismail, N.A. Mohd Kasim, H. Mohd Nawawi (Malaysia)

SAG46.5 HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA IN GREECE: EPIDEMIOLOGY, PHENOTYPIC AND GENOTYPIC CHARACTERISTICS FROM 39 PATIENTS
E. Drogari, E. Laios, P. ProgiA, V. Mollaki (Greece)

SAG46.6 A CASE OF HOMOZYGOUS FAMILIAL HYPERCHOLESTROLEMIA IN PREGNANCY
N.A. Mohd Kasim, A. Al-Khateeb, Y. Chua, S. Ismail, A. Sanusi, A. Rosman, H. Nawawi (Malaysia)
MONDAY, MAY 07
13.45-14.45
Clinical aspects of lipids, genetics, and interventions II
Chair: P. Kovanen (Finland)

SAG7.1 ELEVATED LDL CHOLESTEROL FROM BIRTH IS ASSOCIATED WITH DIFFERENT RISK OF VARIOUS TYPES OF ATHEROSCLEROTIC DISEASE

SAG7.2 KINETICS OF PLASMA APOLIPOPROTEIN E ISOFORMS IN HUMANS BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS)
M. Croyal, V. Blanchard, S. Ramin-Mangata, K. Ouguerram, G. Lambert, M. Krempf (France)

SAG7.3 GENETIC VARIATION IN CLUSTERIN AND RISK OF DEMENTIA AND ISCHEMIC VASCULAR DISEASE IN THE GENERAL POPULATION - COHORT STUDIES AND META-ANALYSES OF 362,338 INDIVIDUALS
L.T. Nordestgaard, A. Tybjaerg-Hansen, K.L Rasmussen, B.G. Nordestgaard, R. Frikke-Schmidt (Denmark)

SAG7.4 REDUCTIONS IN GLYCAEMIC PARAMETERS THAN CHANGES IN LDL-C OR TOTAL APOLIPOPROTEIN B

SAG7.5 PCSK9-INHIBITOR TREATMENT OF CARDIOVASCULAR HIGH RISK PATIENTS IN CLINICAL PRACTICE – NEW DATA REGARDING SAFETY AND EFFECTIVITY
T. Hollstein, T. Grenkowitz, H. Scharnagl, W. März, E. Steinhagen-Thiessen, U. Kassner (Germany, Austria)
MONDAY, MAY 07
14.45-15.45

**Novelties in the pathogenesis of atherosclerosis**
Chair: P. Rensen (The Netherlands)

SAG10.1 **LEPTIN AND RESISTIN AFFECT PCSK9 EXPRESSION: IN VITRO AND IN VIVO EVIDENCE**
C. Macchi, M. Botta, S. Marchiano, P. Dongiovanni, L. Valenti, A. Cicero, P. Magni, A. Corsini, N. Ferri, M. Ruscica (Italy)

SAG10.2 **METABOLIC SYNDROME PREVALENCE IS INCREASED WITH INCREASING THYROID HORMONE RESISTANCE LEVELS AMONG NORMOTHYROID SUBJECTS**
M. Laclaustra, B. Moreno-Franco, R. Mateo-Gallego, S. Perez-Calahorra, I. Lamiquiz-Moneo, V. Marco-Benedi, A. Cenarro, J.A. Casasnovas, F. Civeira (Spain)

SAG10.3 **MATERNAL GESTATIONAL DIABETES AND OBESITY, IMPACT ON CAROTID ARTERY STIFFNESS AND INTIMA-MEDIA THICKNESS IN THE OFFSPRING - RADIEL STUDY 6 YEARS FOLLOW-UP**
J. Sundholm, L. Litwin, S.B. Koivusalo, K. Rönö, J.G. Eriksson, T. Sarkola (Finland, Poland)

SAG10.4 **OSTEOPROTEGERIN CONCENTRATION IS ASSOCIATED WITH PRESENCE AND SEVERITY OF PERIPHERAL ARTERIAL DISEASE IN TYPE 2 DIABETES MELLITUS**
M. Kozarova, K. Demkova, Z. Malachovska, M. Javorsky, I. Tkac (Slovak Republic)

SAG10.5 **PLASMA LEVEL OF TRIMETHYLAMINE-N-OXIDE IS NOT CORRELATED TO THE INTIMA-MEDIA THICKNESS IN JAPANESE; SHIMANE COHRE STUDY**
S. Yano, Y. Notsu, K. Yamaguchi, T. Abe, K. Yamada, A. Nagai, K. Tanabe, T. Nabika (Japan)

SAG10.6 **ALDOSTERONE INDUCES LONG-TERM PRO-ATHEROGENIC CHANGES IN PRIMARY HUMAN MACROPHAGES**
C. Van Der Heijden, S.T. Keating, L.A.B. Joosten, M.G. Netea, N.P. Riksen (The Netherlands, Germany)
MONDAY, MAY 07
14:45-15:45

**Imaging**
Chair: F.J. Pinto (Portugal)

**SAG13.1** ESTABLISHMENT OF NOVEL IRFP INCORPORATED IN VIVO MURINE ATHEROSCLEROSIS IMAGING SYSTEM
K. Kulathunga, Y. Hiraishi, M. Hamada, M. Tran, T. Sakasai, Y. Miwa, S. Takahashi (Japan)

**SAG13.2** DISSOCIATION BETWEEN CORONARY ARTERY CALCIUM AND CARDIOVASCULAR RISK FACTORS IN ASYMPTOMATIC PATIENTS IN A RISK ASSESSMENT CLINIC
C. Vargas García, J. Pang, G.F. Watts, W. Bishop (Australia)

**SAG13.3** PLAQUE BURDEN IN CAROTID AND FEMORAL ARTERIES MEASURED BY 3D VERSUS 2D ULTRASOUND AND ASSOCIATION WITH CORONARY CALCIUM IN MEN WITH INTERMEDIATE CARDIOVASCULAR RISK
E. Jarauta, M. Laclaustra, R. Villa-Pobo, R. Langarita, V. Marco-Benedi, A. Bea, M. Leon-Latre, < J.A. Casasnovas, F. Civeira (Spain)

**SAG13.4** PROLONGED HEMATOPOIETIC AND MYELOID CELLULAR RESPONSE IN PATIENTS AFTER A MYOCARDIAL INFARCTION MEASURED WITH 18F-DPA-714 PET/CT

**SAG13.5** THE RELATION BETWEEN CORONARY TORTUOSITY AND AORTIC STIFFNESS IN PATIENTS WITH CHRONIC STEABLE ANGINA AND NORMAL CORONARIES BY CT ANGIOGRAPHY
M. El Tahlawi, M. Hasan, M. Zidan, A. Shafie (Egypt)

**SAG13.6** SUBCLINICAL ARTERIOSCLEROSIS IN AN ACTIVE POPULATION GROUP
J. Espildora Hernandez, T. Diaz Antonio, G. Garcia Gutierrez, M Acebal Blanco, I. Alonso Calderón, P. Valdivielso Felices, M.A. Sanchez Chaparro (Spain)
MONDAY, MAY 07
14:45-15:45

**Inflammation and monocyte/macrophage function**
Chair: F.K. Swirski (USA)

**SAG14.1** PHARMACOLOGICAL INHIBITION OF HISTONE DEACETYLASE MITIGATES MARKERS OF OXIDATIVE STRESS AND INFLAMMATION IN HYPERCHOLESTEROLEMIC APOLIPOPROTEIN E DEFICIENT MICE

**SAG14.2** ANTI-APOLIPOPROTEIN A1 (APOA1) AUTOANTIBODIES DISRUPT THE CHOLESTEROL PATHWAY VIA SREBP-2 AND DECREASE CIRCULATING MIR-33A IN HYPERCHOLESTEROLAEMIC CHILDREN
P. Sabrina, A. Magenta, M. D’Agostino, F. Martino, F. Barillà, N. Satta, M. Frias, B. Gencer, F. Mach, N. Vuilleumier (Switzerland, Italy)

**SAG14.3** BLTR1 IN MONOCYTES MEDIATES MONOCYTE DIFFERENTIATION INTO MACROPHAGE AND VASCULAR INFLAMMATION IN WIRE-INJURED MICE FEMORAL ARTERY
S.E. Baek, S.Y. Park, C.D. Kim (South Korea)

**SAG14.4** SOLUBLE NINJURIN-1, A MATRIX METALLOPROTEINASE-9 SUBSTRATE, IS A NOVEL PROTECTIVE FACTOR AGAINST ATHEROSCLEROSIS
S. Jeon, T.K. Kim, G.T. Oh (South Korea)

**SAG14.5** REDUCED SYSTEMIC INFLAMMATION AND INCREASED REVERSE CHOLESTEROL TRANSPORT TOGETHER DRIVE LEUKOCYTE ABCA1-MEDIATED PROTECTION AGAINST ATHEROSCLEROSIS
SCIENCE AT A GLANCE

MONDAY, MAY 07
14.45-15.45
Smooth muscle cells biology - Session 2
Chair: G.K. Owens (USA)

SAG17.1 TWEAK OR FN14 INSUFFICIENCY INHIBITS NEOINTIMAL HYPERPLASIA THROUGH REDUCTION OF CYCLIN/CDKS EXPRESSION AND IMPAIRED VASCULAR SMOOTH MUSCLE CELLS PROLIFERATION

SAG17.2 IL-22 DEFICIENCY REDUCES PROGRESSION OF ADVANCED ATHEROSCLEROTIC CAROTID PLAQUES IN APOE DEFICIENT MICE

SAG17.3 HIF-1 ACTIVATION IN VASCULAR SMOOTH MUSCLE CELLS TRIGGERS OSTEOCHONDROGENIC REPROGRAMMING AND CONTRIBUTES TO VASCULAR CALCIFICATION
E. Balogh, A. Tóth, G. Méhes, Gy. Paragh, V. Jeney (Hungary)

SAG17.4 NLRP3 INFLAMMASOME AS A POTENTIAL PHARMACOLOGICAL TARGET IN DAMAGE-ASSOCIATED VASCULAR INFLAMMATION
C.D. Kim, E.J. Kim, S.E. Baek, S.Y. Park (South Korea)
MONDAY, MAY 07
14.45-15.45
HDL metabolism
Chair: M. Jauhiainen (Finland)

SAG2.1 A BENEFICIAL ROLE OF ATP-BINDING CASSETTE TRANSPORTER G1-MEDIATED CHOLESTEROL EFFLUX CAPACITY IN REGRESSION OF CORONARY LIPID CONTENT ASSESSED BY NEAR-INFRARED SPECTROSCOPY

SAG2.2 HUMAN APOA-I OVEREXPRESSION AMELIORATES TWO MAIN CARDIOPROTECTIVE FUNCTIONS OF HDL IN DB/DB MICE
K.A. Méndez Lara, N. Farré, D. Santos, J.L. Sánchez-Quesada, J.C. Escolá- Gil, J.M. Martín- Campos, F. Blanco Vaca, J. Julve (Spain)

SAG2.3 APOLIPOPROTEIN A-I DEFICIENCY ALTERS THE SMALL INTESTINE TRANSCRIPTOME AND INCREASES THE EXPRESSION OF THE ANTIMICROBIAL ENZYME DUOX2
M. Busnelli, S. Manzini, A. Colombo, C. Parolini, G. Chiesa (Italy)

SAG2.4 HYPERLIPIDEMIA MODIFIES HDL-MIRNA PROFILE AND ENHANCES ENDOTHELIAL DELIVERY OF HDL- MIR126-3P/-5P THROUGH A SRB-1-DEPENDENT MECHANISM
S. Ben-Aicha Gonzalez, S. Camino Lopez, T. Padro Capmany, L. Casani Arazo, G. Mendieta Badimon, R. Escate Chavez, L. Badimon Maestro, G. Vilahur Garcia (Spain)

SAG2.5 APOA-1 IS OXIDIZED IN ABDOMINAL AORTIC ANEURYSM AND PROMOTES DYSFUNCTIONAL HDLS
D. Martínez López, L. Cedo, E. Camafeita, R. Montero Roldan, I. Jorge, E. Burillo, F. Blanco Vaca, L. Blanco Colio, J. Egido, J. Baptiste Michel, J. Vázquez , J. Escola Gil, J. Martín Ventura (Spain, France)

SAG2.6 METABOLICALLY ACTIVATED AND CLASSICALLY ACTIVATED PRO-INFLAMMATORY M1 MACROPHAGES EXHIBIT DIVERGENT EFFECTS ON ABCA1 CHOLESTEROL EFFLUX CAPACITY
M. O’Reilly, S. Kajani, M. Goodwin, K. Hughes, H. Roche, F. McGillicuddy (Ireland)
Vascular biology - Session 3
Chair: L. Yvan-Charvet (France)

SAG20.1 Predilection of Low Protein C-Induced Spontaneous Atherothrombosis for the Right Coronary Sinus in Apolipoprotein E-Deficient Mice
A. Ouweneel, M. Heestermans, J. Hassan, M. Kloosterman, M.J.J. Gijbels, B.J.M. Van Vlijmen, M. Van Eck (The Netherlands)

SAG20.2 Reduced Thrombin-Mediated Platelet Activation in Dapagliflozin-Treated LDLR-Deficient Mice: Implications for Atherosclerosis

SAG20.3 SOCS1-Based Therapies Mitigate Vascular and Renal Oxidative Stress in Diabetic Mice through STAT1 and PI3K-Dependent Mechanisms
L. López Sanz, S. Bernal, I. Lazaro, I. Jimenez Castilla, A. Melgar, J. Egido, C. Gomez Guerrero (Spain)

SAG20.4 Hyperglycemia Does Not Affect Tissue Repair in Mouse Models of Arterial Lesions with Different Morphologies

SAG20.5 Studies in Zebrafish Annotate CNNM2 and NT5C2 as the Most Likely Causal Genes at the Blood Pressure Locus on Chromosome 10q24.32
K.K. Vishnolia, K. Tarhbalouti, S. Wrobel, Z. Aherrahrou, J. Erdmann (Germany)

SAG20.6 The Expressions of HSA-MIR-4530 and HSA-MIR-133B are Inversely Correlated with Calcium Scores in Carotid Plaques
H. Katano, M. Mase (Japan)
MONDAY, MAY 07
14:45-15:45

CVD risk models
Chair: O. Wiklund (Sweden)

SAG29.1 CLINICAL RELEVANCE OF SCREENING TESTS TO IDENTIFY DIABETES IN PATIENTS WITH Atherosclerotic Cardiovascular Disease: A Prospective Population-Based Cohort Study

SAG29.2 MULTILEVEL MODELS TO ESTIMATE STANDARD INTIMA-MEDIA THICKNESS CURVES FOR INDIVIDUAL CARDIOVASCULAR RISK EVALUATION

SAG29.3 COST-UTILITY ANALYSIS OF SEARCHING ELECTRONIC HEALTH RECORDS AND CASCADE TESTING TO IDENTIFY AND DIAGNOSE FAMILIAL HYPERCHOLESTEROLAEMIA IN ENGLAND AND WALES
S. Humphries, P. Crosland, R. Maconachie, S. Buckner, H. Mcguire, J. Pink, N. Qureshi (United Kingdom, Australia)

SAG29.4 CLINICAL UTILITY OF A NEW PREDICTIVE MODEL OF CARDIOVASCULAR RISK IN A YOUNG AND MIDDLE-AGED WORKING POPULATION
P. Valdivielso-Felices, M.A. Sánchez-Chaparro, C. Fernández-Labandera Ramos, C. Catalina-Romero, L. Quevedo-Aguado, P. Martínez-Muñoz, E. Calvo-Bonacho (Spain)

SAG29.5 TELEMEDICINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE SPANISH HEALTH SYSTEM. ENREDA2 STUDY.
P. Rodríguez-Fortúnez, J. Franch-Nadal, J. Fornos-Perez, L. Orera-Peña, M. Rodríguez de Miguel (Spain)

SAG29.6 THE EFFECT OF LONG-TERM LOW LIPOPROTEINS ON NEUROCOGNITIVE FUNCTION
R. Verbeek, S.M. Boekholdt, R. Luben, E.S.G. Stroes, K-T Khaw, G.K. Hovingh (The Netherlands, United Kingdom)
MONDAY, MAY 07
14.45-15.45
Genetics of FH and dyslipidemia
Chair: A. Tybjaerg-Hansen (Denmark)

SAG35.1 LOW SNP SCORE FOR POLYGENIC HYPERCHOLESTEROLEMIA ASSOCIATES WITH POOR METABOLIC PROFILE
C. Gustafsson, L. Håkansson, C. Pirazzi, R. Mancina, S. Romeo, O. Wiklund (Sweden)

SAG35.2 A MENDELIAN RANDOMIZATION STUDY COMPARING THE EFFECT OF LOW-DENSITY LIPOPROTEINS AND TRIGLYCERIDE-RICH VERY LOW-DENSITY LIPOPROTEINS ON THE RISK OF CORONARY HEART DISEASE
B.A. Ference, J.J.P. Kastelein, A.D. Sniderman, M.S. Sabatine, A.L Catapano (United Kingdom, Canada, The Netherlands, USA, Italy)

SAG35.3 MUTATIONS IN LDLR, APOB, PCSK9 AND APOE GENES CONTRIBUTE TO THE GENETIC SPECTRUM OF FAMILIAL HYPERCHOLESTEROLAEMIA IN THE NORTH OF ENGLAND
L. Johnston, A. Potter, P. Carey, A. Luvai, P. McKenna, J. Weaver, S. Pattman, S. Kamaruddin, V. Arutchevelam, M. Anderson, M. Burns, N. Hopper, R. Sutton, C. McAnulty, A. Curtis, R. Neely (United Kingdom)

SAG35.4 DNA COPY NUMBER VARIATION SCREENING IN FAMILIAL HYPERCHOLESTEROLEMIA-RELATED GENES
M. Iacocca, J. Wang, J. Dron, H. Cao, J. Robinson, A. McIntyre, R. Hegele (Canada)

SAG35.5 THE FREQUENCY AND THE SPECTRUM OF CAUSATIVE MUTATIONS IN JAPANESE FAMILIAL HYPERCHOLESTEROLEMIA HETEROZYGOTES
M. Hori, N. Ohta, H. Masuda, C. Son, K. Hosoda, M. Ogura, Y. Miyamoto, M. Harada-Shiba (Japan)

SAG35.6 THE IMPORTANCE TO TRACK VARIANTS IN A GENES CAUSING RECESSIVE DISORDERS WITHIN THE FAMILY: A FH/SITOSTEROLEMIA CLINICAL CASE
R. Graça, L. Abrantes, N. Rossi, A. Alves, A. Medeiros, M. Zimon, T. Rausch, V. Benes, R. Pepperkok, M. Bourbon (Portugal, Germany)

SAG35.7 CLINICAL, DEMOGRAPHIC AND GENETIC CHARACTERISTICS OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WORLDWIDE: INTERIM RESULTS FROM THE HOFH INTERNATIONAL CLINICAL COLLABORATORS (HICC) REGISTRY
M. Hartgers, M. Cuchel, G.K. Hovingh, D.J. Blom, F.J. Raal (The Netherlands, USA, South Africa)
MONDAY, MAY 07
14.45-15.45

Effects of statin and anti-PCSK9 treatment in special populations
Chair: P. Moulin (France)

SAG38.1 INFLUENCE OF EFFECTIVE LIPID-LOWERING THERAPY ON WORSENING OF HEART FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
V. Oleynikov, Y. Barmenkova, E. Dushina, Y. Tomashevskaya (Russia)

SAG38.2 BENEFIT OF LDL-C LOWERING WITH EVOLOCUMAB ON CARDIOVASCULAR OUTCOMES BY AGE & SEX: AN ANALYSIS OF THE FOURIER TRIAL
P. Sever, I. Gouni-Berthold, A. Keech, R Giugliano, T. Pedersen, S. Wasserman, K. Im, M. Sabatine, M. O’Donoghue (United Kingdom, Germany, Australia, USA, Norway)

SAG38.3 PERIOPERATIVE STATINS PREVENT EARLY COMPLICATIONS OF THE SURGICAL REVASCULARIZATION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
I. Shklianka, O. Zhariav, K. Mikhailiev, O. Yepanchintseva (Ukraine)

SAG38.4 HYPERLIPIDAEMIA MANAGEMENT IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND STATIN INTOLERANCE
R. Hossain, C. Rallison (United Kingdom)

SAG38.5 STATIN THERAPY IN VERY FRAIL OLDER ADULTS
M. Ferreira, M.J. Pinto, D. Ferreira, H. Esperto, M.T. Verissimo, A. Carvalho (Portugal)
MONDAY, MAY 07
14.45-15.45
Dyslipidemia
Chair: M. Teixeira Veríssimo (Portugal)

SAG41.1 IDENTIFICATION AND DIAGNOSIS OF PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS): EXPERT PANEL RECOMMENDATIONS AND PROPOSAL OF AN “FCS SCORE”
P. Moulin (France)

SAG41.2 HIGH DENSITY LIPOPROTEIN PARTICLES PROFILE BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND LONG TERM TOTAL AND CARDIOVASCULAR MORTALITY IN CORONARY ARTERY PATIENTS: THE GENES STUDY
A. Genoux, J.B. Ruidavets, J. Ferrieres, B. Perret, L.O. Martinez (France)

SAG41.3 A COMPARISON OF CHOLESTEROL LEVELS IN UMBILICAL CORD BLOOD AND IN NEONATAL BLOOD - THE COMPARE STUDY
N. Strandkjaer, R. Frikke-Schmidt, M.K. Hansen, P.R. Kamstrup, A. Tybjærg-Hansen, B. Nordestgaard, A. Tabor, K. Sundberg, H. Bundgaard, K. Iversen (Denmark)

SAG41.4 LIPID TARGET ATTAINMENT IN A SPECIALIZED LIPOID CLINIC
F. Barkas, E. Pappa, E. Liberopoulos, T. Filippatos, M. Florentin, F. Christopoulou, M. Elisaf, G. Liamis (Greece)

SAG41.5 REAL-WORLD EVIDENCE ON LDL-C GOAL ATTAINMENT RATE AND LIPOID MANAGEMENT PATTERNS POST-ACS IN GREECE: THE POST-ACUTE CORONARY SYNDROME STUDY (PACSS)
C. Vlachopoulos, F. Spanoudi, L. Michalis, F. Parthenakis, D. Richter, F. Triposkiadis, E. Tsougos, G. Hahalis (Greece)

SAG41.6 DYSLIPIDEMIA ACCELERATES VASCULAR AGING
D. Terentes-Printzios, C. Vlachopoulos, I. Koutagiar, N. Ioakeimidis, K. Aznaouridis, P. Xaplanteris, C. Georgakopoulos, D. Tousoulis (Greece)
**MONDAY, MAY 07**

14.45-15.45

**Clinical aspects of lipids, genetics, and interventions III**

Chair: U. Laufs (Germany)

SAG9.1  A RARE CASE OF SEVERE FAMILIAL HYPERTRIGLYCERIDEMIA WITH VARIABLE PHENOTYPIC EXPRESSION AND RESPONSE TO LIPID LOWERING TREATMENTS

D. Di Monte, A. Giammanco, R. Spina, F. Caradio, A.B. Cefalu, F. Cipollone, M. Bucci (Italy)

SAG9.2  A BASELINE METABOLOMIC SIGNATURE IS ASSOCIATED WITH IMMUNOLOGICAL CD4+ T-CELL RECOVERY AFTER 36 MONTHS OF ART IN HIV-INFECTED PATIENTS


SAG9.3  LIPOPROTEIN LIPASE GENE REPLACEMENT THERAPY LONG-TERM EFFECT ON FAMILIAL HYPERCHYLOMICRONEMIA GENE EXPRESSION PROFILE

K. Tremblay, D. Brisson, D. Gaudet (Canada)

SAG9.4  STATIN TREATMENT, GENETIC INHIBITION OF HMGCR AND RISK OF SYMPTOMATIC GALLSTONE DISEASE

F. Qayyum, B.K. Lauridsen, R. Frikke-Schmidt, B.G. Nordestgaard, A. Tybjaerg-Hansen (Denmark)

SAG9.5  BARIATRIC SURGERY ENHANCES REVERSE CHOLESTEROL TRANSPORT AND HIGH DENSITY LIPOPROTEIN FUNCTIONALITY

J.H. Ho, S. Adam, T. Siahmansur, Y. Liu, S. Azmi, R. Aghamohammadmazdeh, K. Siddals, R.A. Malik, A.A. Syed, B.J. Ammori, P.N. Durrington, R. Donn, H. Soran (United Kingdom, Qatar, United Kingdom)

SAG9.6  METABOLIC EFFECTS OF PHLEBOTOMY IN SUBJECTS WITH HYPERTRIGLYCERIDEMIA AND IRON OVERLOAD: A PROSPECTIVE, RANDOMIZED, CONTROLLED TRIAL

A. Cenarro, R. Mateo-Gallego, L. Lacalle, S. Perez-Calahorra, V. Marco-Benedi, V. Recasens, N. Padron, I. Lamiquiz-Moneo, L. Baila-Rueda, E. Jarauta, P. Calmarza, F. Civeira (Spain)
Poster Sessions
POSTER SESSIONS

SUNDAY, MAY 06
17.00-18.30

1. Atherosclerosis

1.1 Inflammation and immunity in atherosclerosis

P1.1.001 CCL22 EXPRESSION AND MACROPHAGE DIFFERENTIATION VIA HISTAMINE IN ATHEROSCLEROSIS
S. Kimura, H. Noguchi, T. Nakayama (Japan)

P1.1.002 FORMYL PEPTIDE RECEPTORS 1-3 AND ANNEXIN 1 IN ATHEROSCLEROTIC PLAQUES - TAMPERE VASCULAR STUDY

P1.1.003 PER OS COLCHICINE ADMINISTRATION IN CHOLESTEROL FED RABBITS: TRIGLYCERIDES LOWERING EFFECTS WITHOUT AFFECTING ATHEROSCLEROSIS PROGRESS
V.V. Kaminiotis, G. Agrogiannis, P. Konstantopoulos, V. Androutsopoulos, L.M. Korou, I.S. Vlachos, I. Dontas, D. Perrea, D. Iliopoulos (Greece)

P1.1.004 MONOMERIC C-REACTIVE PROTEIN AND LOCAL INFLAMMATORY RESPONSE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
I. Melnikov, P. Chumachenko, S. Kozlov, A. Majorova, O. Saburova, T. Portnaya, M. Osidak, S. Domogatsky, L. Buryachkovskaya, Z. Gabbasov (Russia)

P1.1.005 THE DYNAMICS OF THE INFLAMMATORY STATUS BIOMARKER UNDER THE TREATMENT WITH NEBIVOLOL IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY DEPENDING ON THE STENT’S LENGTH
L. Simionov (Republic of Moldova)

P1.1.006 PLATELET-DERIVED MICROPARTICLES INDUCE THE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS
I. Moschonas, A. Tselepis (Greece)

P1.1.007 OXYSTEROLS OF VARIOUS ORIGIN AFFECT MEMBRANE ENDOGLIN EXPRESSION DIFFERENTLY IN HUMAN AORTIC ENDOTHELIAL CELLS
M. Vicen, M. Varejckova, R. Havelek, E. Dolezelova, A. Prasnicka, P. Nachtigal (Czech Republic)
P1.008  RELATION BETWEEN SOME MARKERS OF INFLAMMATION, THROMBOSIS, HOMOCYSTEIN, LIPIDS AND CAROTID ARTERIES STENOSIS IN PATIENTS WITH CAROTID ATHEROSCLEROSIS
M. Akhvlediani, E. Vorobiova, M. Emukhvari, D. Gachechiladze, T. Kvantaliani (Georgia)

P1.009  HIGH PREVALENCE OF DYSLIPEMIA AND PREMATURE CARDIOVASCULAR EVENTS IN HIV PATIENTS UNDER MONITORING
E. Clavero Fernández, M.A. Castro Iglesias, A. Mena De Cea, J.L. Diaz Diaz, V. Balboa Barreiro (Spain)

P1.010  NEW INSIGHT INTO RAYNAUD’S IN VIEW OF STABLE CORONARY SYNDROME
T. Kvantaliani, M. Akhvlediani (Georgia)

P1.011  EFFECT OF CAROTENOIDS ON CONNEXINS EXPRESSION IN LEFT VENTRICLE DURING MODERATE INFLAMMATION
K. Frimmel, R. Sotnikova, J. Navarova, V. Knezl, J. Krizak, L. Okruhlicova (Slovak Republic)

P1.012  ACUTE MYOCARDIAL INFARCTION IN ELDERLY PATIENTS: PROINFLAMMATORY INFRINGEMENTS
V. Pasko, V. Batushkin (Ukraine)

P1.013  EFFECTS OF ANTIRETROVIRAL THERAPY ON LIPID AND IMMUNOVIROLOGICAL PROFILE: FOCUS ON PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9
V. Bianconi, E. Schiaroli, D. Francisci, M. R Mannarino, F. Bagaglia, F. Baldelli, M. Pirro (Italy)

P1.014  NOVEL RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
N. Latsabidze (Georgia)

P1.015  CLINICAL AND PATHOGENETIC SIGNIFICANCE OF ANTIPHOSPHOLIPID SYNDROME COMPONENTS IN PATIENTS WITH CORONARY HEART DISEASE
M. Nazarova (Ukraine)

P1.016  DECREASED INFLAMMASOME ACTIVATION IN HEALTHY SUBJECTS TREATED WITH BENZBROMARONE
Y. Kimura, T. Yanagida, D. Tsukui, K. Asako, H. Kikuchi, H. Kono (Japan)

P1.017  RHYNCHOPHYLLINE DECREASES INFLAMMATORY DAMAGE AND ALLEVIATES PRETHROMBOTIC STATE THROUGHT RESCUING THE AUTOPHAGY IMPAIRMENT MEDIATED BY TNF-A
C. Li, Y.L. Li, W.Q. Yang, L. Zhang, L. Lin, Z.B. Gai (China, Switzerland)
P1.1.018 MODULATION OF EPIGENETIC BET PROTEINS WITH RVX-208 IN INFLAMMATORY MONOCYTES FROM DIABETIC SUBJECTS
I. Nicorescu, N. Timmers, E. Stroes, S. Bernelot, M. Bahjat (Canada)

P1.1.019 ESTIMATION OF INFLAMMATION MARKER LEVELS, AS WELL AS MMP-2 PRIOR AND AFTER CORONARY STENTING ACCORDING TO ATHEROSCLEROSIS PLAQUE MORPHOLOGY
N. Abduzhamalova, A. Tereschenko, V. Masenko, E. Merkulov, V. Naumov (Russia)

P1.1.020 URINARY LEUKOTRIENES AND THROMBOXANES - NEW PROGNOSTIC BIOMARKER OF RECURRING RESTENOSIS IN PATIENTS WITH LOWER LIMB ISCHEMIA?
M. Maga, A. Wachsmann, P. Maga, R. Nizankowski (Poland)

P1.1.021 TRANSGELIN AS A PROMISING MARKER FOR THE STUDY OF IMMUNE STATUS IN ATHEROSCLEROSIS
R. Zhetisheva, M. Kovaleva, I. Kamenihina, T. Isaykina, M. Shogenova, A. Karpov, L. Kovalev, V. Naumov (Russia)

P1.1.022 TRADITIONAL AND NON-TRADITIONAL RISC FACTORS FOR CARDIOVASCULAR DISEASES IN PATIENTS WITH RHEUMATOID ARTHRITIS
A. Bijedic, Z. Kusljugic, I. Bijedic, D. Loncar, E. Tulumovic, A. Pilavdzic (Bosnia and Herzegovina)

P1.1.023 SOME INFLAMMATORY MARKERS IN METABOLIC SYNDROME - ROLE OF EOSINOPHILS
E.A. Coman, E. Popa, M. Boanca, A. Wattad, M.G. Traian, A. I. Bacusca (Romania)

P1.1.024 INTERLEUKIN 10 GENE POLYMORPHISMS ARE ASSOCIATED WITH A DECREASED RISK OF DEVELOPING PREMATURE CORONARY ARTERY DISEASE AND SOME CLINICAL AND METABOLIC PARAMETERS. THE GEA STUDY

P1.1.025 ASSOCIATION BETWEEN SERUM URIC ACID AND ATHEROSCLEROTIC CAROTID DISEASE IN PATIENTS WITH ACUTE ISCHEMIC STROKE
J.C. Arévalo-lorido, J. Carretero-Gómez, N.R. Robles (Spain)

P1.1.026 INTERLEUKIN 17 AND PRE-CLINICAL VASCULAR DAMAGE IN METABOLIC SYNDROME
V. Veca, F. Barsotti, I. Bellofatto, G. Lupattelli, D. Siepi, C. Vacca, M.A. Ricci, C. Natali, G. Vaudo (Italy, United Kingdom)
POSTER SESSIONS

P1.1.027 POSTPRANDIAL INTERLEUKIN RESPONSE AFTER AN ORAL FAT LOAD TEST IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
E. Perelló, E. Savall, S. Martínez-Hervás, M. Civera, J.T. Real, J.F. Ascaso (Spain)

P1.1.028 AN INHIBITOR TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES INHIBITED PRO-INFLAMMATORY EFFECT IN ATHEROSCLEROTIC PLAQUES
M. Rahman, J. Steuer, P. Gilgren, A. Liu, J. Frostegård (Sweden)

P1.1.029 THE EFFECTS OF NORDIC WALKING TRAINING ON BLOOD ANTIOXIDANT DEFENCE IN PATIENTS WITH INTERMITTENT CLAUDICATION
E. Rosloniec, M. Wiecek, P. Mika (Poland)

P1.1.030 THE ROLE OF LIPOPROTEIN METABOLISM AND INFLAMMATORY GENE POLYMORPHIMS ON THE CORONARY ARTERY DISEASE WITH TYPE 2 DIABETES MELLITUS

P1.1.031 RELATIONSHIP BETWEEN METABOLIC SYNDROME AND ORAL/DENTAL PATHOLOGY
B. Gonzalez Navarro, E. J. Salas, J. López López, A. Rodriguez Sánchez, X. Corbella, X. Pintó Sala (Spain)

P1.1.032 ROLE OF CD4+ T CELLS IN ANGIOTENSIN II-INDUCED ATHEROSCLEROSIS AND PLAQUE VULNERABILITY IN 2-KIDNEY, 1-CLIP APOE-/- MICE
M. Pellegrin, K. Bouzourene, J. Aubert, L. Mazzolai (Switzerland)

P1.1.033 CYTOMEGALOVIRUS ACTIVATION IS ASSOCIATED WITH ENDOTHELIAL FUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
A. Lebedeva, E. Maryukhnich, W. Fitzgerald, E. Nikitskaya, N. Ryazankina, J. Grivel, A. Shpektor, L. Margolis, E. Vasilieva (Russia, USA, Qatar)

P1.1.034 THE STATES OF INTERLEUKIN-10 IN PLASMA IN PATIENTS WITH ACUTE CORONARY SYNDROME
A. Nizomov, K. Gulyamova, M. Mukhamedova (Uzbekistan)

P1.1.035 DEVELOPMENT OF METHODS FOR MODELING KEY ASPECTS OF THE PATHOGENESIS OF ATHEROSCLEROSIS IN GENETICALLY MODIFIED ANIMALS
A. Deykin, A. Orekhov (Russia)

P1.1.036 LIPID PROFILE AND BIOCHEMICAL MARKERS OF INFLAMMATION IN PATIENTS WITH UNSTABLE ANGINA AND OBSTRUCTIVE VERSUS NON-OBSTRUCTIVE CORONARY ARTERY DISEASE
N. Musikhina, T. Petelina, N. Galeeva, A. Kostousova, L. Gapon (Russia)
P1.1.037  ASGR1 - TARGETING THREE ASPECTS OF ATHEROSCLEROSIS
L. Ali, M.A.W.V.D. Boogert, E.G.S. Stroes (The Netherlands)

P1.1.038  EVALUATION OF APOPTOSIS IN LYMPHOCYTES FROM PATIENTS WITH ACUTE CORONARY SYNDROMES
C.R. Revnic, C. Ginghina, F. Revnic, B. Paltineanu, S. Voinea (Romania)

P1.1.039  BIOCHEMICAL STUDIES OF POLYMORPHONUCLEAR CELLS (PMN) ACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES
C.R. Revnic, C. Ginghina, F. Revnic, S. Voinea (Romania)

P1.1.040  MODULATIONS IN HUMORAL IMMUNE RESPONSES TO AUTOANTIGENS ARE BLOOD-SITES DEPENDENTS
V. Sant Anna, R. Souza, A. Barbosa, M. T. Souza, J. Sousa, C. Alves, A. Carvalho, F. Fonseca, M. Izar, M. Gidlund, H. Fonseca (Brazil)

P1.1.041  PERCUTANEOUS CORONARY INTERVENTION MODULATES INFLAMMATORY RESPONSE AFTER STENT IMPLANTATION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
V. Sant Anna, R. Souza, A. Barbosa, M. Souza, J. Sousa, C. Alves, A. Carvalho, F. Fonseca, M. Izar, M. Gidlund, H. Fonseca (Brazil)

P1.1.041bis  LOW-GRADE INFLAMMATION IN PATIENTS WITH CORONARY ARTERY DISEASE AND TYPE 2 DIABETES MELLITUS
V. Genkel, A. Salashenko, K. Nikushkina, T. Shamaeva, I. Shaposnik (Russia)

1.2 Macrophages in lipid metabolism and atherosclerosis

P1.2.042  MACROPHAGES OF ADIPOSE TISSUE MIGHT AFFECT LIFE EXPECTANCY OF FH INDIVIDUALS
R. Poledne, I. Kralova Lesna, G.H. Hovingh, J.J.P. Kastelein (Czech Republic), (The Netherlands)

P1.2.043  TRANSCRIPTOME ANALYSIS REVEALED INFLAMMATORY GENES RESPONSIBLE FOR FOAM CELL FORMATION
A. Orekhov, Y. Oishi, N. Nikiforov, A. Zhelankin, I. Sobenin, A. Kel, D. Stelmashenko, V. Makeev, K. Foxx, H. Kruth, X. Jin, M. Bukrinsky (Russia, Japan, USA),
P1.2.044  TNF-ALFA AND CCL18 ASSOCIATE WITH ATHEROSCLEROTIC LIPID ACCUMULATION IN SITU AND IN VITRO
A. Orekhov, N. Nikiforov, N. Elizova, G. Korobov, A. Aladinskaya, Y. Bobryshev, I. Sobenin (Russia, Australia)

P1.2.045  THE INTERCONNECTION BETWEEN LXR ACTIVATION AND AUTOPHAGY IN PRIMARY HUMAN MACROPHAGES
P. Saliba-Gustafsson, M. Pedrelli, O. Werngren, P. Parini, E. Ehrenborg (Sweden)

P1.2.046  LYSOSOMAL EXOCYTOSIS INDUCED BY A NOVEL IDENTIFIED FAMILY OF LIPIDS PLAYS A CRITICAL ROLE IN ATHEROGENESIS
O. Vieira (Portugal)

P1.2.047  PPAR-ALPHA INDEPENDENT ANTI-INFLAMMATORY EFFECTS OF FENOFIBRATE IN ATRANSGENIC MODEL OF ATHEROSCLEROSIS
A. Tzani, A. Daskalopoulou, I.P. Doulamis, P. Konstantopoulos, A. Antoranz, A. Minia, G. Marinos, L. Alexopoulos, D.N. Perrea (Greece)

P1.2.048  MACROPHAGE-BASED MODELS FOR DIAGNOSTICS AND THERAPY DEVELOPMENT
A. Melnichenko, T. Kirichenko, M. Stepanova, A. Orekhov (Russia)

P1.2.049  MONOCYTE ACTIVATION: CELLULAR TEST FOR DEVELOPMENT OF DIAGNOSTICS AND THERAPY
M. Stepanova, Y. Oishi, T. Kirichenko, A. Orekhov (Russia, Japan)

1.3 Endothelial dysfunction: clinical assessment

P1.3.050  THE CORRELATION BETWEEN ENDOTHELIAL DYSFUNCTION AND THE TREATMENT WITH NEBIVOLOL IN PATIENTS WITH DIABETES AND ANGINA PECTORIS UNDERGOING CORONARY ANGIOPLASTY
L. Simionov, V. Ivanov (Republic of Moldova)

P1.3.051  PERIPHERAL MICROVASCULAR DYSFUNCTION IN SUBJECTS WITH TYPE2 DIABETES IN ACCORDANCE WITH ABSENCE OR PRESENCE OF CORONARY ARTERY DISEASE
T. Ueda (Japan)
P1.3.052  EFFECTS OF NEBIVOLOL COMBINED WITH RAMIPRIL VS NEBIVOLOL ASSOCIATED AMLODIPINE AND RAMIPRIL ON BIOMARKER OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ANGINA PECTORIS AND ESSENTIAL HYPERTENSION
L. Simionov (Republic of Moldova)

P1.3.053  PATIENTS WITH PRIMARY ALDOSTERONISM HAVE LOWER CIRCULATING ADENOSINE LEVELS BUT SIMILAR SUSCEPTIBILITY TO ISCHEMIA-REPERFUSION COMPARED TO PATIENTS WITH ESSENTIAL HYPERTENSION

P1.3.054  IMPROVING PERIPHERAL ARTERY DISEASE DIAGNOSIS: RESULTS OF A MODERN MULTIMARKER APPROACH

P1.3.055  RELATION OF GLUCIDIC-LIPIDIC PROFILE WITH SEVERAL VALUES OF ENDOTHELIAL INJURY: RESULTS OF A COHORT OF PATIENTS WITH ESSENTIAL HYPERTENSION
F. Espinosa, R. Muñoz, V. Alfaro, P. Jiménez, H.C. Macher, A. Carrasco, L.M. Beltrán, P. Stiefel (Spain)

P1.3.056  SECRETORY CHANGES AND INFLAMMATION ARE ASSOCIATED WITH VASCULAR DYSFUNCTION IN OBSESE PATIENTS
F. Schinzari, M. Tesauro, A. Veneziani, A. Baroni, N. Mores, C. Cardillo (Italy)

P1.3.057  CAROTID ATHEROSCLEROSIS IN FEMALES WITH LOW-ACTIVITY RHEUMATOID ARTHRITIS AND ITS PREDICTORS
O. Sireno, O. Kuryata (Ukraine)

P1.3.058  ELEVATED PLASMA INTERLEUKIN-6 LEVELS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
A. Nizomov (Uzbekistan)

P1.3.059  SYSTEMIC LUPUS ERYTHEMATOSUS AND ATHEROSCLEROSIS: ACCIDENTAL ASSOCIATION OR PATHOGENIC CONSEQUENCE?
M. Parvu, S. Coman, M. Tilinca, S. Voidazan (Romania)
P1.3.060  DO THE CLINICAL OUTCOMES IN PATIENTS WITH PERIPHERAL ARTERY DISEASE UNDERGOING ENDOVASCULAR TREATMENT DEPEND ON PULSE WAVEFORM ANALYSIS INDICES AND ENDOTHELIAL FUNCTION PARAMETERS IN 1 YEAR FOLLOW-UP?
P. Klapacz, J. Krezel, M. Maga, A. Wachsmann, P. Maga, P. Kaczmarczyk, M. Frolow (Poland)

P1.3.060bis  CAROTID WALL SHEAR RATE AND ARTERIAL STIFFNESS IN PATIENTS WITH HYPERTENSION AND PERIPHERAL ARTERIAL DISEASE
V. Genkel, T. Shamaeva, A. Salashenko, V. Sumerkina, I. Shaposhnik (Russia)

1.4 Endothelium and smooth muscle cells

P1.4.061  A SYSTEMS BIOLOGICAL APPROACH TO THE ANTI-ATHEROGENICITY OF HIGH DENSITY LIPOPROTEINS

P1.4.062  SERUM CONCENTRATIONS OF SST2 AND CD40L IN PATIENTS WITH CARDIAC SYNDROME X
G. Aslan, E. Polat, V. Polat, S. Opan, D. Ural (Turkey)

P1.4.063  THE EFFECT OF EXPERIMENTAL HYPERGLYCAEMIA ON ENDOTHELIAL FUNCTION AND MITOCHONDRIAL ACTIVITY IN HUMAN AORTIC ENDOTHELIAL CELLS
A. Strembitska, I.P. Salt, G. Baillie (United Kingdom)

P1.4.064  MIR299, 145, AND 494 REGULATE HUMAN AORTIC SMOOTH MUSCLE CELL AGING VIA DIRECT TARGETING OF VEZF1
T. Kim, K. Chang, K. Kang, C. Kim, E. Kim, H. Park, E. Park, J. Kim, E. Lee, I. Kim, E. Seong (South Korea)

P1.4.065  IN VITRO MEASUREMENT OF MONOCYTE ADHESION TO THE ENDOTHELIUM
H. Kubátová, S. Cejková, I. Králová-Lesná, R. Poledne (Czech Republic)

P1.4.066  EXPRESSION OF NEURONAL GUIDANCE CUES UNDER PRO-ATHEROGENIC CONDITIONS

P1.4.067  THE EFFECT OF VORAPAXAR ON THE INTERACTION OF CD34+ PROGENITOR CELLS WITH PLATELETS
S. Papadaki, I. Moschonas, A. Tselepis (Greece)
P1.4.068 HIGH SOLUBLE ENDOGLIN LEVELS ACCOMPANIED BY MILD HYPERCHOLESTEROLEMIA ARE A RISK FACTOR FOR THE DEVELOPMENT OF ENDOTHELIAL DYSFUNCTION IN MICE
B. Vitverová, K. Blazícková, I. Najmanová, M. Vicen, M. Pericacho, P. Nachtigal (Czech Republic, Spain)

P1.4.069 DIFFERENTIAL EXPRESSION OF THE MIRNA ACCORDING TO TWO DIFFERENT TYPES OF OIL IN HUVECS

P1.4.070 NUTRITIONAL MODULATION OF THE TOXICITY OF ENVIRONMENTAL POLLUTANTS AND IMPLICATIONS IN ATHEROSCLEROSIS
B. Hennig, M. Petriello (USA)

P1.4.071 ENDOTHELIAL DYSFUNCTION IN AORTIC AND CARDIAC MICROVASCULAR ENDOTHELIAL CELLS: THE HETEROGENEOUS RESPONSE TO THE PRO-INFLAMMATORY CYTOKINE, TUMOR NECROSIS FACTOR-ALPHA (TNF-)
M. Mthethwa, A. Genis, C. Westcott, H. Strijdom (South Africa)

P1.4.072 RGC-32 MEDIATES EXTRACELLULAR MATRIX PRODUCTION IN HUMAN ATHEROSCLEROTIC LESIONS
S. Vlaicu, A. Tatomir, D. Boodhoo, C.A. Tegla, V. Rus, H. Rus (Romania, USA)

P1.4.073 SONO- PHOTODYNAMIC COMBINATION THERAPY OF INTIMAL HYPERPLASIA STENOSIS IN THE RAT ABDOMINAL AORTA: MONITORED BY B- MODE ULTRASONOGRAPHY AND HISTOPATHOLOGY
H. Mehrad, A. Foletti, L. Zeinalizad, F. Nasirzadegan (Iran, Italy)

P1.4.074 PREGNANCY-ASSOCIATED PLASMA PROTEIN A AS THE CRITERION OF CORONARY ARTERY DISEASE DESTABILIZATION
V. Romanova (Ukraine)

P1.4.075 EXPERIMENTAL ATHEROSCLEROSIS AND LUNG STRUCTURAL REMODELING
N. Kakauridze, Z. Tsagareli, L. Gogiashvili (Georgia)

P1.4.076 EFFECT OF PHOTOBIOMODULATION THERAPY ON ENDOTHELIAL FUNCTION IN THE RAT INJURED ABDOMINAL AORTA: EVALUATION WITH B- MODE ULTRASONOGRAPHY AND ELECTRON MICROSCOPY
H. Mehrad, A. Foletti, Z. Pishezari, M. Jabbardokht (Iran, Italy)
P1.4.077  MEASURING THE DYNAMICS OF HYPOXIA INDUCIBLE FACTOR (HIF)-1 RELEASE AS A POTENTIAL BIOMARKER OF HYPOXIA IN INJURY MODELS
L. Heikal, P. Ghezzi, G. Ferns (United Kingdom)

P1.4.078  NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN-CONTAINING PROTEIN (NOD)-RECEPTORS 1 AND 2 REGULATE MICRORNA EXPRESSION IN ENDOTHELIAL CELLS
A. Vlacil, E. Vollmeister, W. Bertrams, F. Schösser, R. Oberoi, J. Schütt, B. Schmeck, B. Schieffer, K. Grote (Germany)

P1.4.079  DETERMINANTS OF ENDOTHELIAL FUNCTION IN A COHORT OF HIV-INFECTED AND HIV-FREE PARTICIPANTS: THE ROLE OF CARDIOVASCULAR RISK FACTORS, BIOMARKERS OF INFLAMMATION AND HIV-DEPENDENT PARAMETERS
H. Strijdom, N. Goswami, P. De Boever, T. Nawrot, M. Essop, M. Mthethwa, N. Mashele, F. Everson, S. Charania, Y. Espach, I. Webster (South Africa, Austria, Belgium)

P1.4.080  ANGIogenesis INHIBITION WITH NOVEL COMPOUNDS TARGETING THE KEY GLYCOLYTIC ENZYME PFKFB3
A. Abdali, A. Corsini, D. Baci, C. De Dominicis, M. Zanda, M.L. Gelmi, S. Bellota (Italy, United Kingdom)

P1.4.081  MC1R REGULATES P38 MAPK PATHWAY TO REDUCE HUMAN AORTIC SMOOTH MUSCLE CELL MIGRATION
V. Alfieri, F. Saporiti, F. Ferrari, L. Piacentini, M. Chiesa, G.I. Colombo (Italy)

P1.4.082  TARGETING FABP4 CELLULAR UPTAKE MECHANISM IN ENDOTHELIAL CELLS AS A NEW STRATEGY TO REDUCE FABP4 MEDIATED ACTIVATION OF INFLAMMATION AND OXIDATIVE STRESS
N. Martínez-Micaelo, R. Rodríguez-Calvo, S. Guaita-Esteruelas, M. Heras, J. Girona, L. Masana (Spain)

P1.4.083  TARGETING PHOSPHOinositide 3-KINASE CII ALPHA IMPAIRS THE INTERPLAY BETWEEN PRIMARY CILIUM AND AUTOPHAGy IN ENDOTHELIAL CELL: A ROLE IN ATHEROSCLEROSIS DEVELOPMENT
POSTER SESSIONS

P1.4.084 THE MRE11A RS13447720 AND RS499952 POLYMORPHISMS ARE ASSOCIATED WITH DECREASED RISK OF DEVELOPING SUBCLINICAL ATHEROSCLEROSIS AND WITH SOME CARDIOVASCULAR RISK FACTORS. THE GEA MEXICAN STUDY

P1.4.085 DETECTION OF HOMOPLASMIC MTDNA MUTATIONS BY NGS METHOD IN PATIENTS WITH CAROTID ATHEROSCLEROSIS
M.A. Sazonova, V.V. Sinyov, A.I. Ryzhkova, M.D. Sazonova, A.V. Zhelankin, Z.B. Khasanova, A.Y. Postnov, A.N. Orekhov, I.A. Sobenin (Russia)

P1.4.085bis ALPHA-ISOCUBE BENE MODULATES VASCULAR TONE BY INHIBITING MYOSIN LIGHT CHAIN PHOSPHORYLATION IN MURINE THORACIC AORTA
E.J. Kim, B.H. Ye, S.E. Baek, Y.W. Choi, S.Y. Park, C.D. Kim (South Korea)

P1.4.086 ENDOTHELIAL BETA-2 SPECTRIN: A CRITICAL PLAQUE STIFFNESS DEPENDENT REGULATOR OF MICROVESSEL LEAKAGE IN HUMAN ATHEROSCLEROTIC PLAQUE

P1.4.086bis HMGB1 ACTIVATE 5-LO-LTB4 SIGNALING AXIS IN VASCULAR SMOOTH MUSCLE CELLS
E.J. Jang, S.E. Baek, S.Y. Park, C.D. Kim (South Korea)

1.5 Extracellular matrix and atherosclerosis

P1.5.087 MMP-3, MMP-9, APOLIPOPROTEINS E, CII AND CIII ARE MARKERS OF AGGRAVATION OF ACUTE CORONARY DISEASE (CAD)
A. Ben Braiek, B. Baudin, F. Dumont, M. Vaubourdolle, K. Hamda, M. Hassine, H. Chahed (Tunisia, France)

P1.5.088 INCREMENT OF CHONDROCYTE-LIKE CELLS IN AORTIC VALVES IN HYPERCHOLESTEROLAEMIC MICE
J. Weisell, A.-K. Ruotsalainen, J. Rysä (Finland)
P1.5.089 DIRECT CONTACT WITH INTRA-TISSUE SENESECT ERYTHROCYTES ACCUMULATED FOLLOWING ENDOTHELIAL INJURY TRIGGERS THE ACQUISITION OF AN OSTEOBLASTIC PHENOTYPE BY AORTIC VALVE INTERSTITIAL CELLS

P1.5.090 CONTRIBUTION OF GENES INVOLVED IN FIBROGENESIS TO MYOCARDIAL ECHOCARDIOGRAPHIC PARAMETERS IN PATIENTS WITH ATHEROSCLEROSIS
I. Goncharova, T. Pecherina, A. Markov, M. Golubenko, M. Nazarenko, V. Kashtalap, N. Tarasenko, O. Barbarash, V. Puzyrev (Russia)

P1.5.091 GENE POLYMORPHISMS OF MMPS-7, -9, -13 AND -14 ARE PREDICTORS OF AGGRAVATION IN CORONARY ARTERY DISEASE?
A. Ben Braiek, B. Baudin, C. Delomenie, F. Dumont, H. Chahed, H. Gamra, F. Maatouk (Tunisia, France)

P1.5.092 ACTIVATION OF VALVULAR INTERSTITIAL CELLS AND REMODELING OF EXTRACELLULAR MATRIX IN CALCIFIC AORTIC VALVE STENOSIS
I. Brecs, J. Sekretarjovs, P. Stradins, S. Skuja, V. Groma, J. Pavars, R. Lacis (Latvia)

1.6 Vascular biology of the arterial wall

P1.6.093 THE EVOLUTION OF THE OXIDATIVE STRESS BIOMARKERS UNDER THE TREATMENT WITH NEBIVOLOL VS BISOPROLOL IN PATIENTS WITH STABLE ANGINA PECTORIS UNDERGOING CORONARY ANGIOPLASTY
L. Simionov, V. Ivanov (Republic of Moldova)

P1.6.094 ANGIOGENIN AND OSTEOPOLNTIN LEVELS ARE ASSOCIATED WITH BETTER DEVELOPED CORONARY COLLATERAL CIRCULATION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
P1.6.095 PREATHEROSCLEROTIC LESIONS IN INTERNAL THORACIC ARTERIES FROM HYPERTENSIVE PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING
D.A. Fonseca, P.E. Antunes, M.J. Antunes, M.D. Cotrim (Portugal)

P1.6.096 PIGMENT EPITHELIUM DERIVED FACTOR AND C1Q/TNF-RELATED PROTEIN 9 IN PATIENTS WITH TYPE 2 DIABETES: RELATIONSHIP TO METABOLIC SYNDROME AND VASCULAR DAMAGE
D. Karásek, J. Spurná, V. Kubícková, L. Cibícková, D. Goldmannová, H. Vaverková (Czech Republic)

P1.6.097 PROPROTEIN CONVERTASE SUBTILISIN/ KEXIN TYPE 9 LEVELS AND ARTERIAL FUNCTION
I. Koutagiar, C. Vlachopoulos, D. Terentes-Printzios, J. Skoumas, N. Skliros, A. Rigatou, N. Ioakeimidis, S. Pantou, C. Georgakopoulos, A. Miliou, D. Tousoulis (Greece)

P1.6.098 CHANGE OF INFLAMMATORY, DESTRUCTIVE, OXIDATIVE, ENDOTHelial DYSFUNCTION BIOMOLECULES CONTENTS DURING OF UNSTABLE ATHEROSCLEROTIC PLAQUE FORMATION
Y. Ragino, Y. Polonskaya, A. Volkov, I. Murashov, E. Kashtanova, A. Chernyavskii (Russia)

P1.6.099 CASEIN KINASE-2 (CK2) INHIBITION BY TBCA ATTENUATES VSMC AND FIBROBLAST PROLIFERATION WITHOUT ADVERSE EFFECTS ON ENDOTHELIAL CELL BEHAVIOUR OR INFLAMMATION
B. Brown, P.S. Jayaraman, M. Zakkar, G. Pula, K.L. Gaston, S.J. George (United Kingdom)

P1.6.100 DOES THE FIBROUS CAP STRIKE BACK? MOLECULES IMPLICATED IN MECHANOTRANSDUCTION IN ATHEROSCLEROTIC PLAQUES
U. Rauch, E. Bengtsson, I. Gonçalves, A. Hultgårdh-Nilsson (Sweden)

P1.6.101 INVOLVEMENT OF ATP-SENSITIVE AND LARGE-CONDUTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS IN PINACIDIL EFFECTS ON THE ISOLATED INTERNAL MAMMARY ARTERY GRAFTS FROM PATIENTS WITH TYPE-2 DIABETES MELLITUS
J. Rajkovic, M. Peric, J. Stanisic, J. Rakocvic, R. Novakovic, V. Djokic, M. Labudovic-Borovic, S. Tepavcevic, V. Kanjuh, H. Heinle, L.J. Gojkovic-Bukarica (Serbia, Germany)

P1.6.102 MUSCULAR ARTERY MORPHOLOGY IS ASSOCIATED WITH LEAN BODY MASS IN CHILDREN OF MOTHERS WITH OBESITY AND GDM – RADIEL STUDY 6 YEARS FOLLOW-UP
J. Sundholm, L. Litwin, K. Rönö, S.B. Koivusalo, J.G. Eriksson, T. Sarkola (Finland, Poland)

P1.6.103 GENOMIC ALTERATIONS IN CELLS INVOLVED IN THE ATHEROSCLEROTIC PROCESS
A.A. Sleptsov, M. Nazarenko, N. Skryabin, E. Denisov, L. Tashireva, I. Lebedev, V. Puzyrev (Russia)
P1.6.104  COMPARSION OF BARE METAL STENT (BMS) AND NON-DRUG ELUTING BIORESORBABLE VASCULAR SCAFFOLD SYSTEM (BVS) IN SMALL SIZE INFRAPOPLITEAL ARTERY: PRECLINICAL STUDY IN PORCINE FEMORAL ARTERIES  
J. Ahn, Y.H. Lim, S.W. Rha (South Korea)

P1.6.105  IMMUNOHISTOCHEMICAL DETECTION OF ADIPONECTIN IN ATHEROSCLEROTIC PLAQUE  
D. Tanianskii, P.V. Pigarevsky, S.V. Maltceva, A.D. Denisenko (Russia)

P1.6.106  FSI ANALYSIS IN STENOTIC CORONARY ARTERY MODEL: PROGRESS OF ATHEROSCLEROSIS AND VULNERABLE HEMORHEOLOGY  
B. Lee, H. Kwon, H. Kim, S. Suh (South Korea)

P1.6.107  THE EXPRESSION OF RENIN-ANGIOTENSIN-SYSTEM COMPONENTS (ACE, ACE2 AND COLLECTRIN (TMEM27) IN THE HUMAN CAROTID PLAQUES DEPENDING ON GENDER AND PLAQUE PHENOTYPE  
A. Kolakovic, M. Zivkovic, T. Djuric, I. Koncar, A. Stankovic (Serbia)

P1.6.108  EFFECT OF COMBINED HIGH AND LOW FREQUENCY SONICATION ACCOMPANIED BY HIGH-DOSE ATORVASTATIN ADMINISTRATION AND DISCONTINUATION OF CHOLESTEROL-RICH DIET ON MECHANICAL PARAMETERS OF CAROTID ARTERY  
H. Mehrad, M. Mokhtari-Dizaji, H. Ghanaati, G. Torkaman (Iran)

P1.6.109  VITAMIN B COMPLEX MITIGATES CARDIAC DYSFUNCTION IN HIGH-METHIONINE DIET-INDUCED HYPERHOMOCYSTEINEMIA  
V. Jakovljevic, J. Jeremic, T. Nikolic-Turnic, V. Zivkovic, N. Jeremic, I. Milosavljevic, I. Srejovic, B. Jakovljevic, D. Djuric (Serbia, Russia)

P1.6.110  ACUTE EFFECTS OF SULFUR AMINO ACIDS ON REDOX STATUS IN DL-HOMOCYSTEINE-TREATED RATS  
D. Djuric, T. Sobot, A. Djuric, V. Jakovljeric, T. Nikolic-Turnic, V. Zivkovic, I. Srejovic, N. Jeremic (Serbia, Bosnia and Herzegovina)
1.7 Hormones and atherosclerosis

P1.7.111  THE ASSOCIATION OF THE FASTING SERUM LEVEL OF GLUCAGON LIKE PEPTIDE-1 (GLP-1) WITH OXIDATIVE STRESS, ATHEROSCLEROTIC VASCULAR CHANGES AND CARDIOMETABOLIC RISK FACTORS IN TYPE 2 DIABETIC PATIENTS
T. Abdel Aaty, M. Rezk, E. Morsy, K. Moghazy, N. Amin, H. El Harby (Egypt)

P1.7.112  THE ADIPOKINE C1Q/TUMOR NECROSIS FACTOR RELATED PROTEIN-3 IS HIGHLY EXPRESSED IN ATHEROSCLEROTIC LESIONS AND IS RELATED TO SEVERITY OF CORONARY ARTERY DISEASE
A.M. Alyahya, A.A. Al Masri, A.S. Hersi, E.A. Eleter (Saudi Arabia, Egypt)

P1.7.113  IGF-1 REGULATES CARDIAC HYPERTROPHY AND INOS EXPRESSION IN OBESE MALE RATS THROUGH ERK1/2 SIGNALING PATHWAY
A. Panic, J. Stanimirovic, M. Obradovic, E. Sudar-Milovanovic, E.R. Isenovic (Serbia)

P1.7.114  IGF-1 AMELIORATES DETRIMENTAL EFFECTS OF OBESITY IN RAT HEART BY PROMOTING AKT AND FOXO1
J. Stanimirovic, A. Panic, M. Obradovic, S. Zafirovic, E.R. Isenovic (Serbia)

P1.7.115  THE ROLE OF LIPID, SEX HORMONE AND INFLAMMATION PATHWAY GENES POLYMORPHIMS ON CORONARY ARTERY DISEASE IN TURKS

P1.7.116  TELOMERE LENGTH AND THE AGE-RELATED FACTORS GDF-11 AND SIRT-1 IN CAD
T.B. Opstad, A.A. Kalstad, A.A. Pettersen, H. Arnesen, I. Seljeflot (Norway)

P1.7.117  PHYSIOLOGICAL STUDIES OF CARDIAC CONTRACTILITY OF RABBIT HEART WITH EXPERIMENTAL HYPERTHYROIDISM
C.R. Revnic, F. Revnic, B. Paltineanu, S. Voinea (Romania)
1.8 Imaging atherosclerosis

P1.8.118  NON-CORONARY ATHEROSCLEROSIS: IS IT FEASIBLE TO USE IT FOR NON-INVASIVE PREDICTION OF CORONARY RISK?  
N. Gavrilova, V. Metelskaya, M. Zhatkina (Russia)

P1.8.119  ECG STRESS-TESTS AND SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY WITH 99MTC-MIBI IN REST AND IN COMBINATION WITH PHYSICAL ACTIVITY STRESS-TEST IN DIAGNOSTICS OF CORONARY DISEASE IN RHEUMATOID ARTHRITIS  

P1.8.120  MYOCARDIAL PERFUSION ABNORMALITIES AND SEVERITY OF ATHEROSCLEROTIC CAROTID ARTERY LESIONS IN PATIENTS WITH DIFFERENT PROBABILITY OF FH DIAGNOSIS  
Y. Prus, I. Sergienko, A. Ansheles (Russia)

P1.8.121  HIGH-DOSE ATORVASTATIN ADMINISTRATION ACCOMPANIED BY DISCONTINUATION OF CHOLESTEROL-RICH DIET INCREASES LIPID-RICH ATHEROSCLEROTIC PLAQUE ECHOGENICITY USING A NEW ULTRASOUND IMAGE PROCESSING METHOD  
H. Mehrad, M.H. Daghighi, L. Zeinalizad, F. Nasirzadegan (Iran)

P1.8.122  PREDICTIVE VALUE OF 3D INTIMA-MEDIA THICKNESS FOR CORONARY CALCIUM SCORE IN SUBJECTS WITH INTERMEDIATE CARDIOVASCULAR RISK  
E. Jarauta, M. Laclaustra, R. Langarita, V. Marco-Benedi, A. Bea, R. Villa-Pobo, M. Leon-Latre, J.A. Casasnovas, F. Civeira (Spain)

P1.8.123  ULTRASONOGRAPHIC DETECTION OF XANTHOMAS IN ACHILLES TENDON OF PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA  

P1.8.124  MUTATIONS OF MITOCHONDRIAL DNA FROM CIRCULATING BLOOD CELLS AND CAROTID ATHEROSCLEROSIS  
E. Galitsyna, A. Meinichenko, I.A. Sobenin, T. Shkurat (Russia)

P1.8.125  DYNAMICS OF LOCAL ARTERIAL RIGIDITY PARAMETERS IN STEMI PATIENTS DEPENDING ON THE EFFICIENCY OF ACHIEVING THE Atherogenic lipids target level ON THE BACKGROUND OF ATORVASTATIN THERAPY  
A. Khromova, L. Salyamova, N. Burko, V. Oleynikov, E. Dushina (Russia)
1.9 Atherosclerosis regression

P1.9.126 SYSTEMS TOXICOLOGICAL ASSESSMENT OF TWO CANDIDATE MODIFIED RISK TOBACCO PRODUCTS ON CARDIOVASCULAR AND RESPIRATORY EFFECTS IN APOE DEFICIENT MICE - A 6 MONTH INHALATION STUDY

S. Lebrun, B. Phillips, J. Szostak, E. Guedj, E. Wong, M. Talikka, B. Tietz, F. Martin, G. Vuillaume, P. Leroy, A. Buettner, N. Ivanov, P. Vanscheeuwijk, M. Peitsch, J. Hoeng (Switzerland, Singapore, Germany)

P1.9.127 CHANGES IN CLAUDICATION WALKING TIME MEASURED ON TREADMILL AND IN COMMUNITY SETTING OUTDOOR WALKING AFTER A 12-WEEK SUPERVISED TREADMILL TRAINING IN PATIENTS WITH CLAUDICATION

A. Kulik, E. Rosloniec (Poland)

P1.9.128 INSTABILITY OF GENOME IN Atherosclerosis

M. Gaiozishvili, N. Kakauridze, T. Buadze, T. Sigua, T. Jokhadze, T. Lezhava (Georgia)

P1.9.129 INTRAVENOUS HIGH-DOSE ATORVASTATIN-LOADED PESDA MICROBUBBLES ADMINISTRATION ACCOMPANIED BY SONO-SHOCK WAVE COMBINATION THERAPY FOR ADVANCED Atherosclerotic Plaque Regression

H. Mehrad, S.M. Tabatabaei, L. Zeinalizad, M. Haji Sagati (Iran)

P1.9.130 ELEMENTAL COMPOSITION OF CAROTID ENDOARTERECTOMY MATERIALS AND NORMAL CAROTID TISSUE: CALL FOR TREATMENT CHANGE

Olcay, E. Tezcan, E. Canturk, B. Inan, H. Karaoglu, C. Kucuk (Turkey)

P1.9.131 CARDIOPROTECTIVE EFFECTS OF COMBINED THERAPY WITH HYPERBARIC OXYGEN ON MYOCARDIAL ISCHEMIA-REPERFUSION INJURY IN RATS

B. Jakovljevic, N. Simonovic, J. Jeremic, I. Srejovic, T. Nikolic-Turnic, V. Zivkovic, D. Djuric, V. Jakovljevic (Serbia, Russia)
1.10 Aneurysms and arteriopathies

P1.10.132 THE EXCESS RISK OF HOSPITALIZATION FOR AORTIC ANEURISM IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: A REGISTRY STUDY
L. Mundal, J. Igland, K.B. Holven, M.P. Bogsrud, T.P. Leren, K. Retterstøl (Norway)

P1.10.133 PREDICTIVE FACTORS FOR ARTERIAL INVOLVEMENT IN BEHÇET DISEASE: A RETROSPECTIVE TUNISIAN COHORT
M. Kechida, M. Mahjoub, R. Mesfar, R. Klii, S. Hammami, I. Khochtali (Tunisia)

P1.10.134 SIMVASTATIN AND PERINDOPRIL ADMINISTRATION AMELIORATE INFLAMMATORY PROCESS ON THE AORTIC WALL IN EXPERIMENTAL MODEL OF THORACIC AORTIC ANEURYSM FORMATION
V. Androutsopoulos, I.P. Doulamis, A. Tzani, N. Kavantzas, D. Angouras, D.N. Perreas, D.C. Iliopoulos (Greece)

P1.10.135 THE ROLE OF LDL CHOLESTEROL ON EXCESS RISK OF AORTIC STENOSIS: A REGISTRY STUDY

P1.10.136 CFD SIMULATION OF BLOOD FLOW THROUGH NEW DESIGNED STENT GRAFT IN ABDOMINAL AORTA
T. Kostic, N. Begic, A. Botonjic (Germany, Bosnia and Herzegovina)

P1.10.137 ENERGY METABOLISM AS A POTENTIAL SOURCE OF BIOLOGICAL MARKERS IN ABDOMINAL AORTIC ANEURYSM

P1.10.138 DEVELOPMENT AND CHARACTERISATION OF A HUMAN EX-VIVO MODEL OF ANEURYSM
R. Bianco, K. Di Gregoli, M. Caputo, M. Zakkar, S. George, J. Johnson (United Kingdom)

P1.10.139 ELEMENTAL COMPOSITION OF EXCISED SEVERELY STENOTIC AORTIC CUSPS
Olcay, E. Tezcan, O. Yolay, E. Canturk, B. Inan, H. Karaoglu, C. Kucuk (Turkey)
1.11 Coagulation and thrombosis

P1.11.140 PLATELET AGGREGATION IN PATIENTS WITH HEART FAILURE OF ISCHEMIC ORIGIN DEPENDS ON BLOOD LEVELS OF IRON AND BILIRUBIN
V. Pasko, V. Batushkin (Ukraine)

P1.11.141 STATE OF HAEMOSTASIS IN DIFFERENT AGE GROUPS OF PATIENTS WITH CORONARY ARTERY DISEASE
V. Pasko, V. Netiazhenko (Ukraine)

P1.11.142 SIGNIFICANT HEMOSTASIS AND ENDOTHELIAL DYSFUNCTION BLOOD BIOMARKERS OF UNSTABLE ATHEROSCLEROTIC PLAQUES IN CORONARY ARTERIES
E. Striukova, E. Kashtanova, Y. Polonskaya, E. Stakhneva, A. Chernyavskii, A. Kurguzov, O. Kamenskaya, I. Murashov, Y. Ragino (Russia)

P1.11.143 ACUTE MYOCARDIAL INFARCTION IN ELDERLY AND SENILE PATIENTS: HEMOCOAGULATIVE INFRINGEMENTS
V. Pasko, V Batushkin (Ukraine)

P1.11.144 PORTAL VEIN THROMBOSIS REVEALING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
M. Kechida, W. Benyahia, W. Mneri, R. Mesfar, A. Laatiri, S. Hammami, I. Khochtali (Tunisia)

P1.11.145 ASSOCIATION OF GENES POLYMORPHISMS WITH WARFARIN DOSE REQUIREMENT IN GEORGIAN POPULATION
G. Tchitashvili, N. Kakauridze, T. Buadze, M. Gaiozishvili, T. Lezhava (Georgia)

P1.11.146 ONE-YEAR CARDIOVASCULAR OUTCOMES IN RUSSIAN ACS PATIENTS RECEIVING TICAGRELOR (STREAM STUDY)
O. Apanova, N. Gurina, E. Oshchepkova, B. Kvasnikov (Russia)

P1.11.147 PHOTOMECHANICAL EFFECT OF Q-SWITCHED ND:YAG LASER ENHANCE THROMBOLYSIS USING OF PLGA-BASED ENCAPSULATED TISSUE PLASMINOGEN ACTIVATOR (TPA) NANOPARTICLES
H. Mehrad, J. Mahmoudi, A. Keshavarz, A. Rahimkhani (Iran)

P1.11.148 CLOT FORMATION AND FIBRINOLYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROME AND HEALTHY VOLUNTEERS
P. Savvinova, A. Kalinskaya, A. Shpektor, E. Vasilieva (Russia)
P1.11.149  TREATMENT OF PEDIATRIC PATIENTS WITH HOMOZYGOTE FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
T. Szamosi (Hungary)

SUNDAY, MAY 06
17.00-18.30

2. Lipids, lipoproteins, and adipose tissue
2.1 Lipid and lipoprotein metabolism

P2.1.150  DECREASE OF PROPROTEIN CONVERTASE SUBTILISIN KAXEXIN 9 (PCSK9) FOLLOWING RHEOPHERESIS IN AGE-RELATED MACULAR DEGENERATION
M. Blaha, H. Langrova, V. Blaha, M. Lanska, J. Studnicka, A. Stepanov, S. Vesela, M. Burova, H. Dvorakova (Czech Republic)

P2.1.151  LIPID METABOLISM, ENDOTHELIAL FUNCTION, PARAMETERS OF ELASTIC PROPERTIES AND INFLAMMATION IN PATIENTS WITH CORONARY HEART DISEASE COMBINED WITH HEPATIC STEATOSIS DEPENDING FROM BODY MASS INDEX
M. Grechanyk, N. Grechanyk, A. Kuryata (Ukraine)

P2.1.152  SERUM CONTENT OF SATURATED FATTY ACIDS AND THE PREVALENCE OF ATRIAL FIBRILLATION - A NORWEGIAN CROSS-SECTIONAL STUDY

P2.1.153  CIRCULATING METABOLOMIC PROFILE INDICATES MITOCHONDRIAL DYSFUNCTION IN HIV-DYSLIPIDEMIA

P2.1.154  CHOLESTEROL CONTENT AND SYNTHESIS IN THE BRAIN OF APOE KNOCKOUT MICE
V. Sutti Nunes, P.M. Cazita, S. Catanozi, E.R. Nakandakare, E.C.R. Quintão (Brazil)
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.1.155</td>
<td>FREQUENCY OF ACHILLES TENDON XANTHOMA IN PATIENTS WITH ACUTE CORONARY SYNDROME</td>
<td>S. Oikawa, T. Harada, K. Inagaki-Tanimura, M. Nagao, Y. Sato, M. Sudo, F. Okajima, H. Sugihara (Japan)</td>
</tr>
<tr>
<td>P2.1.156</td>
<td>EFFECT OF ATHEROSCLEROSIS ON THE MRNA AND PROTEIN EXPRESSION OF THE MAIN COMPONENTS OF THE LIPOLYTIC SYSTEM IN HUMAN MYOCARDIUM</td>
<td>M. Knapp, A. Miklosz, J. Lewkowicz, A. Lisowska, M. Gil, B. Wojcik, T. Hirnle, A. Chabowski, J. Gorski (Poland)</td>
</tr>
<tr>
<td>P2.1.157</td>
<td>DIAGNOSTIC LIPID CHANGES IN PATIENTS WITH VISCERAL LEISHMANIASIS</td>
<td>A. Kei, V. Tsimihodimos, F. Apostolou, M. Elisaf (Greece)</td>
</tr>
<tr>
<td>P2.1.158</td>
<td>TWO TAGSNPS IN PCSK9 ARE ASSOCIATED WITH TG METABOLISM IN PATIENTS WITH TYPE 2 DIABETES AND METABOLIC SYNDROME</td>
<td>M. Guardiola, I. Oliva, N. Plana, D. Ibarretxe, L. Masana, J. Ribalta (Spain)</td>
</tr>
<tr>
<td>P2.1.161</td>
<td>LUNG FUNCTIONAL STATUS IN PATIENTS WITH CHD AND DYSLIPIDEMIA</td>
<td>N. Kakauridze, M. Makalatia, A. Kistauri (Georgia)</td>
</tr>
<tr>
<td>P2.1.162</td>
<td>FIBROBLAST GROWTH FACTOR 21 SERUM CONCENTRATIONS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND TYPE 2 DIABETES MELLITUS (DM2)</td>
<td>M. Walus-Miarka, B. Idzior-Walus, M. Kapusta, A. Trojan, P. Miarka, M.T. Malecki (Poland)</td>
</tr>
<tr>
<td>P2.1.163</td>
<td>HYPERTRANSAMINASEMIA (HT) IN A COHORT WITH FAMILIAL COMBINED HYPERLIPIDEMIA (FCH): PREVALENCE AND RISK FACTORS</td>
<td>P. Vázquez Rodríguez, A.B. Porto Perez, R. Argüeso Armesto, R. Suárez Fuentetaja, R. De La Fuente Cid, S. Ruanova Suárez, J.L. Díaz Díaz (Spain)</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

P2.1.164  HSP27 IMMUNIZATION ATTENUATES Atherogenesis by Markedly Reducing Plasma PCSK9 and Cholesterol Levels

P2.1.165  Clinical Implications of Cigarette Smoking in Stable Coronary Artery Disease: Angiographic and Laboratory Findings

P2.1.166  Serum Concentration of Non-Esterified Fatty Acids (NEFAS) in Non-Surgical Critically Ill Patients: The Impact of Specific Types of Total Parenteral Nutrition (TPN)
P. Skorepa, J. Fortunato, V. Blaha, J. M. Horacek (Czech Republic)

P2.1.167  Subfractional Distribution of Apo B-Containing Lipoproteins in Men with Coronary Atherosclerosis at Normolipidemia
V. Metelskaya, I. Ozerova, N. Gavrilova (Russia)

P2.1.168  A Systematic Functional Activity Characterization of the Most Frequent GOF and LOF PSCK9 Variants
A. Benito Vicente, K.B. Uribe, K. Chemello, U. Galicia Garcia, R. Alonso, G. Lambert, C. Martin (Spain, France)

P2.1.169  Biophysics as a Tool for a Precise Diagnosis and Nanotheranostics in Cardiovascular Disease
K. Beloso-Uribe, A. Benito-Vicente, U. Galicia, S. Jebary, A. Etxebarria, H. Ostolaza, C. Fernández-Hernando, C. Martín (Spain, USA)

P2.1.170  A Low-Fat Spread with Added Plant Sterols and Fish Oil Lowers Serum Triglyceride and LDL-Cholesterol Concentrations in Individuals with Modest Hypercholesterolaemia and Hypertriglyceridaemia
W. Blom, W. Koppenol, H. Hiemstra, T. Stojakovic, H. Scharnagl, E. Trautwein (The Netherlands, Austria)

P2.1.171  Familial Hypobetalipoproteinemia: Analysis by Next Generation Sequencing and Identification of Novel Mutations in the APOB Gene
<table>
<thead>
<tr>
<th>POSTER SESSIONS</th>
</tr>
</thead>
</table>
| **P2.1.172** DETECTION OF COPY NUMBER VARIATIONS (CNVS) IN LDLR GENE BY NEXT GENERATION SEQUENCING IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA  
| **P2.1.173** CONSEQUENCES OF HEPATOCYTE-SPECIFIC LYSOSOMAL ACID LIPLASE DEFICIENCY ON LIPID AND CARBOHYDRATE METABOLISM  
*C. Leopold*, M. Duta-Mare, S. Rainer, D. Kolb, B. Radovic, D. Kratky (Austria) |
| **P2.1.174** ADIPOSE-DERIVED FATTY ACID-BINDING PROTEINS PLASMA CONCENTRATIONS ARE INCREASED IN BREAST CANCER PATIENTS  
*S. Guaita-Esterurelas*, P. Saavedra, A. Bosquet, J. Borràs, J. Girona, K. Amiliano, M. Rodríguez-Balada, M. Heras, L.L. Masana, J. Gumà (Spain, United Kingdom) |
| **P2.1.175** CLUSTER ANALYSIS OF PATTERNS GENERATED FROM A WEB REPOSITORY OF HEPG2 TRANSCRIPTOMES. GENES OF UNKNOWN FUNCTIONS COREGULATED IN CONCERT WITH CHOLESTEROL SYNTHESIS PATHWAY  
| **P2.1.176** BENZO(A)PYRENE - ACTIVATED AHR REGULATES APOLIPOPROTEINS EXPRESSION IN HEPATOCYTES  
*I. Tudorache*, V. Trusca, A. Gafencu (Romania) |
| **P2.1.177** TREM2 DEFICIENCY INCREASES PLASMA CHOLESTEROL AND TRIGLYCERIDE LEVELS WITHOUT INFLUENCING LESION FORMATION IN LDLR-DEFICIENT MICE  
*M. Kiss*, F.S. Porsch, A. Hladik, L. Göderle, O. Sharif, S. Knapp, C.J. Binder (AUSTRIA) |
| **P2.1.178** MAY CELLULAR LIPIDS AND OXIDATIVE STRESS PLAY A ROLE IN ARRHYTHMOGENIC CARDIOMYOPATHY PATHOGENESIS? A LIPIDOMIC STUDY IN CARDIAC MESENCHYMAL Stromal CELLS  
*L. Arnaboldi*, S. De Metrio, I. Stadiotti, A. Granata, A. Corsini, C. Tondo, G. Pompilio, E. Sommariva (Italy) |
| **P2.1.179** BENZO(A)PYRENE - ACTIVATED AHR REGULATES APOLIPOPROTEINS EXPRESSION IN HEPATOCYTES  
*I. Tudorache*, V. Trusca, A. Gafencu (Romania) |
2.2 TG-rich lipoprotein metabolism

P2.2.180 ASSESSING THE DISEASE BURDEN AMONG PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) ON VOLANESORSEN: RESULTS OF THE RE-FOCUS STUDY
M. Arca, H. Soran, A. Digenio, A. Hsieh, P. Rosenblit, M. Stevenson (Italy, United Kingdom, USA)

P2.2.181 PLASMA CLEARANCE OF CHYLOMICRON REMNANTS IS DELAYED IN AGED SUBJECTS: A STUDY WITH ARTIFICIAL EMULSIONS
T.M. Tavoni, C.G. Vinagre, F.R. Freitas, C.H. Mesquita, J.C. Vinagre, A.C. Mariani, R. Kalil-Filho, R.C. Maranhao (Brazil)

P2.2.182 CHYLOMICRON METABOLISM IS IMPAIRED IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA: EFFECTS OF TREATMENT WITH CONTINUOUS POSITIVE AIRWAY PRESSURE

P2.2.183 GENERALIZED LIPODYSTROPHY WITH SEVERE HYPERTRIGLYCERIDEMIA
M. Muzalevskaia, S. Urazgildeeva, T. Nekrasova, A. Tregubov, D. Malenkovskaya, V. Gurevich, M. Pyatchenkov, A. Sokolov (Russia)

P2.2.184 SEQUENCE VARIANTS IN THE GPIHBP1 GENE IN PATIENTS WITH SEVER HYPERTRIGLYCERIDEMIA
Pérez López, F. Almagro, A. Brea, MA. Sánchez-Chaparro, O. Muñiz, L. Álvarez-Sala, M.J. Ariza, P. Valdivielso (Spain)

P2.2.185 POSTPRANDIAL EFFECTS OF DIFFERENT DAIRY PRODUCTS ON BLOOD LIPIDS IN LEAN AND OVERWEIGHT SUBJECTS

P2.2.186 IS ENDOTHELIAL LIPASE A SUPPORTING ACTOR OF LIPOPROTEIN LIPASE IN OBESITY?
G.A. Berg, M. Barchuk, V. Zago, A. Cevey, N. Goren, S. Friedman, C. Morales, L. Schreier, V. Miksztowicz (Argentina)

P2.2.187 GROWTH HORMONE (GH) AND TRIGLYCERIDE-RICH LIPOPROTEIN (TRL) METABOLISM: EFFECT OF ONE MONTH OF DISCONTINUED GROWTH HORMONE TREATMENT IN GROWTH HORMONE DEFICIENT PATIENTS
Calabrese, A. Nicolay, E. Wolff, J. Dupont, R. Valero, S. Beliard, M. Maraninchi (France)
2.3 Lipoproteins: Lp(a)

P2.3.188 HIGH LIPOPROTEIN(A) LEVEL IS A PREDICTOR OF SEVERE CAROTID ATHEROSCLEROSIS AND ISCHEMIC STROKE
N. Tmoyan, M. Ezhov, O. Afanasieva, M. Afanasieva, T. Balakhonova, S. Pokrovsky (Russia)

P2.3.189 LIPOPROTEIN(A), APOLIPOPROTEIN(A) PHENOTYPES AND MULTISITE ATHEROSCLEROSIS
N. Tmoyan, M. Ezhov, O. Afanasieva, E. Klesareva, M. Afanasieva, O. Razova, S. Pokrovsky (Russia)

P2.3.190 APOLIPOPROTEIN E2 (APOE2) IS ASSOCIATED WITH REDUCED LIPOPROTEIN (A) [LP(A)] IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH)
V. Blanchard, M. Croyal, D. Blom, D. Marais, G. Lambert (Reunion Island, France, South Africa)

P2.3.191 LIPOPROTEIN(A) TESTING EXPERIENCE IN A SPECIALIST LIPID CLINIC IN SCOTLAND SUGGESTS A NEED TO MORE COMMONLY MEASURE
C. Kanonidou, N. Sattar, M. Panarelli (United Kingdom)

P2.3.192 REGULATION OF LIPOPROTEIN(A) EXPRESSION BY MICRORNAS IN HUMAN HEPATOMA CELL LINE HEP3B
T. Rawther, L.F. Cuesta Torres, K.A. Rye, F. Tabet (Australia)

P2.3.193 VARIABLE REDUCTIONS IN APOLIPOPROTEIN (A) [APO(A)] ISOFORMS CONCENTRATIONS AFTER LIPAPHERESIS TREATMENT IN PATIENTS WITH ISOLATED HYPER LIPOPROTEIN (A) [LP(A)]
G. Lambert, J. Ramin-Mangata, V. Blanchard, J. Garcia Nafria, U. Galicia-Garcia, M. Croyal, C. Martin (Reunion Island, United Kingdom, Spain, France)

P2.3.194 LIPOPROTEIN (A) IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
A. Galyavich, A. Gimadeeva, R. Galyavi, L. Baleeva, Z. Galeeva (Russia)

P2.3.195 POSITIVE ASSOCIATION OF LIPOPROTEIN(A) WITH CT CORONARY CALCIUM SCORE IN ASYMPTOMATIC CAUCASIANS BUT NOT IN OTHER ETHNICITIES
W.J. Loh, A. David, S. Walji, J. Scott, J. Cegla (Singapore, United Kingdom)

P2.3.196 ASSOCIATION OF LP(A) CONCENTRATION WITH THE VARIABILITY IN THE LIPID-LOWERING RESPONSE OF PCSK9 INHIBITORS
M.V. Marco Benedí, S. Perez Calahorra, A.M Bea, L. Baila Rueda, I. Lamiquiz Moneo, A. Cenarro, E. Jarauta, M. Laclaustra, F. Civeira (Spain)
P2.3.197 LIPOPROTEIN(A) SCREENING IN PATIENTS WITH PREMATURE MYOCARDIAL INFARCTION: CLINICAL ROLE AND IMPACT ON DECISION-MAKING  
F. Gragnano, F. Fimiani, F. Natale, A. Cesaro, R. Bianchi, M. Crisci, A. Shatri, S. Sperlongano,  
C. Annoiato, A. Scarda, P. Limongelli, R. Calabrò, P. Calabrò (Italy)

P2.3.198 THE EFFECT OF LP(A) ON CARDIOVASCULAR STRUCTURE IN CHILDREN AGED 6-16 YEARS OLD. FINDINGS IN THE FAMILIAL HYPERCHOLESTEROLEMIA POPULATION  
E. Griva, K. Kyrkou, K. Stamatelopoulos, E. Drogari (Greece)

P2.3.199 VARIABLES ASSOCIATED WITH LIPOPROTEIN (A) LEVELS AND CLINICAL SIGNIFICANCES  
C.J. Kim, M. Kim (South Korea)

P2.3.200 THE ROLE OF LIPOPROTEIN(A) AND APOLIPOPROTEIN(A) PHENOTYPES IN SEVERE Atherosclerosis OF CORONARY, CAROTID AND LOWER LIMBS ARTERIES  
N. Tmoyan, M. Ezhov, O. Afanasieva, E. Klesareva, O. Pogorelova, M. Tripoten, M. Afanasieva, O. Razova, S. Pokrovsky (Russia)

P2.3.201 DISTRIBUTION OF LIPOPROTEIN (A) IN A POPULATION WITH CARDIOVASCULAR EVENTS OR DYSLIPIDAEMIA  

P2.3.202 PLASMA LP(A) LEVELS CORRELATE WITH CARDIOVASCULAR DISEASE BEYOND LDL-CHOLESTEROL IN AN ITALIAN COHORT OF FH  
C. Pavanello, L. Mosca, M.S. Cigoli, U. Cavallari, G. Mombelli, S. Romeo, L. Calabresi (Italy, Sweden)

P2.3.203 HYPERLIPOPROTEINEMIA(A) AS A RISK FACTOR OF CORONARY HEART DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA  
S. Bliznyuk, M. Ezhov, O. Afanasieva, M. Afanasieva, S. Pokrovsky (Russia)

P2.3.204 VARIATION OF THE CONCENTRATION OF LIPOPROTEIN (A) ACCORDING TO CONCENTRATION OF TRIGLYCERIDES  

P2.3.205 LIPOPROTEIN A: EXTREME ELEVATION AND GENETIC POLYMORPHISM ASSOCIATION WITH CARDIAC AND VASCULAR LESIONS EVALUATED BY COMPUTED TOMOGRAPHY  
P. Corral, S. Quintana, M. Rodriguez, D. Quirós, A. Sigismondi (Argentina)
**POSTER SESSIONS**

**P2.3.206** ELEVATED AUTOTAXIN PLASMA LEVEL AS A MARKER OF AORTIC VALVE STENOSIS IN PATIENTS WITH CORONARY HEART DISEASE  
O. Afanasieva, O. Razova, N. Tmoyan, H. Klesareva, M. Afanasieva, A. Burdeynaya, M. Ezhov, S. Pokrovsky (Russia)

**2.4 Lipoprotein receptors**

**P2.4.207** THE SIGNIFICANCE OF DETERMINING NON-HDL CHOLESTEROL IN CHILDREN  
G. Grujic Ilic, M. Jerkan (Serbia)

**P2.4.208** DIAGNOSTIC DISCORDANCE BETWEEN THE DUTCH LIPID CRITERIA NETWORK AND SIMON BROOME PHENOTYPIC DIAGNOSTIC TEST FOR FAMILIAL HYPERCHOLESTEROLAEMIA  
D.C. Chan, J. Pang, A.J. Hooper, D.A. Bell, T.A. Bates, J.R. Burnett, G.F. Watts (Australia)

**P2.4.209** COMPARATIVE ANALYSIS OF THE PHENOTYPIC PREDICTORS OF MUTATIONS IN FAMILIAL HYPERCHOLESTEROLAEMIA: STANDARDIZING DIAGNOSTIC TESTING IN THE CLINIC  

**P2.4.210** PRODUCTION AND PURIFICATION OF RECOMBINANT PCSK9 TO STUDY PCSK9 GAIN OF FUNCTION (GOF) AND LOSS OF FUNCTION (LOF) MUTANTS  
K. Chemello, A.B. Vicente, A.L. Setubal, C. Martin, G. Lambert (Reunion Island, Spain)

**P2.4.211** INTAKE OF SFA COMPARED TO PUFA INDUCE LOWER POSTPRANDIAL LDL RECEPTOR GENE EXPRESSION IN PBMC IN SUBJECTS WITH AND WITHOUT FH  

**P2.4.212** FUNCTIONAL CHARACTERIZATION AND CLASSIFICATION OF FREQUENT VARIANTS LOCATED IN THE LDLR BETA-PROPELLER  
U. Galicia García, A. Benito-Vicente, K.B. Uribe, S. Jebari, L. Palacios, M. Stef, H. Ostolaza, C. Martin (Spain)

**P2.4.213** LDL RECEPTOR MUTATION IN A FAMILIAL HYPERCHOLESTEROLEMIA COHORT-RESULTS OF A SINGLE CENTRE STUDY FROM SINGAPORE  
P2.4.214  FAMILIAL HYPERCHOLESTEROLEMIA-CLINICAL CHARACTERISTICS OF PATIENTS WITH LDLR, APOB MUTATIONS & NO MUTATIONS-SINGLE CENTRE STUDY

2.5 HDL metabolism
P2.5.215  APABETALONE (RVX-208) ATTENUATES HYPERGLYCEMIA AND TMAO INDUCED ADHESION OF THP-1 MONOCYTES TO HUVEC ENDOTHELIAL CELLS

P2.5.216  ADVANCED GLYCATED APOAIV IS LESS EFFICIENT IN REDUCING INFLAMMATION IN MACROPHAGES AND UNABLE TO PREVENT THE REDUCTION IN ABCA1 AND ABCG1 mRNA INDUCED BY LPS
L. Shimabukuro Okuda, R. Tallada Iborra, P. Ramos Pinto, M. Patel, U.F. Machado, K.A. Rye, M. Passarelli (Brazil, Australia)

P2.5.217  LIPID TRANSFERS TO HDL ARE DIMINISHED IN WOMEN WITH OVERT HYPOTHYROIDISM AFTER TOTAL THYROIDECTOMY
G.A. Sigal, T.M. Tavoni, F.R. Freitas, B.M.O. Silva, L.G. Brandao, R.C. Maranhao (Brazil)

P2.5.218  DEFECTIVE HDL REMODELING AND MACROPHAGE CHOLESTEROL EFFLUX IN ADULT AND ADOLESCENT FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS

P2.5.219  CHANGES IN HDL SUBFRACTION DISTRIBUTION AND MYELOPEROXIDASE/PARAOXONASE-1 RATIO IN UNTREATED DYSLIPEDEMATIC PATIENTS
B. Nadro, A. Szentpeteri, H. Lorincz, L. Juhasz, I. Seres, D. Pall, G. Paragh, M. Harangi (Hungary)

P2.5.220  THE RELATIONSHIP BETWEEN HIGH LEVELS OF HDL CHOLESTEROL AND MORTALITY RISK IN PATIENTS WITH WELL-REGULATED TYPE 2 DIABETES
T. Athanasopoulos, I. L. Matsoukis, K. Kanellopoulou, A. Ganotopoulou, N. Zimpounoumi, C. Triantafillopoulou, D. Klonos, L. Skorda, A. Sianni (Greece)
P2.5.221 IMPACT OF OBESITY IN PATIENTS WITH CORONARY ARTERY DISEASE

P2.5.222 THE LEVEL OF CAT S IS INCREASED AND HDL-C IS DECREASED AT THE SAME TIME IN PLASMA OF PATIENTS WITH ABDOMINAL AORTIC ANEURYSM AND AORTOILIAC OCCLUSIVE DISEASE
B. Mirjanic-Azaric, N. Vasic, J. Kos, D. Cerne (Bosnia and Herzegovina, Slovenia)

2.6 Cholesterol efflux and reverse cholesterol transport

P2.6.223 A LINK EXISTS BETWEEN HDL CHOLESTEROL EFFLUX CAPACITY AND PLASMA GUT MICROBIOTA METABOLITE LEVELS IN SUBJECTS WITH CALCIFIC AORTIC VALVE STENOSIS

P2.6.224 CONTRIBUTION OF CHOLESTEROL-BINDING MOTIFS IN ABCA1, ABCG1 AND SR-B1 STRUCTURE TO CELLULAR CHOLESTEROL TRANSPORT
A. Dergunov, E. Savushkin, L. Dergunova, D. Litvinov (Russia)

P2.6.225 CHOLESTEROL EFFLUX CAPACITY IN YOUNG ACUTE CORONARY SYNDROME IN MALAYSIA

P2.6.226 POLYUNSATURATED FATTY ACIDS (PUFAS) DIFFERENTIALLY AFFECTED ABCA1-MEDIATED CHOLESTEROL EFFLUX FROM CHOLESTEROL-LOADED MOUSE OR HUMAN MACROPHAGES
N. Fournier, J.F. Benoist, F. Allaoui, M. Nowak, G. Sayet, B. Vedie, J.L. Paul (France)

P2.6.227 CHOLESTERYL ESTER TRANSFER PROTEIN, LECITHIN CHOLESTEROL ACYLTRANSFERASE, LOW DENSITY LIPOPROTEIN PARTICLE SIZE AND INTIMA MEDIA THICKNESS IN PATIENTS WITH CORONARY HEART DISEASE
K. Tosheska-Trajkovska, D. Labudovic, S. Jovanova, I. Kostovska, G. Bosilkova, S. Topuzovska (Republic of Macedonia – Fyrom)
P2.6.228  COMPOUND FROM MARINE ECHINODERM AS A NEW DRUG IN TREATING HYPERCHOLESTEROLEMIA VIA REVERSE CHOLESTEROL TRANSPORT
L. Abu-Bakar, N. Ismail, V. Sevakumaran, T.S. Tengku Muhammad (Malaysia)

P2.6.229  ADEQUATE GLYCEMIC CONTROL PREVENTS CHOLESTEROL EFFLUX IMPAIRMENT AND LIPID ACCUMULATION IN MACROPHAGES INDUCED BY ADVANCED GLYCATED ALBUMIN
A. Machado-Lima, R.T. Iborra, L.S. Okuda, R.S. Pinto, E.R. Nakandakare, M.L.C. Corrêa-Giannella, M. Passarelli (Brazil)

P2.6.230  ALTERED CETP CONCENTRATION AND HDL FUNCTION IN CAD PATIENTS
S. Sailer, V. Haller, T. Bernscherer, M. Hunjadi, M. Wanitschek, H. Alber, A. Ritsch (Austria)

P2.6.231  NOVEL LXR AGONIST INHIBIT ATHEROSCLEROSIS THROUGH CROSS-REGULATING CHOLESTEROL METABOLISM AND INFLAMMATION
N. Li, X. Wang, Y.N. Xu, P. Liu, Y.Z. Fan, D. Lu, S.Y. Si (China)

P2.6.232  ASSOCIATION BETWEEN ALPHA-TOCOPHEROL CONCENTRATION IN HDL FRACTION AND CHOLESTEROL EFFLUX CAPACITY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
M. Ogura, Y. Hirowatari, D. Manita, M. Harada-Shiba (Japan)

P2.6.233  OBESITY RELATED NEUROPATHY IS ASSOCIATED WITH HDL FUNCTIONALITY

2.7 Adipose tissue biology

P2.7.234  CARDIAC MRI CHARACTERISTICS OF EPICARDIAL FAT IN A VERY HIGH RISK PATIENTS WITH A MULTIVESSEL CORONARY ARTERY DISEASE
M. Haberka, Z. Gasior (Poland)

P2.7.235  VISCERAL ADIPOSE TISSUE, INFLAMMATION AND FIBROSIS IN PATIENTS WITH ATRIAL FIBRILLATION AND METABOLIC SYNDROME
V. Ionin, E. Zaslavskaya, Y. Ma, A. Morozov, E. Polyakova, S. Nifontov, K. Malikov, O. Listopad, O. Belyaeva, S. Yashin, E. Baranova, E. Shlyakhto (Russia)
P2.7.236  BODY FAT DISTRIBUTION AND GENETIC VARIANTS ARE ASSOCIATED WITH SEX DIFFERENCES IN SERUM LEPTIN AND ADIPONECTIN CONCENTRATIONS

P2.7.237  GENE EXPRESSION OF FNDC5 AND RELATED GENES IN GLUTEAL SUBCUTANEOUS ADIPOSE TISSUE AND PLASMA IRISIN LEVELS AFTER ACUTE INACTIVITY

P2.7.238  ABCA1 GENE EXPRESSION IN EPICARDIAL ADIPOSE TISSUE OF PATIENTS WITH CORONARY ARTERY DISEASE
  V. Miroshnikova, A. Panteleeva, I. Pobozheva, N. Razgildina, E. Polyakova, O. Belyaeva, O. Berkovitch, E. Baranova, S. Pchelina (Russia)

P2.7.239  OMENTIN1 GENE EXPRESSION IN EPICARDIAL AND SUBCUTANEOUS ADIPOSE TISSUE DURING OBESITY RELATED CORONARY HEART DISEASE
  N. Razgildina, A. Panteleeva, V. Miroshnikova, I. Pobozheva, E. Polyakova, O. Berkovitch, O. Belyaeva, E. Baranova, S. Pchelina (Russia)
MONDAY, MAY 07
17.00-18.30

3. Genetics

3.1 Familial dyslipidemias

P3.1.240 ASSESSMENT OF LP(a) AND DETECTION OF MONOGENIC AND POLYGENIC HYPERCHOLESTEROLAEMIA IN A COHORT OF PATIENTS PRESENTING WITH AN ACUTE CORONARY SYNDROME
P. Downie, L. Hirt, L. Gritzmacher, T. Johnson, G. Bayly (United Kingdom)

P3.1.241 SCREENING AND MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLEMIA IN VIETNAM: ACHIEVEMENTS AND CHALLENGES

P3.1.242 FAMILIAL HYPERCHOLESTEROLAEMIA AND RISK OF PERIPHERAL ARTERIAL DISEASE AND CHRONIC KIDNEY DISEASE: THE COPENHAGEN GENERAL POPULATION STUDY
F. Emanuelsson, B.G. Nordestgaard, M. Benn (Denmark)

P3.1.243 ADHERENCE TO LIPID-LOWERING THERAPY IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
V. Korneva, T. Kuznetsova (Russia)

P3.1.244 THE IMPACT OF AGE AND SEX ON EXCESS RISK OF CORONARY HEART DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: A REGISTRY STUDY

P3.1.245 IDENTIFICATION OF A NEW GENETIC DETERMINANT OF FAMILIAL HYPERCHOLESTEROLEMIA (FH)
C. Pirazzi, J. Sandstedt, L. Håkansson, C. Gustafsson, O. Wiklund, S. Romeo, R. Mancina (Sweden)

P3.1.246 CARBOHYDRATE METABOLISM IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: DATA FROM THE HELLAS-FH REGISTRY
C. Rizos, F. Barkas, V. Athyros, C. Antza, A. Attilakos, M. Elisaf, E. Zacharis, L. Rallidis, E. Kiouri, G. Kolovou, M. Loulakakis, A. Boufidou, I. Skoumas, E. Liberopoulos (Greece)
P3.1.247 THE ACHIEVEMENT OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL TARGET IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: THE ROLE OF PCSK9 INHIBITORS

P3.1.248 CORONARY HEART DISEASE MORTALITY IN TREATED FAMILIAL HYPERCHOLESTEROLAEMIA: UPDATE OF THE UK SIMON BROOME FH REGISTER

P3.1.249 KNOWLEDGE, AWARENESS AND PRACTICE PREFERENCES REGARDING FAMILIAL HYPERCHOLESTEROLAEMIA AMONG PRIMARY CARE DOCTORS IN MALAYSIA

P3.1.250 FAMILIAL DYSBETALIPOPROTEINEMIA - YES, OR NO? - RETROSPECTIVE PATIENT STUDY OF THE CENTER FOR PREVENTIVE CARDIOLOGY OF THE 3RD INTERNAL CLINIC FIRST FACULTY OF MEDICINE AND GENERAL UNIVERSITY HOSPITAL

P3.1.251 PRIMARY PREVENTION IN PAEDIATRIC FH PATIENTS IN A TERTIARY CARDIAC CENTRE
T.Z. Khan, J. Breen, L. Priestly-Barnham, E. Neves, Z. Slavik, M. Barbir (United Kingdom)

P3.1.252 EXCESS RISK OF PERIPHERAL ARTERIAL DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA

P3.1.253 FAMILIAL HYPERCHOLESTEROLEMIA IN HOSPITAL SCREENING PROGRAM IN BOSNIA AND HERZEGOVINA
L. Pojskic, E. Stimjanin, H. Selimovic, B. Pojskic (Bosnia And Herzegovina)

P3.1.254 GENERAL CHARACTERISTICS OF PATIENTS WITH HOMOZYGOUS FORM OF FAMILIAL HYPERCHOLESTEROLAEMIA IN THE CZECH REPUBLIC
P3.1.255 POLYUNSATURATED FATTY ACIDS REDUCE LEVELS OF LDL AND TRIGLYCERIDES IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

P3.1.256 CLINICAL CASE: THE DEVELOPMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN A PATIENT WITH RS879255191 IN LDLR GENE
E. Shakhtshneider, D. Ivanoshchuk, K. Makarenkova, P. Orlov, O. Timoshchenko, S. Bazhan, M. Voevoda (Russia)

P3.1.257 PREVALENCE OF PREMATURE ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS INCLUDED IN THE LATVIAN REGISTRY OF FAMILIAL HYPERCHOLESTEROLEMIA

P3.1.258 IS THERE A CORRELATION BETWEEN PATIENT’S SINGLE NUCLEOTIDE POLYMORPHISM (SNP) SCORE AND FAMILIAL HYPERCHOLESTEROLAEMIA (FH) WELSH SCORE?
F. Palmer, L. Gritzmacher, K. Haralambos, A. Hills (United Kingdom)

P3.1.259 ROMANIAN REGISTRY FOR FAMILIAL HYPERCHOLESTEROLEMIA: A TALE THAT STARTS TODAY

P3.1.260 ACHILLES TENDON ULTRASONOGRAPHY MAY PREDICT A POSITIVE GENETIC TEST IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
F. Nascimbeni, S. Cagnacci, M. Dolci, A. Mondelli, M. Bertoldi, A. Dalla Salda, M. Milazzo, F. Carubbi (Italy)

P3.1.261 A CASE-CONTROL STUDY OF THE LOCALISATION AND COMPOSITION OF CORONARYATHEROSCLEROTIC PLAQUES IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA AS ASSESSED BY CARDIAC CT SCANNING
J. Pang, C. Vargas-Garcia, T. Bates, A. Abraham, G. Watts (Australia)

P3.1.262 HOMOZYGOUS MUTATIONS OF LOW-DENSITY LIPOPROTEIN RECEPTOR GENE IN A FAMILY WITH FAMILIAL HYPERCHOLESTEROLAEMIA
A. AL-Khateeb, N.A. Mohd Kasim, Y.A. Chua, S N F Ismail, L.K. Teh, H. Nawawi (Malaysia)

P3.1.263 FAMILIAL HYPERCHOLESTEROLEMIA STUDY IN DYSLIPIDEMIC CHILDREN AND ADOLESCENTS: “LIKE FATHER, LIKE SON”
I. Gomes, S. Abreu, M. BourboN, F. Pinto (Portugal)
**POSTER SESSIONS**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.1.264</td>
<td>ASSOCIATION OF POLYMORPHISM THE APOE GENE WITH CARDIOVASCULAR RISK FACTORS AND UNFAVORABLE LONG-TERM PROGNOSIS</td>
<td>E. Shakhtshneider, D. Ivanoshchuk, P. Orlov, L. Shcherbakova, S. Malyutina, Y. Ragino, M. Voevoda</td>
<td>Russia</td>
</tr>
<tr>
<td>P3.1.265</td>
<td>A COMPARISON OF SIMON BROOME AND WELSH CRITERIA FOR SELECTING PATIENTS FOR FAMILIAL HYPERCHOLESTEROLAEMIA (FH) GENETIC TESTING</td>
<td>P. Ashfield-Watt, L. Gritzmacher, I. McDowell, G. Bayly, K. Haralambos</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>P3.1.266</td>
<td>INFLUENCE OF THE PRESENCE OF MUTATION IN LDLR, ON THE CLINICAL CHARACTERISTICS OF A POPULATION OF FAMILIAL HYPERCHOLESTEROLEMIA IN THE CITY OF BUENOS AIRES</td>
<td>A. Gómez, L. Helman, M. Parolin, L. Kaeser, L. Cuniberti, M. Aguiló Iztueta, U. Toscanini</td>
<td>Argentina</td>
</tr>
<tr>
<td>P3.1.267</td>
<td>HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND RARE GENETIC COMBINATION IN ARGENTINA</td>
<td>M.B. Araujo, A. Agustinho, V. Bañares</td>
<td>Argentina</td>
</tr>
<tr>
<td>P3.1.268</td>
<td>DIFFERENT PHENOTYPES IN SIBLINGS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMA</td>
<td>O. Kyselak, V. Soska</td>
<td>Czech Republic</td>
</tr>
</tbody>
</table>

### 3.2 Gene-environment interactions

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.2.270</td>
<td>STENT RESTENOSIS IN A HISPANIC POPULATION-THE IMPORTANCE OF GENETICS</td>
<td>P. Altieri, H.L. Banchs</td>
<td>Puerto Rico</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

P3.2.271  ABDOMINAL OBESITY AND LIPID ABNORMALITIES IN KYRGYZ POPULATION WITH T1264G OF CD36 GENE POLYMORPHISM
O. Lunegova, A. Kerimkulova, S. Abilova, E. Bektasheva, A. Aldashev, M. Mirrakhimov (Kyrgyzstan)

P3.2.272  GENE-ENVIRONMENTAL INTERACTION AND THE METABOLIC SYNDROME IN ASIAN INDIANS WITH INSULIN RESISTANCE
T. Maistry, M. Gordon, B. Sartorius, D.P. Naidoo (South Africa)

P3.2.273  THE EXPRESSION OF CONNEXIN 37 GENE IN THE AORTA OF RAT MODELS OF DYSLIPIDEMIA, HYPERTENSION AND DICARBONYL STRESS
I. Markova, J. Pitha, M. Pravenec (Czech Republic)

P3.2.274  PREVALENCE OF RISK ALLELES OF POLYGENIC HYPERTRIGLYCERIDEMIA AND ASSOCIATION WITH MAXIMUM TRIGLYCERIDE SERUM CONCENTRATION ON SOUTHERN BARCELONA METROPOLITAN AREA POPULATION

P3.2.275  BISPHENOL A EXERTS PRO-ATHEROGENIC EFFECTS THROUGH NF-KB ACTIVATION AND DOWN-REGULATION OF APOLIPOPROTEIN A1 EXPRESSION IN HEPATOCYTES
V.G. Trusca, M. Dumitrescu, I.M. Fenyo, I.F. Tudorache, A.V. Gafencu (Romania)

P3.2.276  CONNEXIN 37 GENE POLYMORPHISM AND ATHEROSCLEROTIC CHANGES IN WOMEN WITH DIABETES TYPE 1 AND 2
J. Pitha, P. Pithova, P. Stavek, J.A. Hubacek, O. Auzky, R. Houdkova, S. Eisenreichova, T. Neskudla, T. Pelikanova, M. Kvapil (Czech Republic)

3.3 Genomics, GWAS, and population genetics

P3.3.277  SINGLE NUCLEOTIDE POLYMORPHISMS AT THE HMGCGR GENE LOCUS SIGNIFICANTLY PREDICT TOTAL MORTALITY IN ANGIOPHAGIED CORONARY PATIENTS WITH THE METABOLIC SYNDROME
A. Leiherer, A. Muendlein, C.H. Saely, A. Vonbank, A. Mader, B. Larcher, P. Fraunberger, H. Drexel (Austria, Liechtenstein, USA, Switzerland)
POSTER SESSIONS

P3.3.278 APOE GENE VARIANTS IN PRIMARY HYPERLIPIDEMIAS
A.M. Bea Sanz, I. Lamiquiz-Moneo, C. Martin, R. Mateo-Gallego, A. Cenarro, F. Civeira (Spain)

P3.3.279 EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE SODIUM GLUCOSE CO-TRANSPORTER 2 GENE WITH GLUCOSE HOMEOSTASIS AND TYPE 2 DIABETES

P3.3.280 SELECTION OF GENES WITH TRANSCRIPTIONAL ACTIVITY IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND ASSOCIATED WITH ATHEROPROTECTIVE EFFECT OF HDL IN PATIENTS WITH CORONARY ARTERY DISEASE
L. Dergunova, V. Dmitrieva, E. Zuikova, E. Nosova, S. Limborska, D. Litvinov, A. Dergunov (Russia)

P3.3.281 LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) : REPORT OF NEW FOUR SPANISH UNRELATED CASES
A. Sánchez Ramos, M. Casañas Martinez, D. Ibarretxe, R. Tomasini, J. Anglada, N. Plana, A. Brea, P. Valdivielso (Spain)

P3.3.282 GENE SCORE AS PREDICTOR OF HYPERTRIGLYCERIDEMIA IN CZECH POPULATION
J. Hubacek, V. Adamkova, M. Vrablik, R. Ceska (Czech Republic)

P3.3.283 ASSOCIATION OF HETEROPLASMY LEVEL OF MITOCHONDRIAL MUTATION M.13513G> IN GENEMT-ND5 WITH CAROTID ATHEROSCLEROSIS IN RUSSIAN POPULATION
S. Timofeeva, E. Butenko, K. Derevyanchuk, T. Shkurat (Russia)

P3.3.284 THE RESULTS OF EXOME SEQUENCING OF PARTICIPANTS OF EPIDEMIOLOGICAL STUDY WITH AND WITHOUT ISCHEMIC HEART DISEASE
N. Shcherbakova, A. Meshkov, A. Ershova, A. Zharikova, A. Kiseleva, E. Khlebus, S. Shalnova, S. Boytsov, O. Drapkina (Russia)

P3.3.285 STUDY OF ASSOCIATIONS OF POLYMORPHIC VARIANTS OF LIPID AND CARBOHYDRATE METABOLISM GENES, VASCULAR INFLAMMATION AND NEUROTRANSMITTER SYSTEMS WITH THE DEVELOPMENT OF THE FIRST ISCHEMIC STROKE
V. Shishkova, A. Remennik, V. Valyaeva, T. Adasheva (Russia)

P3.3.286 THE IMPACT OF RARE AND LOW-FREQUENCY GENETIC VARIANTS IN OXIDIZED LDL LEVEL
E. Khlebus, V. Kutsenko, A. Shevtsov, D. Choklya, N. Shcherbakova, A. Ershova, A. Kiseleva, S. Boytsov, O. Drapkina, E. Yarovaya, A. Meshkov (Russia)
P3.3.287 MITOCHONDRIAL DNA POLYMORPHISM STUDY IN PATIENTS WITH CAROTID ATHEROSCLEROSIS SUGGESTS PROTECTIVE EFFECT OF HAPLOGROUP J M.V. Golubenko, N.V. Tarasenko, O.A. Makeeva, I.A. Goncharova, A.V. Frolov, A.N. Kazantsev, A.V. Markov, A.A. Sleptcov, A.A. Komar, M.S. Nazarenko, O.L. Barbarash, V.P. Puzyrev (Russia)

P3.3.288 PREVALENCE OF ANGPTL4, SVEP1, LPL AND PCSK9 VARIANTS IN CZECH REPUBLIC J. Kvasnicka, Z. Krska, P. Bobcikova, J. Hajkova, T. Kvasnicka (Czech Republic)

3.4 Epigenetics and microRNAs


P3.4.290 DNA METHYLATION PROFILING WITHIN MICRORNA GENES IN ATHEROSCLEROTIC PLAQUE DESTABILIZATION A. Markov, A. Kucher, I. Koroleva, D. Sharysh, A. Zarubin, A. Kazantsev, O. Barbarash, M. Nazarenko (Russia)

P3.4.291 THE METHYLATION LEVEL OF MIR10B AND MIR21 GENES PROMOTERS IN CAROTID ATHEROSCLEROSIS I. Koroleva, M. Nazarenko, A. Markov, A. Kazantzev, O. Barbarash, V. Puzyrev (Russia)

P3.4.292 STUDYING THE EPGENETIC BASIS OF AGE RELATED AND CARDIOMETABOLIC DISEASES IN HUMANIZED MOUSE MODELS C. Peri, M. Zocchi, N. Mitro, D. Caruso, E. De Fabiani, M. Crestani (Italy)

P3.4.293 NOVEL IMMUNOASSAY APPROACH TO INVESTIGATE MICRORNA BIOMARKERS IN ACUTE MYOCARDIAL INFARCTION M. Hlozankova, J. Izakova, B. Dvorakova, M. Buresova, M. Holcapkova, L. Chalupova, K. Cuchnova, M. Karpisek, T. Mrackova, E. Bace, Z. Motovska, M. Hromadka, V. Ruzicka (Czech Republic)
P3.4.294  ACCOUNTING LEUKOCYTE INFILTRATION IN GENOME-WIDE DNA METHYLATION STUDIES OF Atherosclerotic Plaque
A. Zarubin, A. Markov, D. Sharysh, O. Barbarash, M. Nazarenko, V. Puzyrev (Russia)

P3.4.295  A NOVEL MIRSNP AT THE IGF1 3'UTR MAY MODULATE THE MIRNA-MEDIATED GENE EXPRESSION IN CARDIOVASCULAR DISEASE
4. Clinical manifestations
4.1 Non-alcoholic fatty liver disease

P4.1.296 EARLY MARKER OF ATHEROSCLEROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND SUBCLINICAL HYPOTHYROIDISM
O. Kolesnikova, V. Nemtsova (Ukraine)

P4.1.297 MELATONIN SIRTUIN1-DEPENDENT MECHANISM OF ACTION IN AN HYPERCHOLESTEROLEMIC ANIMAL MODEL
F. Bonomini, G. Favero, L.F. Rodella, M.H. Moghadasian, R. Rezzani (Italy, Canada)

P4.1.298 SERUM LIPID PROFILES IN A MOUSE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) INDUCED BY CHOLINE-DEFICIENT HIGH FAT DIET (CDHFD)
N. Kume, H. Torii, D. Yasuda, R. Shimizu, Y. Hiraoka (Japan)

P4.1.299 REACTIVE HYPEREMIA INDEX IS SUITABLE FOR SCREENING ENDOTHELIAL DYSFUNCTION ESPECIALLY IN OBESE SUBJECTS WITH NON-ALCOHOLIC HEPATITIS
S. Yano, H. Tobita, C. Uno, Y. Ishibashi, S. Mishima, A. Nagai (Japan)

P4.1.300 PRE-CLINICAL VASCULAR DAMAGE IN METABOLIC SYNDROME: CORRELATION BETWEEN NAFLD AND CAROTID DISEASE
V. Veca, V. Gandolfo, C. Natali, F. Barsotti, G. Lupattelli, D. Siepi, M.A. Ricci, G. Vaudo (Italy)

P4.1.301 HYPERTRANSAMINASEMIA AND HEPATIC STEATOSIS: CHARACTERISTICS AND TEMPORARY EVOLUTION IN A COHORT OF FAMILIAL COMBINED HYPERLIPIDAEMIA PATIENTS
A.B. Porto Pérez, P. Vázquez Rodríguez, S. Ruanova Súarez, R. Suárez Fuentetaja, R. De La Fuente Cid, R. Argüeso Armesto, J.L. Díaz Díaz (Spain)
4.2 Chronic kidney disease

P4.2.302 Loading doses statins for prevention of CI-AKI at the elective PCI
E. Vershinina, A. Repin (Russia)

P4.2.303 Increased blood pressure variability was associated with future kidney disease in essential hypertension
W. Tsai, C. Chou (Taiwan)

P4.2.304 Interconnection between CAVI1 and kidney filtration function
N. Koziolova, A. Chernyavina (Russia)

P4.2.305 Estimated glomerular filtration rate is an independent determinant of arterial stiffness
C. Antza, I. Doundoulakis, S. Stabouli, V. Kotsis (Greece)

P4.2.306 Nephrin and podocalyxin - podocyte markers for early detection of hypertensive nephropathy
I. Kostovska, K. Tosheska Trajkovska, D. Labudovic, S. Topuzovska, G. Bosilkova, S. Cekovska, G. Spasovski (Republic of Macedonia)

P4.2.307 The predictive role of serum triglyceride to high-density lipoprotein cholesterol ratio according to renal function in patients with acute myocardial infarction
W. Kim, J.H. Cho, J.Y. Rhew (South Korea)

P4.2.308 Metabolic phenotype and glomerular filtration rate among the non-diabetic obese individuals
B. Ilincic, M. Djeric, M. Todorovic, J. Sudji, R. Zeravica, V. Cabarkapa (Serbia)

P4.2.309 Dyslipidemia and the state of the main head arteries in patients with CKD 1-3A in combination with subclinical hypothyroidism
I. Garmish, A.V. Kuryata (Ukraine)

P4.2.310 Lipid profiles associated with MACES among hemodialysis patients with percutaneous coronary intervention: From the FU-REGISTRY
N. Ishida, A. Ike, Y. Matsuoka, M. Sugihara, H. Nishikawa, K. Saku, S. Miura (Japan)
4.3 Diabetes and insulin resistance

P4.3.311 ANTI-INFLAMMATORY ACTION OF N-STEAROYLETHANOLAMINE IN RAT PERITONEAL MACROPHAGES DURING HIGH FAT FEEDING
O. Onopchenko, H. Kosiakova, A. Berdyshev, N. Hula (Ukraine)

P4.3.312 HIGH-DENSITY LIPOPROTEIN BEHAVIOUR, AS AN ADIPONECTIN PREDICTOR, IMPLIES THE RISK OF TYPE 2 DIABETES
S. Ljubic, A. Piljac, I. Antal, A. Jazbec, L. Smircic Duvnjak (Croatia)

P4.3.313 THE EFFECT OF METFORMIN ON ENERGETIC METABOLISM IN PATIENTS WITH TYPE 2 DIABETES/PREDIABETES AND CHRONIC HEART FAILURE
E. Stolarikova, J. Kopecky, K. Velebova, J. Veleba, L. Belinova, H. Malinska, M. Segetova, V. Elenovsky, T. Pelikanova (Czech Republic)

P4.3.314 MICRONIZED SILYMARIN EXTRACT REDUCED HEPATOTOXIC EFFECT OF FENOFIBRATE IN HEREDITARY HYPERTRIGLYCERIDEMIC RATS
O. Oliyarnyk, I. Markova, H. Malinska, J. Trnovska, M. Hüttl, V. Skop, Z. Matuskova, M. Poruba, R. Vecera, L. Kazdova (Czech Republic)

P4.3.315 ATHEROGENIC DYSLIPIDEMIA INCREASED THE RISK OF INCIDENT DIABETES IN STATIN-TREATED INDIVIDUALS
F. Barkas, M. Elisaf, E. Liberopoulos, C. Rizos, T. Dimitriou, D. Sferopoulos, E. Rizos (Greece)

P4.3.316 NON-ALCOHOLIC FATTY LIVER DISEASE AND ITS ASSOCIATION WITH INCIDENT DIABETES IN STATIN-TREATED INDIVIDUALS
F. Barkas, M. Elisaf, E. Liberopoulos, E. Klouras, A. Kei, A. Liantos, E. Megapanou, C. Lamouri, E. Rizos (Greece)

P4.3.317 BENEFICIAL EFFECTS OF GREEN BANANA BIOMASS CONSUMPTION IN PATIENTS WITH PRE-DIABETES AND DIABETES: A RANDOMIZED CONTROLLED TRIAL

P4.3.318 RELATIONSHIPS BETWEEN PLASMA LEPTIN LEVELS, LEPTIN RECEPTOR GLN223ARG POLYMORPHISM AND INSULIN RESISTANCE IN KYRGYZ NATIVE SUBJECTS
A. Kerimkulova, O. Lunegova, S. Abilova, E. Bektasheva, A. Aldashev, E. Mirrakhimov (Kyrgyzstan)
P4.3.319  BMS309403 DECREASES FATTY ACID-INDUCED ENDOPLASMIC RETICULUM STRESS-ASSOCIATED INFLAMMATION IN SKELETAL MUSCLE
R. Rodriguez-Calvo, A. Bosquet, J. Girona, S. Guaita-Esteruelas, M. Heras, P. Saavedra-García, N. Martínez-Micaelo, L. Masana (Spain)

P4.3.320  DISTURBANCES IN CARDIAC INSULIN SIGNALING AND NITRIC OXIDE SYNTHASE IN OVARIECTOMIZED RATS ON FRUCTOSE DIET CAN BE PREVENTED BY LOW INTENSITY EXERCISE
J. Stanisic, G. Koricanac, M. Stojiljkovic, T. Culafic, S. Romic, M. Kostic, M. Pantelic, S. Tepavcevic (Serbia)

P4.3.321  CLINICAL AND GENETIC PROFILES IN TYPE 2 DIABETES PATIENTS WITH MODERATE TO SEVERE HYPERTRIGLYCERIDEMIA

P4.3.322  CROCUS SATIVUS EFFECTS ON VASPIN LEVELS IN DIABETIC RATS
A. Daskalopoulou, I. Doulamis, A. Tzani, P. Konstantopoulos, M. Korou, A. Levantis, C. Kagiou, G. Marinos, C. Gaitanaki, D. Perrea (Greece)

P4.3.323  ASSOCIATION OF CYSTATIN C WITH MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME
T. Ovrakh, S. Serik (Ukraine)

P4.3.324  PLANT STEROLS LOWERS BOTH FASTING LDL-CHOLESTEROL AND TRIGLYCERIDES IN DYSLIPIDEMIC INDIVIDUALS WITH OR AT RISK OF DEVELOPING TYPE 2 DIABETES
E. Trautwein, W. Koppenol, A. deJong, H. Hiemstra, M. Vermeer, M. Noakes, N. Luscombe-Marsh (The Netherlands, Australia)

P4.3.325  REDUCED TESTOSTERONE LEVELS ARE RELATED TO IMPAIRED METABOLIC PROFILE, SMALLER HDL AND LDL SUBFRACTIONS AND ENHANCED INFLAMMATION AND LEUKOCYTE-ENDOTHELIUM INTERACTIONS IN TYPE 2 DIABETIC MEN

P4.3.326  PROTEOMIC DISCOVERY OF BIOMARKERS ASSOCIATED WITH MORBID OBESITY IN PATIENTS UNDERGOING BARIATRIC SURGERY
I. Doulamis, P. Konstantopoulos, A. Tzani, A. Antoranz, A. Daskalopoulou, A. Minia, A. Charalampopoulos, D.N. Perrea, L. Alexopoulos, E. Menenakos (Greece)
P4.3.327  ADIPOKINES AND ATHEROGENIC PARAMETERS IN INSULIN RESISTANT AND NON-INSULIN RESISTANT WOMEN WITH POLYCYSTIC OVARY SYNDROME
A. Atanasova Boshku, V. Jovanovska, B. Zafirova Ivanovska (Republic of Macedonia)

P4.3.328  THE RATIO OF GLYLATED ALBUMIN TO GLYLATED HEMOGLOBIN IS ASSOCIATED WITH INSULIN RESISTANCE-RELATED FEATURES IN NON-DIABETIC JAPANESE SUBJECTS
Y. Ikeda, N. Hisakawa, H. Takata, T. Ohguro, J. Nishiuchi, Y. Kumon (Japan)

P4.3.329  DAILY DOSE OF BASAL INSULIN IN A POPULATION OF OBESE DIABETIC WOMEN
C. Jemai, N. Ben Amor, M. Zarrouk, A. Temessek, H. Tertek, F. Ben Mami (Tunisia)

P4.3.330  CLINICO-METABOLIC PROFILE OF A GROUP OF WOMEN WITH TYPE 2 DIABETES WITH HIGH DOSES OF INSULIN
C. Jemai, N. Ben Amor, M. Zarrouk, H. Tertek, A. Temessek, F. Ben Mami (Tunisia)

P4.3.331  MEDIATION ANALYSIS ON THE ASSOCIATION BETWEEN STATIN USE AND FASTING GLUCOSE LEVEL
D. Lee, H. Joo, H. Jung, D. Lim (South Korea)

P4.3.332  CHARACTERIZATION OF GLYCPROTEIN PROFILES OF TYPE-1 OR TYPE-2 DIABETES MELLITUS AND ATHEROGENIC DYSLIPIDAEMIA PATIENTS BY 1H-NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
R. Fuertes Martín, N. Amigó, L. Brugnara, A. Novials, L. Masana, X. Correig (Spain)

P4.3.333  TYPE 2 DIABETES AND LIPID PROFILE: IS LOW-DENSITY LIPOPROTEIN - CHOLESTEROL ENOUGH?
L. Fonseca, S. Paredes, J. Vilaverde, M. Alves, J.C. Oliveira, I. Palma (Portugal)

P4.3.334  HYPERCHOLESTEROLEMIA AND DIABETES MELLITUS TYPE I: CLINICAL CASE
E. Slastnikova, D. Sadykova, A. Shakirova, Z. Khabibrakhmanova, N. Krinitskaya, O. Pecheritsa, L. Galimova (Russia)
**POSTER SESSIONS**

### 4.4 Diabetic angiopathies

**P4.4.335**  
SERUM UROMODULIN IS SIGNIFICANTLY ASSOCIATED WITH BOTH TYPE 2 DIABETES AND PREDIABETES  
(Austria, Liechtenstein, USA, Switzerland)

**P4.4.336**  
POTENTIAL APPLICATION OF THE VARIATION SITES, RS429358 AND RS7412, IN THE APOE GENE FOR EVALUATING THE RISK FACTORS, LIPID DISORDERS, CLINICAL SEVERITY AND PROGNOSIS IN PATIENTS WITH ST-SEGMENT ELEVATION  
A. Inozemtseva, V. Kashtalap, A. Argunova, L. Gordeeva, O. Barbarash  
(Russia)

**P4.4.337**  
ADIPONECTIN AND HIGH-DENSITY LIPOPROTEIN ARE CLOSELY RELATED TO FATTY LIVER, YET CYSTATIN C EMERGES AS AN IMPORTANT FACTOR IN THE PREDICTION OF DIABETIC NEPHROPATHY  
A. Piljac, S. Ljubic, A. Jazbec, M. Vucic Lovrencic, L. Smircic Duvnjak  
(Croatia)

**P4.4.338**  
THE CREATININE TO UROMODULIN RATIO IN SERUM PREDICTS MAJOR CARDIOVASCULAR EVENTS INDEPENDENTLY FROM THE PRESENCE OF TYPE 2 DIABETES  
(Austria, Liechtenstein, USA, Switzerland)

**P4.4.339**  
SERUM UROMODULIN PREDICTS MORTALITY INDEPENDENTLY FROM THE PRESENCE OF TYPE 2 DIABETES  
(Austria, Liechtenstein, USA, Switzerland)

**P4.4.340**  
TYPE 2 DIABETES, CHRONIC KIDNEY DISEASE, AND MORTALITY IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE  
(Austria, Liechtenstein, USA, Switzerland)

**P4.4.341**  
PRO-B-TYPE NATRIURETIC PEPTIDE STRONGLY PREDICTS ALL CAUSE AND CARDIOVASCULAR MORTALITY IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH AS WELL AS IN THOSE WITHOUT TYPE 2 DIABETES  
(Austria, Liechtenstein, USA, Switzerland)
P4.4.342 SCREENING FOR SUBCLINICAL PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
J. Ena, C.R. Argente, S. Perez (Spain)

P4.4.343 CONTRIBUTION OF ADDITIONAL RISK FACTORS TO THE DIFFUSENESS OF CORONARY ATHEROSCLEROSIS IN DIABETIC PATIENTS WITH AND WITHOUT STATIN THERAPY
B. Koroglu, E. Ural, I. Karauzum, K. Karauzum, D. Ural, U. Bildirici, T. Kilic, A. Agacdiken Agir (Turkey)

P4.4.344 THE ROLE OF HBA1C ON MORTALITY IN PATIENTS WITH MEDICAL HISTORY OF ISCHEMIC STROKE AND PAROXYSMAL ATRIAL FIBRILLATION (PAFIB)
K. Kanellopoulou, I.L. Matsoukis, T. Athanasopoulou, A. Ganotopoulou, N. Zimpounoumi, C. Triantafillopoulou, D. Klonos, L. Skorda, A. Sianni (Greece)

P4.4.345 THE ROLE OF HYPOGLYCAEMIA ON PROVOKING TACHYARRHYTHMIAS IN PATIENTS WITH DMT2, PAROXYSMAL ATRIAL FIBRILLATION (PAFIB) AND ISCHEMIC STROKE
I.L. Matsoukis, K. Kanellopoulou, T. Athanasopoulou, A. Ganotopoulou, N. Zimpounoumi, C. Triantafillopoulou, D. Klonos, L. Skorda, A. Sianni (Greece)

P4.4.346 PHARMACEUTICAL AND BIOPHARMACEUTICAL EVALUATION OF EXTRACTS FROM DIFFERENT PLANT PARTS OF INDIGENOUS ORIGIN FOR THEIR HYPOGLYCEMIC RESPONSES IN RATS
N. Kumar, R. Khanna (India)

P4.4.347 RISCK FACTORS CONTROL IN TYPE 2 DIABETIC PATIENTS WITH PERIPHERAL ARTERY DISEASE. TWELVE YEARS EXPERIENCE OF A CENTER
J. Sequeira Duarte, C. Ferrinho, C. Bello, J. Azinheira, C. Vasconcelos (Portugal)

P4.4.348 CHANGES OF OXIDATIVE STRESS MARKERS AFTER TREATMENT OF DIABETIC NEUROPATHY WITH ALPHA-LIPOIC ACID
F.S. Ferenc Sztanek, H. Lorincz, D. Banyai, P. Sandor, A. Molnar, I. Seres, G. Paragh (Hungary)

P4.4.349 PREDICTORS OF IMPROVEMENT OF LEFT VENTRICULAR CONTRACTILE FUNCTION IN PATIENTS WITH MYOCARDIAL INFARCTION
M. Mirmaksudov, S. Kenjaev, A. Alyavi, M. Kenjaev, S. Turgunboyev (Uzbekistan)

P4.4.350 SCREENING OF THE LOWER EXTREMITY OCCLUSIVE ARTERIAL DISEASE BY THE SYSTOLIC PRESSURE INDEX
N. Ben Amor, C. Jemai, H. Tertek, A. Temesk, M. Zarrourk, F. Ben Mami (Tunisia)
POSTER SESSIONS

P4.4.351 CARDIOVASCULAR EVENTS ARE ASSOCIATED TO GLICEMIC EXPOSURE IN TYPE 2 DIABETIC PATIENTS. EXPERIENCE OF A CENTER FROM 2006 TO 2017

4.5 Nutrition and obesity

P4.5.352 EFFECTS OF DIET-INDUCED WEIGHT LOSS ON POSTPRANDIAL VASCULAR FUNCTION AFTER CONSUMPTION OF A MIXED MEAL: RESULTS OF A RANDOMIZED CONTROLLED TRIAL IN ABDOMINALLY OBESE MEN

P4.5.353 ASSOCIATION BETWEEN SERUM TIGHT JUNCTION PROTEINS AND INSULIN RESISTANCE IN MORBIDLY OBESE SUBJECTS

P4.5.354 OPPOSITE RESPONSE OF CHOLESTEROL METABOLISM TO MATERNAL FRUCTOSE INTAKE IN MALE AND FEMALE PROGENY
E. Fauste, M. De la Cuesta, S. Rodrigo, L. Rodríguez, J.J. Álvarez-Millán, M.I. Panadero, P. Otero, C. Bocos (Spain)

P4.5.355 EFFECT OF HIGH COMPLEX CARBOHYDRATE DIET ON WEIGHT REDUCTION AND THE METABOLIC AND INFLAMMATORY MARKERS IN POSTMENOPAUSAL WOMEN
O. Raz, T. Rosenzweig, O. Rogovsky, I. Shapira, S. Berliner (Israel)

P4.5.356 THE EFFECTS OF N-ACETYL-L-CYSTEINE ON SUBCHRONIC METHIONINE LOAD IN MALE WISTAR RATS: FOCUS ON STANDARD BIOCHEMICAL PARAMETERS AND MARKERS OF HOMOCYSTEINE METABOLISM IN BLOOD

P4.5.357 BARIATRIC SURGERY LEADS TO A REDUCTION IN ANTI-APOLIPOPROTEIN-A-1 IGG ANTIBODIES
S. Adam, T. Sliahmansur, Y. Liu, J.H. Ho, S. Pagano, S. Azmi, A.A. Syed, S.S. Dhage, R.A. Malik, R. Donn, B.J. Ammori, N. Vuilleumier, H. Soran (United Kingdom, Switzerland, Qatar)
POSTER SESSIONS

P4.5.358  MEDITERRANEAN DIET, A WAY TO REDUCE ATHEROSCLEROSIS: THE ADHERENCE IN A PORTUGUESE SAMPLE
B. Sousa (Portugal)

P4.5.359  THE SHORT-TERM EFFECT OF DIFFERENT WEIGHT LOSS DIETARY APPROACHES ON LIPID PROFILES IN REAL LIFE
Y. Varaeva, A. Starodubova, S. Kosyura, E. Livantsova (Russia)

P4.5.360  A NUTRACEUTICAL COMBINATION TARGETING DYSLIPIDEMIA AND SUBCLINICAL INFLAMMATION IN HIV PATIENTS ON STABLE ANTIRETROVIRAL THERAPY
V. Bianconi, E. Schiaroli, D. Francisci, M.R. Mannarino, F. Barsotti, A. Spinozzi, F. Bagaglia, F. Baldelli, M. Pirro (Italy)

P4.5.361  SERUM VITAMIN D STATUS, VITAMIN D RECEPTOR POLYMORPHISM AND GLUCOSE HOMEOSTASIS IN HEALTHY SUBJECTS
O. Mayer, J. Seidlerová, V. Cerná, M. Hronová, P. Karnosová, M. Pesta, J. Filipovský, R. Cífková (Czech Republic)

P4.5.362  AN INCREASED WAIST-TO-HIP RATIO IS A KEY DETERMINANT OF ATHEROSCLEROTIC BURDEN IN OVERWEIGHT SUBJECTS
R. Scicali, D. Rosenbaum, A. DI Pino, P. Giral, P. Cluzel, A. Redheuil, S. Piro, A.M. Rabuazzo, F. Purrello, E. Bruckert, A. Gallo (Italy, France)

P4.5.363  PROOF OF THE ROLE OF HYPEROSMOLAL FOOD IN DEVELOPMENT OF ATHEROSCLEROSIS
R. Mathur (USA)

P4.5.363bis LOW GLYCEMIC DIET IMPROVES LIPID PROFILE IN PATIENTS WITH CORONARY HEART DISEASE
A. Alyavi, B. Alyavi, J. Uzokov (Uzbekistan)
POSTER SESSIONS

MONDAY, MAY 07
17.00-18.30

5. Epidemiology, risk management, and treatment
5.1 Epidemiology of cardiovascular disease and risk factors

P5.1.364 CIRCadian Influence on Atherosclerosis in extreme north conditions
N. Shurkevich, A. Vetoshkin, L. Gapon, D. Gubin (Russia)

P5.1.365 Increase of body mass index predicts development of metabolic syndrome criteria in apparently healthy individuals with 2 and 5 years follow-up
E. Fisher, I. Shapira, S. Berliner, O. Rogowski, S. Shenhar-Tsarfaty (Israel)

P5.1.366 Prevalence of familial hypercholesterolemia among hospitalized patients with cerebrovascular diseases
R. Khokhlov, V.T.H. Burlachuk, L.V. Tribuntseva, L.R. Khokhlov (Russia, Czech Republic)

P5.1.367 Design and rationale of Gulf Familial Hypercholesterolemia registry
K. Al-Rasadi (Oman)

P5.1.368 The atherosclerotic plaque of the carotid artery is and the traditional risk factors are not the predictors of cardiovascular events in patients with low score risk
A.E. Golovina, N.O. Katamadze, E.V. Bondareva, S.A. Saiganov, L.L. Berstein (Russia)

P5.1.369 The oxidized low-density lipoprotein/B2-glycoprotein I complex in artherothrombosis
P. Ames, G. Di Girolamo, G. D'Andrea, L. Iannaccone, L. Lopez, M. Margaglione (Portugal, Italy, USA)

P5.1.370 HACD4 Haplotype confers risk of myocardial infarction among males in the population of Serbia
I. Zivotic, T. Duric, A. Stankovic, G. Stankovic, D. Milasinovic, M. Dekleva, N. Markovic Nikolic, D. Alavantic, M. Zivkovic (Serbia)

P5.1.371 Age-dependence pattern of the magnitude of height, waist circumference and BMI resemblance between first degree relatives: family study of patients with early ischemic heart disease
M. Konnov, A. Deev (Russia)
P5.1.372 AGE-DEPENDENCE PATTERN OF THE MAGNITUDE OF FASTING GLYCEMIA, INSULINEMIA AND HOMA-IR RESEMBLANCE BETWEEN FIRST DEGREE RELATIVES: FAMILY STUDY OF PATIENTS WITH EARLY ISCHEMIC HEART DISEASE
M. Konnov, A. Deev (Russia)

P5.1.373 CARDIOVASCULAR RISK FACTORS AMONG CARDIOLOGISTS AND GENERAL PRACTITIONERS IN ALBANIA
A. Goda, H. Gjergo, J. Dragoti, E. Hasimi (Albania)

P5.1.374 SAFETY AND TOLERABILITY OF ATORVASTATIN CALCIUM ANHYDROUS IN KOREAN PATIENTS WITH DYSLIPIDEMIA: AN UPDATED SECOND INTERIM ANALYSIS FROM THE LAMP STUDY
S.J. Hong, S.Y. Choi, S.H. Han, Y.J. Choi, T. Ahn (South Korea)

P5.1.375 PREVALENCE OF SEVERE HYPERCHOLESTEROLEMIA IN RUSSIAN ACUTE CORONARY SYNDROME REGISTRY
M. Ezhov, N. Lazareva, O. Sagaydak, U. Chubykina, V. Vygodin, E. Oshchepkova (Russia)

P5.1.376 CARDIOVASCULAR PROFILE IN HOSPITALIZED PATIENTS WITH AN ISCHEMIC EVENT

P5.1.377 IDENTIFICATION OF CORONARY ATHEROSCLEROSIS AMONG RAILWAY WORKERS FOR THE PREVENTION OF TRAFFIC ACCIDENTS
M. Kachkovskii, O. Krasnoslobodskaya, E. Kamenev, A. Osipenko (Russia)

P5.1.378 THE CARDIOMETABOLIC CHARACTERISTICS OF THE PREMORBID METABOLIC SYNDROME IN WOMEN, DATA FROM THE IBERICAN STUDY

P5.1.379 RELATIONSHIP BETWEEN LEFT VENTRICULAR HYPERTROPHY AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE
V. Vasilikova, T. Mokhort, I. Pchelin, V. Bayrasheva, M. Zmailik, E. Naumenko (Belarus, Russia)

P5.1.380 THE PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN RESPONDENTS WITH EARLY MENOPAUSE IN THE UKRAINIAN URBAN POPULATION
G. Iliushyna, O. Mitchenko, T. Kolesnik, V. Romanov, I. Chulaevska (Ukraine)
P5.1.381 THE IMPORTANCE OF LDL-CHOLESTEROL AND TRIGLYCERIDES LEVELS ASSESSMENT FOR FAMILIAL HYPERCHOLESTEROLEMIA SCREENING IN THE MIDDLE-AGED LITHUANIAN ADULTS

P5.1.382 ASSOCIATION OF SERUM LIPID PROFILE AND CIGARETTE SMOKING AMONG MIDDLE-AGED LITHUANIAN ADULTS

P5.1.383 ASSOCIATION OF SERUM LIPID PROFILE AND PHYSICAL ACTIVITY AMONG MIDDLE AGED LITHUANIAN ADULTS
S. Kutkiene, Z. Petrlioniene, A. Laucevicius, U. Gargalskaite, A. Saulyte, A. Navickaite, M. Kovaite, E. Rinkuniene, V. Dzenkeviciute (Lithuania)

P5.1.384 THE ANALYSIS OF NON-HDL CHOLESTEROL QUANTITY AMONG MIDDLE-AGED LITHUANIAN ADULTS WITH DIFFERENT LIPID PROFILES

P5.1.385 ASSOCIATION OF SERUM LIPID PROFILE AND FAMILY HISTORY OF CORONARY HEART DISEASE AMONG MIDDLE AGED LITHUANIAN ADULTS
S. Kutkiene, Z. Petrlioniene, A. Laucevicius, U. Gargalskaite, A. Saulyte, E. Petrulionyte, M. Kovaite, E. Rinkuniene, V. Dzenkeviciute (Lithuania)

P5.1.386 ASSOCIATION OF SERUM LIPID PROFILE AND DIETARY HABITS AMONG MIDDLE-AGED LITHUANIAN ADULTS

P5.1.387 ASSOCIATION OF SERUM LIPID PROFILE AND ARTERIAL HYPERTENSION AND AMONG MIDDLE-AGED LITHUANIAN ADULTS

P5.1.388 ASSOCIATION OF SERUM LIPID PROFILE AND DIABETES MELLITUS AMONG MIDDLE AGED LITHUANIAN ADULTS
S. Kutkiene, Z. Petrlioniene, A. Laucevicius, U. Gargalskaite, A. Saulyte, M. Kovaite, E. Rinkuniene, V. Dzenkeviciute (Lithuania)
P5.1.389 HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASES IN PATIENTS WITH TRANSPLANTED KIDNEY
D. Loncar, E. Tulumovic, I. Bijedic, A. Bijedic (Bosnia and Herzegovina)

P5.1.390 QUANTIFICATION BY MRI OF VISCERAL FAT AND ITS CORRELATION WITH THE PRESENCE OF CRITERIA OF METABOLIC SYNDROME

P5.1.391 DYSLIPIDEMIA AND CARDIOVASCULAR RISK FACTORS, DATA FROM THE IBERICAN STUDY

P5.1.392 DYSLIPIDEMIA AND CARDIOVASCULAR RISK FACTORS IN A SAMPLE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS

P5.1.393 THE REINA STUDY: EVALUATION OF SATISFACTION AND ADHERENCE IN PATIENTS WITH DYSLIPIDAEMIA TREATED WITH PITAVASTATIN

P5.1.394 THE WESTERNIZATION OF LIFE STYLE AND ATHEROSCLEROSIS IN JAPAN – THE BALANCE OF EPA AND AA

P5.1.395 COMPLEX ASSESSMENT OF THE PSYCHO-SOCIAL STATUS IN KYRGYZS WITH CORONARY HEART DISEASE
I. Zalesskaia, O. Korotenko, A. Djumagulova, R. Kydyralieva, V. Ten, T. Neliubova (Kyrgyzstan)
POSTER SESSIONS

P5.1.396  BODY MASS INDEX AND SALT INTAKE MAY LACK CLUSTERING WITH OTHER RISK MARKERS FOR HYPERTENSION IN YOUNG AND MIDDLE ADULTS  
A. Pereira, A. Sposito, L. Fonseca, A. Saldanha, V. Gazon, R. Santos Fo, M.C. Elias, T. Martinez (Brazil)

P5.1.397  VASCULAR COMORBIDITIES IN NEVER SMOKERS  
J.A. Díaz-Peromingo, A. García-Villafranca, E.M. Paez-Guillán, A. González-Quintela (Spain)

P5.1.398  THE PREVALENCE OF FAMILIAR HYPERCHOLESTEROLEMIA IN PATIENTS OF LODZ HOSPITAL AND THEIR TREATMENT ANALYSIS  
P. Gorzelak-Pabis, A. Pawlik, J. Kovtsun, L. Sanz Rekalde, M. Broncel (Poland)

P5.1.399  EXPLORING THE KNOWLEDGE, THE REASONS AND THE PREVALENCE OF THE CONTRAINDICATED USE OF COMBINED ORAL CONTRACEPTIVES  
M. Suciu, L. Vlaia, L. Suciu, L. Dragan, V. Vlaia, M. Voicu, V. Buda, C.M. Minda, M. Andor, S. Negres, C. Cristescu (Romania)

P5.1.400  SIGNIFICANT ASSOCIATION OF SIRT1 RS12765828T ALLELE WITH RISK OF EARLY-ONSET ISCHEMIC STROKE  
F. Hsieh, J. Huang, L. Lien, H. Chiou (Taiwan)

P5.1.401  POTENTIAL MEDIATORS ON THE ASSOCIATION BETWEEN STATIN USE AND CORONARY ARTERY CALCIFICATION  
D. Lee, H. Joo, H. Lee, D. Lim (South Korea)

P5.1.402  CAROTID AND FEMORAL ATHEROSCLEROSIS IN THE MIDDLE-AGED GENERAL POPULATION OF THE RUSSIAN FEDERATION: ITS PREVALENCE AND ASSOCIATION WITH CORONARY ARTERY DISEASE  
A. Ershova, A. Meshkov, E. Alexandrova, N. Lishchenko, A. Novikova, E. Shutemova, O. Belova, T. Balakhonova, S. Shalnova, O. Drapkina, S. Boytsov (Russia)

P5.1.403  HYPERTENSIVE WOMEN HAVE HIGH INCIDENCE OF METABOLIC SYNDROME  
J. Papadakis, V. Theodorakopoulou, A. Plevritaki, G. Vrentzos (Greece)

P5.1.404  KNOWLEDGE, ATTITUDES AND PRACTICES ON SELF-MONITORING BLOOD PRESSURE AND BLOOD GLUCOSE LEVEL IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE II DIABETES MELLITUS  
M. Suciu, L. Vlaia, M. Andor, V. Vlaia, S. Negres, C. Cristescu (Romania)
P5.1.405 ABDOMINAL AORTA ATHEROMATOSIS IS ASSOCIATED WITH THE PRESENCE OF RISK FACTORS IN PRIMARY PREVENTION PATIENTS

P5.1.406 COMPARATIVE ANALYSIS OF THE COMORBIDITIES IMPORTANCE IN PATIENTS WITH PERIPHERAL ARTERY DISEASE

P5.1.407 SDLDL-C - A PROMISING PRECOCIOUS BIOMARKER FOR CORONARY ARTERY DISEASE IN AZOREAN SUBJECTS

P5.1.408 INCIDENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN PATIENTS FROM THE TERCET REGISTRY
D. Krzysztof, T. Osadnik, M. Gasior, M. Banach, A. Desparak (Poland)

P5.1.409 MORTALITY AND LIPID TRENDS IN ACS POPULATIONS: A STUDY FROM THE MALAYSIAN NATIONAL CARDIOVASCULAR DISEASE DATABASE - ACUTE CORONARY SYNDROME (NCVD-ACS) REGISTRY
S. Kasim, T.G. Mohd Ikhwan, T.G. Abu Bakar Sidik, G. Selvaraj, Y. Yip Alan Fong, W. Azman W. Ahmad (Malaysia)

P5.1.410 IMPACT OF DIFFERENT DOSES OF ROSUVASTATIN THERAPY ON FUNCTIONAL AND STRUCTURAL MARKERS OF ENDOTHELIUM DAMAGE IN HYPERTENSIVE PATIENTS DETERMINED BY SMOKING STATUS
M. Suciu, L. Vlaia, M. Andor, V. Vlaia, M. Tomescu, C. Cristescu (Romania)
5.2 Gender and cardiovascular risk

P5.2.411 LIPID ACCUMULATION PRODUCT (LAP), ANTHROPOMETRIC AND METABOLIC PARAMETERS ASSOCIATED WITH HORMONAL PROFILE IN WOMEN WITH PCOS
A. Atanasova Boshku, D. Panova Ivanova (Republic of Macedonia – Fyrom)

P5.2.412 LIPID PROFILE IN HYPERTENSIVE MEN WITH ANDROGEN DEFICIENCY
O. Nasonenko, V. Vizir, A. Sadomov (Ukraine)

P5.2.413 AHEROGENIC POTENTIAL OF SUBCLINICAL HYPOTHYROIDISM AND CARDIOVASCULAR RISK IN WOMEN WITH HYPERTENSION AND HYPOTHYROIDISM
V. Romanov, O. Mitchenko, I. Chulaevska, A. Illuschina (Ukraine)

P5.2.414 THE ROLE OF STATINS IN PREVENTION OF ACUTE CORONARY EVENTS IN PATIENTS WITH CORONARY HEART DISEASE BEFORE AND AFTER CORONARY ANGIOPLASTY AND STENTING
T. Petelina, N. Musikhina, L. Gapon, U. Sharoyan (Russia)

P5.2.415 ESTIMATION OF THE INTIMA-MEDIA THICKNESS OF THE COMMON CAROTID ARTERY IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA
L. Galimova, D. Sadykova, I. Leonteva, E. Slastnikova (Russia)

P5.2.416 SEX DIFFERENCE BETWEEN TARGET LEVELS OF CHOLESTEROL-RELATED PARAMETERS AND POST-PCI LONG-TERM CLINICAL OUTCOMES: FROM THE FU-REGISTRY

5.3 Epidemiology of dyslipidemias

P5.3.417 MANAGEMENT OF CARDIOVASCULAR RISK AND TREATMENT IN PATIENTS WITH AHEROGENIC DYSLIPIDEMIA. PERSPECTIVE OF PRIMARY CARE PHYSICIANS. AVANZA STUDY
P. Rodríguez-Fortúnez, M. Blasco, A. Diaz, M. Rodríguez-de Miguel, L. Orera-Peña (Spain)

P5.3.418 OPTIMIZATION OF SPECIALIZED OUTPATIENT CARE FOR PATIENTS WITH SEVERE LIDID METABOLISM DISORDERS IN THE OUTPATIENT LIPID CENTER
V. Kashtalap, N. Fedorova, T. Pecherina, I. Strokolskaya, O. Barbarash (Russia)
P5.3.419  AGE AND GENDER PECULIARITIES OF LIPID SPECTRUM IN RUSSIAN URBAN POPULATION

P5.3.420  CARDIOVASCULAR PROFILE OF PATIENTS ADMITTED IN MEDICINE INTERNAL. DO WE COLLECT THE RISK FACTORS CARDIOVASCULAR IN CLINICAL HISTORY?

P5.3.421  PCSK9 GENETIC VARIANTS IN PATIENTS WITH CORONARY ARTERY DISEASE - A PILOT STUDY
T.F. Ashavaid, A. Bane, C.K. Ponde, R.M. Rajani, S. Pillai (India)

P5.3.422  DYSLIPIDEMIA PROFILE AND DEGREE OF CONTROL, DATA FROM THE IBERICAN STUDY

P5.3.423  RISK OF SUFFERING FROM DYSLIPIDEMIA PATIENTS INCLUDED IN THE IBERICAN STUDY

P5.3.424  THE DISTRIBUTION OF LDL-CHOLESTEROL LEVELS IN THE MIDDLE-AGED LITHUANIAN ADULTS DURING THE PERIOD OF 2009-2016

P5.3.425  THE DISTRIBUTION OF TRIGLYCERIDES LEVELS IN MIDDLE-AGED LITHUANIAN MEN AND WOMEN DURING THE PERIOD OF 2009-2016
P5.3.426  EFFECTS ON THE GLYCEMIC PROFILE OF PITAVASTATIN TREATMENT IN DYSLIPIDEMIC PATIENTS, DATA FROM THE REINA STUDY

P5.3.427  EFFECTS ON THE RENAL PROFILE OF PITAVASTATIN TREATMENT IN DYSLIPIDEMIC PATIENTS, DATA FROM THE REINA STUDY

P5.3.428  STUDY OF RARE FAMILIAL MONOGENIC DYSLIPIDAEMIAS IN PORTUGAL

P5.3.429  CORRELATION OF BODY MASS INDEX & TRIGLYCERIDE LEVELS IN MIDDLE AGED WOMEN
S. Joshi, A. Pranita, J. Kharche, G. Godbole (India)

P5.3.430  TEMPORAL TRENDS IN OBESITY AND STATUS OF DYSLIPIDEMIA IN TURKEY: A META-ANALYSIS OF EPIDEMIOLOGICAL STUDIES
L. Tokgözoglu, D. Ural, M. Kayikcioglu, U. Kiliçkap, H. Göksülük, D. Karaaslan (Turkey)

P5.3.431  THE RISK FACTORS FOR CARDIOVASCULAR DISEASE AND THE VASCULAR AGE OF THE POPULATION OF HEALTHY MEN ARE 40 TO 60 YEARS
O. Smolenskaya, S. Suslov, A. Shimkevich (Russia)
5.4 Lipid-lowering therapies

P5.4.432 COMPARATIVE EFFECTS OF HIGH-DOSE ATORVASTATIN VERSUS ROSUVASTATIN ON LIPID PARAMETERS, OXIDIZED-LDL AND PCSK9 LEVELS IN ACUTE CORONARY SYNDROME
M.U. Yalcin, B.B. Altunkeser, A. Tuncez, B. Ozturk, H. Tezcan, M.S. Ates, C. Yilmaz, N. Aygul, K. Demir (Turkey)

P5.4.433 STATIN THERAPY AND THE RISK OF HERPES VIRUS REACTIVATION
K. Shipman, A. Shipman, N. Maghsoodi (United Kingdom)

P5.4.434 PRAVASTATIN VERSUS FLUVASTATIN IN PATIENTS WHO DISCONTINUED OTHER STATINS DUE TO STATIN INTOLERANCE
S. Lee, J.W. Roh, S. Park, S.M. Kang (South Korea)

P5.4.435 LOWER CORONARY DISEASE IN HISPANIC COUNTRIES DUE TO ADMIXTURE OF GENES-IN PUERTO RICO 3 PROTECTIVE GENES
P. Altieri, H.L. Banchs, J.E. Muñoz (Puerto Rico)

P5.4.436 DESCRIPTIVE ANALYSIS OF EFFICACY AND SAFETY OF THE IPCSK9 AFTER MORE ONE YEAR OF ITS USE IN A THIRD LEVEL HOSPITAL

P5.4.437 LIPID-LOWERING EFFICACY OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITORS (IPCSK9) IN THE INTERDOSIS PERIOD. A DESCRIPTIVE STUDY

P5.4.438 STATIN USE AND SLEEP DISTURBANCE - OWN EXPERIENCE
K. Trambowicz, P. Gorzelak-Pabis, A. Durma, A. Pypec, E. Lis, I. Rozmarynowska, N. Jurzak, M. Ignaczak, M. Broncel (Poland)

P5.4.439 LIPOHILIC STATINS DECREASE INSULIN SECRETION BY AUGMENTING H2S SIGNALING IN PANCREATIC ISLETS
J. Beltowski, G. Wojcicka, A. Jamroz-Wisniewska (Poland)

P5.4.440 A CASE OF LIVER ENZYME DERANGEMENT WITH EVOLOCUMAB
R. Almazrouei, F. Alkaabi, S. Walji, J. Scott, J. Cegla (United Kingdom)
<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5.4.441</td>
<td>EFFECT OF LONG-TERM THERAPY WITH ATORVASTATIN VARIOUS DOSES ON THE GLOBAL MYOCARDIAL DEFORMATION PARAMETERS IN STEMI PATIENTS</td>
<td>V. Oleynikov, V. Galimskaya, A. Golubeva, S. Kupriyanova, E. Dushina</td>
<td>Russia</td>
</tr>
<tr>
<td>P5.4.442</td>
<td>QUALITY OF LIFE AND PREDICTION IN POSTINFARCTION PATIENTS DEPENDING ON THE STATIN THERAPY EFFICIENCY</td>
<td>V. Oleynikov, E. Dushina, Y. Barmenkova, N. Burko</td>
<td>Russia</td>
</tr>
<tr>
<td>P5.4.443</td>
<td>EARLY CORONARY HEART DISEASE AFTER PCSK9-INHIBITORS WITHDRAWAL IN VERY HIGH-RISK SUBJECTS</td>
<td>A. Gallo, M. Halbron, E. Bruckert</td>
<td>France</td>
</tr>
<tr>
<td>P5.4.444</td>
<td>COMBINATION LIPID LOWERING THERAPY WITH ROSUVASTATIN AND EZETIMIBE IN DYSLIPIDEMIC PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND METABOLIC SYNDROME</td>
<td>J. Uzokov, B. Alyavi</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>P5.4.445</td>
<td>THE INFLUENCE OF LIPID LOWERING DIET ON LIPID PROFILE AND INFLAMMATORY BIOMARKERS(CRP AND FIBRINOGEN) IN PATIENTS WITH DIFFERENT PSYCHOLOGICAL STATUS IN CASE OF CORONARY ARTERY DISEASE</td>
<td>M. Bitskinashvili, N. Kakauridze</td>
<td>Georgia</td>
</tr>
<tr>
<td>P5.4.446</td>
<td>EFFECT OF ROSUVASTATIN ON METABOLIC PARAMETERS AND RENAL FUNCTION AT ESSENTIAL HYPTERTENSIVE PATIENTS</td>
<td>G. Bozhenko</td>
<td>Ukraine</td>
</tr>
</tbody>
</table>
P5.4.449 CONNECTION OF GENOTYPE NO-SYNTHETASE WITH RESISTANCE IN THERAPY OF HYPERLIPIDEMIAS AT THE PATIENTS WITH ISCHEMIC HEART DISEASE
G. Mal, M. Dudka (Russia)

P5.4.450 EFFICACY OF PCSK9 INHIBITORS IN THE CLINICAL PRACTICE. FIRST YEAR EXPERIENCE
G. Navarro, C. Fuentes, S. Bellon, D. Fernandez de Velasco, M. Casas, C. Guijarro (Spain)

P5.4.451 A RANDOMISED TRIAL EVALUATING THE EFFECT OF A SMART PHONE-BASED PATIENT SUPPORT TOOL ON TREATMENT DURATION IN PATIENTS PRESCRIBED ROSUVASTATIN IN CHINA: RESULTS FROM EHELP

P5.4.452 THE EFFECT OF ANTIHYPERTENSIVE TREATMENT EFFECT OF ROSUVASTATIN ON LEFT VENTRICULAR HYPERTROPHY AT ESSENTIAL HYPERTENSIVE PATIENTS
G. Bozhenko (Ukraine)

P5.4.453 PATIENT EDUCATION AND EFFICACY OF BLOOD PRESSURE AND CHOLESTEROL CONTROL IN HIGH AND VERY HIGH RISK POPULATION
G. Isayeva, M. Vovchenko, O. Buryakovska, L. Reznik (Ukraine)

P5.4.454 SIMVASTATIN AND EZETIMIBE REDUCE PLASMA LIPOPROTEIN BINDING TO HUMAN ARTERIAL PROTEOGLYCANS IN GALLSTONE DISEASED PATIENTS

P5.4.455 DUALITY OF STATIN ACTION ON LIPOPROTEIN SUBPOPULATIONS IN THE MIXED DYSLIPIDEMIA OF METABOLIC SYNDROME OVER TIME: QUANTITY VERSUS QUALITY
M.J. Chapman, A. Orsoni, P. Robillard, P. Therond, P. Giral (France)

P5.4.456 CLINICAL EXPERIENCE WITH PCSK-9 INHIBITORS IN OUTPATIENTS CLINIC FOR DYSLIPIDEMIA IN A TERTIARY HOSPITAL
A. Blanco, E. Resino, R. Costa (Spain)
**5.5 Prevention and treatment of cardiovascular disease**

**P5.5.458** COMPLETE VERSUS CULPRIT ONLY LESION INTERVENTION IN ACS PATIENTS WITH MULTI-VESSEL DISEASE: INCIDENCE AND OUTCOMES FROM THE LONDON HEART ATTACK GROUP  
**K. Rathod**, S. Koganti, A. Mathur, A. Wragg, D. Jones (United Kingdom)

**P5.5.459** A GENDER GAP EXISTS IN SECONDARY PREVENTION FROM CORONARY ARTERY DISEASE IN TURKISH POPULATION  
**D. Kocyigit**, L. Tokgozoglu, M. Kayikcioglu, C. Erol (Turkey)

**P5.5.460** IMPLICATION OF ECHOCARDIOGRAPHY IN THE FOLLOW-UP OF FAMILIAL CARDIOMYOPATHIES SECONDARY TO MUTATION OF THE LMNA GENE  

**P5.5.461** MANAGEMENT OF CARDIOVASCULAR DISEASES CAN BE MORE SUCCESSFUL BY REDUCTION OF THE PRE-ANALYTICAL VARIATIONS IN LIPID ASSESSMENT  
**I. Kostovska**, K. Tosheska Trajkovska, G. Bosilkova (Republic of Macedonia)

**P5.5.462** EVALUATION OF THE CARDIAC REHABILITATION AND SECONDARY PREVENTION PROGRAM IN A THIRD LEVEL HOSPITAL  

**P5.5.463** A CLINICAL RESEARCH INVESTIGATION ON THE EFFECTS OF CIGARETTE SMOKING, E-CIGARETTE VAPING AND SMOKING CESSATION ON VASCULAR CELL BIOLOGY  

**P5.5.464** THE PREVALENCE OF DISABILITY AT THE ELDERLY WITH PERIPHERAL OBLITERATIVE ARTERIOPATHY  
**A. Capisizu**, S.M. Aurelian, A. Zamfirescu, L. Vlad, R. Dascalescu (Romania)

**P5.5.465** OMEGA-3 FATTY ACIDS ARE CAPABLE TO DECREASE THE LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 BLOOD LEVEL  
**M. Stojanovic**, M. Radenkovic (Serbia)
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5.5.466</td>
<td>PITAVASTATIN 1MG VERSUS 4MG ON CORONARY NEOINTIMAL HYPERPLASIA AT 12-MONTH IN DIABETES WITH ACUTE CORONARY SYNDROME: OPTICAL COHERENCE TOMOGRAPHY ANALYSIS &lt;br&gt;S.J. Hong, H.S. Jeong (South Korea)</td>
</tr>
<tr>
<td>P5.5.467</td>
<td>CLINICAL MANAGEMENT OF HIGH AND VERY HIGH RISK PATIENTS WITH HYPERLIPIDEMIA IN CENTRAL AND EASTERN EUROPE: AN OBSERVATIONAL STUDY &lt;br&gt;I. Petrov, A. Dumitrescu, R. Ceska, B. Zafrir, B. Wozakowska-Kaplon, L. Fabryova, H. Pintaric, I. Bridges, R. Petkova (Bulgaria, România, Czech Republic, Israel, Poland, Slovak Republic, Croatia, United Kingdom)</td>
</tr>
<tr>
<td>P5.5.468</td>
<td>CLINICAL APPLICATION OF PCSK9 INHIBITORS IN A SPECIALIZED LIPID CLINIC &lt;br&gt;F. Barkas, S. Filippas-Ntekouan, E. Liberopoulos, E. Christopoulou, A. Pantazi, E. Tzavella, M. Elisaf, G. Liamis (Greece)</td>
</tr>
<tr>
<td>P5.5.469</td>
<td>FIVE DIFFERENT CAUSES OF SUBACUTE AND VERY LATE STENT THROMBOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION TO ANGINA PECTORIS &lt;br&gt;S. Ito, Y. Hatano, M. Morisaki, T. Amimiya (Japan)</td>
</tr>
<tr>
<td>P5.5.471</td>
<td>ETHNIC DIFFERENCES OF ATHEROSCLEROTIC PARAMETERS &lt;br&gt;U. Shuumarjav, K. Kotani, N. Taniguchi (Mongolia, Japan)</td>
</tr>
<tr>
<td>P5.5.472</td>
<td>ANKLE-BRACHIAL DIFFERENCE PULSE WAVE VELOCITY (ABD-PWV) MEASURED WITH A NEW DEVICE CORRELATES WITH CAROTID INTIMA-MEDIA THICKNESS (IMT) &lt;br&gt;S. Rico Martin, J.M. De Nicolás Jimenez, J.F. Calderón García, J.F. Sánchez Muñoz-Torrero (Spain)</td>
</tr>
<tr>
<td>P5.5.473</td>
<td>REVIEW OF REFERRAL CRITERIA TO LIPID CLINICS AND OUTCOMES OF TREATMENT IN 4 UK CENTRES &lt;br&gt;A. Wierzbicki, A. Viljoen, S. Viljoen, S. Martin, M. Crook, T. Reynolds (United Kingdom)</td>
</tr>
<tr>
<td>P5.5.474</td>
<td>ANKLE-BRACHIAL DIFFERENCE PULSE WAVE VELOCITY (ABD-PWV) MEASURED WITH A NEW DEVICE IS RELATED TO THE PRESENCE OF ATHEROSCLEROTIC CAROTID PLAQUES &lt;br&gt;S. Rico Martin, J.M. De Nicolás Jiménez, J.F. Calderón García, J.F. Sánchez Muñoz-Torrero (Spain)</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

P5.5.475 WHAT IS THE CARDIOVASCULAR PROFILE OF THE PATIENT HOSPITALIZED WITH CHRONIC OBLITERANT ARTERIOPATHY?

P5.5.476 HOMOCYSTEINE IS AN INDEPENDENT PREDICTOR OF LONG-TERM CARDIOVASCULAR MORTALITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE IN THE ERA OF STATINS
L. Rallidis, C. Kotakos, A. Viliaeti, A. Katsimardos, C. Grassos, P. Moutsatou, E. Ilidromitis (Greece)

P5.5.477 CAROTID ARTERY INTIMA-MEDIA THICKENING IN PREGNANCY: ASSOCIATION WITH RISK-FACTORS, PARITY, OFFSPRING BIRTH WEIGHT, CLINICAL DATA
T. Vakhtangadze, T. Motsonelidze, N. Gakhokidze, S. Gegechkory (Georgia)

P5.5.478 INFLUENCE OF CAD ON HEART REMODELING AT PATIENTS WITH MITRAL VALVE REGURGITATION
A. Zhadan, O. Romanenko, V. Tseluyko (Ukraine)

P5.5.479 IMPACT OF THE HYPERTENSION AND CAROTID INTIMA-MEDIA THICKNESS TO THE INFARCTS VOLUME IN THE STROKE PATIENT
N. Lobjanidze, N. Chitauri (Georgia)

P5.5.480 EFFECTS OF COLONIC BACTERIAL METABOLITES OF QUERCETIN ON VASCULAR SMOOTH MUSCLE
I. Najmanova, T. Migkos, J. Pourova, M. Voprsalova, P. Mladenka (Czech Republic)

P5.5.481 CARDIOVASCULAR PROFILE OF PATIENTS WITH ACCIDENT CEREBROVASCULAR HOSPITALIZED IN INTERNAL MEDICINE SERVICE

P5.5.482 DOES THE FAMILY MEDICINE SPECIALIST USE THE SEARCH FOR SUBCLINICAL ARTERIOSCLEROSIS IN HIS CLINICAL PRACTICE?
POSTER SESSIONS

P5.5.483  PSYCHIATRIC MORBIDITY IN PATIENTS WITH INTERMITTENT CLAUDICATION  
E. Rosloniec, A. Kulik, R. Nowobilski, P. Mika (Poland)

P5.5.484  DETECTION OF FABRY DISEASE IN PATIENTS WITH PREMATURE CARDIOVASCULAR DISEASE  
M. Fanlo, M.A. Rodriguez, B. Candas, H. Lafuente, X. Corbella, E. Corbella, A. Padro, X. Pinto (Spain)

P5.5.485  BENEFICIAL EFFECT OF LAUGHTER YOGA AND CLAPPING EXERCISE IN CORONARY HEART DISEASE (CHD) PATIENTS IN SOUTH DELHI METRO POPULATION  
V. Sharma (India)

P5.5.486  NOVEL MARKER PANEL OF 10 METABOLITES FOR A BETTER IDENTIFICATION OF PATIENTS WITH HIGH CV RISK  

P5.5.487  DO CLAUDICANTS UNDERESTIMATE THEIR WALKING DISTANCE?  
E. Rosloniec, M. Gocal, P. Mika (Poland)

P5.5.488  CARDIOVASCULAR RISK FACTORS AND OTHER PATHOLOGIES RELATED TO CARDIOPATHY PATIENTS ADMITTED IN THE INTERNAL MEDICAL SERVICE OF A PRIVATE HOSPITAL  
B.E. Montenegro Puche, V. Manzano Roman, A. Martin Jimenez (Spain)

P5.5.489  ECHOCARDIOGRAPHIC PATTERNS IN IDIOPATHIC AND FAMILIAL DILATED CARDIOMYOPATHY  

P5.5.490  HEART RATE AND HEART RATE VARIABILITY CHANGE WHILE FALLING ASLEEP DURING DRIVING A CAR  
S. Jo, J. Kim, D. Kim (South Korea)

P5.5.491  IMPACT ON THE CHANGES IN BLOOD PRESSURE GOALS OF ESSENTIAL HYPERTENSION IN MEDICAL GUIDELINES 2017 ON “REAL WORLD” IN MEXICAN CARDIOVASCULAR PATIENTS  
L.M. Lugo Gavidia, M.O. De los Rios Ibarra, M.A. Alcocer Gamba, A. Vargas Hernandez, H. Rodriguez Reyes, L.R. Virgen Carrillo, C. Hernandez Herrera, S. Rodriguez Bastidas (Mexico)

P5.5.492  RELATIONSHIP BETWEEN ALCOHOL-RELATED FACIAL FLUSHING AND CAROTID ATHEROSCLEROSIS  
Y. Bae, J. Kim, S. Kim, J. Jung, S. Yoon, Y. Seo (South Korea)
<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5.5.493</td>
<td>Hyperlipoproteinemia and Markers of Atherosclerosis Progression in Long-Term Survivors of Hodgkin Lymphoma</td>
<td>P. Kraml, M. Cepelova, P. Cepela, J. Potockova (Czech Republic)</td>
</tr>
<tr>
<td>P5.5.494</td>
<td>Association Between Cholesterol Changes and PPRG, ADRB2 and ADRB3 Polymorphism During Lifestyle Modification Programme in Obese Patients</td>
<td>G. Isayeva, M. Vovchenko, O. Buryakovska, Y. Isakova, I. Komir (Ukraine)</td>
</tr>
<tr>
<td>P5.5.495</td>
<td>The Reliability of the Ankle-Brachial Index and Toe-Brachial Index in the Daily Practice of Peripheral Artery Disease Monitoring in Vascular Medicine Ward</td>
<td>J. Krezel, P. Klapacz, M. Maga, A. Wachsmann, M. Plachno, N. Nawara, P. Maga (Poland)</td>
</tr>
<tr>
<td>P5.5.496</td>
<td>Quality of Life in Patients with Stable Coronary Artery Disease and Preserved Systolic Function After CABG is Related to the Left Ventricular Diastolic Function and Brain Natriuretic Peptide</td>
<td>Y. Borkhalenko, O. Yepanchintseva, K. Mikhaliev, O. Zharinov, B. Todurov (Ukraine)</td>
</tr>
<tr>
<td>P5.5.497</td>
<td>Effect of Intravenous Microbubbles Administration on TPA-Loaded PLGA Microspheres-Mediated Extracorporeal Shock Wave Intracranial Thrombolysis</td>
<td>H. Mehrad, M. Farhoudi (Iran)</td>
</tr>
<tr>
<td>P5.5.498</td>
<td>Clinical Case of a Patient with a Family Heterozygous Hypercholesterolemia</td>
<td>T. Pecherina, V. Kastalap, O. Barbarash (Russia)</td>
</tr>
<tr>
<td>P5.5.498bis</td>
<td>Effects of Statin Therapy on Clinical Outcomes After Acute Myocardial Infarction in Patients with Advanced Renal Dysfunction: A Propensity Score-Matched Analysis</td>
<td>J.Y. Rhew, W. KIM, J.H. Cho (South Korea)</td>
</tr>
<tr>
<td>P5.5.499</td>
<td>Effect of Intravenous HDL-Loaded Microbubbles Administration on Ultrasound-Guided Pulsed-High Intensity Focused Ultrasound-Mediated Histotripsy of Carotid Artery Advanced Atherosclerotic Plaque</td>
<td>H. Mehrad, M. Farhoudi (Iran)</td>
</tr>
</tbody>
</table>
“CLINICAL DECISION SUPPORT SYSTEM” WITH “SMART DATA ANALYSIS” CAN IMPROVE DETECTION AND TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA AND HIGH VASCULAR RISK PATIENTS

A. Zamora Cervantes, B. López, F. Torrent-Fontbona, A. Pozo-Alonso, G. Paluzie, J. García-Vilches, A. García Flores, R. Massa, A. Martín-Urda, D. Capellá (Spain)

5.6 Novel risk markers

P5.6.500 STIFFNESS PARAMETER BETA OF BRACHIAL ARTERY, VASCULAR STRUCTURE, AND CARDIOVASCULAR RISK FACTORS

T. Ueda (Japan)

P5.6.501 COMBINED SERUM FREE LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CAROTID ATHEROSCLEROSIS IN TYPE 2 DIABETES MELLITUS


P5.6.502 DEVELOPMENT OF MARKERS FOR PROGRESSION OF CORONARY PLAQUES USING WHHLMI RABBITS, AN ANIMAL MODEL OF FAMILIAL HYPERCHOLESTEROLEMIA


P5.6.503 LIPID METABOLISM DISORDERS IN MYOCARDIAL INFARCTION PATIENTS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION DEPENDING ON THE PRESENCE OF OBESITY

V. Kashtalap, N. Fedorova, A. German, T. Pecherina, A. Kokov, N. Brel, O. Barbarash (Russia)

P5.6.504 ADIPOR1 POLYMORPHISM G.202940846G>C (RS7539542) IS ASSOCIATED WITH HIGHER CARDIOVASCULAR RISK IN MIDDLE-AGED POPULATION

M. Sopic, M. Mihajlovic, A. Ninic, N. Bogavac-Stanojevic, Z. Stepanovic, J. Vekic, A. Zeljkovic, J. Janac, V. Kalimanovska-Spasojevic, Z. Jelic-Ivanovic (Serbia)
P5.6.505 CIRCULATING MICRORNAS AS EMERGING CARDIAC BIOMARKERS: RESPONSE TO ACUTE EXERCISE AND IMPLICATIONS FOR CLINICAL PRACTICE  

P5.6.507 CIRCULATING URINARY EXTRACELLULAR VESICLE SECRETION AND MICRORNA-155 EXPRESSION ARE ALTERED IN PATIENTS WITH SEVERE CORONARY ARTERY DISEASE  
S. Fitzsimons, N. Mahon, O. Belton (Ireland)

P5.6.508 ASSOCIATION OF M235T POLYMORPHISM OF ANGIOTENSINOGEN GENE, ST2 LEVEL AND LIPID PARAMETERS IN HEART FAILURE PATIENTS WITH TYPE 2 DIABETES MELLITUS  
O. Medentseva, M. Udovychenko, I. Rudyk (Ukraine)

P5.6.509 SPECTRUM OF FATTY ACIDS AND THEIR CORRELATIONS WITH PARAMETERS OF OXIDATIVE STRESS, ANTIOXIDANT DEFENSE, LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) AND ADMA UNDER CORONARY ATHEROSCLEROSIS  

P5.6.510 PSORIASIS SPECIFIC CHANGES IN OXIDIZED LIPOPROTEINS AND ITS ASSOCIATION WITH NON-CALCIFIED CORONARY PLAQUE  

P5.6.511 ESTIMATION OF REGIONAL ARTERIAL STIFFNESS PARAMETERS AS PREDICTORS OF EARLY VASCULAR AGING IN PATIENTS WITH CHD  
A. Khromova, L. Salyamova, N. Burko, I. Matrosova, V. Oleynikov, E. Dushina (Russia)

P5.6.512 DYNAMICS OF CENTRAL PRESSURE PARAMETERS IN PATIENTS WITH MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION AT THE BACKGROUND OF ATORVASTATIN THERAPY  
V. Oleynikov, E. Melnikova, A. Khromova, A. Golubeva, I. Matrosova, N. Burko, E. Dushina (Russia)

P5.6.513 IL-6 AS A MARKER OF CORONARY ARTERY DISEASE IN RHEUMATOID ARTHRITIS PATIENTS WITH CARDIOVASCULAR RISK FACTORS  
P5.6.514 PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) IN A PATIENTS WITH TYPE 1 DIABETES MELLITUS. CORRELATION WITH METABOLIC CONTROL AND LIPOID METABOLISM

P5.6.515 PLASMA METHIONINE AND RISK OF ACUTE MYOCARDIAL INFARCTION: EFFECT MODIFICATION BY LIPOIDS
I. Dhar, V. Lysne, R. Seifert, G.F.T. Svingen, P.M. Ueland, O.K. Nygård (Norway)

P5.6.516 AGE DEPENDANT ASSOCIATION OF URIC ACID AND HYPERTENSION
A. Pereira, T. Abrao, A. Saldanha, V. Gason, L. Fonseca, R. Santos, T. Martinez (Brazil)

P5.6.517 TELOMERE LENGTH AND THE SERUM FATTY ACIDS IN ELDERLY SURVIVORS OF MYOCARDIAL INFARCTION

P5.6.518 STUDY OF BIOMARKERS TO PREDICT UNFAVORABLE COURSE OF CORONARY ATHROSCLEOROSIS
E. Kashtanova, I. Polonskaia, A. Kurhuzov, A. Cherniavsky, V. Shramko, E. Stryukova, Y. Ragino (Russia)

P5.6.519 SERUM PCSK9 LEVELS ARE INCREASED IN OBESE SUBJECTS AND NEGATIVELY CORRELATED WITH A MEDITERRANEAN DIET SCORE
A. Angouridis, M. Georgoula, C.C. Tellis, T.D. Filippatos, A. Tselepis, E. Liberopoulos, M.S. Elisaf (Greece)

P5.6.520 PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) AND LIPOID PARAMETERS IN PATIENTS WITH END STAGE RENAL FAILURE BEFORE AND AFTER KIDNEY ALLOTRASPLANTATION

P5.6.521 CHANGES IN NT-PROCNP LEVELS IN PATIENTS WITH END STAGE RENAL FAILURE BEFORE AND AFTER KIDNEY ALLOTRASPLANTATION
R. Szentimrei, M. Harangi, A. Szentpéteri, V. Varga, H. Lorincz, I. Seres, B. Nemes, G. Paragh (Hungary)

P5.6.522 IDENTIFYING THE PRESENCE OF CORONARY ARTERY DISEASE: PREDICTION OF CORONARY LESIONS
<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5.6.523</td>
<td>ASSESSMENT OF BLOOD HYDROGEN PEROXIDE BREAK-DOWN ACTIVITY (HBA) IN HEALTHY SUBJECTS AND IN PATIENTS WITH ATRIAL FIBRILLATION: RELATION TO CARDIOVASCULAR EVENTS</td>
<td>D. Pastori, C. Nocella, P. Pignatelli, M. Novo, V. Cammisotto, F. Violi, R. Carnevale</td>
<td>Italy</td>
</tr>
<tr>
<td>P5.6.524</td>
<td>THE STUDY OF THE COMPLEX OXIDATIVE AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH CORONARY ATHEROSCLEROSIS</td>
<td>I. Polonskaia, E. Kashtanova, A. Kurhuzov, S. Shramko, E. Stryukova, A. Cherniavsky, Y. Ragino</td>
<td>Russia</td>
</tr>
<tr>
<td>P5.6.525</td>
<td>POSITIVE ASSOCIATION BETWEEN SMALL DENSE LOW-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATION AND BIOMARKERS OF INFLAMMATION, THROMBOSIS, AND PREDIABETES IN NON-DIABETIC ADULTS</td>
<td>T. Su</td>
<td>Taiwan</td>
</tr>
<tr>
<td>P5.6.526</td>
<td>THE EFFECT OF PCSK9 INHIBITION ON BIOMARKERS OF ATHEROSCLEROTIC PLAQUE DESTABILIZATION RELEASE IN PATIENT WITH DYSLIPIDEMIA.</td>
<td>M. Basiak, G. Machnik, M. Konopka, M. Dziubinska-Basiak, W. Szkrobka, L. Buldak, B. Okopien</td>
<td>Poland</td>
</tr>
<tr>
<td>P5.6.527</td>
<td>H-FABP – A SENSITIVE BIOMARKER OF EARLY DIAGNOSIS AND PREDICTION OF MYOCARDIAL DAMAGE</td>
<td>E. Bace, Z. Hanulova, J. Parenica, M. Hlozankova, M. Karpisek, V. Ruzicka</td>
<td>Czech Republic, Slovak Republic</td>
</tr>
<tr>
<td>P5.6.529</td>
<td>CELLULAR RESPIRATION IN CYTOPLASMIC HYBRIDS WITH DIFFERENT HETEROPLASMY LEVELS OF MITOCHONDRIAL GENOME MUTATIONS</td>
<td>V. Sinyov, M.A. Sazonova, A.I. Ryzhkova, A.D. Doroshchuk, A.V. Kuzmin, M. Sazonova, Z.B. Khasanova, A.N. Orekhov, I.A. Sobenin</td>
<td>Russia</td>
</tr>
</tbody>
</table>
P5.6.530 Niacin Action in the Atherogenic Mixed Dyslipidemia of Metabolic Syndrome: Insights from Metabolic Biomarker Profiling and Network Analysis
M. Adiels, M.J. Chapman, P. Robillard, M. Krempf, M. Laville, J. Borén, on behalf of the Niacin Study Group (Sweden, France)

P5.6.531 Hypercysteinemia vs Hyperhomocysteinemia as a Risk Factor for Coronary Artery Disease: A Case-Control Study
A. Lima, R. Ferin Borges, E. Santos, A. Fontes, D. Martins, J. Baptista, M. Pavão (Portugal)
LIST OF COMPANIES
AKCEA THERAPEUTICS

Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, is a drug development and commercialisation company focused on impacting the lives of patients with serious cardiometabolic diseases. Akcea Therapeutics Inc., Inc was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced RNA-targeted antisense therapeutics. Our priority is to bring important new therapeutics to patients in need, with molecules currently under regulatory filing for the management of Familial Chylomicronaemia Syndrome (FCS), and Hereditary Transthyretin Amyloidosis (hATTR).

www.akceatx.com

ALEXION PHARMA GMBH

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies – Kanuma™ (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D), and Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP). Alexion also developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas.
AMARIN

Amarin Pharma, Inc.
1430 Route 206, Suite 200
Bedminster, NJ 07921

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin’s first FDA-approved product, is a highly-pure, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

AMGEN (EUROPE) GMBH

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
BASF SE

BASF SE
Nutrition & Health
Chemiestraße 22
68623 Lampertheim
www.newtrition.com
www.basf.com

BASF’s Nutrition and Health division develops, produces and markets a comprehensive range of products and services for the human and animal nutrition, pharmaceutical as well as flavor and fragrance industries. The division strives to contribute to a better life through improving the nutrition, health and wellbeing of people across the world. Important human nutrition products are vitamins and carotenoids, plant sterols and omega-3 fatty acids. Its feed activities such as vitamins, carotenoids, enzymes and organic acids make Nutrition & Health a worldwide leader for the animal nutrition market. The division provides the pharmaceutical industry with active ingredients such as ibuprofen as well as excipients. Furthermore, the division produces aroma ingredients such as citral, geraniol and L-menthol for the flavor and fragrance industry.

DENKA SEIKEN CO. LTD

Denka Seiken offers assays directly quantifying (without any sample pretreatment) lipid subfractions, and also latex-enhanced turbidimetric immunoassays for specific protein biomarkers to be run on automated chemistry analyzers. The range of lipid subfraction assays includes small dense LDL, HDL3, Remnant Lipoproteins and Triglycerides in LDL particles. The latex-enhanced turbidimetric immunoassays are available for Lp(a), Cystatin C, hsCRP, RF, Myoglobin, IgE, Ferritin, etc.
ESPERION
THE LIPID MANAGEMENT COMPANY

Esperion is a pharmaceutical company that specializes in developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The Company has two late-stage therapies in development; both with confirmed regulatory pathways to approval and defined global pivotal Phase 3 clinical development plans. Bempedoic acid and the Company’s lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies that have been shown to significantly reduce elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies.

FUJIFILM VISUALSONICS

Based out of Toronto, Ontario, Canada with operations in more than 30 countries. Founded in 1999 by medical physicist Dr. Stuart Foster, a Senior Scientist at Sunnybrook Research Institute, who had been involved in the development of high-frequency ultrasonic systems since 1983. The company’s intellectual property was based on research supported by the Canadian Institutes of Health Research (CIHR), Ontario Research and Development Challenge Fund (ORDCF), the Terry Fox Foundation, and venture capital investment, with infrastructure support from the Canada Foundation for Innovation and Ontario Research Fund. FUJIFILM VisualSonics designs and manufactures ultra-high frequency in vivo ultrasound imaging systems, for both research and clinical use. Our company specifically focuses on developing ultrasound technology that has been scaled to much higher frequencies than commonly found in many of the conventional ultrasound systems on the market today. As a result, our ultrasound platform provides images at resolutions that far exceed any other system available on the market; as fine as 30 micrometers, a clear advantage for healthcare professionals that require a non-invasive ultrasound solution.

The Vevo® platform was the world’s first commercially available high-frequency array based ultrasound imaging system and has since emerged as the gold standard in small animal anatomical and functional in vivo imaging. The Vevo Family of high-frequency ultrasound products enables the researcher to obtain in vivo anatomical, functional, physiological and molecular data simultaneously, in real-time and with a resolution down to 30 μm. The system is easy to use, non-invasive and fast, providing extremely high throughput when needed. It is designed with the researcher in mind, with system presets and animal handling tools for fast image acquisition and numerous protocols, software and data management tools optimized for today’s scientists.
HEALTH IN CODE, S.L.

Health in Code is a biotechnological company specialized in high-quality sequencing services and in the interpretation of genetic testing, providing clinicians with a tool to offer personalized medical care. Our distinctive competence is the combination of our in-house developed Knowledge Management System with a dedicated expert multidisciplinary team, which allows us to provide a unique level of interpretation for the best genotyping. We are European leaders on the diagnosis of inherited cardiovascular diseases, such as dyslipidemias - early atherosclerosis.

IMMUNO-BIOLOGICAL LABORATORIES CO.

“LipoSEARCH” is a sophisticated comprehensive lipoprotein profiling service (using HPLC-based system) that can deliver a reliable and promising complete set of data on Cholesterol and Triglyceride profiled in 4 major classes (CM, VLDL, LDL and HDL) and 20 subclasses classified by particle size. In addition, it also can deliver number of the lipoprotein particles that is recognized as an important factor in recent international research of atherosclerosis and dyslipidemia. “LipoSEARCH” is used by over 500 laboratories, research/medical institutions and academians across the world. More than 350 scientific papers has been published based on the test data by our method. The proprietary system and service “LipoSEARCH” is operated and provided by Skylight Biotech Inc. who is owned by Immuno-Biological Laboratories Co., Ltd. (IBL Co., Ltd.) located in Japan.
KOWA

Kowa Company, Ltd.
6-29, Nishiki 3-chome, Naka-ku, Nagoya, Aichi 460-8625, Japan
http://www.kowa.co.jp/eng/

Kowa Company, Ltd. (Kowa) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceuticals, life science, information technology, textiles, machinery and various consumer products. Especially, the pharmaceutical field is positioned as the key business segment; prescription (ethical drug), Over-the-Counter (OTC) / Consumer Healthcare / Dietary supplement and Medical equipment. Moreover, the pharmaceutical R&D division is focused on research and development for cardiovascular therapeutics (dyslipidemia, type 2 diabetes and atherosclerosis), ophthalmology and antiinflammatory agents. To visit Kowa Company, Ltd.’s website, please visit <www.kowa.co.jp/eng>.
MENARINI INTERNATIONAL FOUNDATION

The Fondazione Internazionale Menarini was founded in spring of 1976 to promote research and knowledge in the fields of biology, pharmacology and medicine but also in the fields of economy and human sciences all within a broad perspective that focuses on the problems and puts them in order in a professional and practical sense.

One of the main instruments the Foundation uses to achieve its goals is the organisation of international congresses, with specific focus in medical disciplines.

During the course of its activities, the Foundation has organized 300 International Conferences addressing particularly innovative medical and biological issues and topics of specific interest for the medical world in terms of widespread scientific implications and repercussions of a practical nature.

Flanking the Foundation as an instrument of vast cultural information, is the scientific journal “Minuti Menarini”, published in collaboration with the American scientific journal “American Family Physician”.

It is forwarded free of charge to the 115 thousand Italian physicians who are subscribers and contains updated articles and discussions on entire chapters of pathology that have brought about important evolutions.

The issues dealing with immunology, oncology, nephrology, lung and metabolic diseases, cardiology and other topics of medical interest are the subject of particular discussion. One feature of the journal is that of coupling the literary-scientific section with a wide range of iconographic documentation integrated with diagrams allowing easy access to topics that are at times emely complex.

The first issue of the scientific edition “Minuti Menarini” is dated September 1977. It is wellknown that the Italian University and Hospital world greatly appreciates these publications with their wide ranging scientific content and at the same time, a concrete and realistic approach. All this in the aim of always giving an important contribution to Italian health professionals. In addition to the scientific edition, the Foundation also publishes an artistic edition of “Minuti Menarini” for all Italian physicians who are also art enthusiasts.

The Fondazione Menarini has always kept the antique and glorious tradition of the humanist-physician alive, devoting attention and passion to art and its highest forms as an expression of man.
MERCODIA AB

Mercodia AB is a Swedish biotech company focusing on the development of immunoassays for research within the field of metabolic disorders. Our assays are applicable to both animal and human models and are used for research ranging from basic scientific studies to large pre-clinical and clinical phase trials.

The company was founded in 1991 and is today a world-leading supplier of products to all major international markets. More than 90 percent of our production is exported from our facilities in Uppsala to approximately 100 different countries around the world.

MSD

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.
MYLAN

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to make service excellence a habit; do what’s right, not what’s easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, market our products in more than 165 countries and territories and are one of the world’s largest producers of active pharmaceutical ingredients. Every member is dedicated to creating better health for a better world, one person at a time.

NUMARES

numares AG, based in Regensburg develops and markets innovative diagnostic tests based on NMR metabolomics. Essentially, our tests consist of metabolic constellations that are characteristic of certain diseases. To find these, we apply machine learning to clinical study cohorts measured with our AXINON® NMR system. We have a successful commercial base especially in laboratories in the USA.
RAISIO GROUP

Raisio Group
P.O. Box 101,
FI-21201 Raisio,
Finland

Benecol® - proven to lower cholesterol

Raisio is an international food company focusing on health, wellbeing and sustainability. The core of Raisio's strategy consists of plant-based, healthy and responsible branded products. Benecol® is the expert brand in cholesterol lowering and a pioneer in the cholesterol-lowering functional food category. We promote sustainable food chain and develop innovations to enhance wellbeing.

Raisio Group produces plant stanol ester, the unique cholesterol-lowering ingredient in Benecol foods and food supplements, and markets Benecol products in its home markets. Raisio also sells plant stanol ester and licenses the Benecol brand to a global partner company network. Benecol products are sold in some 30 countries worldwide.

Over 80 published clinical studies and key international and national cardiovascular guidelines support the use of plant stanol ester as an effective, easy and safe dietary tool to lower LDL-cholesterol. The cholesterol-lowering effect of plant stanol ester is additive to those of a healthy diet and statin medication.

Raisio - Food for Health, Heart and Earth.

SANOFI

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
SANOFI AND REGENERON

Sanofi is a global biopharmaceutical company focused on human health dedicated to supporting people through their health challenges. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

UNILEVER

Unilever is one of the world’s leading suppliers of Beauty & Personal Care, Home Care, and Foods & Refreshment products with sales in over 190 countries and reaching 2.5 billion consumers a day. It has 161,000 employees and generated sales of €53.7 billion in 2017. Over half (57%) of the company’s footprint is in developing and emerging markets. Unilever has more than 400 brands found in homes all over the world, including Dove, Domestos, Knorr, Hellmann’s, Lipton, Wall’s, PG Tips, Ben & Jerry’s, Magnum, Rama, Becel/Flora and ProActiv.

Unilever’s Sustainable Living Plan underpins the company’s strategy and commits to: Helping more than a billion people take action to improve their health and well-being by 2020, halving the environmental impact of our products by 2030 and enhancing the livelihoods of millions of people by 2020. Unilever was ranked number one in its sector in the 2017 Dow Jones Sustainability Index. In the FTSE4Good Index, it achieved the highest environmental score of 5. It led the list of Global Corporate Sustainability Leaders in the 2017 GlobeScan/SustainAbility annual survey for the seventh year running, and achieved four A ratings across Climate Change, Water, Forests and Supplier Engagement in CDP’s 2018 Global Supply Chain report. Unilever has pledged to become carbon positive in its operations by 2030, and to ensure 100% of its plastic packaging is fully reusable, recyclable or compostable by 2025.

For more information about Unilever and its brands, the Unilever Sustainable Living Plan and the range of cholesterol-lowering products with added plant sterols Becel or Flora ProActiv please visit https://www.unilever.com; www.unilever.com/sustainable-living/; http://www.floraproactiv.co.uk/
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you - Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
EXHIBITORS LIST & MAP
Centro de Congresso de Lisboa

PAVILION 4

MEETING ROOMS

LIST OF COMPANIES

EXHIBITOR | BOOTH
---|---
AKCEA | 3
ALEXION | 16
AMGEN | 15
DENKA SEIKEN | 7-8-9
FUJIFILM VISUALSONICS | 11
HEALTH IN CODE | 1
IBL CO. LTD | 6
MERCODIA | 10
MYLAN | 13
NUMARES | 2
SANOFI AND REGENERON | 14
NATIONAL SOCIETY RELAX AREA | 12
WISEPRESS | 5
ACKNOWLEDGEMENTS
EAS CORPORATE PARTNERS

GOLD-LEVEL CORPORATE PARTNERS

- AMGEN
- SANOFI
- REGENERON

SILVER-LEVEL CORPORATE PARTNER

- ALEXION

BRONZE-LEVEL CORPORATE PARTNERS

- MSD
- Kowa

JOINT BRONZE PARTNERS

- BASF
- RAISIO
- Unilever
The Organising Committee and the EAS Executive Committee would like to express their gratitude and acknowledgement to the following companies for their generous support in the 86th EAS Congress.

**PLATINUM SPONSORS**

![Amgen Logo](image)

![MSD Logo](image)

![Mylan Logo](image)

![Sanofi Logo](image)

![Regeneron Logo](image)
SILVER SPONSORS

AKCEA THERAPEUTICS
ALEXION
AMARIN
BASF

ESPERION
RAISIO
SANOFI
UNILEVER

SPONSORS

KOWA

EXHIBITORS

DENKA SEIKEN - FUJIFILM VISUALSONICS - HEALTH IN CODE - IBL CO. LTD
MERCODIA - NUMARES - WISEPRESS
LIST OF COMPANIES
INDEX OF AUTHORS

A
Abduzhamalova N. 138
Abrantes L. 130
Abu-Bakar L. 165
Adam S. 182
Agrawal D. 100
Ahmed O. 96
Ahn J. 149
Akhter T. 94
Akhvlediani M. 137
Alfieri V. 145
Ali L. 140
Alonso-Herranz L. 74
Altieri G.I. 158
Altieri P. 170, 193
Alves A.C. 192
Aliyahya A.M. 150
Ames P. 184
Amin N. 150
Andrade L. 103
Androutsopoulou V. 153
Antza C. 176
Arangalage D. 147
Araujo F. 92
Araujo M.B. 170
Arca M. 77
Arévalo-lorido J.C. 138
Ariza M.J. 102
Arnaboldi L. 158
Arnesen E. 107
Arnesen K. 120, 170
Ashavaid T.F. 191
Ashfield-Watt P. 170
Atanasova Boshku A. 179, 190
Averkova A. 121

Averna M. 82
Awoyemi A. 92

B
Bace E. 204
Bachler M. 94
Badimon L. 75
Baek S.E. 125
Bae Y. 199
Bahjat M. 68
Bakker G.J. 93
Balogh E. 126
Banach M. 67, 82
Bañuls Morant C. 93
Baragetti A. 65
Baratta F. 104
Barkas F. 97, 103, 177, 197
Basatemur G. 71
Basiak M. 186
Batuca J. 107
Baumgartner S. 98
Bax J.J. 73, 79
Bea Sanz A.M. 172
Begic N. 153
Bekkering S. 65
Bektaševa E. 171
Belloso-Uribé K. 157
Bellosta S. 90, 145
Beltowski J. 193
Ben-Aicha Gonzalez S. 127
Ben Amor N. 181
Ben Braiek A. 146, 147
Benito Vicente A. 157
Bennett M. 90
Benn M. 99
Berg G.A. 159
Bernini F. 109
Bianconi V. 137, 183
Bianco R. 153
Biessen E.A.L. 71, 113, 146
Bijedic I. 138
Binder C.J. 66, 67, 74
Blaha V. 155
Blahova T. 106
Blanchard V. 160
Blanco A. 195
Blauw L. 108
Bliznyuk S. 161
Boisvert W. 112
Bonacina F. 84
Bonomini F. 175
Borén J. 60, 72
Bork C. 83, 116
Borkhalenko Y. 194, 200
Bo M. 117
Bozenko G. 195
Bratseth V. 114
Brüns D. 133
Brown B. 148
Bruckert E. 66
Bruen R. 64
Bruikman C. 119, 143
Brunham L. 79
Busnelli M. 127

C
Cabré N. 117
Caligiuri G. 74, 101
Camacho Carrasco A. 118
Camargo A. 69, 105
Cannon C. 68
Capizzi A. 196
Carubbi F. 169
Casula M. 120
Catapano A.L. 58, 73, 82
Cesovschi A. 142, 189
Cegla J. 160, 193
Cejkova S. 100
Cenarro A. 133
Chapman M.J. 75, 195, 205
Charriere S. 94
Chemello K. 162
Cho M.K. 100
Chora J.R. 120
Christen T. 166
Christoffersen C. 69
Christoffersen M. 98
Chua Y.A. 95
Clavero Fernández E. 137
Coban N. 139, 150, 174
Colonna R. 117, 166
Coman E.A. 138
Coornaert I. 85
Corral P. 161
Couto L. 117
Cramb R. 95
Crestani M. 84
<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Croyal M.</td>
<td>122</td>
</tr>
<tr>
<td>Cui Y.</td>
<td>118</td>
</tr>
<tr>
<td>Da Dalt L.</td>
<td>91</td>
</tr>
<tr>
<td>Dallinga-Thie G.M.</td>
<td>65, 115</td>
</tr>
<tr>
<td>Daskalopoulou A.</td>
<td>116, 117, 141, 178</td>
</tr>
<tr>
<td>De Backer G.</td>
<td>82, 118</td>
</tr>
<tr>
<td>De Beer F.</td>
<td>64</td>
</tr>
<tr>
<td>De Boer J.F.</td>
<td>79</td>
</tr>
<tr>
<td>De Fays C.</td>
<td>99</td>
</tr>
<tr>
<td>De Gonzalo Calvo D.</td>
<td>202</td>
</tr>
<tr>
<td>Delgado-Lista J.</td>
<td>105, 116</td>
</tr>
<tr>
<td>Della Pepa G.</td>
<td>108</td>
</tr>
<tr>
<td>Dennis E.A.</td>
<td>75</td>
</tr>
<tr>
<td>D’Erasmo L.</td>
<td>102</td>
</tr>
<tr>
<td>Dergunov A.</td>
<td>164</td>
</tr>
<tr>
<td>Dergunova L.</td>
<td>172</td>
</tr>
<tr>
<td>Derosa G.</td>
<td>93</td>
</tr>
<tr>
<td>De Stefano D.</td>
<td>99</td>
</tr>
<tr>
<td>Deykin A.</td>
<td>139</td>
</tr>
<tr>
<td>Dhage S.S.</td>
<td>165</td>
</tr>
<tr>
<td>Dhar I.</td>
<td>203</td>
</tr>
<tr>
<td>Díaz-Peromingo J.A.</td>
<td>188</td>
</tr>
<tr>
<td>Diaz Rodriguez A.</td>
<td>187, 191, 192</td>
</tr>
<tr>
<td>Dinnamon S.</td>
<td>72</td>
</tr>
<tr>
<td>Di Monte D.</td>
<td>133</td>
</tr>
<tr>
<td>Dissanayake S.</td>
<td>162, 163</td>
</tr>
<tr>
<td>Di Taranto M.D.</td>
<td>115</td>
</tr>
<tr>
<td>Djuric A.</td>
<td>182</td>
</tr>
<tr>
<td>Djuric D.</td>
<td>149</td>
</tr>
<tr>
<td>Dolezelova E.</td>
<td>96</td>
</tr>
<tr>
<td>Doulamis I.</td>
<td>178</td>
</tr>
<tr>
<td>Downie P.</td>
<td>102, 167</td>
</tr>
<tr>
<td>Drogi E.</td>
<td>121, 161</td>
</tr>
<tr>
<td>Dushina E.</td>
<td>131, 151, 194, 202</td>
</tr>
<tr>
<td>Duta-Mare M.</td>
<td>84</td>
</tr>
<tr>
<td>Ehrenborg E.</td>
<td>84, 110, 121</td>
</tr>
<tr>
<td>Elisaf M.</td>
<td>156</td>
</tr>
<tr>
<td>Ellis K.</td>
<td>120</td>
</tr>
<tr>
<td>El Tahlawi M.</td>
<td>124</td>
</tr>
<tr>
<td>Emanuellsson F.</td>
<td>75, 167</td>
</tr>
<tr>
<td>Ena J.</td>
<td>181</td>
</tr>
<tr>
<td>Erlinge D.</td>
<td>82</td>
</tr>
<tr>
<td>Ershova A.</td>
<td>188</td>
</tr>
<tr>
<td>Escola-Gil J.C.</td>
<td>163</td>
</tr>
<tr>
<td>Eshah N.</td>
<td>101</td>
</tr>
<tr>
<td>Espildora Hernandez J.</td>
<td>124</td>
</tr>
<tr>
<td>Espinosa F.</td>
<td>142</td>
</tr>
<tr>
<td>Estruch R.</td>
<td>58</td>
</tr>
<tr>
<td>Ezhov M.</td>
<td>88, 162, 185</td>
</tr>
<tr>
<td>Fanlo Maresma M.</td>
<td>171</td>
</tr>
<tr>
<td>Farnier M.</td>
<td>77</td>
</tr>
<tr>
<td>Fauste E.</td>
<td>182</td>
</tr>
<tr>
<td>Febbraio M.</td>
<td>80</td>
</tr>
<tr>
<td>Ference B.A.</td>
<td>58, 67, 70, 82, 130</td>
</tr>
<tr>
<td>Fisher E.</td>
<td>184</td>
</tr>
<tr>
<td>Fitzsimons S.</td>
<td>202</td>
</tr>
<tr>
<td>Fonseca D.A.</td>
<td>148</td>
</tr>
<tr>
<td>Fonseca L.</td>
<td>179</td>
</tr>
<tr>
<td>Fontes A.</td>
<td>157, 164, 203</td>
</tr>
<tr>
<td>Fortunato J.</td>
<td>108</td>
</tr>
<tr>
<td>Fournier N.</td>
<td>164</td>
</tr>
<tr>
<td>Franck G.</td>
<td>80</td>
</tr>
<tr>
<td>Frias Vargas M.</td>
<td>185, 187, 198</td>
</tr>
<tr>
<td>Frikkke-Schmidt R.</td>
<td>73, 77, 105</td>
</tr>
<tr>
<td>Frimmel K.</td>
<td>137</td>
</tr>
<tr>
<td>Fuertes Martin R.</td>
<td>179</td>
</tr>
<tr>
<td>Fuster V.</td>
<td>62</td>
</tr>
<tr>
<td>Gaoizhivili M.</td>
<td>152</td>
</tr>
<tr>
<td>Gaita L.</td>
<td>169</td>
</tr>
<tr>
<td>Gakhokidze N.</td>
<td>198</td>
</tr>
<tr>
<td>Galicia Garcia U.</td>
<td>162</td>
</tr>
<tr>
<td>Galimberti F.</td>
<td>107</td>
</tr>
<tr>
<td>Galimova L.</td>
<td>190</td>
</tr>
<tr>
<td>Gallo A.</td>
<td>194</td>
</tr>
<tr>
<td>Gapon L.</td>
<td>139</td>
</tr>
<tr>
<td>Garcia-Rios A.</td>
<td>103</td>
</tr>
<tr>
<td>Garmish I.</td>
<td>176</td>
</tr>
<tr>
<td>Garrido Sánchez L.</td>
<td>144</td>
</tr>
<tr>
<td>Gavrilova N.</td>
<td>151</td>
</tr>
<tr>
<td>Genkel V.</td>
<td>140, 143</td>
</tr>
<tr>
<td>Genoux A.</td>
<td>132</td>
</tr>
<tr>
<td>Gerszten R.</td>
<td>63</td>
</tr>
<tr>
<td>Gibney M.</td>
<td>66</td>
</tr>
<tr>
<td>Gielen S.</td>
<td>73</td>
</tr>
<tr>
<td>Gil Serret M.</td>
<td>98</td>
</tr>
<tr>
<td>Gimadeeva A.</td>
<td>160</td>
</tr>
<tr>
<td>Ginsberg H.</td>
<td>75, 77, 104</td>
</tr>
<tr>
<td>Girona J.</td>
<td>115</td>
</tr>
<tr>
<td>Gitt A.</td>
<td>60</td>
</tr>
<tr>
<td>Giunta G.</td>
<td>170</td>
</tr>
<tr>
<td>Goda A.</td>
<td>185</td>
</tr>
<tr>
<td>Gogiashvili L.</td>
<td>144</td>
</tr>
<tr>
<td>Gojkovic T.</td>
<td>102</td>
</tr>
<tr>
<td>Golovina A.E.</td>
<td>184</td>
</tr>
<tr>
<td>Gomaraschi M.</td>
<td>96</td>
</tr>
<tr>
<td>Gomes I.</td>
<td>169</td>
</tr>
<tr>
<td>Gonzalez Navarro B.</td>
<td>139</td>
</tr>
<tr>
<td>Gorski J.</td>
<td>156</td>
</tr>
<tr>
<td>Gorzelak-Pabis P.</td>
<td>188</td>
</tr>
<tr>
<td>Goyale A.</td>
<td>104</td>
</tr>
<tr>
<td>Graça R.</td>
<td>120</td>
</tr>
<tr>
<td>Gragnano F.</td>
<td>161</td>
</tr>
<tr>
<td>Author</td>
<td>Page(s)</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Grandoch M.</td>
<td>128</td>
</tr>
<tr>
<td>Grechanyk M.</td>
<td>155</td>
</tr>
<tr>
<td>Grobbee D.</td>
<td>73</td>
</tr>
<tr>
<td>Groen A.K.</td>
<td>79, 96</td>
</tr>
<tr>
<td>Groh L.</td>
<td>74</td>
</tr>
<tr>
<td>Groselj U.</td>
<td>121</td>
</tr>
<tr>
<td>Grujic Ilic G.</td>
<td>162</td>
</tr>
<tr>
<td>Guaita-Esterurela S.</td>
<td>158</td>
</tr>
<tr>
<td>Guardiola M.</td>
<td>156</td>
</tr>
<tr>
<td>Guerra Ruiz A.R.</td>
<td>161, 187, 203</td>
</tr>
<tr>
<td>Guido M.C.</td>
<td>113</td>
</tr>
<tr>
<td>Guijarro C.</td>
<td>195</td>
</tr>
<tr>
<td>Guillamat-Prats R.</td>
<td>112</td>
</tr>
<tr>
<td>Guillot E.</td>
<td>88</td>
</tr>
<tr>
<td>Gurina N.</td>
<td>154</td>
</tr>
<tr>
<td>Gurses K.M.</td>
<td>147</td>
</tr>
<tr>
<td>Gustafsen C.</td>
<td>65</td>
</tr>
<tr>
<td>Gustafsson C.</td>
<td>130</td>
</tr>
<tr>
<td>H</td>
<td></td>
</tr>
<tr>
<td>Haberka M.</td>
<td>165</td>
</tr>
<tr>
<td>Haghikia A.</td>
<td>92</td>
</tr>
<tr>
<td>Hande L.</td>
<td>169</td>
</tr>
<tr>
<td>Hansson P.</td>
<td>159</td>
</tr>
<tr>
<td>Haralambos K.</td>
<td>68</td>
</tr>
<tr>
<td>Haranghi M.</td>
<td>163</td>
</tr>
<tr>
<td>Hartgers M.</td>
<td>130</td>
</tr>
<tr>
<td>Hayes C.</td>
<td>194</td>
</tr>
<tr>
<td>Helman L.</td>
<td>189</td>
</tr>
<tr>
<td>Hennig B.</td>
<td>144</td>
</tr>
<tr>
<td>Hernández Aguilera A.</td>
<td>153</td>
</tr>
<tr>
<td>Herz J.</td>
<td>65</td>
</tr>
<tr>
<td>Hlozankova M.</td>
<td>173</td>
</tr>
<tr>
<td>Ho J.H.</td>
<td>133</td>
</tr>
<tr>
<td>Hong S.J.</td>
<td>185, 197</td>
</tr>
<tr>
<td>Hoogeveen R.M.</td>
<td>88</td>
</tr>
<tr>
<td>Ho-Plagaro A.</td>
<td>182</td>
</tr>
<tr>
<td>Hori M.</td>
<td>130</td>
</tr>
<tr>
<td>Hossain R.</td>
<td>131</td>
</tr>
<tr>
<td>Hsieh F.</td>
<td>188</td>
</tr>
<tr>
<td>Hsiung S.</td>
<td>128</td>
</tr>
<tr>
<td>Hubacek J.</td>
<td>172</td>
</tr>
<tr>
<td>Humphries S.</td>
<td>129, 168</td>
</tr>
<tr>
<td>Hunjadi M.</td>
<td>165</td>
</tr>
<tr>
<td>I</td>
<td></td>
</tr>
<tr>
<td>Iacocca M.</td>
<td>130</td>
</tr>
<tr>
<td>Ibi D.</td>
<td>108</td>
</tr>
<tr>
<td>Ike A.</td>
<td>190</td>
</tr>
<tr>
<td>Ikeda Y.</td>
<td>179</td>
</tr>
<tr>
<td>Ilinic B.</td>
<td>176</td>
</tr>
<tr>
<td>Illushyna G.</td>
<td>185</td>
</tr>
<tr>
<td>Ingrassia V.</td>
<td>157</td>
</tr>
<tr>
<td>Inozemtseva A.</td>
<td>180</td>
</tr>
<tr>
<td>Ionin V.</td>
<td>165</td>
</tr>
<tr>
<td>Isayeva G.</td>
<td>195, 200</td>
</tr>
<tr>
<td>Ishida N.</td>
<td>176</td>
</tr>
<tr>
<td>Ito S.</td>
<td>197</td>
</tr>
<tr>
<td>Ito Y.</td>
<td>108</td>
</tr>
<tr>
<td>Izar M.C.D.</td>
<td>177</td>
</tr>
<tr>
<td>J</td>
<td></td>
</tr>
<tr>
<td>Jakovljevic B.</td>
<td>152</td>
</tr>
<tr>
<td>Jakovljevic V.</td>
<td>149</td>
</tr>
<tr>
<td>Janczura M.</td>
<td>103</td>
</tr>
<tr>
<td>Jang E.J.</td>
<td>146</td>
</tr>
<tr>
<td>Jarauta E.</td>
<td>124, 151</td>
</tr>
<tr>
<td>Jauhiainen M.</td>
<td>127</td>
</tr>
<tr>
<td>Jayaraman S.</td>
<td>96</td>
</tr>
<tr>
<td>Jemai C.</td>
<td>179</td>
</tr>
<tr>
<td>Jorai P.J.</td>
<td>182</td>
</tr>
<tr>
<td>Jo S.</td>
<td>199</td>
</tr>
<tr>
<td>Joshi S.</td>
<td>192</td>
</tr>
<tr>
<td>Jukema J.W.</td>
<td>76, 108</td>
</tr>
<tr>
<td>K</td>
<td></td>
</tr>
<tr>
<td>Kachkovskii M.</td>
<td>185</td>
</tr>
<tr>
<td>Kai H.</td>
<td>119</td>
</tr>
<tr>
<td>Kajani S.</td>
<td>109</td>
</tr>
<tr>
<td>Kakauridze N.</td>
<td>156, 194</td>
</tr>
<tr>
<td>Kakino A.</td>
<td>110</td>
</tr>
<tr>
<td>Kalinskaya A.</td>
<td>154</td>
</tr>
<tr>
<td>Kalstad A.</td>
<td>155</td>
</tr>
<tr>
<td>Kalstad A.A.</td>
<td>155, 203</td>
</tr>
<tr>
<td>Kaminiotis V.V.</td>
<td>136</td>
</tr>
<tr>
<td>Kanellopoulou K.</td>
<td>181</td>
</tr>
<tr>
<td>Karasek D.</td>
<td>148</td>
</tr>
<tr>
<td>Kardassis D.</td>
<td>111</td>
</tr>
<tr>
<td>Karlsson B.</td>
<td>195</td>
</tr>
<tr>
<td>Kashatalap V.</td>
<td>190, 201</td>
</tr>
<tr>
<td>Kasim S.</td>
<td>164, 189</td>
</tr>
<tr>
<td>Kassner U.</td>
<td>122</td>
</tr>
<tr>
<td>Katano H.</td>
<td>128</td>
</tr>
<tr>
<td>Kayikcioğlu M.</td>
<td>192</td>
</tr>
<tr>
<td>Kechida M.</td>
<td>153, 154</td>
</tr>
<tr>
<td>Kerimkulova A.</td>
<td>177</td>
</tr>
<tr>
<td>Khan T.Z.</td>
<td>110, 168</td>
</tr>
<tr>
<td>Khlebus E.</td>
<td>172</td>
</tr>
<tr>
<td>Khokhlov R.</td>
<td>184</td>
</tr>
<tr>
<td>Kim C.D.</td>
<td>126</td>
</tr>
<tr>
<td>Kim C.J.</td>
<td>161</td>
</tr>
<tr>
<td>Kim E.J.</td>
<td>146</td>
</tr>
<tr>
<td>Kim N.T.</td>
<td>167</td>
</tr>
<tr>
<td>Kim T.</td>
<td>143</td>
</tr>
<tr>
<td>Kimura S.</td>
<td>136</td>
</tr>
<tr>
<td>Kimura Y.</td>
<td>137</td>
</tr>
<tr>
<td>Kim W.</td>
<td>176</td>
</tr>
<tr>
<td>Kiss M.</td>
<td>85, 158</td>
</tr>
<tr>
<td>Klapacz P.</td>
<td>143</td>
</tr>
<tr>
<td>Knutsson A.</td>
<td>126</td>
</tr>
<tr>
<td>Kocyigit D.</td>
<td>164, 196</td>
</tr>
<tr>
<td>Kolakovic A.</td>
<td>149</td>
</tr>
<tr>
<td>Kolesnikova O.</td>
<td>175</td>
</tr>
<tr>
<td>Konnov M.</td>
<td>184, 185</td>
</tr>
<tr>
<td>Kopecký J.</td>
<td>103</td>
</tr>
<tr>
<td>Korneva V.</td>
<td>167</td>
</tr>
<tr>
<td>Koroglu B.</td>
<td>181</td>
</tr>
<tr>
<td>Kosinova A.</td>
<td>97</td>
</tr>
<tr>
<td>Kostovska I.</td>
<td>176, 196</td>
</tr>
<tr>
<td>Kotseva K.</td>
<td>78</td>
</tr>
<tr>
<td>Koutagiar I.</td>
<td>148</td>
</tr>
<tr>
<td>Kovanen P.</td>
<td>122</td>
</tr>
<tr>
<td>Kozarova M.</td>
<td>123</td>
</tr>
<tr>
<td>Koziolova N.</td>
<td>176</td>
</tr>
<tr>
<td>Kraml P.</td>
<td>200</td>
</tr>
<tr>
<td>Krezel J.</td>
<td>200</td>
</tr>
<tr>
<td>Krougly L.</td>
<td>151, 202</td>
</tr>
<tr>
<td>Krzysztof D.</td>
<td>189</td>
</tr>
<tr>
<td>Kubátová H.</td>
<td>143</td>
</tr>
<tr>
<td>Kulathunga K.</td>
<td>124</td>
</tr>
<tr>
<td>Kulik A.</td>
<td>152</td>
</tr>
<tr>
<td>Kumar N.</td>
<td>181</td>
</tr>
<tr>
<td>Kume N.</td>
<td>175</td>
</tr>
<tr>
<td>Kutkiene S.</td>
<td>186, 191</td>
</tr>
<tr>
<td>Authors</td>
<td>Pages</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Kvantaliani T.</td>
<td>137</td>
</tr>
<tr>
<td>Kvasnicka J.</td>
<td>173</td>
</tr>
<tr>
<td>Kwon S.U.</td>
<td>94</td>
</tr>
<tr>
<td>Kyselak O.</td>
<td>170</td>
</tr>
<tr>
<td>Laclaustra M.</td>
<td>123</td>
</tr>
<tr>
<td>Laffargue M.</td>
<td>145</td>
</tr>
<tr>
<td>Lafuente González H.E.</td>
<td>99</td>
</tr>
<tr>
<td>Lafuente H.</td>
<td>199</td>
</tr>
<tr>
<td>Lambert C.</td>
<td>92</td>
</tr>
<tr>
<td>Lambert G.</td>
<td>160</td>
</tr>
<tr>
<td>Lamiquiz-Moneo I.</td>
<td>105</td>
</tr>
<tr>
<td>Landmesser U.</td>
<td>62, 70</td>
</tr>
<tr>
<td>Latsabidze N.</td>
<td>137</td>
</tr>
<tr>
<td>Laufs U.</td>
<td>68, 73, 133</td>
</tr>
<tr>
<td>Lavie G.</td>
<td>107</td>
</tr>
<tr>
<td>Lebedeva A.</td>
<td>139</td>
</tr>
<tr>
<td>Lebrun S.</td>
<td>152</td>
</tr>
<tr>
<td>Lee B.</td>
<td>149</td>
</tr>
<tr>
<td>Lee D.</td>
<td>179, 188</td>
</tr>
<tr>
<td>Lee E.M.</td>
<td>119</td>
</tr>
<tr>
<td>Lee K.Y.</td>
<td>114</td>
</tr>
<tr>
<td>Learper N.J.</td>
<td>85</td>
</tr>
<tr>
<td>Lee S.</td>
<td>193</td>
</tr>
<tr>
<td>Leiberer A.</td>
<td>114, 171, 172, 173, 180</td>
</tr>
<tr>
<td>Leitersdorf E.</td>
<td>78</td>
</tr>
<tr>
<td>Leopold C.</td>
<td>158</td>
</tr>
<tr>
<td>Libby P.</td>
<td>66</td>
</tr>
<tr>
<td>Liberopoulos E.</td>
<td>118, 167, 168, 203</td>
</tr>
<tr>
<td>Li C.</td>
<td>137</td>
</tr>
<tr>
<td>Li N.</td>
<td>165</td>
</tr>
<tr>
<td>Littmann K.</td>
<td>195</td>
</tr>
<tr>
<td>Liu A.</td>
<td>112</td>
</tr>
<tr>
<td>Liu Y.</td>
<td>122</td>
</tr>
<tr>
<td>Ljubic S.</td>
<td>177</td>
</tr>
<tr>
<td>Lobjanidze N.</td>
<td>198</td>
</tr>
<tr>
<td>Lomelino Araujo J.</td>
<td>107</td>
</tr>
<tr>
<td>Loncar D.</td>
<td>187</td>
</tr>
<tr>
<td>Lopez L.</td>
<td>97</td>
</tr>
<tr>
<td>López Sanz L.</td>
<td>128</td>
</tr>
<tr>
<td>Lugo Gavidia L.M.</td>
<td>93, 199</td>
</tr>
<tr>
<td>Lusis A.J.</td>
<td>73</td>
</tr>
<tr>
<td>Macchi C.</td>
<td>123</td>
</tr>
<tr>
<td>Machado-Lima A.</td>
<td>165</td>
</tr>
<tr>
<td>Machal J.</td>
<td>97</td>
</tr>
<tr>
<td>Mach F.</td>
<td>78</td>
</tr>
<tr>
<td>Maga M.</td>
<td>138</td>
</tr>
<tr>
<td>Maggioni A.P.</td>
<td>78</td>
</tr>
<tr>
<td>Maistry T.</td>
<td>171</td>
</tr>
<tr>
<td>Mal G.</td>
<td>195</td>
</tr>
<tr>
<td>Mallat Z.</td>
<td>64, 112</td>
</tr>
<tr>
<td>Mandraffino G.</td>
<td>100</td>
</tr>
<tr>
<td>Manea A.</td>
<td>125</td>
</tr>
<tr>
<td>Manea S.</td>
<td>113</td>
</tr>
<tr>
<td>Manea V.</td>
<td>114</td>
</tr>
<tr>
<td>Manzini S.</td>
<td>97</td>
</tr>
<tr>
<td>Maraninchi M.</td>
<td>159</td>
</tr>
<tr>
<td>Marco Benedi M.V.</td>
<td>160</td>
</tr>
<tr>
<td>Mardngolu A.</td>
<td>73</td>
</tr>
<tr>
<td>Markov A.</td>
<td>147, 173</td>
</tr>
<tr>
<td>Markova I.</td>
<td>171</td>
</tr>
<tr>
<td>Marleau S.</td>
<td>91</td>
</tr>
<tr>
<td>Marrott S.</td>
<td>93</td>
</tr>
<tr>
<td>Marques da Silva P.</td>
<td>110</td>
</tr>
<tr>
<td>Márquez Lópe L.</td>
<td>187</td>
</tr>
<tr>
<td>Martinez-Gonzalez M.A.</td>
<td>58</td>
</tr>
<tr>
<td>Martinez Gonzalez P.J.</td>
<td>98</td>
</tr>
<tr>
<td>Martínez López D.</td>
<td>127</td>
</tr>
<tr>
<td>Martinez-Micaelo N.</td>
<td>145</td>
</tr>
<tr>
<td>Martin Toro M.A.</td>
<td>193, 196</td>
</tr>
<tr>
<td>Masana L.</td>
<td>68</td>
</tr>
<tr>
<td>Massberg S.</td>
<td>82</td>
</tr>
<tr>
<td>Mateo-Gallego R.</td>
<td>103, 161</td>
</tr>
<tr>
<td>Mathur R.</td>
<td>183</td>
</tr>
<tr>
<td>Matsoukis I.L.</td>
<td>181</td>
</tr>
<tr>
<td>Matsuzawa Y.</td>
<td>61</td>
</tr>
<tr>
<td>Matsuo N.</td>
<td>116, 187</td>
</tr>
<tr>
<td>Matsuzawa Y.</td>
<td>63</td>
</tr>
<tr>
<td>Mattina A.</td>
<td>118</td>
</tr>
<tr>
<td>Mayer O.</td>
<td>183</td>
</tr>
<tr>
<td>Mayr M.</td>
<td>73, 119</td>
</tr>
<tr>
<td>McGillicuddy F.</td>
<td>109</td>
</tr>
<tr>
<td>Medentseva O.</td>
<td>202</td>
</tr>
<tr>
<td>Mehrd H.</td>
<td>94, 100, 144, 149, 151, 152, 154, 200</td>
</tr>
<tr>
<td>Melhem N.J.</td>
<td>74</td>
</tr>
<tr>
<td>Mello e Silva A.</td>
<td>58, 61, 62, 68</td>
</tr>
<tr>
<td>Melnikov I.</td>
<td>136</td>
</tr>
<tr>
<td>Mendez-Barbero N.</td>
<td>126</td>
</tr>
<tr>
<td>Méndez Lara K.A.</td>
<td>127</td>
</tr>
<tr>
<td>Merlin J.</td>
<td>89</td>
</tr>
<tr>
<td>Metelskaya V.</td>
<td>157</td>
</tr>
<tr>
<td>Minniti M.E.</td>
<td>110</td>
</tr>
<tr>
<td>Mirjanic-Azaric B.</td>
<td>164</td>
</tr>
<tr>
<td>Mirmaksudov M.</td>
<td>181</td>
</tr>
<tr>
<td>Mirrakhimov E.</td>
<td>83</td>
</tr>
<tr>
<td>Mirzaee S.</td>
<td>118</td>
</tr>
<tr>
<td>Miyoshi T.</td>
<td>88</td>
</tr>
<tr>
<td>M.K. Cho.</td>
<td>100</td>
</tr>
<tr>
<td>Mohd Nawawi H.</td>
<td>95, 121</td>
</tr>
<tr>
<td>Montenegro Puche B.E.</td>
<td>199</td>
</tr>
<tr>
<td>Mora S.</td>
<td>63, 116</td>
</tr>
<tr>
<td>Moregola A.</td>
<td>115</td>
</tr>
<tr>
<td>Moschonas I.</td>
<td>136</td>
</tr>
<tr>
<td>Moulin P.</td>
<td>66, 69, 131, 132</td>
</tr>
<tr>
<td>Mthethwa M.</td>
<td>144</td>
</tr>
<tr>
<td>Mulder W.J.M.</td>
<td>68</td>
</tr>
<tr>
<td>Mussbacher M.</td>
<td>71</td>
</tr>
<tr>
<td>Muzaelevskaia M.</td>
<td>159</td>
</tr>
<tr>
<td>Myasoedova V.</td>
<td>101</td>
</tr>
<tr>
<td>Najmanova I.</td>
<td>198</td>
</tr>
<tr>
<td>Narverud I.</td>
<td>118</td>
</tr>
<tr>
<td>Nasias D.</td>
<td>106</td>
</tr>
<tr>
<td>Nasonenko O.</td>
<td>190</td>
</tr>
<tr>
<td>Navas Madroñal M.</td>
<td>101</td>
</tr>
<tr>
<td>Nawawi H.</td>
<td>121, 168, 169</td>
</tr>
<tr>
<td>Nazarova M.</td>
<td>137</td>
</tr>
<tr>
<td>Neely R.</td>
<td>130</td>
</tr>
<tr>
<td>Nicorescu I.</td>
<td>138</td>
</tr>
<tr>
<td>Nilsen A.</td>
<td>107</td>
</tr>
<tr>
<td>Nizomov A.</td>
<td>139, 142</td>
</tr>
<tr>
<td>Nohara A.</td>
<td>95</td>
</tr>
<tr>
<td>Noordam R.</td>
<td>83</td>
</tr>
<tr>
<td>Norata G.D.</td>
<td>65, 78</td>
</tr>
<tr>
<td>Author</td>
<td>Page(s)</td>
</tr>
<tr>
<td>------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Nordestgaard B.</td>
<td>98</td>
</tr>
<tr>
<td>Nordestgaard L.T.</td>
<td>122</td>
</tr>
<tr>
<td>Notsu Y.</td>
<td>123</td>
</tr>
<tr>
<td>Novakovic A.</td>
<td>106</td>
</tr>
<tr>
<td>Novakovic R.</td>
<td>101</td>
</tr>
<tr>
<td>Noz M.P.</td>
<td>89</td>
</tr>
<tr>
<td>Pang J.</td>
<td>162, 169</td>
</tr>
<tr>
<td>Pang K.T.</td>
<td>111</td>
</tr>
<tr>
<td>Panic A.</td>
<td>150</td>
</tr>
<tr>
<td>Panteleeva A.</td>
<td>166</td>
</tr>
<tr>
<td>Papadaki S.</td>
<td>143</td>
</tr>
<tr>
<td>Papadakis J.</td>
<td>188</td>
</tr>
<tr>
<td>Papagianni M.</td>
<td>117</td>
</tr>
<tr>
<td>Pappa E.</td>
<td>132</td>
</tr>
<tr>
<td>Paragh G.</td>
<td>203</td>
</tr>
<tr>
<td>Paredes S.</td>
<td>108</td>
</tr>
<tr>
<td>Parini P.</td>
<td>77</td>
</tr>
<tr>
<td>Park J.</td>
<td>197</td>
</tr>
<tr>
<td>Parolini C.</td>
<td>92</td>
</tr>
<tr>
<td>Parvui M.</td>
<td>142</td>
</tr>
<tr>
<td>Pasko V.</td>
<td>137, 154</td>
</tr>
<tr>
<td>Passarelli M.</td>
<td>103</td>
</tr>
<tr>
<td>Pasterkamp G.</td>
<td>72</td>
</tr>
<tr>
<td>Pastori D.</td>
<td>119, 204</td>
</tr>
<tr>
<td>Pavanello C.</td>
<td>161</td>
</tr>
<tr>
<td>Pecherina T.</td>
<td>200</td>
</tr>
<tr>
<td>Pek S.L.T.</td>
<td>178</td>
</tr>
<tr>
<td>Pellegrin M.</td>
<td>139</td>
</tr>
<tr>
<td>Pereira A.</td>
<td>188, 203</td>
</tr>
<tr>
<td>Pereira de Moura J.</td>
<td>99</td>
</tr>
<tr>
<td>Pérez López</td>
<td>159</td>
</tr>
<tr>
<td>Perez-Martinez P.</td>
<td>58, 129</td>
</tr>
<tr>
<td>Peri C.</td>
<td>173</td>
</tr>
<tr>
<td>Petelina T.</td>
<td>190</td>
</tr>
<tr>
<td>Piepoli M.</td>
<td>59</td>
</tr>
<tr>
<td>Piljac A.</td>
<td>180</td>
</tr>
<tr>
<td>Pinegina N.</td>
<td>97</td>
</tr>
<tr>
<td>Pitarianc H.</td>
<td>197</td>
</tr>
<tr>
<td>Pinto F.J.</td>
<td>70, 124</td>
</tr>
<tr>
<td>Pinto X.</td>
<td>58</td>
</tr>
<tr>
<td>Pirazze C.</td>
<td>167</td>
</tr>
<tr>
<td>Pirro M.</td>
<td>59</td>
</tr>
<tr>
<td>Pitha J.</td>
<td>171</td>
</tr>
<tr>
<td>Pojskic L.</td>
<td>168</td>
</tr>
<tr>
<td>Poledne R.</td>
<td>140</td>
</tr>
<tr>
<td>Poli A.</td>
<td>58</td>
</tr>
<tr>
<td>Porsch F.S.</td>
<td>112</td>
</tr>
<tr>
<td>Porsgaard T.</td>
<td>156</td>
</tr>
<tr>
<td>Porto Pérez A.B.</td>
<td>175</td>
</tr>
<tr>
<td>Posadas-Sánchez R.</td>
<td>138</td>
</tr>
<tr>
<td>Potente M.</td>
<td>71</td>
</tr>
<tr>
<td>Poussin C.</td>
<td>196</td>
</tr>
<tr>
<td>Preston Mason R.</td>
<td>69</td>
</tr>
<tr>
<td>Prus Y.</td>
<td>151</td>
</tr>
<tr>
<td>Puig Grifol N.</td>
<td>110</td>
</tr>
<tr>
<td>Qi Y.F.</td>
<td>90</td>
</tr>
<tr>
<td>Ragno Y.</td>
<td>148, 154, 202, 203, 204</td>
</tr>
<tr>
<td>Rahman M.</td>
<td>139</td>
</tr>
<tr>
<td>Rajkovic J.</td>
<td>148</td>
</tr>
<tr>
<td>Rakovac Tisdall A.</td>
<td>95</td>
</tr>
<tr>
<td>Rallidis L.</td>
<td>198</td>
</tr>
<tr>
<td>Ramin-Mangata S.</td>
<td>115</td>
</tr>
<tr>
<td>Rather R.</td>
<td>75</td>
</tr>
<tr>
<td>Rathod K.</td>
<td>94, 196</td>
</tr>
<tr>
<td>Rauch U.</td>
<td>148</td>
</tr>
<tr>
<td>Ray K.</td>
<td>63, 67, 78, 82, 120</td>
</tr>
<tr>
<td>Razgildina N.</td>
<td>166</td>
</tr>
<tr>
<td>Raz O.</td>
<td>182</td>
</tr>
<tr>
<td>Real J.T.</td>
<td>139</td>
</tr>
<tr>
<td>Reesekamp L.F.</td>
<td>69</td>
</tr>
<tr>
<td>Reiner Z.</td>
<td>79, 97</td>
</tr>
<tr>
<td>Rensen P.</td>
<td>85, 123</td>
</tr>
<tr>
<td>Ressia A.</td>
<td>95</td>
</tr>
<tr>
<td>Retterstel K.</td>
<td>122, 153, 167, 168</td>
</tr>
<tr>
<td>Revnic C.R.</td>
<td>140, 150</td>
</tr>
<tr>
<td>Rhew J.Y.</td>
<td>200</td>
</tr>
<tr>
<td>Riccardi G.</td>
<td>66</td>
</tr>
<tr>
<td>Ricci M.A.</td>
<td>117</td>
</tr>
<tr>
<td>Rico Martin S.</td>
<td>197</td>
</tr>
<tr>
<td>Rimbert A.</td>
<td>105</td>
</tr>
<tr>
<td>Rine P.</td>
<td>81</td>
</tr>
<tr>
<td>Rioja J.</td>
<td>102</td>
</tr>
<tr>
<td>Ritsch A.</td>
<td>109</td>
</tr>
<tr>
<td>Rivas Urbina A.</td>
<td>156</td>
</tr>
<tr>
<td>Robinson J.</td>
<td>76</td>
</tr>
<tr>
<td>Rodriguez-Calvo R.</td>
<td>104, 178</td>
</tr>
<tr>
<td>Rodriguez de Miguel M.</td>
<td>129</td>
</tr>
<tr>
<td>Rodriguez-Fortúnez P.</td>
<td>190</td>
</tr>
<tr>
<td>Rodriguez-Gallego E.</td>
<td>133</td>
</tr>
<tr>
<td>Rodriguez Leal C.</td>
<td>185, 191</td>
</tr>
<tr>
<td>Romanova V.</td>
<td>144</td>
</tr>
<tr>
<td>Romanov V.</td>
<td>190</td>
</tr>
<tr>
<td>Romeo S.</td>
<td>63, 104</td>
</tr>
<tr>
<td>Ros E.</td>
<td>58, 83, 106</td>
</tr>
<tr>
<td>Rosloniec E.</td>
<td>139, 199</td>
</tr>
<tr>
<td>Rossi N.</td>
<td>121</td>
</tr>
<tr>
<td>Rovira-Llopis S.</td>
<td>178</td>
</tr>
<tr>
<td>Ruhanen H.</td>
<td>104</td>
</tr>
<tr>
<td>Rull Aixa A.</td>
<td>155</td>
</tr>
<tr>
<td>Rundblad A.</td>
<td>116</td>
</tr>
<tr>
<td>Ruuth M.</td>
<td>110</td>
</tr>
<tr>
<td>Rydén L.</td>
<td>63</td>
</tr>
</tbody>
</table>

230
SATURDAY MAY 05, 18.00
OPENING CEREMONY
& WELCOME RECEPTION

The Opening Ceremony is the official starting point of the Congress and includes the prestigious Anitschkow Lecture, followed by traditional local music and entertainment.

All participants are invited to the Opening Ceremony, which will be held in the Anitschkow Hall – Auditorium I, followed by a Welcome Reception in the Exhibition area at the Centro de Congressos de Lisboa.

MONDAY MAY 07, 19.30
AT PATIO DA GALÉ
EAS NETWORKING EVENING

The enjoyable International evening will be held in one of the most beautiful building of Lisbon, Patio da Galé.

An award ceremony, dinner buffet and live music will make this evening a special souvenir for the Congress guests. Tickets are subject to availability.
PCSK9 INHIBITION to PREVENT and TREAT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Identifying High Risk Patients and Clinical Profiles—Diabetes, Statin Intolerance and Resistance, Recent ACS, Hypercholesterolemia, Advanced ASCVD—for PCSK9 Inhibitor-Based Management

A YEAR 2018 EVIDENCE-TO-THERAPY, CV OUTCOMES-FOCUSED UPDATE FOR THE Atherosclerosis, Thrombosis, Lipid, Diabetes, and Cardiovascular Specialist

Funded by an independent educational grant from Sanofi and Regeneron Pharmaceuticals

Save the Time and Date: Saturday Afternoon, May 5, 2018

Time: 14:30 – 16:00 | Program Registration and Lunch: 14:00

City: Lisbon, Portugal Location: Centro de Congressos de Lisboa, Lisbon, Portugal | Conference Room: Auditorium VI – Garcia de Orta Hall

No Pre-Registration is Required

JOIN US on Saturday Afternoon, May 5, 2018 – A CME Clinical Excellence Lunch Summit

The Landmark Trial-Based Evidence and Rationale for

PROFESSOR PHILIPPE GABRIEL STEG, MD
Professor of Cardiology | Université Paris — Diderot, Sorbonne-Paris Cité | Professor, National Heart and Lung Institute | Imperial College, London, UK | Director, Coronary Care Unit | Hôpital Bichat | Paris, France

PROFESSOR DEEPAK L. BHATT, MD, MPH
Executive Director of Interventional Cardiovascular Programs | Brigham and Women's Hospital Heart and Vascular Center | Professor of Medicine | Harvard Medical School | Boston, Massachusetts

Program Co-Chairs

CMEducation Resources, LLC
A Medical Education Company